Program	Session Title	Session Subtitle	Date	Start Time	End Time	Session	CME Credit	Paper Title	First Name	Last Name	Credentials	Affiliation	Role	Presenting	Type	Disclosure	Employment	Consultancy	Equity Ownership	Research Funding	Honoraria	Patents & Royalties	Speakers Bureau	Membership on an entity's Board of Directors or advisory committees	Other	Presentation includes discussion of off-label use of a drug or medical device	Off-label comments
Oral and Poster Abstracts	113. Hemoglobinopathies, Excluding Thalassemia&#8^ Basic and Translational Science: Novel Therapeutic Approaches for Pain and Organ Pathology in Sickle Cell Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation	Oshoto	Abdulmalik	OVM	Children's Hosp. of Phila.	Presenter	Yes	Oral	Disclosure made											No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Non-Intensive Therapy		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Sameem	Abedin	MD	Medical College of Wisconsin	Moderator	No	Oral	Disclosure made				Actinium Pharmaceuticals; Pfizer Inc; Helsinn Healthcare	Agios; Jazz Pharmaceuticals							
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Sameem	Abedin	MD	Medical College of Wisconsin	Moderator	No	Oral	Disclosure made				Actinium Pharmaceuticals; Pfizer Inc; Helsinn Healthcare	Agios; Jazz Pharmaceuticals							
Oral and Poster Abstracts	905. Outcomes Research&#8^Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial	Gregory	Abel	MD,MPH	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose											No	
General Sessions	Presidential Symposium	The Use of Big Data in Hematology Research and Delivery of Personalized Healthcare	Tuesday, December 10, 2019	9:45 AM	11:15 AM	Yes	1.5	Big Data Informatics&#8^^ Role in Healthcare Delivery and in Speeding the Pipeline for New Therapeutics	Amy	Abernethy	MD, PhD	U.S. Food and Drug Administration	Speaker	Yes	Oral	Nothing to disclose											No	
Spotlight Sessions	Diving Into Rare Childhood Leukemias		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Oussama	Abla	MD	Hospital for Sick Children Division of Hematology	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML	Iman	Abouelelle	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies	Simon	Abrams	PhD, BSc	University of Liverpool	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	636. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)&#8^: Results from Prospective Clinical Trials: Results from CAR T-Cell Trials		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas	Jeremy	Abramson	MD, MMSc	Massachusetts General Hospital Cancer Center	Presenter	Yes	Oral	Disclosure made		Abbvie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, EMD Serono Inc, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite Pharma Inc, Merck, Novartis, Seattle Gen									No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database	Elisabetta	Abruzzese	MD	Hematology Unit, S. Eugenio Hospital, Tor Vergata University	Presenter	Yes	Oral	Disclosure made		BMS; Incyte; Novartis; Pfizer									Yes	Informations on the use of interferon and/or TKIs (imatinib, nilotinib) during pregnancy.
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Elisabetta	Abruzzese	MD	Hematology Unit, S. Eugenio Hospital, Tor Vergata University	Moderator	No	Oral	Disclosure made		BMS; Incyte; Novartis; Pfizer										
Oral and Poster Abstracts	637. Myelodysplastic Syndromes&#8^:Clinical Studies: Targeting Gene Mutations in MDS		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Lionel	Adès	MD, PhD	Hopital Saint Louis	Moderator	No	Oral	Disclosure made				Amgen				Helsinn Healthcare; Celgene; Novartis; Takeda; Silence Therapeutics; Agios; Jazz; Abbvie; Astellas				
Education Program	Management of Sickle Cell Disease Complications Beyond Acute Chest		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Osteonecrosis in sickle cell disease: an update on risk factors and therapeutic interventions	Oyebimpe	Adesina	MD, MS	Seattle Cancer Care Alliance	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Management of Sickle Cell Disease Complications Beyond Acute Chest		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Osteonecrosis in sickle cell disease: an update on risk factors and therapeutic interventions	Oyebimpe	Adesina	MD, MS	Seattle Cancer Care Alliance	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	904. Outcomes Research&#8^Non-Malignant Conditions III		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Perioperative Bridging of Anticoagulation &#8^ Does Protocol Adherence Improve Outcomes?	Ijele	Adimora		The Geisel School of Medicine at Dartmouth	Presenter	Yes	Oral	Disclosure made											No	
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: Fusion Genes		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Non-Coding HOX Fusions in Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia	Fabienne	Adriaanse	MSc	Erasmus MC-Sophia Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	803. Health Services Research&#8^Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Risk Stratification and Transfusion Dependence Are Independent Risk Factors for Cardiovascular Disease (CVD) in Myelodysplastic Syndrome (MDS)	Diego	Adriansen Herrera	MD	Larner College of Medicine at The University of Vermont	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Navigating the Nexus of MRD and Novel Agents in ALL	Anjali	Advani	MD	Cleveland Clinic	Speaker	Yes	Oral	Disclosure made		Glycomimetics; Kite Pharmaceuticals		Glycomimetics; Amgen; Pfizer; Macrogenics; Abbvie	Pfizer							
Education Program	Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Navigating the Nexus of MRD and Novel Agents in ALL	Anjali	Advani	MD	Cleveland Clinic	Speaker	Yes	Oral	Disclosure made		Glycomimetics; Kite Pharmaceuticals		Glycomimetics; Amgen; Pfizer; Macrogenics; Abbvie	Pfizer							
Oral and Poster Abstracts	634. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refining the Approach		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	ENOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia	Anjali	Advani	MD	Cleveland Clinic	Presenter	Yes	Oral	Disclosure made		Glycomimetics; Kite Pharmaceuticals		Glycomimetics; Amgen; Pfizer; Macrogenics; Abbvie	Pfizer						No	
Education Program	Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Anjali	Advani	MD	Cleveland Clinic	Chair	No	Oral	Disclosure made		Glycomimetics; Kite Pharmaceuticals		Glycomimetics; Amgen; Pfizer; Macrogenics; Abbvie	Pfizer							
Education Program	Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Anjali	Advani	MD	Cleveland Clinic	Chair	No	Oral	Disclosure made		Glycomimetics; Kite Pharmaceuticals		Glycomimetics; Amgen; Pfizer; Macrogenics; Abbvie	Pfizer							
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Innovative Approaches in Allogeneic Transplantation for Pediatric or Nonmalignant Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency	Rajni	Agarwal	MD	Stanford University Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Clonal Evolution		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors	Inhye	Ahn	MD	National Institutes of Health	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Chromatin Structure in Development and Disease		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Three-D Codes in the Human Genome	Erez Lieberman	Aiden	PhD	Baylor College of Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Chromatin Structure in Development and Disease		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Three-D Codes in the Human Genome	Erez Lieberman	Aiden	PhD	Baylor College of Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Chromatin Structure in Development and Disease		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Erez Lieberman	Aiden	PhD	Baylor College of Medicine	Speaker	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	905. Outcomes Research&#8^Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis	Skander	Alawadhi	MD	Mayo Clinic	Presenter	Yes	Oral	Disclosure made		Celgene; Amgen; Janssen; Takeda		Amgen; Pharmacyclics; Cellectar; Janssen								
Oral and Poster Abstracts	902. Health Services Research&#8^Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers	Skander	Alawadhi	MD	Mayo Clinic	Presenter	Yes	Oral	Disclosure made		Celgene; Amgen; Janssen; Takeda		Amgen; Pharmacyclics; Cellectar; Janssen							No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)	Skander	Alawadhi	MD	Mayo Clinic	Presenter	Yes	Oral	Disclosure made		Celgene; Amgen; Janssen; Takeda		Amgen; Pharmacyclics; Cellectar; Janssen							No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Hemophilia--Associated Complications		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	The Use of Chromogenic Factor VIII Assay Changes Treatment Approach in a Portion of Mild Hemophilia A Patients with Factor VIII Assay Discrepancy	Muntadhar	Al-Moosawi	MD	University of British Columbia	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	904. Outcomes Research&#8^Non-Malignant Conditions III		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Survival Pattern Among Venous Thromboembolism (VTE) Patients with Hematologic Malignancy in Alberta, Canada from 2003 to 2015	Arafat Ul	Alam	MBBS	University of Alberta	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of Pathogenesis, Drug Sensitivity, and Resistance; and Role of Bone Marrow Microenvironment and Host Microbiome in Myeloma Pathogenesis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)	Jean-Baptiste	Alberge		Universite de Nantes	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	636. Myelodysplastic Syndromes&#8^:Basic and Translational Studies: RNA Processing and Signatures in MDS		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Mutant U2AF1^{S34F} and U2AF1^{S34Y} Induce Distinct RNA Splicing and Hematopoietic Phenotypes In Vivo	Michael	Alberti	MD,PhD	Washington University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical JAK Inhibitors and Combination Therapies		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Peri-Transplant Administration of Ruxolitinib is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning	Haris	Ali	MD	City of Hope National Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Molecular, Epigenetic and Gene Expression Profiling of Triple Negative Essential Thrombocythaemia	Sam	Alimam		King's College, London	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma&#8^:Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Brief Pembrolizumab(P)M) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD	Pamela	Allen	MD,MSc	Emory University Winship Cancer Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Speaker 2	Jessica	Altman		Northwestern University	Speaker	Yes	Oral	Disclosure made		Novartis; Cancer Expert Now; Agios; Glycomimetics; Theradex; Abbvie; Daiichi Sankyo			Agios; Glycomimetics; Theradex; Abbvie; Daiichi Sankyo		PeerView; prIME Oncology; France Foundation	Agios; Theradex; Abbvie; Daiichi Sankyo			
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Aspacytarabine (BST-236) is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy: Integrated Results from a Phase 1/2a and an Ongoing Phase 2b	Jessica	Altman		Northwestern University	Presenter	Yes	Oral	Disclosure made		Novartis; Cancer Expert Now; Agios; Glycomimetics; Theradex; Abbvie; Daiichi Sankyo			Agios; Glycomimetics; Theradex; Abbvie; Daiichi Sankyo		PeerView; prIME Oncology; France Foundation	Agios; Theradex; Abbvie; Daiichi Sankyo			No
General Sessions	Presidential Symposium	The Use of Big Data in Hematology Research and Delivery of Personalized Healthcare	Tuesday, December 10, 2019	9:45 AM	11:15 AM	Yes	1.5	Role of Pharmacogenomics, Computational Biology, and Other "Omics" Approaches in Precision Medicine and Regulatory Science	Russ	Altman	MD, PhD	Stanford University	Speaker	Yes	Oral	Disclosure made		Karius; Personalis; Pfizer									No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Global Rnaseq/Proteomic-Phosphoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM	Emanuela	Altomare	PhD	Magna Graecia University	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	ASH Practice Partnership Lunch	Genomic/Genetic Testing: The Who, What, Where, When, & Why	Sunday, December 8, 2019	11:15 AM	12:30 PM	Yes	1.25		Joseph	Alvarnas	MD	City of Hope National Medical Center	Chair	No	Oral	Nothing to disclose												
Scientific Program	Targeting Apoptosis in Myeloma		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Targeting Bcl-2 Proteins in Myeloma	Martine	Amiot	PhD	Nantes University	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Targeting Apoptosis in Myeloma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Targeting Bcl-2 Proteins in Myeloma	Martine	Amiot	PhD	Nantes University	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2	The Power of ONE: Immunology in the Age of Single Cell Genomics	Ido	Amit	PhD	Weizmann Institute of Science	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2	The Power of ONE: Immunology in the Age of Single Cell Genomics	Ido	Amit	PhD	Weizmann Institute of Science	Speaker	Yes	Oral	Nothing to disclose											No	

Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Insights Into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	11:30 AM	12:30 PM	Yes		1	Ido	Amit	PhD	Weizmann Institute of Science	Speaker	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	803. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	Integrated Anemia Detection and Hemoglobin Variant Identification Using Point-of-Care Microchip Electrophoresis	Ikan	Ao	PhD	Case Western Reserve University	Presenter	Yes	Oral	Disclosure made		Hemex Health, Inc	Hemex Health, Inc			Hemex Health, Inc					No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5	Identification of Recurrent Alternative RNA Splicing in Adverse-Risk Acute Myeloid Leukemia	Govardhan	Anande		University of New South Wales	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia&#8"Clinical: Emerging Therapies: Reports from Recent Clinical Trials		Monday, December 9, 2019	10:30 AM	12:30 PM	Yes		1.5		Biree	Andemariam	MD	University of Connecticut Health Center	Moderator	No	Oral	Nothing to disclose											
Education Program	Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	The Microbiome and Its Role in Hematology	Tessa	Andermann	MD	University of North Carolina at Chapel Hill	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	The Microbiome and Its Role in Hematology	Tessa	Andermann	MD	University of North Carolina at Chapel Hill	Speaker	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Speaker 3	David	Anderson	MD	Dalhousie University	Speaker	Yes	Oral	Nothing to disclose											
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5	Identifying the Leukemia Stem Cell Niche Mediating Drug Resistance in FLT3-ITD Acute Myeloid Leukemia	Nick	Anderson	BS	University of Alabama at Birmingham	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Intrinsic and Extrinsic Control of HSPC Maintenance and Differentiation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Higher Vertebrate Specific Gene Ribonuclease Inhibitor (RNH1) Is Essential for Adult Hematopoietic Stem Cell Function and Cell Cycle Regulation	Nicola	Andina	MD, PhD	Inselspital, Bern University Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	602. Health Services Research&#8"Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma	Rachael	Andrie		Clinical Care Options, LLC	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	801. Health Services Research&#8"Non-Malignant Conditions: Improving Quality in Hematology		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5		Dana	Angelini	MD	Cleveland Clinic	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	Excellent Outcomes with Reduced-Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B-Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children&#8"s Oncology Group (COG) Study AALL0932	Anne	Angiolillo	MD	Children&#8"s National Health System/George Washington University SMHS	Presenter	Yes	Oral	Disclosure made		Servier Pharmaceuticals									No	
Oral and Poster Abstracts	634. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refining the Approach		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells in Vivo	Colleen	Annesley	MD	Seattle Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	621. Lymphoma&#8"Genetic/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma	Tomohiro	Aoki	MD, PhD	British Columbia Cancer	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)	Jacob	Appelbaum	MD,PhD	Fhcrc/Seattle Cancer Care Alliance	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	113. Hemoglobinopathies, Excluding Thalassemia&#8"Basic and Translational Science: Novel Therapeutic Approaches for Pain and Organ Pathology in Sickle Cell Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5		David	Ascher	PhD	Aflac Cancer & Blood Disorders Center of Children&#8"s Healthcare of Atlanta and the Department of Pediatrics, Emory University	Moderator	No	Oral	Disclosure made		Global Blood Therapeutics; Prolong Pharmaceuticals		Global Blood Therapeutics; AstraZeneca								
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)&#8"Results from Prospective Clinical Trials: Results from CAR T-Cell Trials		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Phase 1/2 Study of AUTO1 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study	Kirit	Ardeshna	MB&BChir	University College London Hospital NHS Foundation Trust	Presenter	Yes	Oral	Nothing to disclose											No	This is a phase 1/2 trial on an investigational agent.
Oral and Poster Abstracts	113. Hemoglobinopathies, Excluding Thalassemia&#8"Basic and Translational Science: Novel Therapeutic Approaches for Pain and Organ Pathology in Sickle Cell Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	Downregulation of Spr1a Contributes to the Pathobiology of Sickle Cell Disease	Donovan	Argueta	BSc	University of California, Irvine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Microbiome and Immune Regulation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT	James	Astes		Barts Cancer Institute, Queen Mary University of London	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Intrinsic and Extrinsic Control of HSPC Maintenance and Differentiation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Activated but Not Quiescent Hematopoietic Stem Cells Rely Readily on Glycolysis As Their Main Source of Energy	Tasleem	Arif	PhD	Icahn School of Medicine at Mount Sinai	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: New Regulators of Stem and Progenitor Cell Survival and Differentiation		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Lysosomal Activation Is Required for Priming of Quiescent Hematopoietic Stem Cells	Tasleem	Arif	PhD	Icahn School of Medicine at Mount Sinai	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	906. Outcomes Research&#8"Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases		Monday, December 9, 2019	10:30 AM	12:30 PM	Yes		1.5	Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) &#8" a Report from the BMT Survivor Study (BMTSS)	Saro	Armenian	DO, MPH	City of Hope	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Advances in ITP Therapy		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5	Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial	Donald	Arnold	MD	Department of Medicine, McMaster University	Presenter	Yes	Oral	Disclosure made		Rigel; Principia		Novartis; Rigel; Bristol-Myers Squibb	Novartis						Yes	Eltrombopag is not licenced for perioperative treatment in patients with ITP.
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5		Donald	Arnold	MD	McMaster University	Moderator	No	Oral	Disclosure made		Rigel; Principia		Novartis; Rigel; Bristol-Myers Squibb	Novartis							
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects		Monday, December 9, 2019	10:30 AM	12:30 PM	Yes		1.5	Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors &#8" a BMT Survivor Study (BMTSS)	Mukta	Arora	MD	University of Minnesota Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	622. Lymphoma Biology&#8"Non-Genetic Studies: Molecular Mechanisms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	NFKB2Y 346* UTR Mutations Confer Selective Growth Advantage and Activate Genes with Therapeutic Implications in Diffuse Large B-Cell Lymphoma	Sarah	Arthur	BSc	Simon Fraser University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: MPC and Beyond		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Leukemogenic Functions of Mutant ASXL1 Are Regulated By CDK-Mediated Phosphorylation	Shuhei	Asada	MD,PhD	Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	Cells Deficient in the Shwachman-Diamond Syndrome Protein SBDS or the Diamond-Blackfan Anemia Protein RPS19 Have Impaired Homologous Recombination	Elif	Ask	PhD	Baylor College of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Functional Characterization of Novel Molecular Drivers and Vulnerabilities of Myeloma Cells		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5		Fotis	Avimakopoulos	PhD,MBBChir,	University of California San Diego & Moores Cancer Center	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)&#8"Results from Retrospective/Observational Studies: Cellular Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral	Sarit	Assouline	MD	McGill University Jewish General Hospital	Presenter	Yes	Oral	Disclosure made		Janssen; Abbvie; F. Hoffmann-La Roche Ltd; Pfizer			Janssen; Abbvie; F. Hoffmann-La Roche Ltd; Pfizer		Janssen; Pfizer				No	
Oral and Poster Abstracts	621. Lymphoma&#8"Genetic/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Single-Cell RNA Sequencing Identifies a Pseudo-Immune Differentiation Axis As the Main Source of Functional Heterogeneity in Follicular Lymphoma B-Cells	Noualpaud	Attaf		Centre d&#8"Immunologie de Marseille-Luminy (CIML), Aix Marseille Univ, CNRS, INSERM	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5		Keith	August	MD,MS	Children's Mercy Hospital	Moderator	No	Oral	Disclosure made						Novartis Pharmaceuticals					
Oral and Poster Abstracts	631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-Free Remission		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1.5	BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact	Shady	Awad	MD	Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	Paracrine Bone Morphogenetic Protein Signaling in Iron Homeostasis	Jodie	Babitt	MD	Massachusetts General Hospital	Speaker	Yes	Oral	Disclosure made		Keryx Biopharmaceuticals, Inc (now part of Akebia Therapeutics); Disc Medicine	Ferrumax Pharmaceuticals, Inc			Ferrumax Pharmaceuticals, Inc					No	
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	Paracrine Bone Morphogenetic Protein Signaling in Iron Homeostasis	Jodie	Babitt	MD	Massachusetts General Hospital	Speaker	Yes	Oral	Disclosure made		Keryx Biopharmaceuticals, Inc (now part of Akebia Therapeutics); Disc Medicine	Ferrumax Pharmaceuticals, Inc			Ferrumax Pharmaceuticals, Inc					No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)&#8"Results from Prospective Clinical Trials: Results from CAR T-Cell Trials		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)	Veronika	Bachanova	MD, PhD	University of Minnesota	Presenter	Yes	Oral	Disclosure made				Gamida Cell; GT Biopharma; Incyte; Celgene; Novartis				Kite; Seattle Genetics			No	
Oral and Poster Abstracts	704. Immunotherapies II		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Results of a Phase 1 Trial of Gde-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)	Veronika	Bachanova	MD, PhD	University of Minnesota	Presenter	Yes	Oral	Disclosure made				Gamida Cell; GT Biopharma; Incyte; Celgene; Novartis				Kite; Seattle Genetics			No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)	Pavan	Bachireddy	MD	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	904. Outcomes Research&#8"Non-Malignant Conditions II		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Home-Based Assessment of Patient Reported Outcome Measures Using a Smartphone App Platform: A Feasibility Study	Sherif	Badawy	MD	Ann & Robert H. Lurie Children&#8"s Hospital of Chicago, Feinberg School of Medicine Northwestern University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5		Nizar	Bahlis	MD	University of Calgary	Moderator	No	Oral	Disclosure made		Janssen; Celgene; Amgen; Takeda; AbbVie			Janssen; Celgene; Amgen; Takeda; AbbVie							
Oral and Poster Abstracts	621. Lymphoma&#8"Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	Deep Profiling of Genetic Alternations and Clonal Evolution in Follicular Lymphoma	Baoyan	Bai	PhD	Dalio Lrniversity Hospital	Presenter	Yes	Oral	Nothing to disclose											No	

Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Comparative Analyses		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Ashish	Bajel	FRACP	Royal Melbourne Hospital, Parkville	Moderator	No	Oral	Disclosure made								Abbvie; Pfizer			No	
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Three-D Models for Megakaryopoiesis and Platelet Production	Alessandra	Balduini	MD	University of Pavia	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Three-D Models for Megakaryopoiesis and Platelet Production	Alessandra	Balduini	MD	University of Pavia	Speaker	Yes	Oral	Nothing to disclose											No	
Meet the Scientist	Three-D Models for Megakaryopoiesis and Platelet Production		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Alessandra	Balduini	MD	University of Pavia	Speaker	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy	Brian	Ball		Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Molecular Drivers and Targets in Myeloproliferative Neoplasms		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)	Marpola	Balliu	PhD	CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi and Department of Experimental and Clinical Medicine, University of Florence	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	605. Molecular Pharmacology, Drug Resistance&#8"Lymphoid and Other Diseases		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Vendra	Banerji	MD	University of Manitoba and CancerCare Manitoba	Moderator	No	Oral	Disclosure made	CancerCare Manitoba/University of Manitoba	Janssen; Abbvie; Gilead; Astra-Zeneca		Janssen; Roche; Gilead; CIHR; LLSC; Research Manitoba; CCMF	Janssen; Roche; Abbvie; Gilead; Astra-Zeneca; CAPHO							
Oral and Poster Abstracts	636. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas&#8"Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)	Rajat	Bannerji	MD,PhD	Rutgers Cancer Institute of New Jersey	Presenter	Yes	Oral	Disclosure made		Abbvie, Inc; Abbvie, Inc; Celgene; Celgene; Regeneron Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.		Regeneron Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.						Yes	The data described in the abstract will report on use REGN1979 in a Phase 1 clinical trial of patients with B-NHL.
Oral and Poster Abstracts	605. Molecular Pharmacology, Drug Resistance&#8"Lymphoid and Other Diseases II		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism	Natalia	Baran	PhD,MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	A Phase 1/2 Study of Lintrabulib Utilituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)	Paul	Barr	MD	Wilmot Cancer Institute, University of Rochester	Presenter	Yes	Oral	Disclosure made		Pharmacyclics LLC, an AbbVie company; TG Therapeutics; Celgene; Merck; Seattle Genetics; Genentech; Verastem; Gilead; Astra Zeneca; Janssen; AbbVie		Pharmacyclics LLC, an AbbVie company; TG Therapeutics; Astra Zeneca						Yes	umbralisib and ublituximab as treatment of CLL
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma&#8"Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Nancy	Bartlett	MD	Washington University Sch. of Med: Siteman Cancer Center	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Novel Molecular Dependencies and Targets in Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease	Benjamin	Bunwick	PhD	Emory University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Benjamin	Bunwick	PhD	Emory University	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorder		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Qaiser	Bashir	MBBS	University of Texas MD Anderson Cancer Center	Moderator	No	Oral	Nothing to disclose												
General Sessions	Late-Breaking Abstracts Session		Tuesday, December 10, 2019	7:30 AM	9:00 AM	Yes	1.5		Elisabeth	Buettnelli	MD, PhD	Brigham and Women's Hospital	Co-chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT	Giorgia	Battipaglia	MD	Hematology Department, AR pital Saint Antoine, Service d'HÃ©matologie et ThÃ©rapie Cellulaire, Paris	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Special Symposium on Quality: ASH IQUIPS - Learning from Medical Errors and Other Incidents		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Abinav	Baweja	MD	University of California Irvine	Panelist	No	Oral	Nothing to disclose												
Special Scientific Symposia	Machine Learning in Hematology		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Machine Learning For Precision Medicine in Acute Myeloid Leukemia	Pamela	Becker	MD, PhD	University of Washington Institute for Stem Cell and Regenerative Medicine	Speaker	Yes	Oral	Disclosure made		Accordant Health Services/Caremark		Abbvie, Amgen, Bristol-Myers Squibb, Glycomimetics, Invivoscribe, JW Pharmaceuticals, Novartis, Trovagene	The France Foundation						Yes	
Special Scientific Symposia	Machine Learning in Hematology		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Pamela	Becker	MD, PhD	University of Washington Institute for Stem Cell and Regenerative Medicine	Chair	No	Oral	Disclosure made		Accordant Health Services/Caremark		Abbvie, Amgen, Bristol-Myers Squibb, Glycomimetics, Invivoscribe, JW Pharmaceuticals, Novartis, Trovagene	The France Foundation							
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Predicting Results		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Neili	Bejanyan	MD	Moffitt Cancer Center	Moderator	No	Oral	Disclosure made												
Oral and Poster Abstracts	636. Myelodysplastic Syndromes&#8"Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies	Ruger	Beltraine	MD, PhD	Brigham & Women's Hospital, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	801. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Pavan	Bendapudi	MD	Massachusetts General Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage	CamÃ©lia	Benlabiod		Gustave Roussy	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma&#8"Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma	N. Nora	Bennani	MD	Mayo Clinic	Presenter	Yes	Oral	Disclosure made				Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb								
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas&#8"Results from Retrospective/Observational Studies: Cellular Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium	N. Nora	Bennani	MD	Mayo Clinic	Presenter	Yes	Oral	Disclosure made				Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb							No	
Oral and Poster Abstracts	232. Anticoagulation and Antithrombotic Therapy I		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	In Vitro Effects of the Novel Platelet Toll&#8"2 Receptor Antagonist RUC-4 on the Verifynow Assays: Potential for Point-of-Care Monitoring of RUC-4 Therapy	Ohad	Bentur	MD	The Rockefeller University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results from Prospective Clinical Trials		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)	Jesus	Berdeja	MD	Sarah Cannon Research Institute	Presenter	Yes	Oral	Disclosure made		Amgen Inc, BioClinica, Celgene Corporation, CRISPR Therapeutics, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, Prothena, Servier, Takeda Oncology		AbbVie Inc, Amgen Inc, Acetylon Pharmaceuticals Inc, Bluebird Bio, Bristol-Myers Squibb Company, Celgene Corporation, Constellation Pharma, Curis Inc, Genentech, Glenmark Pharmaceuticals, Janssen Biotech Inc, Kesios Therapeutics, Lilly, Novartis, Poseida, Poseida							Yes	Yes, this was an investigational clinical study of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant-eligible patients newly diagnosed with multiple myeloma.
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chemo Immuno and Targets--Improving Combinations in ALL		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Julie	Bergeron	MD	CEMTL installation Maisonneuve-Rosemont	Moderator	No	Oral	Disclosure made		Celgene; Abbvie; Novartis; Astellas; AVR pharma; Novartis			JAZZ pharma; Novartis; Amgen							
How I Treat: Bringing Science to Clinical Dilemmas	What&#8"s New in the Diagnosis and Treatment of HLH?		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Nancy	Berliner	MD	Brigham and Women's Hospital	Speaker	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	637. Myelodysplastic Syndromes&#8"Clinical Studies: Targeting Gene Mutations in MDS		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes	Elsa	Bernard	PhD	Memorial Sloan-Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made				Celgene							No	
Scientific Program	Chromatin Structure in Development and Disease		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Kathrin	Bernt	MD	Children's Hospital of Philadelphia	Chair	No	Oral	Disclosure made		Agios										
Scientific Program	Chromatin Structure in Development and Disease		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Kathrin	Bernt	MD	Children's Hospital of Philadelphia	Chair	No	Oral	Disclosure made		Agios										
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Chromatin Structure in Development and Disease		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Kathrin	Bernt	MD	Children's Hospital of Philadelphia	Chair	No	Oral	Disclosure made		Agios										
Oral and Poster Abstracts	802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High Throughput Screening		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Kathrin	Bernt	MD	Children's Hospital of Philadelphia	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Chimeric Antigen Receptor Modified Memory-like (CAR-M) NK Cells Exhibit Potent Responses to NK-Resistant Tumors	Melissa	Berrien-Elliott	PhD	Washington University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2		Alison	Bertuch	MD, PhD	Baylor College of Medicine	Co-Chair	No	Oral	Nothing to disclose												
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Sunday, December 8, 2019	9:30 AM	11:30 AM	Yes	2		Alison	Bertuch	MD, PhD	Baylor College of Medicine	Co-Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	231. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Incidence, Natural History and Outcomes of Transient and Persistent Antiphospholipid Antibodies in Children and Young Adults with Provoked Venous Thromboembolism: Analysis of the Kids-DOTT Trial	Marisol	Betensky	MD,MPH	Johns Hopkins All Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Comparative Analyses		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease	Evandro	Bezerra	MD	University of Washington	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Breakthroughs in Preclinical Development of Aleukemin (PTC124) As Therapeutic Option for Patients Affected by Shwachman-Diamond Syndrome: Towards the First Clinical Trial	Valentino	Bezzerri	PhD	Azienda Ospedaliero Universitaria Ospedali Riuniti	Presenter	Yes	Oral	Disclosure made											No	
Oral and Poster Abstracts	802. Health Services Research&#8"Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Impact of Competing Treatment Scenarios on Lifetime Disease Burden and Quality Adjusted Life Expectancy (QALE) Among Survivors of High-Risk Childhood Hodgkin Lymphoma (HR-HL): A Modeling Study Based on the St. Jude Lifetime (SJLIFE) Cohort	Nickhill	Bhakta		St. Jude Children's Research Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Why Patients Fail After Allogeneic Stem Cell Transplantation		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Late Mortality without Relapse	Smita	Bhatia	MD,MPH	University of Alabama at Birmingham	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Why Patients Fail After Allogeneic Stem Cell Transplantation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Late Mortality without Relapse	Smita	Bhatia	MD,MPH	University of Alabama at Birmingham	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Smita	Bhatia	MD,MPH	University of Alabama at Birmingham	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chemo Immuno and Targets--Improving Combinations in ALL		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Bhavana	Bhatnagar	DO	The Ohio State University	Moderator	No	Oral	Disclosure made		Novartis and Astellas			Novartis and Astellas							

Special-Interest Sessions	TRTH Scientific Symposium: A Decade of Training the Future Leaders in Translational Research		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2	TRTH Symposium: A Decade of Training the Future Leaders in Translational Research	Ami	Bhatt	MD, PhD	Stanford University	Speaker	Yes	Oral	Disclosure made		Kaleido Biosciences; Janssen Human Microbiome Institute		Agilent	Illumina						No	
Oral and Poster Abstracts	906. Outcomes Research†Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)	Neel	Bhatt		St. Jude Children's Research Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Innovative Approaches in Allogeneic Transplantation for Pediatric or Nonmalignant Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Sima	Bhatt	MD	Washington University in St. Louis	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	635. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML)	Vijaya	Bhatt	MD	University of Nebraska Medical Center	Presenter	Yes	Oral	Disclosure made		Pfizer; CSL Behring; Agios; Abbvie; Partner therapeutics; Incyte; National Marrow Donor Program		Incyte; Tolero Pharmaceuticals							Yes	Single agent azacitidine and decitabine as well as decitabine in combination with midostaurin are not approved by the US FDA for acute myeloid leukemia.
Oral and Poster Abstracts	653. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche	Giade	Bianchi	MD	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of Pathogenesis, Drug Sensitivity, and Resistance; and Role of Bone Marrow Microenvironment and Host Microbiome in Myeloma Pathogenesis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Giade	Bianchi	MD	Dana-Farber Cancer Institute	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia†Clinical: Emerging Therapies: Reports from Recent Clinical Trials		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis: A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)	Bart	Biemond	MD, PhD	Amsterdam UMC, Academic Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic Factors and Evaluation of Therapy Response in AML		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge-Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols	Marius	Gill	MD, PhD	The Ohio State University, Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	802. Health Services Research†Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Adam	Binder	MD	Sidney Kimmel Cancer Center, Thomas Jefferson University	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	805. Outcomes Research†Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States	Moritz	Binder	MD,MPH	Mayo Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Noa	Biran	MD	John Theurer Cancer Center, Hackensack Meridian Health, Division of Multiple Myeloma	Moderator	No	Oral	Disclosure made		Amgen; Janssen; Celgene; Takeda		Amgen; Merck; Janssen; Bristol Meyers Squibb	Amgen; Janssen; Celgene; Takeda							
Oral and Poster Abstracts	203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hemophagocytic Lymphohistiocytosis and Other Immune Disorders		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Genetic of Sporadic Hemophagocytic Lymphohistiocytosis	Coralie	Bloch	MD, PhD	Institut Imagine, Institut des maladies g‚n‚tiques, INSERM U1163/CNRS ERL 8254 and INSERM UMR-S1134 * Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	805. Outcomes Research†Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era	Nicholas	Boddicker	PhD	Mayo Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	No Evidence for Hematopoietic Stem Cell Self-Renewal in Vivo Following Inflammatory Challenge	Ruzhica	Bogdeska	PhD	German Cancer Research Center (DKFZ)	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	605. Molecular Pharmacology, Drug Resistance†Lymphoid and Other Diseases: II		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Exome Sequencing of Relapsed Multiple Myeloma Combined with Pooled CRISPR/Cas9 Screens Identifies Gene Mutations Associated with Drug-Specific Resistance	Stephan	Buhl		Ulm University Hospital	Presenter	Yes	Oral	Disclosure made					Pfizer						No	
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Preclinical Models, Immunotherapy, and CAR-T Cells		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Riccardo	Bumben	PhD	IRCCS Centro Di Riferimento Oncologico	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma†Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma	David	Bond	MD	The Ohio State University Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hemophagocytic Lymphohistiocytosis and Other Immune Disorders		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Challice	Bonifant	MD,PhD	Johns Hopkins University School of Medicine	Moderator	No	Oral	Disclosure made													
Oral and Poster Abstracts	652. Myeloma: Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma	Cecilia	Bonolo De Campos	PhD	Mayo Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	627. Myelodysplastic Syndromes†Clinical Studies: Combination Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)	Uma	Borate	MD	Oregon Health & Science University	Presenter	Yes	Oral	Disclosure made		Novartis; Takeda; Pfizer; Daiichi Sankyo; AbbVie; Agios		Incyte							Yes	MBG453 is an investigational anti-TIM-3 antibody that is being evaluated in hematological malignancies and solid tumors
Oral and Poster Abstracts	803. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial	Uma	Borate	MD	Oregon Health & Science University	Presenter	Yes	Oral	Disclosure made		Novartis; Takeda; Pfizer; Daiichi Sankyo; AbbVie; Agios		Incyte							No	
Oral and Poster Abstracts	805. Outcomes Research†Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Uma	Borate	MD	Oregon Health & Science University	Moderator	No	Oral	Disclosure made		Novartis; Takeda; Pfizer; Daiichi Sankyo; AbbVie; Agios		Incyte									
Education Program	Immunotherapy in Myeloma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	It's Not All CAR-T. Other Cellular Therapy in Myeloma	Ivan	Borrello	MD	Johns Hopkins University	Speaker	Yes	Oral	Disclosure made		BMS	WindMIL Therapeutics	WindMIL Therapeutics; Celgene	Celgene	WindMIL Therapeutics	Celgene				Yes	Use of MILs and other cell sources for therapy in the treatment of myeloma
Education Program	Immunotherapy in Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	It's Not All CAR-T. Other Cellular Therapy in Myeloma	Ivan	Borrello	MD	Johns Hopkins University	Speaker	Yes	Oral	Disclosure made		BMS	WindMIL Therapeutics	WindMIL Therapeutics; Celgene	Celgene	WindMIL Therapeutics	Celgene				Yes	Use of MILs and other cell sources for therapy in the treatment of myeloma
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Cladarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)	Gautam	Borthakur	MD	University of Texas MD Anderson Cancer Center, Department of Leukemia	Presenter	Yes	Oral	Disclosure made		BioLine Rx; NKarta; PTC Therapeutics		AbbVie; Incyte; Janssen; GSK; Cyclacel; BioLine Rx; Oncoceutics, Inc.; Eli Lilly and Co.; BMS; AstraZeneca; Bayer Healthcare AG; Aptenyo; Oncoceutics; Novartis; Xbiotech USA; Eisai; Tetralogic Pharmaceuticals; Strategia Therapeutics; Polaris; Avinao; Merck; Cantargia AB				BioLine Rx; FTC Therapeutics; Argenx; BioTheryX		No	
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Biomarker Modulation By Mivebresib (ABBV-075) +/†" Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia	Gautam	Borthakur	MD	University of Texas MD Anderson Cancer Center, Department of Leukemia	Presenter	Yes	Oral	Disclosure made		BioLine Rx; NKarta; PTC Therapeutics		AbbVie; Incyte; Janssen; GSK; Cyclacel; BioLine Rx; Oncoceutics, Inc.; Eli Lilly and Co.; BMS; AstraZeneca; Bayer Healthcare AG; Aptenyo; Oncoceutics; Novartis; Xbiotech USA; Eisai; Tetralogic Pharmaceuticals; Strategia Therapeutics; Polaris; Avinao; Merck; Cantargia AB				BioLine Rx; FTC Therapeutics; Argenx; BioTheryX		No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical JAK Inhibitors and Combination Therapies		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Prithviraj	Bose	MD	MD Anderson Cancer Center	Moderator	No	Oral	Disclosure made		Incyte Corporation; Celgene Corporation; Blueprint Medicine Corporation; Kartos		Incyte Corporation; Celgene Corporation; Blueprint Medicine Corporation; Kartos; Constellation; Pfizer; Astellas; NS Pharma; Promedior; CTI BioPharma			Incyte Corporation					
Oral and Poster Abstracts	653. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes	Cirino	Botta	MD	University of Catanzaro	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Vassiliki	Boussiotis	MD, PhD	Beth Israel Deaconess Medical Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma†"Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)	Paul	Boll¶Kelmann	MD	Center for Integrated Oncology Aachen Bonn Cologne D‚sseldorf (CIO ABCD), University of Cologne	Presenter	Yes	Oral	Disclosure made		Takeda		Bristol-Myers Squibb; Takeda; MSD Sharpe & Dohme	Bristol-Myers Squibb; Takeda						Yes	Nivolumab 240mg i.v. 2-weekly for 1st-line treatment of classical Hodgkin lymphoma.
Oral and Poster Abstracts	321. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Identification of a Spontaneous Noncoding Mutation on Chromosome 18 Which Suppresses Thrombosis in Factor V Leiden Homozygous, TFPI Deficient Mice	Marisa	Brake	BSc	Oakland University	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	New Diagnostic and Treatment Strategies for Antiphospholipid Syndrome		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	What's New in Obstetric Antiphospholipid Syndrome?	D.	Branch	MD	University of Utah Health	Speaker	Yes	Oral	Disclosure made				UCB Pharmaceuticals									
Education Program	New Diagnostic and Treatment Strategies For Antiphospholipid Syndrome		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	What's New in Obstetric Antiphospholipid Syndrome?	D.	Branch	MD	University of Utah Health	Speaker	Yes	Oral	Disclosure made				UCB Pharmaceuticals									
Scientific Program	From Blood to Single Cells: Emerging Concepts and Technologies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Understanding Erythropoiesis Using Quantitative Proteomics and Single Cell Mass Cytometry	Marjorie	Brand	PhD	Ottawa Hospital Research Institute	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	From Blood to Single Cells: Emerging Concepts and Technologies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Understanding Erythropoiesis Using Quantitative Proteomics and Single Cell Mass Cytometry	Marjorie	Brand	PhD	Ottawa Hospital Research Institute	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	703. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD and Thymus Regeneration: Role of Innate Cells and Non-Hematopoietic Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	DR1 and DR4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of GvHd	Joshua	Brandstadter	MD, PhD	University of Pennsylvania	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Single Cell RNA Sequencing Identifies a Crucial Role for ADAL1 in Neutrophil Development	Theodore	Braun	MD,PhD	Oregon Health & Science University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)†"Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Elizabeth	Brem	MD	UC Irvine Medical Center	Moderator	No	Oral	Disclosure made					Pharmacyclics; Janssen; Bayer; Genetech; Celgene; BMS/Pfizer		Pharmacyclics; Janssen; Celgene						
Oral and Poster Abstracts	802. Health Services Research†Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries	Edward	Brercheck	MD	University of Washington - Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Nothing to disclose											No	

Special-Interest Sessions	Special Symposium on Quality: ASH EQUIPS - Learning from Medical Errors and Other Incidents		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	The Culture of Quality and Incident Learning â€" Nationwide Childrenâ€™s Hospital	Richard	Brilli		Nationwide Children's Hospital	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Advances in ITP Therapy		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies	Catherine	Broome	MD	MedStar Georgetown University Hospital	Presenter	Yes	Oral	Disclosure made				Alexion; Sanofi Genzyme; Rigel; Celgene; Incyte	Alexion; Sanofi Genzyme						No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Microbiome and Immune Evaluation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	*Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide*	Benedetto	Bruno	MD	University of Torino	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Francesco	Bucciano	MD	University Tor Vergata	Moderator	No	Oral	Disclosure made		Novartis					Novartis	Novartis; Janssen; Astellas				
Education Program	Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Integrating Patient-Centered Factors in the Risk Assessment of MDS	Rena	Buckstein	MD, FRCPC	Sunnybrook Odette Cancer Center	Speaker	Yes	Oral	Disclosure made		Celgene		Celgene; Takeda	Celgene						No	
Education Program	Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Integrating Patient-Centered Factors in the Risk Assessment of MDS	Rena	Buckstein	MD, FRCPC	Sunnybrook Odette Cancer Center	Speaker	Yes	Oral	Disclosure made		Celgene		Celgene; Takeda	Celgene						No	
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Speaker 3	Rena	Buckstein	MD, FRCPC	Sunnybrook Odette Cancer Center	Speaker	Yes	Oral	Disclosure made		Celgene		Celgene; Takeda	Celgene						No	
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial	Amy	Burd	PhD	Leukemia and Lymphoma Society	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR-B-ALL): Report from the Childrenâ€™s Oncology Group Study AALL0232	Michael	Burke	MD	Medical College of Wisconsin	Presenter	Yes	Oral	Disclosure made		Amgen, Inc.					Amgen, Inc.					No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 â€" a Retrospective Study From the LAVA GIMOT	Claire	Burney	MRBS	University Hospitals Bristol	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Phase II Trial of the Combination of ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma	Mark	Bustoros, MD		Harvard Medical School	Presenter	Yes	Oral	Disclosure made					Takeda						Yes	Ixazomib, Lenalidomide and Dexamethasone is an investigational combination in high-risk smoldering multiple myeloma and has not been approved by the US Food and Drug Administration or any other regulatory agency worldwide for the use under investigation.
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Michael	Byrne	DO	Vanderbilt University Medical Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Epigenetic Alteration		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Ev1-Dependent Mechanism	Sheng	Cai	MD,PhD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made		Imago Biosciences, Inc.										No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Advances in Understanding the Pathophysiology of AML		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Lncrna *Morrbid* Regulates Myeloid Cell Survival of AML Driven By a Combination of A1/A1D and Epigenetic Mutations	Zhigang	Cai	PhD	Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	901. Health Services Researchâ€"Non-Malignant Conditions: Improving Quality in Hematology		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Cecelia	Calhoun	MD	Washington University School of Medicine	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Cxcl8 Expands Hematopoietic Stem and Progenitor Cells and Alters Their Interaction with the Endothelial Niche	Donn	Calkins	BS	The Ohio State University Comprehensive Cancer Center and Division of Hematology	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5		Jose	Cancelas	MD	Univ. of Cincinnati	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study	Jinsin	Cao		Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Presenter	Yes	Oral	Nothing to disclose												No	Q/A
Oral and Poster Abstracts	506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Nadia	Carlesso	MD	Beckman Research Institute At City of Hope	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Carmelo	Carlo-Stella	MD	Humanitas Clinical and Research Center IRCCS	Presenter	Yes	Oral	Disclosure made		Boehringer Ingelheim; Genentia Science srl; Sanofi; ADC Therapeutics; Novartis; Servier		Sanofi; ADC Therapeutics; Novartis; F. Hoffmann-La Roche Ltd; Rhizen Pharmaceuticals; Celgene	Servier; F. Hoffmann-La Roche Ltd; Amgen; AstraZeneca; Janssen Oncology; MSD; BMS						No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphomas â€"Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma	Carmelo	Carlo-Stella	MD	Humanitas University	Presenter	Yes	Oral	Disclosure made		Boehringer Ingelheim; Genentia Science srl; Sanofi; ADC Therapeutics; Novartis; Servier		Sanofi; ADC Therapeutics; Novartis; F. Hoffmann-La Roche Ltd; Rhizen Pharmaceuticals; Celgene	Servier; F. Hoffmann-La Roche Ltd; Amgen; AstraZeneca; Janssen Oncology; MSD; BMS						No	
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Update from the Clinic: What's New in the Treatment of Cancer-Associated Thrombosis?	Marc	Carrier	MD	University of Ottawa	Speaker	Yes	Oral	Disclosure made				Leo Pharma; BMS; Pfizer	Leo Pharma; BMS; Pfizer; Bayer; Servier						No	
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Update from the Clinic: What's New in the Treatment of Cancer-Associated Thrombosis?	Marc	Carrier	MD	University of Ottawa	Speaker	Yes	Oral	Disclosure made				Leo Pharma; BMS; Pfizer	Leo Pharma; BMS; Pfizer; Bayer; Servier						No	
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Marc	Carrier	MD	University of Ottawa	Chair	No	Oral	Disclosure made				Leo Pharma; BMS; Pfizer	Leo Pharma; BMS; Pfizer; Bayer; Servier							
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Marc	Carrier	MD	University of Ottawa	Chair	No	Oral	Disclosure made				Leo Pharma; BMS; Pfizer	Leo Pharma; BMS; Pfizer; Bayer; Servier							
How I Treat: Bringing Science to Clinical Dilemmas	Implementation of Direct Oral Anticoagulant Reversal Agents in the Critical Care Setting		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Marc	Carrier	MD	University of Ottawa	Speaker	No	Oral	Disclosure made				Leo Pharma; BMS; Pfizer	Leo Pharma; BMS; Pfizer; Bayer; Servier							
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Topic 3: Sickle Cell Disease-Related Pain	Patrick	Carroll	MD	The Johns Hopkins Hospital	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors	Fausto	Castagnetti	MD, PhD	Institute of Hematology "L. e A. Serâ€gnoli", University of Bologna	Presenter	Yes	Oral	Disclosure made		Bristol Myers Squibb			Novartis; Incyte; Pfizer; Bristol Myers Squibb						Yes	Bosutinib is a second generation TKI already registered for the treatment of adult patients with chronic phase CML with resistance or intolerance to prior therapy. In the present study the initial dose is 200 mg instead of 500 mg OAD. A dose increase to 300 or 400 mg is scheduled according to molecular response and tolerability
Oral and Poster Abstracts	205. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: New Concepts and Perspectives		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm	Melissa	Castiglione	BS	Stony Brook School of Medicine	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genomic Landscape and Disease Classification		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Giovanni	Cazzaniga	PhD	Clinica Pediatrica Univ. Milano Bicocca Ospedale San Gerardo	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	622. Lymphoma Biology â€"Non-Genetic Studies: Tumor Microenvironment		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling	Leandro	Cerchietti	MD	Weill Cornell Medicine	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Novel Molecular Dependencies and Targets in Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Recurrent Non-Coding Mutations in BCL7A May Have Significant Functional Consequence in Multiple Myeloma	Chandradilipa	Chakraborty	PhD	Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemiaâ€"Clinical: Predicting Risk: A Focus on Disease Severity and Fertility		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	High Levels of Peripheral Vasoconstriction Detected By Polysomnography Predict More Acute Severe Pain Episodes in Children with Sickle Cell Anemia	Pelpanapom	Chalachewa	PhD	University of Southern California	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS	Richard	Champlin	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Actinium; Johnson and Johnson		Sanofi-Genzyme								Yes	Clofarabine and fludarabine for hematopoietic transplantation
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: Fusion Genes		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias	Anthony	Chen	PhD	City of Hope National Medical Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	605. Molecular Pharmacology, Drug Resistance â€"Lymphoid and Other Diseases		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Lei	Chen		Department of Systems Biology, City of Hope Comprehensive Cancer Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Impact of TP53 gene Mutation-Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation	Onyee	Chen	MD	Moffitt Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	625. Lymphoma: Pre-Clinical â€"Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Ajseern	Chapuy	MD,PhD	Dana-Faber Cancer Institute	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Shruti	Chaturvedi	MRBS,MS	Johns Hopkins University School of Medicine	Moderator	No	Oral	Disclosure made				Sanofi; Alexion		Shire/Takeda							
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results from Prospective Clinical Trials		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Maria	Chaudhry	MD	The Ohio State University	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	503. Clonal Hematopoiesis: Aging and Inflammation		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation	James	Chavez	BS	University of Colorado Anschutz Medical Campus	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Chan Yoon	Cheah	MRBS,MD	NW Cancer Centre	Moderator	No	Oral	Disclosure made				Roche; Gilead; Abbvie; Celgene	Roche; Janssen; MSD; Gilead; Acerta; Loxo Oncology; TG Therapeutics		Roche; Janssen; MSD; Gilead; Acerta; Loxo Oncology; TG Therapeutics					
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma	Christine	Chen	MD	Princess Margaret Cancer Centre	Presenter	Yes	Oral	Disclosure made				Celgene; Janssen	Celgene; Janssen; Amgen						No	
Special-Interest Sessions	78TH Scientific Symposium: A Decade of Training the Future Leaders in Translational Research		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2	Dissecting the DOT1L Epigenetic Networks In MLL-Rearranged Leukemia Using High-Throughput Functional Genomics	Chun-Wei	Chen	PhD	City of Hope National Medical Center	Speaker	Yes	Oral	Nothing to disclose												No	

Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Mechanisms of and Therapies for cGVHD		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Efficacy of Mesenchymal Stem Cells in Bronchiolitis Obliterans Syndrome after Allogeneic HSCT: A Multicenter Prospective Cohort Study	Shan	Chen	MD	Nanfang Hospital, Southern Medical University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	621. Lymphomas&#8^Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis.		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Selina	Chen-Kiang	PhD	Weill-Cornell Medical College	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	The Burden of Clinically Significant Bleeding, Thrombocytopenia and Platelet Transfusions in Myelodysplastic Syndromes	Kathleen	Cheok	MBBS	Royal Adelaide Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	My Metabolism and Myelopoiesis		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Metabolic Control and Systems Immunology in Blood Cell Development	Hongbo	Chi	PhD	St. Jude Children's Research Hospital	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	My Metabolism and Myelopoiesis		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Metabolic Control and Systems Immunology in Blood Cell Development	Hongbo	Chi	PhD	St. Jude Children's Research Hospital	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	901. Health Services Research&#8^Non-Malignant Conditions: Bleeding and Blood Loss		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Heavy Menstrual Bleeding Under-Recognized in Menstruating Women Treated with Oral Anticoagulants	Vivia	Chi	Medical Student	OREGON HEALTH & SCIENCE UNIVERSITY	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chemo Immuno and Targeted—Improving Combinations in ALL		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-ABlo Trial	Sabina	Chiaretti	MD, PhD	Sapienza University, Division of Hematology	Presenter	Yes	Oral	Disclosure made									Incyte; Shire; Amgen; Pfizer		No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)&#8^Results from Prospective Clinical Trials: Results from CAR T-Cell Trials		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Collin	Chin	MBBS	Peter MacCallum Cancer Centre	Moderator	No	Oral	Nothing to disclose												
Education Program	Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Systemic Autoimmune Diseases - Lessons for the Practicing Hematologist	R.	Chinthrajah	MD	Stanford University	Speaker	Yes	Oral	Nothing to disclose												
Education Program	Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Systemic Autoimmune Diseases - Lessons for the Practicing Hematologist	R.	Chinthrajah	MD	Stanford University	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	636. Myelodysplastic Syndromes&#8^Basic and Translational Studies: RNA Processing and Signatures in MDS		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	The Inherited MDS Gene DDX41 Is Required for Ribosome Biogenesis and Cell Viability	Timothy	Chien	PhD	Cincinnati Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Tarantine Apoptosis in Myeloma		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Wee-Joo	Chng	MBBS, PhD	National University Cancer Institute	Chair	No	Oral	Nothing to disclose												
Scientific Program	Tarantine Apoptosis in Myeloma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Wee-Joo	Chng	MBBS, PhD	National University Cancer Institute	Chair	No	Oral	Nothing to disclose												
Special-Interest Sessions	78TH Scientific Symposium: A Decade of Training the Future Leaders in Translational Research		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2		Rajesh	Chopra	MD	Institute of Cancer Research	Co-chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	645. CLL: Biology and Pathophysiology, excluding Therapy: Preclinical Models, Immunotherapy, and CAR T Cells		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice	Charles	Chu	PhD	University of Rochester Medical Center	Presenter	Yes	Oral	Disclosure made				Pfizer	Acerta Pharma							
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study	Chang Chyn	Chua	MBBS	The Alfred Hospital and Monash University	Presenter	Yes	Oral	Nothing to disclose											Yes	Venetoclax is a BCL-2 inhibitor that is FDA-approved in some indications. This presentation will focus on correlative study results in the CAVEAT trial which combines venetoclax with modified intensive chemotherapy in AML, which is not an approved indication.
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Risk Stratification and Novel Approaches to Reduce Toxicity in Allogeneic Transplantation		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis	Stefan	Ciurea	MD	The Univ. of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made					Miltenyi				Kiadis Pharma; MoMed; Spectrum		No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls	Stefan	Ciurea	MD	The Univ. of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made					Miltenyi				Kiadis Pharma; MoMed; Spectrum		No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy; Predictors of TKI Discontinuation and TFR Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)	Simone	Claudiani	MD	Hammersmith Hospital, Imperial College NHS Trust	Presenter	Yes	Oral	Disclosure made							Pfizer; Incyte				No	
Education Program	Why Patients Fail After Allogeneic Stem Cell Transplantation		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Minimal Residual Disease and Stem Cell Transplantation Outcomes	Jacqueline	Cloos	PhD	Amsterdam UMC, Location VUMC	Speaker	Yes	Oral	Disclosure made		Genentech			Takeda; Novartis; Merus; Genentech; Glycomimetics				Daiichi Sankyo		No	
Education Program	Why Patients Fail After Allogeneic Stem Cell Transplantation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Minimal Residual Disease and Stem Cell Transplantation Outcomes	Jacqueline	Cloos	PhD	Amsterdam UMC, Location VUMC	Speaker	Yes	Oral	Disclosure made		Genentech			Takeda; Novartis; Merus; Genentech; Glycomimetics				Daiichi Sankyo		No	
Oral and Poster Abstracts	627. Myelodysplastic Syndromes&#8^Clinical Studies: Targeting Gene Mutations in MDS		Monday, December 9, 2019	10:30 AM	12:30 PM	Yes	1.5	APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): a Phase 2 Study By the Groupe Francophone des Myélodysplasies (GFM)	Thomas	Cluzeau	MD,PhD	Cote D&#^Azur University	Presenter	Yes	Oral	Disclosure made					Menarini; Abbvie; Jazz Pharma							No
Education Program	IRON: How to Manage When There is Too Much or Too Little of It		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Iron Overload in Transfusion-Dependent Patients	Thomas	Coates	MD	Children's Hospital Los Angeles	Speaker	Yes	Oral	Disclosure made		apo pharma; vifor; agios pharma; celgene					apo pharma; vifor; agios pharma; celgene		apo pharma			Yes	I will discuss use of combinations of iron chelators and dosing schedules that are commonly used but not mentioned in the package inserts. I will make this clear in the talk and in the paper.
Education Program	IRON: How to Manage When There is Too Much or Too Little of It		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Iron Overload in Transfusion-Dependent Patients	Thomas	Coates	MD	Children's Hospital Los Angeles	Speaker	Yes	Oral	Disclosure made		apo pharma; vifor; agios pharma; celgene					apo pharma; vifor; agios pharma; celgene		apo pharma			Yes	I will discuss use of combinations of iron chelators and dosing schedules that are commonly used but not mentioned in the package inserts. I will make this clear in the talk and in the paper.
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Maturation and Enucleation		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Theresa	Coetzer	PhD	Univ. of the Witwatersrand	Moderator	No	Oral	Nothing to disclose												
Education Program	Immunotherapy in Myeloma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Myeloma: Next Generation Immunotherapy	Adam	Cohen	MD	University of Pennsylvania	Speaker	Yes	Oral	Disclosure made					Poseida Therapeutics, Inc.						Yes	Pembrolizumab
Education Program	Immunotherapy in Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Myeloma: Next Generation Immunotherapy	Adam	Cohen	MD	University of Pennsylvania	Speaker	Yes	Oral	Disclosure made					Poseida Therapeutics, Inc.						Yes	Pembrolizumab
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Adam	Cohen	MD	University of Pennsylvania	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	901. Health Services Research&#8^Non-Malignant Conditions: Cancers and Thrombosis		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Safety and Effectiveness of Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients with Active Cancer: A Retrospective Analysis Using Four US Claims Databases	Alexander	Cohen	MBBS, MSc, MD	Guys and St Thomas/NHS Foundation Trust	Presenter	Yes	Oral	Disclosure made		AbbVie; ACI Clinical; Aspen; Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; Boston Scientific; CSL Behring; Daiichi-Sankyo; GlaxoSmithKline; GLG; Guidepoint Global; Johnson and Johnson; Leo Pharma; Medscape; McKinsey; Navigant; ONO; Pfizer; Portola; Sanofi; Takeda; Temasek Capital; TRN		Bayer; Bristol-Myers Squibb	Bayer; Bristol-Myers Squibb		Aspen; Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; Daiichi-Sankyo; GlaxoSmithKline; Johnson and Johnson; Medscape; Pfizer; Portola	Bayer; Bristol-Myers Squibb; Daiichi-Sankyo; Johnson and Johnson; ONO; Pfizer; Portola; Sanofi		No	
Oral and Poster Abstracts	901. Health Services Research&#8^Non-Malignant Conditions: Cancers and Thrombosis		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Safety and Effectiveness of Apixaban, LMWH and Warfarin Among Venous Thromboembolism (VTE) Patients with Active Cancer: A Subgroup Analysis of VTE Risk Scale	Alexander	Cohen	MBBS, MSc, MD	Guys and St Thomas/NHS Foundation Trust	Presenter	Yes	Oral	Disclosure made		AbbVie; ACI Clinical; Aspen; Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; Boston Scientific; CSL Behring; Daiichi-Sankyo; GlaxoSmithKline; GLG; Guidepoint Global; Johnson and Johnson; Leo Pharma; Medscape; McKinsey; Navigant; ONO; Pfizer; Portola; Sanofi; Takeda; Temasek Capital; TRN		Bayer; Bristol-Myers Squibb	Bayer; Bristol-Myers Squibb		Aspen; Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; Daiichi-Sankyo; GlaxoSmithKline; Johnson and Johnson; Medscape; Pfizer; Portola	Bayer; Bristol-Myers Squibb; Daiichi-Sankyo; Johnson and Johnson; ONO; Pfizer; Portola; Sanofi		No	
Oral and Poster Abstracts	636. Myelodysplastic Syndromes&#8^Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Simona	Colla	PhD	The University of Texas MD Anderson Cancer Center	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	645. CLL: Biology and Pathophysiology, excluding Therapy: Preclinical Models, Immunotherapy, and CAR T Cells		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia	McKenzie	Collins	BS	University of Pennsylvania	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	102. Regulation of Iron Metabolism: Novel Players in Iron Homeostasis in Health and Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Sensing of Liver Iron Content Requires Cell-Cell Communication between Hepatocytes and Liver Sinusoidal Endothelial Cells	Silvia	Colucci		University of Heidelberg	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Systems-Based Hematology: How to Implement Evidence-Based Programs for Virtual Hematology Consults and Anticoagulation Stewardship		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	1	Introduction to Systems-Based Hematology	Nathan	Connell	MD, MPH	Brigham and Women's Hospital	Speaker	Yes	Oral	Nothing to disclose												
Special-Interest Sessions	Systems-Based Hematology: How to Implement Evidence-Based Programs for Virtual Hematology Consults and Anticoagulation Stewardship		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	1		Nathan	Connell	MD, MPH	Brigham and Women's Hospital	Chair	No	Oral	Nothing to disclose												
Education Program	Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Managing the Competing Risks of Thrombosis, Bleeding, and Anticoagulation in Patients with Malignancy	Jean	Connors	MD	Brigham & Women's Hospital/Dana Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made		Bristol Myer-Squibb; Abbott; Eli Lilly									No	
Education Program	Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Managing the Competing Risks of Thrombosis, Bleeding, and Anticoagulation in Patients with Malignancy	Jean	Connors	MD	Brigham & Women's Hospital/Dana Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made		Bristol Myer-Squibb; Abbott; Eli Lilly									No	
Special-Interest Sessions	Systems-Based Hematology: How to Implement Evidence-Based Programs for Virtual Hematology Consults and Anticoagulation Stewardship		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	1	How I Setup an Anticoagulation Management and Stewardship Program	Jean	Connors	MD	Brigham & Women's Hosp./Dana Farber Cancer Inst.	Speaker	Yes	Oral	Disclosure made		Bristol Myer-Squibb; Abbott; Eli Lilly									No	
Education Program	Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Jean	Connors	MD	Brigham & Women's Hospital/Dana Farber Cancer Institute	Chair	No	Oral	Disclosure made		Bristol Myer-Squibb; Abbott; Eli Lilly									No	
Education Program	Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Jean	Connors	MD	Brigham & Women's Hospital/Dana Farber Cancer Institute	Chair	No	Oral	Disclosure made		Bristol Myer-Squibb; Abbott; Eli Lilly									No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Mechanisms of Iron Clearance from the joint in FVIII-Deficient Mice after Induced Hemarthrosis	Esther	Cooke	PhD	University of California San Diego	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Mechanisms of and Therapies for cGVHD		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Kenneth	Cooke	MD	The Sidney Kimmel Comp. Cancer Center At Johns Hopkins	Moderator	No	Oral	Disclosure made					Jazz pharmaceuticals	Jazz pharmaceuticals		Jazz pharmaceuticals	Jazz pharmaceuticals			
Special Scientific Symposia	Machine Learning in Hematology		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Using Machine Learning to Improve Histological Diagnoses of Hematologic Malignancies	Lee	Cooper	PhD, MS	Northwestern University Feinberg School of Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Immune Thrombocytopenia		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Speaker 4	Nichola	Cooper	MD, MRCP	Hammersmith Hospital, Imperial College	Speaker	Yes	Oral	Nothing to disclose												

Oral and Poster Abstracts	622. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial	Mhairi	Copland	PhD, MBBChir, FRCP, FRCPath	University of Glasgow	Presenter	Yes	Oral	Disclosure made				Incyte; Cyclacel	Incyte; Bristol-Myers Squibb; Novartis; Pfizer; Astellas		Incyte; Bristol-Myers Squibb; Novartis; Pfizer; Astellas	Incyte; Bristol-Myers Squibb; Novartis; Pfizer		Yes	Ponatinib is a tyrosine kinase inhibitor (TKI). It is licensed to treat: - chronic myeloid leukaemia where the leukaemic cells have gene change (mutation) called T315I - acute lymphoblastic leukaemia that has an abnormal chromosome called the Philadelphia chromosome, or has the T315I mutation
Scientific Program	Mx Metabolism and Myelopoiesis		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Seth	Corey	MD	Cleveland Clinic	Chair	No	Oral	Nothing to disclose													
Scientific Program	Mx Metabolism and Myelopoiesis		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Seth	Corey	MD	Cleveland Clinic	Chair	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	903. Health Services Research	Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)	Jorge	Cortes	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Bristol-Myers Squibb; Takeda; Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Jazz Pharmaceuticals; Immunogen; Menarini; Forma Therapeutics; Biopath Holdings; Biolineille		Bristol-Myers Squibb; Takeda; Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Jazz Pharmaceuticals; Sun Pharma; Immunogen; Menarini; Forma Therapeutics	Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Immunogen; Menarini; Forma Therapeutics; Biopath Holdings					No	
Oral and Poster Abstracts	627. Myelodysplastic Syndromes	Clinical Studies: Targeting Gene Mutations in MDS		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Glutasolinib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single-Agent Treatment and Combination with Azacitidine	Jorge	Cortes	MD	MD Anderson Hospital	Presenter	Yes	Oral	Disclosure made		Bristol-Myers Squibb; Takeda; Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Jazz Pharmaceuticals; Immunogen; Menarini; Forma Therapeutics; Biopath Holdings; Biolineille		Bristol-Myers Squibb; Takeda; Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Jazz Pharmaceuticals; Sun Pharma; Immunogen; Menarini; Forma Therapeutics	Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Immunogen; Menarini; Forma Therapeutics; Biopath Holdings					No	
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2-2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)	Jorge	Cortes	MD	UT Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Bristol-Myers Squibb; Takeda; Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Jazz Pharmaceuticals; Immunogen; Menarini; Forma Therapeutics; Biopath Holdings; Biolineille		Bristol-Myers Squibb; Takeda; Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Jazz Pharmaceuticals; Sun Pharma; Immunogen; Menarini; Forma Therapeutics	Novartis; Daiichi Sankyo; Pfizer; Astellas Pharma; Immunogen; Menarini; Forma Therapeutics; Biopath Holdings					No	This abstract discusses the use of an investigational drug in the context of a clinical trial.
Oral and Poster Abstracts	638. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Biology and Therapeutic Opportunities		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation	Kadriye	Cosgun	PhD	Department of Systems Biology, City of Hope Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up	Luciano	Costa	MD, PhD	University of Alabama at Birmingham	Presenter	Yes	Oral	Disclosure made		Amgen; Celgene; Sanofi; GSK; AbbVie; Karyopharm		Amgen; Janssen; Celgene; GSK	Amgen; Celgene; Sanofi; GSK		Amgen; Janssen; Sanofi			No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial	Luciano	Costa	MD, PhD	University of Alabama at Birmingham	Presenter	Yes	Oral	Disclosure made		Amgen; Celgene; Sanofi; GSK; AbbVie; Karyopharm		Amgen; Janssen; Celgene; GSK	Amgen; Celgene; Sanofi; GSK		Amgen; Janssen; Sanofi			No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)	Luciano	Costa	MD, PhD	University of Alabama at Birmingham	Presenter	Yes	Oral	Disclosure made		Amgen; Celgene; Sanofi; GSK; AbbVie; Karyopharm		Amgen; Janssen; Celgene; GSK	Amgen; Celgene; Sanofi; GSK		Amgen; Janssen; Sanofi			Yes	Carfilzomib for newly diagnosed multiple myeloma
Oral and Poster Abstracts	902. Health Services Research	Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study	Andrew	Cowan	MD	Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Disclosure made		Janssen; Celgene; Cellectar; Sanofi		Janssen; AbbVie; Celgene; Juno						No	
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Preclinical Models, Immunotherapy, and CAR T Cells		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)	Michelle	Cox		University of Minnesota Graduate School	Presenter	Yes	Oral	Disclosure made						Humanigen				No	
Oral and Poster Abstracts	904. Outcomes Research|Non-Malignant Conditions II		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Susan	Creary	MD, MSc	Nationwide Children's Hospital	Moderator	No	Oral	Disclosure made				AIH									
Special Scientific Symposia	Dragging the Undruggable		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	PROTAC-mediated Protein Degradation: A New Therapeutic Modality	Craig	Crews	PhD	Yale University	Speaker	Yes	Oral	Disclosure made		Arvinas, Inc; Haldia Therapeutics; Amgen	Arvinas, Inc; Haldia Therapeutics	Arvinas, Inc; Haldia Therapeutics		Arvinas, Inc; Haldia Therapeutics; Amgen		Arvinas, Inc; Haldia Therapeutics		No	
Meet the Scientist	PROTACs and Protein Degradation		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Craig	Crews	PhD	Yale University	Speaker	No	Oral	Disclosure made		Arvinas, Inc; Haldia Therapeutics; Amgen	Arvinas, Inc; Haldia Therapeutics	Arvinas, Inc; Haldia Therapeutics		Arvinas, Inc; Haldia Therapeutics; Amgen		Arvinas, Inc; Haldia Therapeutics			
Special-Interest Sessions	Global Hematology Symposium	Exploring Models of Global Affordable Access to Cutting-Edge Drugs	Monday, December 9, 2019	12:15 PM	1:15 PM	Yes	1		Mark	Crowther	MD	St. Joseph's Hospital	Co-chair	No	Oral	Disclosure made			Alnylam	Bayer; BMS Canada; Servier Canada; Diagnostica Stago			Bayer; Servier Canada; Alexion		BMS Canada; Servier Canada; Shionogi; Octapharma; Asahi Kasei			
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Adam	Cuker	MD, MS	University of Pennsylvania	Chair	No	Oral	Disclosure made		Synergy											
How I Treat: Bringing Science to Clinical Dilemmas	Approach to the Patient with Microangiopathic Hemolytic Anemia		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Adam	Cuker	MD, MS	University of Pennsylvania	Speaker	No	Oral	Disclosure made		Synergy											
Special-Interest Sessions	Special Symposium on Quality: ASH SQUIPS: Learning from Medical Errors and Other Incidents		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Hemovigilence: Incident Learning in Transfusion Medicine â€" Feasibility of Large-Scale Implementation	Melissa	Cumming	MS	Massachusetts Department of Public Health	Speaker	Yes	Oral	Nothing to disclose													
Education Program	Primary Immunodeficiencies for the Hematologist: Finding the Needle in the Haystack		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Common Variable Immunodeficiency: What's New in Diagnosis and Treatment	Charlotte	Cunningham-Rundles	MD, PhD	Mount Sinai School of Medicine	Speaker	Yes	Oral	Nothing to disclose												No	
Education Program	Primary Immunodeficiencies for the Hematologist: Finding the Needle in the Haystack		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Common Variable Immunodeficiency: What's New in Diagnosis and Treatment	Charlotte	Cunningham-Rundles	MD, PhD	Mount Sinai School of Medicine	Speaker	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of Pathogenesis, Drug Sensitivity, and Resistance; and Role of Bone Marrow Microenvironment and Host Microbiome in Myeloma Pathogenesis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Single Cell Transcriptomic Analysis of the Multiple Myeloma Bone Marrow Identifies a Unique Inflammatory Stromal Cell Population Associated with TNF Signaling	Tom	Cupedo		Erasmus University Medical Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	901. Health Services Research|Non-Malignant Conditions: Bleeding and Blood Loss		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Is Hemophilia B Clinically Less Severe Than Hemophilia a? Evidence from the Hugs Va and Va Studies	Randall	Curtis	MBA	Factor VIII Computing	Presenter	Yes	Oral	Disclosure made		Bayatta, now part of Takeda; Bayer Foundation; CSL Behring; Novo Nordisk; Wyeth, now Pfizer										No	
Oral and Poster Abstracts	332. Anticoagulation and Antithrombotic Therapy I		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Mary	Cushman	MD	Larner College of Medicine at the University of Vermont	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Corey	Cutler	MD, MPH, FRCPC	Dana-Farber Cancer Institute	Moderator	No	Oral	Disclosure made		Pharmacyclics; Fate Therapeutics; Incyte; Jazz; BMS; Genentech; Elisa;ys; Kadmon; Omeros											
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Mechanisms of and Therapies for cGVHD		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients	Hao	Dai		German Cancer Research Centre, DKFZ	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Family Studies of Whim Syndrome	David	Dale	MD	University of Washington	Presenter	Yes	Oral	Disclosure made		Amgen; Sanofi Aventis; Hospira; Prolong; Behringer/Ingelheim; Coherus; aKpharma	Athelas	Amgen; aKpharma	Sanofi Aventis; aKpharma							No	
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		David	Dale	MD	University of Washington	Moderator	No	Oral	Disclosure made		Amgen; Sanofi Aventis; Hospira; Prolong; Behringer/Ingelheim; Coherus; aKpharma	Athelas	Amgen; aKpharma	Sanofi Aventis; aKpharma								
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia|Clinical: Predicting Risk: A Focus on Disease Severity and Fertility		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5		Deepika	Darbari	MD	Children's National Medical Center	Moderator	No	Oral	Disclosure made									Novartis; Hilton Publishing				
Oral and Poster Abstracts	621. Lymphoma|Genetics/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma	Sandeep	Dave	MD	Duke University	Presenter	Yes	Oral	Disclosure made			Data Driven Bioscience									No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Severity of Thrombocytopenia at the Time of Platelet Transfusion Influences Post-Transfusion Platelet Kinetics and the Effects of Platelets on Plasma Cytokines in a Model of Murine Neonatal Sepsis	Patricia	Davenport	MD	Boston Children's Hospital and Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Updated Results From the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy	Naval	Daver	MD	University of Texas, MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Jazz; Daiichi Sankyo; Astellas; BMS; Immunogen; Forty-Seven; Novartis; Agios; Abbvie; Genentech; Pfizer; Karyopharm; Incyte; Sunesis; Otsuka; Celgene		Daiichi Sankyo; BMS; Immunogen; Novartis; Abbvie; Genentech; Pfizer; Servier; Karyopharm; Incyte; Sunesis; NOHLA; Glycomimetics; Hanmi Pharm Co., Ltd.							Yes	Venetoclax (VEN; ABT-199/GDC-0199) is a highly selective, potent, oral B-cell lymphoma-2 (BCL-2) inhibitor. Idasanutlin (Idasa; RG7388) is an orally available, small molecule antagonist of MDM2 (mouse double minute; Mdm2 p53 binding protein homolog).
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	Naval	Daver	MD	University of Texas MD Anderson Cancer Center, Department of Leukemia	Presenter	Yes	Oral	Disclosure made		Jazz; Daiichi Sankyo; Jazz; Astellas; Daiichi Sankyo; BMS; Immunogen; Astellas; Forty-Seven; BMS; Novartis; Immunogen; Agios; Forty-Seven; Abbvie; Genentech; Novartis; Pfizer; Agios; Abbvie; Karyopharm; Genentech; Incyte; Pfizer; Sunesis; Karyopharm; Incyte; Otsuka; Sunesis; Celgene; Otsuka; Celgene		Daiichi Sankyo; Daiichi Sankyo; BMS; Immunogen; BMS; Novartis; Immunogen; Abbvie; Genentech; Novartis; Pfizer; Servier; Abbvie; Karyopharm; Genentech; Incyte; Pfizer; Sunesis; Servier; NOHLA; Karyopharm; Glycomimetics; Incyte; Sunesis; Hanmi Pharm Co., Ltd.; NOHLA; Glycomimetics; Hanmi Pharm Co., Ltd.							No	
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study	Naval	Daver	MD	MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: First Line Treatment		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Matthew	Davids	MD	Dana-Farber Cancer Institute	Moderator	No	Oral	Disclosure made		AbbVie, Astra-Zeneca, Genentech, Janssen, MEI, Pharmacyclics, Syros Pharmaceuticals, Verastem		Acerta Pharma, Ascentage Pharma, Genentech, MEI pharma, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem	Research to Practice			AbbVie, Acerta Pharma, Adaptive, Biotechnologies, Astra-Zeneca, Genentech, Gilead Sciences, Janssen, Pharmacyclics, TG therapeutics				
Education Program	Bone Marrow Failure and Clonal Evolution		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Monitoring and Treatment for MDS in Genetically Susceptible Persons	Stella	Davies	PhD, MBBS, MRCP	Cincinnati Children's Hospital	Speaker	Yes	Oral	Disclosure made				Alexion Pharmaceuticals; Prolactis	Novartis							No	
Education Program	Bone Marrow Failure and Clonal Evolution		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Monitoring and Treatment for MDS in Genetically Susceptible Persons	Stella	Davies	PhD, MBBS, MRCP	Cincinnati Children's Hospital	Speaker	Yes	Oral	Disclosure made				Alexion Pharmaceuticals; Prolactis	Novartis							No	
Education Program	Bone Marrow Failure and Clonal Evolution		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Stella	Davies	PhD, MBBS, MRCP	Cincinnati Children's Hospital	Chair	No	Oral	Disclosure made				Alexion Pharmaceuticals; Prolactis	Novartis								
Education Program	Bone Marrow Failure and Clonal Evolution		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Stella	Davies	PhD, MBBS, MRCP	Cincinnati Children's Hospital	Chair	No	Oral	Disclosure made				Alexion Pharmaceuticals; Prolactis	Novartis								
How I Treat: Bringing Science to Clinical Dilemmas	Strategy for Diagnosis and Management of Bone Marrow Failure Syndromes		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Stella	Davies	PhD, MBBS, MRCP	Cincinnati Children's Hospital	Speaker	No	Oral	Disclosure made				Alexion Pharmaceuticals; Prolactis	Novartis								
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Pavel	Daviaux-Castillo	MD	University of Colorado - Pediatric Hematology/Oncology/BMT	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Stephane	De Botton		Department of Hematology, Gustave Roussy Cancer Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial	Cornelis	De Jong	MD	Erasmus MC Cancer Institute	Presenter	Yes	Oral	Nothing to disclose												No	

Oral and Poster Abstracts	622. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	*Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly-Diagnosed CP-CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-2a in a Prospective Phase III Trial*	Hugues	de Lavallade	MD, PhD	Kings College Hospital, NHS Foundation Trust	Presenter	Yes	Oral	Disclosure made				Incyte biosciences; BMS	Incyte biosciences; Novartis; Pfizer; BMS		Incyte biosciences; Novartis; Pfizer; BMS			Yes	Pegylated interferon alpha 2 a is not licensed in this indication
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	ADAMTS13, an Anti-thrombotic Protein: Evidence Outside of Thrombotic Thrombocytopenic Purpura	Simon	De Meyer	PhD	University of Leuven	Speaker	Yes	Oral	Disclosure made	KU Leuven	Ablynx; WhiteSwell		Fonds voor Wetenschappelijk Onderzoek; KU Leuven; Ablynx				Cerenovus		No	
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	ADAMTS13, an Anti-thrombotic Protein: Evidence Outside of Thrombotic Thrombocytopenic Purpura	Simon	De Meyer	PhD	University of Leuven	Speaker	Yes	Oral	Disclosure made	KU Leuven	Ablynx; WhiteSwell		Fonds voor Wetenschappelijk Onderzoek; KU Leuven; Ablynx				Cerenovus		No	
Education Program	Sickle Cell Disease in Young and Old: A Time for Re-Evaluation		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	A Comprehensive Program of Care From Birth	Mariane	De Montalembert	MD	Referral Center for Sickle Cell Disease, Necker Hospital	Speaker	Yes	Oral	Disclosure made		Addmedica; Novartis			Addmedica; Novartis			Bluebird Bio		No	
Education Program	Sickle Cell Disease in Young and Old: A Time for Re-Evaluation		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	A Comprehensive Program of Care From Birth	Mariane	De Montalembert	MD	Referral Center for Sickle Cell Disease, Necker Hospital	Speaker	Yes	Oral	Disclosure made		Addmedica; Novartis			Addmedica; Novartis			Bluebird Bio		No	
Oral and Poster Abstracts	622. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Erich	De Paula	MD, PhD	University of Campinas	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	624. Myeloproliferative Syndromes: Clinical Molecular Analysis and Areas of Unmet Need		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses	Pierre-Edouard	Debureaux		Centre d'Investigations Cliniques (INSERM CIC 1427), AP-HP, Hopital Saint-Louis, Université Paris-de-Paris	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Enrico	Tarella	MD, PhD	European Institute of Oncology IRCCS	Moderator	No	Oral	Disclosure made				TG-THERAPEUTICS									
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Topic 1: Sickle Cell Disease-Related Cardiopulmonary and Kidney Disease	Ankit	Desai	MD	Indiana University	Speaker	Yes	Oral	Nothing to disclose													
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Immune Thrombocytopenia		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Speaker 2	Jenny	Despotovic	DO, MS	Texas Children's Hospital Baylor College of Medicine	Speaker	Yes	Oral	Disclosure made					Amgen; Novartis	Dova							
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-NaÏ¨ve and Refractory Severe Aplastic Anemia (SAA)	Amy	DeZern	MD	Johns Hopkins University	Presenter	Yes	Oral	Disclosure made		Astex Pharmaceuticals, Inc.; Celgene									No	
Oral and Poster Abstracts	508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Amy	DeZern	MD	Johns Hopkins University	Moderator	No	Oral	Disclosure made		Astex Pharmaceuticals, Inc.; Celgene											
Oral and Poster Abstracts	802. Health Services Research â€"Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of Life		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation	Vinita	Ghir	BSc	Princess Margaret Cancer Centre	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Comparative Analyses		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study	Bhagirathbhai	Dholaria	MB&BS	Vanderbilt University	Presenter	Yes	Oral	Disclosure made						Celgene						No	
How I Treat: Bringing Science to Clinical Dilemmas	Approach to Diagnosis and Management of Patients with Congenital Platelet Disorders		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Jorge	Di Paola	MD	University of Colorado School of Medicine	Speaker	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas â€"Clinical Studies: Follicular Lymphoma: Biomarkers and Clinical Trials		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial	Catherine	Diefenbach	MD	Perlmutter Cancer Center at NYU Langone Health	Presenter	Yes	Oral	Disclosure made		Bristol-Myers Squibb; Genentech; Merck; Seattle Genetics		Bristol-Myers Squibb; Denovo; Genentech; Incyte; LAM Therapeutics; MEI; Merck; Seattle Genetics; Millenium/Takeda; Trillium							Yes	Polatuzumab vedotin (POLIVY, Genentech, Inc.) is a CD79b-directed antibody-drug conjugate. It was approved by the FDA in June 2019 in combination with bendamustine and rituximab for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma after at least two prior therapies.
Education Program	Therapy of Acute Myeloid Leukemia: Adapting to Change		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Single-Agent and Combination Biologics	Courtney	DiNardo	MD,MSc	University of Texas MD Anderson Cancer Center	Speaker	Yes	Oral	Disclosure made		abbvie; agios; celgene			abbvie; agios; celgene; daiichi sankyo; jazz; medimmune; syros			notable labs		Yes	Clinical trials in progress will be discussed.
Education Program	Therapy of Acute Myeloid Leukemia: Adapting to Change		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Single-Agent and Combination Biologics	Courtney	DiNardo	MD,MSc	University of Texas MD Anderson Cancer Center	Speaker	Yes	Oral	Disclosure made		abbvie; agios; celgene			abbvie; agios; celgene; daiichi sankyo; jazz; medimmune; syros			notable labs		Yes	Clinical trials in progress will be discussed.
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Non-Intensive Therapy		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study	Courtney	DiNardo	MD,MSc	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		abbvie; agios; celgene			abbvie; agios; celgene; daiichi sankyo; jazz; medimmune; syros			notable labs		No	
Education Program	Therapy of Acute Myeloid Leukemia: Adapting to Change		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Courtney	DiNardo	MD,MSc	University of Texas MD Anderson Cancer Center	Chair	No	Oral	Disclosure made		abbvie; agios; celgene			abbvie; agios; celgene; daiichi sankyo; jazz; medimmune; syros			notable labs			
Education Program	Therapy of Acute Myeloid Leukemia: Adapting to Change		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Courtney	DiNardo	MD,MSc	University of Texas MD Anderson Cancer Center	Chair	No	Oral	Disclosure made		abbvie; agios; celgene			abbvie; agios; celgene; daiichi sankyo; jazz; medimmune; syros			notable labs			
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Courtney	DiNardo	MD,MSc	UT MD Anderson Cancer Center	Moderator	No	Oral	Disclosure made		abbvie; agios; celgene			abbvie; agios; celgene; daiichi sankyo; jazz; medimmune; syros			notable labs			
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	NADPH Oxidase Controls Neutrophil Infiltration in the Lung in Early Response to Fungal Cell Walls Via LTB4	Mary	Dinauer	MD, PhD	Washington University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	TRTH Scientific Symposium: A Decade of Training the Future Leaders in Translational Research		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2		Mary	Dinauer	MD, PhD	Washington University School of Medicine	Co-chair	No	Oral	Nothing to disclose													
Special-Interest Sessions	Featured Topic: Taking a bite out of CAR T Cells		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		John	DiPersio	MD, PhD	Washington University School of Medicine	Speaker	No	Oral	Disclosure made		Amphivena Therapeutics; Celgene; Incyte; Karyopharm Therapeutics; Riverlend Venture Partners Arch Oncology	Magenta Therapeutics; WUGEN	WUGEN; Amphivena Therapeutics; Incyte; NeoImmune Tech; Macrogenics; Bioline Rx		WUGEN	Macrogenics; Bioline Rx	RiverVest Venture Partners Arch Oncology; Cellworks Group, Inc.			
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR	Elisa	Ciral	MD	University of Milano-Bicocca	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)	Angela	Dispenzieri	MD	Mayo Clinic	Presenter	Yes	Oral	Disclosure made		Alcea; Intellia; Janssen		Pfizer; Takeda; Celgene; Alnylam							Yes	Investigation of the oral proteasome inhibitor ixazomib in combination with dexamethasone versus physician's choice (of which there are no approved treatment options) for the treatment of relapsed/refractory primary systemic amyloidosis.
How I Treat: Bringing Science to Clinical Dilemmas	Monoclonal Gammopathies of Cutaneous, Neuropathic, and Renal Significance		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Angela	Dispenzieri	MD	Mayo Clinic	Speaker	No	Oral	Disclosure made		Alcea; Intellia; Janssen		Pfizer; Takeda; Celgene; Alnylam									
Scientific Program	Ex Vivo Bioengineering of Blood Products for Transfusion		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Bio-Inspired Artificial Red Blood Cell: Design, Pre-Clinical Results and Novel Indications	Allan	Doctor	MD	University of Maryland School of Medicine	Speaker	Yes	Oral	Disclosure made			KaloCyte, Inc.		Fresenius Kabi	KaloCyte, Inc.		KaloCyte, Inc.; Biogen; Etiometry		No	
Scientific Program	Ex Vivo Bioengineering of Blood Products for Transfusion		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Bio-Inspired Artificial Red Blood Cell: Design, Pre-Clinical Results and Novel Indications	Allan	Doctor	MD	University of Maryland School of Medicine	Speaker	Yes	Oral	Disclosure made			KaloCyte, Inc.		Fresenius Kabi	KaloCyte, Inc.		KaloCyte, Inc.; Biogen; Etiometry		No	
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Ex Vivo Bioengineering of Blood Products for Transfusion		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Allan	Doctor	MD	University of Maryland School of Medicine	Speaker	No	Oral	Disclosure made			KaloCyte, Inc.		Fresenius Kabi	KaloCyte, Inc.		KaloCyte, Inc.; Biogen; Etiometry			
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Hax1 Is Indispensable for Neutrophil Development in Zebrafish	Larissa	Doll		University Hospital Tuebingen	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Biology and Therapeutic Opportunities		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Prediction of Patients at Risk of CD19^{TNE} Relapse Following CD19-Directed CAR T Cell Therapy in B-Cell Precursor Acute Lymphoblastic Leukemia	Pablo	Domizi	PhD	Boss Center for Childhood Cancer and Blood Disorders	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Intrinsic and Extrinsic Control of HSPC Maintenance and Differentiation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Chaperone-Mediated Autophagy Ensures Hematopoietic Stem Cell Maintenance	Shuaian	Deng	PhD	Albert Einstein College of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Functional Characterization of Novel Molecular Drivers and Vulnerabilities of Myeloma Cells		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Functional Interactions between Transcription Factors Involved in Myeloma Pathogenesis â€" Biological and Therapeutic Implications	Sondra	Drawney-Kopyosinski	PhD	Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma	Anita	D'Souza	MD,MS	Medical College of Wisconsin	Presenter	Yes	Oral	Disclosure made		Prothena		EDO-Mundapharma, Merck, Prothena, Sanofi, TeneoBio				Pfizer; Imbrium, Akcea		No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM)	Anita	D'Souza	MD,MS	Medical College of Wisconsin	Presenter	Yes	Oral	Disclosure made		Prothena		EDO-Mundapharma, Merck, Prothena, Sanofi, TeneoBio				Pfizer; Imbrium, Akcea		No	
Oral and Poster Abstracts	802. Health Services Research â€"Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation	Anita	D'Souza	MD,MS	Medical College of Wisconsin	Presenter	Yes	Oral	Disclosure made		Prothena		EDO-Mundapharma, Merck, Prothena, Sanofi, TeneoBio				Pfizer; Imbrium, Akcea		No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study	AÑDmy	DuaÑDry	MD	AP-HP.Sorbonne University	Presenter	Yes	Oral	Disclosure made					Kexcyt						No	
Oral and Poster Abstracts	731. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		AÑDmy	DuaÑDry	MD	AP-HP.Sorbonne University	Moderator	No	Oral	Disclosure made					Kexcyt						No	
Oral and Poster Abstracts	622. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Andrew	Dunbar	MD	Memorial Sloan Kettering Cancer Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	603. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Eric	Duncavage	M.D.	Washington University In St Louis	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	TA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults	Jibran	Durrani		Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	606. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2	Ritika	Dutta	BS	Stanford University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hemophagocytic Lymphohistiocytosis and Other Immune Disorders		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders	Olive	Eckstein	MD	Baylor College of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	

Education Program	Response Comes of Age in Chronic Lymphocytic Leukemia		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Relapsed disease, discontinuation, and MRD	Barbara	Eichhorst	MD	University of Cologne	Speaker	Yes	Oral	Disclosure made		Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie		Gilead Sciences, Inc.; Janssen; Roche; AbbVie; BeiGene	Gilead Sciences, Inc.; Janssen; Roche; Celgene; AbbVie		Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie	Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie; AstraZeneca			
Education Program	Response Comes of Age in Chronic Lymphocytic Leukemia		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Relapsed disease, discontinuation, and MRD	Barbara	Eichhorst	MD	University of Cologne	Speaker	Yes	Oral	Disclosure made		Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie		Gilead Sciences, Inc.; Janssen; Roche; AbbVie; BeiGene	Gilead Sciences, Inc.; Janssen; Roche; Celgene; AbbVie		Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie	Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie; AstraZeneca			
Education Program	Response Comes of Age in Chronic Lymphocytic Leukemia		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Barbara	Eichhorst	MD	University of Cologne	Chair	No	Oral	Disclosure made		Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie		Gilead Sciences, Inc.; Janssen; Roche; AbbVie; BeiGene	Gilead Sciences, Inc.; Janssen; Roche; Celgene; AbbVie		Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie	Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie; AstraZeneca			
Education Program	Response Comes of Age in Chronic Lymphocytic Leukemia		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Barbara	Eichhorst	MD	University of Cologne	Chair	No	Oral	Disclosure made		Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie		Gilead Sciences, Inc.; Janssen; Roche; AbbVie; BeiGene	Gilead Sciences, Inc.; Janssen; Roche; Celgene; AbbVie		Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie	Gilead Sciences, Inc.; Janssen; Roche; Novartis; Celgene; AbbVie; AstraZeneca			
Oral and Poster Abstracts	631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-Free Remission		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants	Christopher	Eide		Oregon Health & Science University	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	801. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Type 1 Interferon Promotes RBC Alloimmunization in a Lupus Mouse Model	Najwa	EL Kadi	PhD, BS, MS	Cedars-Sinai	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Shannon	Elf	PhD	The University of Chicago	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	720. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Microbiome and Immune Regulation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS)	Caitlin	Elgarten	MD,MSc	Children's Hospital of Philadelphia	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Molecular Analysis and Areas of Unmet Need		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience	Elena	Elli	MD	Ospedale San Gerardo - ASST Monza	Presenter	Yes	Oral	Disclosure made								Novartis		No	
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Harry	Erba	MD,PhD	University of Alabama At Birmingham	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche	Johanna	Erbani		Mater Research Institute - University of Queensland	Presenter	Yes	Oral	Nothing to disclose										No	
Education Program	New Diagnostic and Treatment Strategies For Antiphospholipid Syndrome		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Is There a Role for Immune Therapy in Antiphospholipid Syndrome?	Doruk	Erkan	MD, MPH	Weill Cornell Medicine	Speaker	Yes	Oral	Disclosure made		Celgene; Momenta		Lupus Clinical Trials Consortium; GSK; ACR/ELLAR; NIH	Up-to-Date						
Education Program	New Diagnostic and Treatment Strategies For Antiphospholipid Syndrome		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Is There a Role for Immune Therapy in Antiphospholipid Syndrome?	Doruk	Erkan	MD, MPH	Weill Cornell Medicine	Speaker	Yes	Oral	Disclosure made		Celgene; Momenta		Lupus Clinical Trials Consortium; GSK; ACR/ELLAR; NIH	Up-to-Date						
Oral and Poster Abstracts	621. Lymphoma'Genetics/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling	Mohammad	Esfahani		Stanford University	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Dynamic Change of the Hematopoietic Stem Cell Niche		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Inflammation Mediated Bone Marrow Remodeline	Marieke	Essers	PhD	German Cancer Research Center	Speaker	Yes	Oral	Nothing to disclose										No	
Scientific Program	Dynamic Change of the Hematopoietic Stem Cell Niche		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Inflammation Mediated Bone Marrow Remodeling	Marieke	Essers	PhD	German Cancer Research Center	Speaker	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	351. Disorders of Platelet Number or Function: Insights into the Pathophysiology of Platelet Disorders		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	The Inherited Platelet Disorder of RUNX1 Haploinsufficiency (Familial Platelet Disorder with Associated Myeloid Malignancy [FPDAMM]) Has a Marked Deficiency of Megakaryocyte-Biased Hematopoietic Progenitor Cells: Mechanistic Studies and Drug Correction	Brian	Estevez	PhD	Children's Hospital of Philadelphia	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Ex Vivo Bioengineering of Blood Products for Transfusion		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Ex vivo *Engineering of Platelets*	Koji	Eto	MD	Kyoto University	Speaker	Yes	Oral	Disclosure made			Megakaryon Co. Ltd.					Megakaryon Co. Ltd.		Yes	Our published results that include some drugs, i.e., TA-316 (Blood Advances, 1(7):468-476, 2017), KP657 (Stem Cells Transl Med, 6(3):720-730, 2017), and SR1 (Cell, 174(3):636-648, 2018)
Scientific Program	Ex Vivo Bioengineering of Blood Products for Transfusion		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Ex vivo *Engineering of Platelets*	Koji	Eto	MD	Kyoto University	Speaker	Yes	Oral	Disclosure made			Megakaryon Co. Ltd.					Megakaryon Co. Ltd.		Yes	Our published results that include some drugs, i.e., TA-316 (Blood Advances, 1(7):468-476, 2017), KP657 (Stem Cells Transl Med, 6(3):720-730, 2017), and SR1 (Cell, 174(3):636-648, 2018)
Continuing Conversations With the Speakers on Ex Vivo Bioengineering of Blood Products for Transfusion	Continuing Conversations With the Speakers on Ex Vivo Bioengineering of Blood Products for Transfusion		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Koji	Eto	MD	Kyoto University	Speaker	No	Oral	Disclosure made			Megakaryon Co. Ltd.					Megakaryon Co. Ltd.			
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Epigenetic Regulation		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Dnmt3a Mutation Confers a Selective Advantage Specifically to Cells within the Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment	Elizabeth	Eudy	BS	The Jackson Laboratory	Presenter	Yes	Oral	Nothing to disclose										No	
Education Program	Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Management of Elderly Patients	Andrew	Evens	DO,MMSc	Rutgers Cancer Institute of New Jersey	Speaker	Yes	Oral	Disclosure made		Seattle Genetics; Verastem; Bayer; Affimed		Takeda; Merck	Research to Practice; Seattle Genetics; Pharmacyclics; Verastem; Bayer; Affimed					Yes	PD-1 inhibitors in untreated Hodgkin lymphoma
Education Program	Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Management of Elderly Patients	Andrew	Evens	DO,MMSc	Rutgers Cancer Institute of New Jersey	Speaker	Yes	Oral	Disclosure made		Seattle Genetics; Verastem; Bayer; Affimed		Takeda; Merck	Research to Practice; Seattle Genetics; Pharmacyclics; Verastem; Bayer; Affimed					Yes	PD-1 inhibitors in untreated Hodgkin lymphoma
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Retrospective/Observational Studies: Population-Based Outcomes		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)	Andrew	Evens	DO, MSc	Rutgers Cancer Institute of New Jersey	Presenter	Yes	Oral	Disclosure made		Seattle Genetics; Pharmacyclics; Epizyme; Verastem		Seattle Genetics; Tesaro	Seattle Genetics; Pharmacyclics; Epizyme; Verastem					No	
Special-Interest Sessions	Blood & Beyond		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	The Spirit Catches You and You Fall Down	Anne	Eadiman		Yale University	Speaker	Yes	Oral	Nothing to disclose											
Oral and Poster Abstracts	321. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Ammon	Fager	MD,PhD	Duke University Medical Center	Moderator	No	Oral	Disclosure made				Otsifo Medical Inc.				CSL Behring; Bayer			
Oral and Poster Abstracts	905. Outcomes Researchâ€"Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)	Angelo	Fama	MD	Ematologia, Azienda UnloÃ¯ Sanitaria Locale - IRCCS di Reggio Emilia	Presenter	Yes	Oral	Nothing to disclose										No	
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Topic 4: Sickle Cell Disease-Related Transfusion Support	Ross	Fasano	MD	Emory University School of Medicine	Speaker	Yes	Oral	Nothing to disclose											
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia'Clinical: Predicting Risk: A Focus on Disease Severity and Fertility		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5		Titilope	Fasiqe	MD,PhD	Baylor College of Medicine	Moderator	No	Oral	Disclosure made		Novartis		Pfizer/American College of Emergency Physicians							
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Markedly Reduced Expression of Annexin A2 Is Associated with Hypofibrinolysis and Provoked and Unprovoked Venous Thromboembolism	Hannah	Fassel	MD	Weill Cornell Medicine	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	638. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Biology and Therapeutic Opportunities		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia	Grazia	Fazio		University of Milano Bicocca; Fondazione MBBM/San Gerardo Hospital	Presenter	Yes	Oral	Nothing to disclose										No	
Spotlight Sessions	Street Drugs: Emerging Hematologic Complications of Illicit Drug Use		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Levamisole and Cocaine: Contaminants in Illicit Drugs and Hematologic Complications	Daniel	Federman		Yale University School of Medicine	Speaker	Yes	Oral	Nothing to disclose											
Oral and Poster Abstracts	627. Myelodysplastic Syndromes'Clinical Studies: Lower-Risk MDS and CMML		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Assessment of Longer Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions	Pierre	Fenaux	MD, PhD	HÃ´pital Saint-Louis, Assistance Publique-HÃ´pitaux de Paris (AP-HP)	Presenter	Yes	Oral	Disclosure made			Celgene Corporation; Astex; Jazz; Agena	Celgene Corporation; Astex; Jazz				Yes	Luspatercept is an investigational therapy that is not approved for any use in any country. Luspatercept is currently being evaluated for potential use in patients with anemia due to myelodysplastic syndromes, beta-thalassemia, or myelofibrosis.
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Retrospective/Observational Studies: Population-Based Outcomes		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Timothy	Fenske	MD	Medical College of Wisconsin	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	102. Regulation of Iron Metabolism: Novel Players in Iron Homeostasis in Health and Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera	Maria	Paola	PhD	Icahn School of Medicine at Mount Sinai	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Genetic Engineering in Hematopoietic Stem Cells for Gene Therapy of Hemoglobinopathies	Giuliana	Ferrari	PhD	San Raffaele Telethon Institute for Gene Therapy	Speaker	Yes	Oral	Nothing to disclose										Yes	Plerixafor
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Genetic Engineering in Hematopoietic Stem Cells for Gene Therapy of Hemoglobinopathies	Giuliana	Ferrari	PhD	San Raffaele Telethon Institute of Gene Therapy	Speaker	Yes	Oral	Nothing to disclose										Yes	Plerixafor
Continuing Conversations With the Speakers on Genome Editing for Transplantation and Cellular Therapies	Continuing Conversations With the Speakers on Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Giuliana	Ferrari	PhD	San Raffaele Telethon Institute of Gene Therapy	Speaker	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial	Andres	Ferreri	MD	on behalf of the Fondazione Italiana Linfomi	Presenter	Yes	Oral	Disclosure made			Roche; Celgene					Celgene; Gilead; Novartis		No	
Oral and Poster Abstracts	905. Outcomes Researchâ€"Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Mark	Fiala	MSW	Washington University School of Medicine	Moderator	No	Oral	Nothing to disclose											
Education Program	Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Ph+ ALL: Is Chemo+TKI or Transplant the Best Road to Cure?	Adele	Fielding	MBBS,PhD,FRCP,FRC Path	UCL Cancer Institute	Speaker	Yes	Oral	Disclosure made		Amgen; Novartis; Pfizer; Incyte								No	
Education Program	Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Ph+ ALL: Is Chemo+TKI or Transplant the Best Road to Cure?	Adele	Fielding	MBBS,PhD,FRCP,FRC Path	UCL Cancer Institute	Speaker	Yes	Oral	Disclosure made		Amgen; Novartis; Pfizer; Incyte								No	
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chemo Immuno and Targeted—Improving Combinations in ALL		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine if the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (EWLK09/R06)	Adele	Fielding	MBBS,PhD,FRCP,FRC Path	University College London	Presenter	Yes	Oral	Disclosure made		Amgen; Novartis; Pfizer; Incyte								Yes	Rituximab- the agent to which patients were randomised during this study
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refinine the Approach		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Adele	Fielding	MBBS,PhD,FRCP,FRC Path	University College London	Moderator	No	Oral	Nothing to disclose											

Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: First Line Treatment		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial	Kirsten	Fischer	MD	Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital	Presenter	Yes	Oral	Disclosure made					AbbVie			AbbVie			No	
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Topic 5: Sickle Cell Disease-Related Stem Cell Transplantation	Courtney	Fitzhugh	MD	National Institutes of Health (Hematology)	Speaker	Yes	Oral	Nothing to disclose												
General Sessions	Best of ASH		Tuesday, December 10, 2019	11:30 AM	1:00 PM	Yes	1.5		Robert	Flaumenhaft	MD, PhD	Beth Israel Deaconess Medical Center	Co-chair	No	Oral	Disclosure made		Relay Therapeutics; PlateletBiomedics										
Education Program	Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Donor Selection for Matched Unrelated Donor Beyond HLA	Katharina	Fleischhauer	MD	University Hospital Essen	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Donor Selection for Matched Unrelated Donor Beyond HLA	Katharina	Fleischhauer	MD	University Hospital Essen	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	725. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Risk Stratification and Novel Approaches to Reduce Toxicity in Allogeneic Transplantation		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Neal	Flomenberg		Jefferson University Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	906. Outcomes Research: Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Patient-Reported Outcome Results From the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia	Kathryn	Flynn	PhD	Medical College of Wisconsin	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overal Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study	James	Foran	MD	Mayo Clinic Florida	Presenter	Yes	Oral	Disclosure made					Agios	Agios					Yes	Use of maintenance Decitabine in AML
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Maturation and Enucleation		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Regulation of eIF4E Guides a Unique Translational Program to Steer Erythroid Maturation	Craig	Forester	MD,PhD	University of California-San Francisco; Benioff Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Matthew	Foster	MD	University of North Carolina	Moderator	No	Oral	Disclosure made		Daiichi Sankyo		Bellicum Pharmaceuticals, Inc; MacroGenics; Celgene								
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma: Clinical Studies: Clinical Trials in Waldenstrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma	Nathan	Fowler	MD	University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Novartis Pharmaceuticals Corporation		Celgene; Roche; Janssen; AbbVie; TG Therapeutics					Celgene; Roche; Janssen; AbbVie; TG Therapeutics		No	
Oral and Poster Abstracts	725. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Innovative Approaches in Allogeneic Transplantation for Pediatric or Nonmalignant Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Characterization of Immune Cells Producing Regulatory Cytokines That Mediate Engraftment in Sickle Cell Disease Patients after Haploidentical Peripheral Blood Stem Cell Transplantation	Berline	Francis		National Heart Lung and Blood Institute, National Institutes of Health	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Ex Vivo Bioengineering of Blood Products for Transfusion		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	*Ex vivo Engineering of Red Blood Cells*	Jan	Frayne	BsC, PhD	University of Bristol	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Ex Vivo Bioengineering of Blood Products for Transfusion		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	*Ex vivo Engineering of Red Blood Cells*	Jan	Frayne	BsC, PhD	University of Bristol	Speaker	Yes	Oral	Nothing to disclose											No	
Continuing Conversations	Continuing Conversations: With the Speakers on Ex Vivo Bioengineering of Blood Products for Transfusion		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Jan	Frayne	BsC, PhD	University of Bristol	Speaker	No	Oral	Nothing to disclose												
Special-Interest Sessions	Medical Educators Symposium: General Session		Sunday, December 8, 2019	7:30 AM	9:30 AM	Yes	2	Developing and Conducting Effective Didactic Presentations for the Millennial Learner	Jason	Freed	MD	Beth Israel Deaconess	Speaker	Yes	Oral	Disclosure made		UWorld LLC			Mount Desert Island Biological Laboratory							
Education Program	Therapy of Acute Myeloid Leukemia: Adapting to Change		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	MRD Evaluation of AML in Clinical Practice: Are We There Yet?	Sylvie	Freeman	MBChB, DPhil	University of Birmingham	Speaker	Yes	Oral	Disclosure made							Jazz Pharmaceuticals				No	
Education Program	Therapy of Acute Myeloid Leukemia: Adapting to Change		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	MRD Evaluation of AML in Clinical Practice: Are We There Yet?	Sylvie	Freeman	MBChB, DPhil	University of Birmingham	Speaker	Yes	Oral	Disclosure made							Jazz Pharmaceuticals				No	
Oral and Poster Abstracts	703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Engineering Naturally Occurring CD2 Negative Cells for the Immunotherapy of CD2 Positive Leukemia	Abdullah	Freiwan	MSc	St. Jude Children's Research Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Featured Topic: Aging and Hematopoiesis		Monday, December 9, 2019	12:15 PM	1:15 PM	Yes	1		Mareike	Frick	MD	CharitÃ© - UniversitÃ¤tsmedizin Berlin	Speaker	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Terry	Fry	MD	CCR, NCI NIH	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	509. Clonal Hematopoiesis: Aging and Inflammation		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment	Takeshi	Fujino	MD	The University of Tokyo	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-Free Remission		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients	Yuki	Fujioka	MD, PhD	Akita University Graduate School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD and Thymus Regeneration: Role of Innate Cells and Non-Hematopoietic Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Mitochondrial Complex II in Intestinal Epithelial Cells is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease	Hideaki	Fujiwara		University of Michigan	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	622. Lymphoma Biology: Non-Genetic Studies: Molecular Mechanisms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	VAV2 Mutations Contributes to the Development of T-Cell Malignancies in Mice	Kota	Fukumoto	MD	University of Tsukuba	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Targeting Apoptosis in Myeloma		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Mechanisms of Deregulation of Apoptosis in Myeloma	Simone	Fulda	MD	Goethe-University Frankfurt	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Targeting Apoptosis in Myeloma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Mechanisms of Deregulation of Apoptosis in Myeloma	Simone	Fulda	MD	Goethe-University Frankfurt	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Shahinaz	Gadalla	MD,PhD	National Cancer Institute	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	134. Hemoglobinopathies, Excluding Thalassemia: Clinical: Predicting Risk: A Focus on Disease Severity and Fertility		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Outcomes of Pregnancies in Patients with Sickle-Cell Disease - Update from European Non-Interventional, Multicentric, Prospective Escort-HU Study	FrÃ©dÃ©ric	GalacteÃ©ros	MD PhD	INSERM-UBSL, EFS, Institut Mondor, UniversitÃ© Paris-Est CrÃ©teil, Team 2 Transfusion et maladies du globule rouge, Laboratoire dÃ'Excellence GR-Ex	Presenter	Yes	Oral	Disclosure made									Addmedica		No	
Oral and Poster Abstracts	134. Hemoglobinopathies, Excluding Thalassemia: Clinical: Optimizing and Improving Access to High-Quality Care		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Primary Prevention of Strokes in Nigerian Children with Sickle Cell Disease (SPIN Trial): Final Results	Najibah	Galadanci	MBBS, MPH	University of Alabama at Birmingham	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Integrated Epigenetic Profiling Identifies E2H2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression	Valentina	Giambacorta	MSc	IRCCS San Raffaele Scientific Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Carlo	Gambacorti-Passerini	MD	University of Milano Bicocca	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	636. Myelodysplastic Syndromes: Basic and Translational Studies: RNA Processing and Signatures in MDS		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS	Irene	Ganan-Gomez	PhD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment	Maher	Gandhi	PhD	University of Queensland	Speaker	Yes	Oral	Disclosure made				Bristol Myers Squibb; Celgene; Gilead; Janssen	Gilead; Roche; Amgen			Bristol Myers Squibb; Celgene; Janssen; Merck		No	
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment	Maher	Gandhi	PhD	University of Queensland	Speaker	Yes	Oral	Disclosure made				Bristol Myers Squibb; Celgene; Gilead; Janssen	Gilead; Roche; Amgen			Bristol Myers Squibb; Celgene; Janssen; Merck		No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Clinical Outcomes and Characteristics of Patients (pts) with FLT2-Internal Tandem Duplication (FLT2-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial	Siddhartha	Ganguly	MD	The University of Kansas Health System	Presenter	Yes	Oral	Disclosure made				Daiichi Sankyo	Kite Pharma; Janssen		Seattle Genetics			No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Intrinsic and Extrinsic Control of HSPC Maintenance and Differentiation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Macrophage Transfer to HSCs Assigns Residence in Bone Marrow	Xin	GAO	PhD	Albert Einstein College of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Epigenetic Regulation		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure	Yimeng	Geo	PhD	Yale University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	725. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High-Risk Myeloid Malignancies	Jacqueline	Garcia	MD	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Disclosure made					AbbVie; Genentech					Yes	Venetoclax is a Bcl2 mimetic and selective BCL-2 inhibitor that was added to standard conditioning chemotherapy (Fludarabine and busulfan) on a clinical trial.
Education Program	Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Meeting the Needs of CML Patients in Resource-Poor Countries: a Roundtable Discussion	Pat	Garcia-Gonzalez	MS	The Max Foundation	Speaker	Yes	Oral	Nothing to disclose										Yes	Use of pioglitazone in combination with TKIs. Use of some ayurvedic products.
Education Program	Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Meeting the Needs of CML Patients in Resource-Poor Countries: a Roundtable Discussion	Pat	Garcia-Gonzalez	MS	The Max Foundation	Speaker	Yes	Oral	Nothing to disclose										Yes	Use of pioglitazone in combination with TKIs. Use of some ayurvedic products.
Special-Interest Sessions	Global Hematology Symposium	Exploring Models of Global Affordable Access to Cutting-Edge Drugs	Monday, December 9, 2019	12:15 PM	1:15 PM	Yes	1	Targeted Therapy for CML and the Max Foundation/Novartis Partnership	Pat	Garcia-Gonzalez	MS	The Max Foundation	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-Free Remission		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	*Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission*	ValentÃ-n	Garcia-GutiÃ©rrez	MD, PhD	Hospital Universitario RamÃ³n y Cajal	Presenter	Yes	Oral	Disclosure made					Novartis						No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromes: Clinical Studies: Lower-Risk MDS and CMML		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross-over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine	Guillermo	Garcia-Manero	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Amphivena; Celgene; Astex		Amphivena; Helsinn; Novartis; AbbVie; Celgene; Astex; Oncovenus; H3 Biomedicine; Merck							No	
Oral and Poster Abstracts	211. Disorders of Platelet Number or Function: Insights into the Pathophysiology of Platelet Disorders		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Elizabeth	Gardiner	PhD	Australian National University	Moderator	No	Oral	Nothing to disclose												
Education Program	Expanding Horizons for Immunotherapy in Pediatric Leukemia		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Mechanisms and Approaches to Overcoming Resistance to Immunotherapy	Rebecca	Gardner	MD	Seattle Children's Hospital	Speaker	Yes	Oral	Disclosure made					Novartis					Yes	off label use of investigational CAR T cells and immune checkpoint inhibitors
Education Program	Expanding Horizons for Immunotherapy in Pediatric Leukemia		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Mechanisms and Approaches to Overcoming Resistance to Immunotherapy	Rebecca	Gardner	MD	Seattle Children's Hospital	Speaker	Yes	Oral	Disclosure made					Novartis					Yes	off label use of investigational CAR T cells and immune checkpoint inhibitors
Oral and Poster Abstracts	508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response	Bhavuk	Garg	PhD	Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No	

Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Norbert	Gattermann	MD	Heinrich-Heine-Universität	Co-Chair	No	Oral	Disclosure made				Alexion; Takeda	Novartis							
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Norbert	Gattermann	MD	Heinrich-Heine-Universität	Co-Chair	No	Oral	Disclosure made				Alexion; Takeda	Novartis							
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results from Prospective Clinical Trials		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients	Francesca	Gay	MD	GIMEMA	Presenter	Yes	Oral	Disclosure made					Celgene; Celgene; Janssen; Takeda; Janssen; Amgen; Takeda; Bristol-Myers Squibb; Amgen; AbbVie; Roche; Bristol-Myers Squibb			Celgene; Celgene; Janssen; Takeda; Janssen; Amgen; Takeda; Roche; Bristol-Myers Squibb; Amgen; AbbVie; Roche; Bristol-Myers Squibb; AbbVie			Yes	The presentation includes discussion of off-label use of a drug or drugs for the treatment of multiple myeloma.
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Therapeutic Questions in Newly Diagnosed Myeloma		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Francesca	Gay	MD	GIMEMA	Moderator	No	Oral	Disclosure made					Celgene; Janssen; Takeda; Amgen; Bristol-Myers Squibb			Celgene; Janssen; Takeda; Amgen; Roche; Bristol-Myers Squibb; AbbVie					
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms	Mohammed	Ghaadamosi	BS	University of Florida College of Pharmacy	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	865. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial	Bernhard	Gentner	MD	IRCCS San Raffaele Scientific Institute	Presenter	Yes	Oral	Disclosure made		Genenta Science	Genenta Science	Genenta Science							No	
Spotlight Sessions	Molecular Hematopathology Tumor Board		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Hematopathologist	Tracy	George	MD	University of Utah	Speaker	Yes	Oral	Disclosure made		Blueprint Medicines; Deciphera; Ablaxis			Novartis						No	
Spotlight Sessions	Molecular Hematopathology Tumor Board		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Tracy	George	MD	University of Utah	Chair	No	Oral	Disclosure made		Blueprint Medicines; Deciphera; Ablaxis			Novartis							
Education Program	Myeloproliferative Neoplasms: Managing the Cup that Runneth Over		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Beyond JAK-STAT: Novel Therapeutic Targets in Ph-negative MPN	Aaron	Gerds	MD, MS	Cleveland Clinic Taussig Cancer Institute	Speaker	Yes	Oral	Disclosure made		Pfizer; Incyte; Celgene Corporation; CTI Biopharma; Pfizer; Incyte		Imago Biosciences; Incyte; Celgene Corporation; CTI Biopharma; Sierra Oncology; Roche; Imago Biosciences; Incyte							Yes	
Education Program	Myeloproliferative Neoplasms: Managing the Cup that Runneth Over		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Beyond JAK-STAT: Novel Therapeutic Targets in Ph-negative MPN	Aaron	Gerds	MD, MS	Cleveland Clinic Taussig Cancer Institute	Speaker	Yes	Oral	Disclosure made		Pfizer; Incyte; Celgene Corporation; CTI Biopharma; Pfizer; Incyte		Imago Biosciences; Incyte; Celgene Corporation; CTI Biopharma; Sierra Oncology; Roche; Imago Biosciences; Incyte							Yes	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical Emerging and Novel Targeted Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia	Aaron	Gerds	MD, MS	Cleveland Clinic	Presenter	Yes	Oral	Disclosure made		Celgene Corporation; CTI Biopharma; Pfizer; Incyte		Celgene Corporation; CTI Biopharma; Sierra Oncology; Roche; Imago Biosciences; Incyte							Yes	Luspatercept is an investigational therapy that is not approved for any use in any country. Luspatercept is currently being evaluated for potential use in patients with anemia due to myelodysplastic syndromes, beta-thalassemia, or myelofibrosis.
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical JAK Inhibitors and Combination Therapies		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Results of PACISI: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib	Aaron	Gerds	MD, MS	Cleveland Clinic Taussig Cancer Institute	Presenter	Yes	Oral	Disclosure made		Celgene Corporation; CTI Biopharma; Pfizer; Incyte		Celgene Corporation; CTI Biopharma; Sierra Oncology; Roche; Imago Biosciences; Incyte							No	
How I Treat: Bringing Science to Clinical Dilemmas	Defining Treatment Strategies for MDS/MPN Overlap Syndromes		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Aaron	Gerds	MD, MS	Cleveland Clinic Taussig Cancer Institute	Speaker	No	Oral	Disclosure made		Celgene Corporation; CTI Biopharma; Pfizer; Incyte		Celgene Corporation; CTI Biopharma; Sierra Oncology; Roche; Imago Biosciences; Incyte								
Oral and Poster Abstracts	903. Health Services Research: Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group	Kelly	Getz		University of Pennsylvania-Perelman School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	903. Health Services Research: Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Home or Away From Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Venous Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia	Kelly	Getz		Children's Hospital of Philadelphia	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Preclinical Models, Immunotherapy, and CAR T Cells		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism	Paolo	Ghia	MD, PhD	Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele	Presenter	Yes	Oral	Disclosure made		AbbVie; Acerta/AstraZeneca; ArQule; BeiGene; Dynamo; Gilead; Janssen; Juno/Celgene; Sunesis; Pharmacyclics LLC, an AbbVie Company		AbbVie; Gilead; Janssen; Sunesis; Novartis	AbbVie; Acerta/AstraZeneca; ArQule; BeiGene; Dynamo; Gilead; Janssen; Juno/Celgene; Sunesis						No	
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Gabriel	Ghiaur	MD, PhD	John's Hopkins Hospital	Moderator	No	Oral	Nothing to disclose												
Education Program	Challenges in Multiple Therapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Irene	Ghobrial	MD	Harvard Medical School	Chair	No	Oral	Nothing to disclose												
Education Program	Challenges in Multiple Therapy		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Irene	Ghobrial	MD	Harvard Medical School	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	654. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refining the Approach		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile	Sara	Ghorashian	FRCPath, PhD	UCL Great Ormond Street Institute of Child Health	Presenter	Yes	Oral	Disclosure made					novartis; Celgene						No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Comparative Analyses		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL): a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis	Nilanjan	Ghosh	MD, PhD	Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System	Presenter	Yes	Oral	Disclosure made		Gilead; Janssen; Pharmacyclics LLC, an AbbVie Company; SGN; TG Therapeutics; Celgene		Janssen; Pharmacyclics LLC, an AbbVie Company; SGN; TG Therapeutics; Celgene; Genentech; Forty Seven Inc	AstraZeneca; Bristol-Myers Squibb; Gilead; Janssen; Pharmacyclics LLC, an AbbVie Company; SGN; TG Therapeutics		AstraZeneca; Bristol-Myers Squibb; Gilead; Janssen; Pharmacyclics LLC, an AbbVie Company; SGN				No	
Oral and Poster Abstracts	113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational Science: Novel Therapeutic Approaches for Pain and Organ Pathology in Sickle Cell Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Hemopexin Replacement Therapy Protects Sickle Cell Disease Mice from Acute Kidney Injury	Samit	Ghosh		University of Pittsburgh	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Reduced Risk of Relapse for Total Body Irradiation + Fludarabine Compared to Busulphan + Fludarabine As Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Treated with Allohsct in First Complete Remission. a Study By the Acute Leukemia Working Party of the EBMT	Sebastian	Giebel	MD, PhD	Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Molecular Insights and Modeling		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	VPS4A mutations Cause a Syndrome with Dyserythropoiesis, Hemolytic Anemia, and Neurodevelopmental Delay	Katie	Giger Seu	PhD	Cincinnati Children's Hospital Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma: Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2016 Phase II Trial	Eva	Gine	MD	Hospital Clinic of Barcelona. IDIBAPS. University of Barcelona	Presenter	Yes	Oral	Disclosure made				Janssen; Gilead; Roche							No	
Education Program	9ION: How to Manage When There is Too Much or Too Little of It		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	New Diagnostic Tools for Iron Deficiency	Yelena	Ginzburg	MD	Mount Sinai School of Medicine	Speaker	Yes	Oral	Disclosure made								La Jolla Pharma			No	
Education Program	9ION: How to Manage When There is Too Much or Too Little of It		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	New Diagnostic Tools for Iron Deficiency	Yelena	Ginzburg	MD	Mount Sinai School of Medicine	Speaker	Yes	Oral	Disclosure made								La Jolla Pharma			No	
Oral and Poster Abstracts	102. Regulation of Iron Metabolism: Novel Players in Iron Homeostasis in Health and Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Yelena	Ginzburg	MD	Icahn School of Medicine at Mount Sinai	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	321. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases	Thomas	Girard		Washington University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	622. Lymphoma Biology: Non-Genetic Studies: Tumor Microenvironment		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		James	Godfrey	MD	University of Chicago	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Multi-Center Phase 2 Study of Pembrolizumab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (EFS≤400 Years) AML Patients	Ivana	Gojo	MD	Johns Hopkins University	Presenter	Yes	Oral	Disclosure made		Amgen Inc; Jazz; Novartis; Abbvie		Amphivena; Amgen Inc; Juno; Merck	Amgen Inc; Jazz; Novartis; Abbvie						Yes	Pembrolizumab - a PD1 checkpoint inhibitor which is not approved in AML (off-label drug use)
Oral and Poster Abstracts	704. Immunotherapies II		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	A Phase 1B Study of Blinatumomab (blina) in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance	Ivana	Gojo	MD	Johns Hopkins University	Presenter	Yes	Oral	Disclosure made		Amgen Inc; Jazz; Novartis; Abbvie		Amphivena; Amgen Inc; Juno; Merck	Amgen Inc; Jazz; Novartis; Abbvie						Yes	Blinatumomab is not labeled for use as post-transplant maintenance therapy or for use in the non-Hodgkin lymphoma.
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Ivana	Gojo	MD	Johns Hopkins University	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	903. Health Services Research: Non-Malignant Conditions: Improving Quality in Hemoglobin		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Venous Thromboembolism (VTE) in Sickle Cell Disease (SCD) Is Associated with Neutropenia	Jahnavi	Gollamudi	MD	University Hospitals Cleveland Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	303. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: New Concepts and Perspectives		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Understanding How Fc-Modification Transforms a Pathogenic Heparin-Induced Thrombocytopenia (HIT)-like Monoclonal Antibody into a Novel Treatment for Sepsis	Kandace	Gollomp	MD	Children's Hospital of Philadelphia	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	603. Clonal Hematopoiesis: Aging and Inflammation		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Lukasz	Gondek	MD,PhD	Johns Hopkins	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	704. Immunotherapies II		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel	Zinaida	Good	PhD	Stanford University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Risk Stratification and Novel Approaches to Reduce Toxicity in Allogeneic Transplantation		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Stacey	Goodman	MD	Vanderbilt University Medical Center	Moderator	No	Oral	Nothing to disclose												
Education Program	Transfusion Medicine: Optimizing Patient Blood Management (PBM)		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Clinic Decision Support to Improve Blood Utilization	Lawrence	Goodnough	MD	Stanford University School of Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Transfusion Medicine: Optimizing Patient Blood Management (PBM)		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Clinic Decision Support to Improve Blood Utilization	Lawrence	Goodnough	MD	Stanford University School of Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Transfusion Medicine: Optimizing Patient Blood Management (PBM)		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Lawrence	Goodnough	MD	Stanford University School of Medicine	Chair	No	Oral	Nothing to disclose												
Education Program	Transfusion Medicine: Optimizing Patient Blood Management (PBM)		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Lawrence	Goodnough	MD	Stanford University School of Medicine	Chair	No	Oral	Nothing to disclose												
Education Program	Indolent Lymphomas: The Marathon Has a New Course		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Where Does Transplant Fit in the Age of Targeted Therapies?	Ajay	Gopal	MD	Seattle Cancer Care Alliance	Speaker	Yes	Oral	Disclosure made		Seattle Genetics; Pfizer; Janssen; Gilead; Sanofi; Spectrum; Amgen; Aptevo; BRIM bio; Acerta; I-Mab-pharma; Takeda; Compliment; Asana Bio; and Incyte.		Teva; Bristol-Myers Squibb; Merck; Takeda; Seattle Genetics; Pfizer; Janssen; Takeda; and Effector	Seattle Genetics; Pfizer; Janssen; Gilead; Sanofi; Spectrum; Amgen; Aptevo; BRIM bio; Acerta; I-Mab-pharma; Takeda; Compliment; Asana Bio; and Incyte						Yes	
Education Program	Indolent Lymphomas: The Marathon Has a New Course		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Where Does Transplant Fit in the Age of Targeted Therapies?	Ajay	Gopal	MD	Seattle Cancer Care Alliance	Speaker	Yes	Oral	Disclosure made		Seattle Genetics; Pfizer; Janssen; Gilead; Sanofi; Spectrum; Amgen; Aptevo; BRIM bio; Acerta; I-Mab-pharma; Takeda; Compliment; Asana Bio; and Incyte.		Teva; Bristol-Myers Squibb; Merck; Takeda; Seattle Genetics; Pfizer; Janssen; Takeda; and Effector	Seattle Genetics; Pfizer; Janssen; Gilead; Sanofi; Spectrum; Amgen; Aptevo; BRIM bio; Acerta; I-Mab-pharma; Takeda; Compliment; Asana Bio; and Incyte						Yes	
Education Program	Expanding Horizons for Immunotherapy in Pediatric Leukemia		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Moving Immunotherapy into the Frontline in ALL	Lia	Gore	MD	University of Colorado, Children's Hospital Colorado	Speaker	Yes	Oral	Disclosure made		Amgen; Novartis; Roche/Genentech	Amgen; Arcchiano; Blueprint Medicines; Celgene; Clovis; Micari; Sanofi Paris		Amgen; Roche/Genentech			Amgen			Yes	

Education Program	Expanding Horizons for Immunotherapy in Pediatric Leukemia		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Moving Immunotherapy into the Frontline in ALL	Lia	Gore	MD	University of Colorado, Children's Hospital Colorado	Speaker	Yes	Oral	Disclosure made		Amgen; Novartis; Roche/Genentech	Amgen; Anchiano; Blueprint Medicines; Celgene; Clovis; Mirati; Sanofi Paris		Amgen; Roche/Genentech			Amgen		Yes	
General Sessions	Late-Breaking Abstracts Session		Tuesday, December 10, 2019	7:30 AM	9:00 AM	Yes	1.5		Jason	Gotlib	MD, MS	Stanford Cancer Center	Co-chair	No	Oral	Disclosure made			Blueprint Medicines; Celgene; Deciphera; Gilead; Incyte; Novartis; Promedior; Pharmacyclics; Seattle Genetics	Abbios; Blueprint Medicines; Celgene; Deciphera; Gilead; Incyte; Novartis			Abbios; Blueprint Medicines; Celgene; Deciphera; Gilead; Incyte; Novartis			
Scientific Program	From Blood to Single Cells: Emerging Concepts and Technologies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Application of Single Cell Technologies to the Study of Hemopoiesis	Bertie	Göttgens	DPhil	University of Cambridge	Speaker	Yes	Oral	Disclosure made		Novo Nordisk; Autolus		Astra Zeneca; GSK; Novo Nordisk; Autolus						No	
Scientific Program	From Blood to Single Cells: Emerging Concepts and Technologies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Application of Single Cell Technologies to the Study of Hemopoiesis	Bertie	Göttgens	DPhil	University of Cambridge	Speaker	Yes	Oral	Disclosure made		Novo Nordisk; Autolus		Astra Zeneca; GSK; Novo Nordisk; Autolus						No	
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Epigenetic Alterations		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Genetic Vulnerabilities of *DNMT3A*^{R882} in Myeloid Malignancies	Malgorzata	Gazdecka	PhD	Haematological Cancer Genetics, Wellcome Sanger Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	ASH Choosing Wisely® Campaign: 2019 ASH Choosing Wisely Champions		Monday, December 9, 2019	12:15 PM	1:15 PM	Yes	1	Recommendations for Newly Diagnosed Children with Immune Thrombocytopenia (ITP)	Rachael	Grace	MD	Dana-Farber Boston Children's Cancer and Blood Disorders Center	Speaker	Yes	Oral	Disclosure made		Agios Pharmaceuticals, Inc		Agios Pharmaceuticals, Inc; Novartis				Agios Pharmaceuticals, Inc			
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Immune Thrombocytopenia		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Speaker 3	Rachael	Grace	MD	Children's Hospital Boston	Speaker	Yes	Oral	Disclosure made		Agios Pharmaceuticals, Inc		Agios Pharmaceuticals, Inc; Novartis				Agios Pharmaceuticals, Inc			
Oral and Poster Abstracts	605. Lymphoma: Pre-Clinical|Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Michael	Green	PhD	University of Texas MD Anderson Cancer Center	Moderator	No	Oral	Nothing to disclose												
General Sessions	E. Donnall Thomas Lecture and Prize	The Long Road to Develop Adoptive Therapy with T cells that can Effectively Target AML and Other Malignancies	Monday, December 9, 2019	9:00 AM	10:00 AM	Yes	1	*The Long Road to Develop Adoptive Therapy with T cells that can Effectively Target AML and Other Malignancies*	Philip	Greenberg	MD	Fred Hutchinson Cancer Research Center	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hemophagocytic Lymphohistiocytosis and Other Immune Disorders		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	The Tetraspanin CD53 Regulates Early B Cell Development By Promoting IL-7R Signaling	Zev	Greenberg	BS	Washington University in St. Louis	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results From Prospective Clinical Trials		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group	Henrik	Gregersen	MD, PhD	Aalborg University Hospital	Presenter	Yes	Oral	Nothing to disclose												No	
General Sessions	ASH-EHA Joint Symposium: Hemato-Metabolism - Linking Cellular Metabolism to Blood Diseases		Sunday, December 8, 2019	12:30 PM	1:30 PM	Yes	1		John	Griffiths	MD, DSc	Barts Cancer Institute, Queen Mary University of London	Co-chair	No	Oral	Disclosure made		Abbvie; Celgene; Acerta/Astra Zeneca; Janssen		Abbvie; Celgene; Acerta/Astra Zeneca; Janssen	Abbvie; Celgene; Acerta/Astra Zeneca; Janssen						
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: MYC and Beyond		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Ilira	Gritsman	MD, PhD	Albert Einstein College of Medicine	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag	Emma	Groarke	MD	National Institutes of Health	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: New Concepts and Perspectives		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Peter	Gross	MD	Thrombosis and Atherosclerosis Research Institute McMaster University	Moderator	No	Oral	Disclosure made					Bayer; Bristol-Meyers-Squibb; Leo Pharma; Pfizer							
Oral and Poster Abstracts	637. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Advances in Understanding the Pathophysiology of AML		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses	Tanja	Gruber	MD, PhD	St. Jude Children's Research Hospital	Presenter	Yes	Oral	Disclosure made					Bristol-Myers Squibb							Na
Oral and Poster Abstracts	221. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Genetic Duplication of Tissue Factor Leads to Partial Specialization of Function in Zebrafish	Steven	Gregorski	BA	University of Michigan	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine	Xiaorong	Gu	PhD	Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion	Yihong	Guan	PhD	Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia	Yihong	Guan	PhD	Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromes|Clinical Studies: Combination Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)	Veronica	Guerra	MD		Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)	Veronica	Guerra	MD		Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	622. Lymphoma Biology|Non-Genetic Studies: Tumor Microenvironment		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL	Carmina Louise	Guerrero	MS	University of the Ryukyus	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hemophagocytic Lymphohistiocytosis and Other Immune Disorders		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Martin	Guimond	PhD	University of Montreal, Maisonneuve-Rosemont Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	906. Health Services Research|Non-Malignant Conditions: Cancers and Thrombosis		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost-Effective Analysis	Shuchi	Gulati	MD	University of Cincinnati	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Epigenetic Alterations		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Olga	Gurynovova	MD,PhD	University of Florida	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	781. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD and Thymus Regeneration: Role of Innate Cells and Non-Hematopoietic Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Thymus Regeneration is Dependent on Distinct Mesenchymal Stromal Cell Populations	Karin	Gustafsson	PhD	Massachusetts General Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	904. Outcomes Research|Non-Malignant Conditions II		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Development and Validation of a Functional Status-Based Pain Assessment Tool	Margaret	Guy	MD	Virginia Commonwealth University	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	What's New in the Diagnosis and Management of von Willebrand Disease?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	New Advances in the Diagnosis of VWD	Sandra	Haberichter	PhD	Medical College of Wisconsin	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	What's New in the Diagnosis and Management of von Willebrand Disease?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	New Advances in the Diagnosis of VWD	Sandra	Haberichter	PhD	Medical College of Wisconsin	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	What's New in the Diagnosis and Management of von Willebrand Disease?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Sandra	Haberichter	PhD	Versiti	Chair	No	Oral	Nothing to disclose												
Education Program	What's New in the Diagnosis and Management of von Willebrand Disease?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Sandra	Haberichter	PhD	Versiti	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	622. Lymphoma Biology|Non-Genetic Studies: Molecular Mechanisms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing	Sarah	Heebe	MD	Stanford University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	606. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Transcription Factor Induction of Ectopic Vascular Blood Stem Cell Niches In Vivo	Elliott	Hagedorn	PhD	Boston Children's Hospital, Howard Hughes Medical Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Disruption of ADAMTS13-Autoantibody Complexes with an ADAMTS13 Spacer Domain As a Potential Therapeutic Strategy for Immune Thrombotic Thrombocytopenic Purpura	Konstantine	Helkofo	MD,PhD	The University of Alabama at Birmingham	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Anna	Halpern	MD	University of Washington	Moderator	No	Oral	Disclosure made				Pfizer Pharmaceuticals; Bayer Pharmaceuticals; Imago								
Oral and Poster Abstracts	902. Health Services Research|Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Mehdi	Hamadani	MD	Medical College of Wisconsin	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Betty	Hamilton	MD	Cleveland Clinic Foundation	Moderator	No	Oral	Nothing to disclose												
Education Program	Aging and Hematologic Disorders: Exploring the Evidence		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Designing Clinical Trials for Older Adults with Hematologic Malignancies	Paul	Hamlin	MD	Memorial Sloan Kettering Cancer Center	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Aging and Hematologic Disorders: Exploring the Evidence		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Designing Clinical Trials for Older Adults with Hematologic Malignancies	Paul	Hamlin	MD	Memorial Sloan Kettering Cancer Center	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Alan	Hanash	MD, PhD	Memorial Sloan Kettering Cancer Center	Co-Chair	No	Oral	Disclosure made		Nexus Global Group LLC										
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Alan	Hanash	MD, PhD	Memorial Sloan Kettering Cancer Center	Co-Chair	No	Oral	Disclosure made		Nexus Global Group LLC										
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Alan	Hanash	MD, PhD	Memorial Sloan Kettering Cancer Center	Co-Chair	No	Oral	Disclosure made		Nexus Global Group LLC										
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma|Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AMU Study	Sasanka	Handunnetti	MBBS, FRACP, FACPA	Peter MacCallum Cancer Centre	Presenter	Yes	Oral	Disclosure made					Gilead						Yes	While ibrutinib is FDA approved for use in relapsed and refractory mantle cell lymphoma, venetoclax and combination venetoclax and ibrutinib are not licensed for use in mantle cell lymphoma. The use of venetoclax and ibrutinib for this indication is investigational.
Education Program	Sickle Cell Disease in Young and Old: A Time for Re-Evaluation		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	A Program of Transition to Adult Care	Jane	Hankins	MD, MS	St. Jude Children's Research Hospital	Speaker	Yes	Oral	Disclosure made		National Committee for Quality Assurance; Bluebird Bio		Global Blood Therapeutics; NHLBI; LYMIS Foundation; Novartis	NHLBI; ASPHO						No	
Education Program	Sickle Cell Disease in Young and Old: A Time for Re-Evaluation		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	A Program of Transition to Adult Care	Jane	Hankins	MD, MS	St. Jude Children's Research Hospital	Speaker	Yes	Oral	Disclosure made		National Committee for Quality Assurance; Bluebird Bio		Global Blood Therapeutics; NHLBI; LYMIS Foundation; Novartis	NHLBI; ASPHO						No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia|Clinical: Optimizing and Improving Access to High-Quality Care		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Jane	Hankins	MD, MS	St. Jude Children's Rsch. Hosp.	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results From Prospective Clinical Trials		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Parameswaran	Hari	MBBS, MD	Medical College of Wisconsin	Moderator	No	Oral	Disclosure made		Celgene; Takeda; BMS; Janssen; Kite; Spectrum; AbbVie	Cell Vault	Celgene; Takeda; BMS; Amgen; Spectrum; Sanofi	Celgene; Takeda; Janssen; Kite; Sanofi; AbbVie							
Oral and Poster Abstracts	904. Outcomes Research|Non-Malignant Conditions II		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	The Relationship between Mental Health, Educational Attainment, Employment Outcomes, and Pain in Sickle Cell Disease	Kelly	Harris	PhD	Washington University in St. Louis, School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	

Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib	Claire	Harrison	Professor	Guy's and St Thomas NHS Foundation Trust	Presenter	Yes	Oral	Disclosure made				Novartis	Novartis; ADIP; Celgene; Roche; Sierra Oncology; Promedior		Novartis; Janssen; Celgene; CTI; Gilead; Incyte; Shire			No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis	Claire	Harrison	Professor	Guy's and Saint Thomas' NHS Foundation Trust	Presenter	Yes	Oral	Disclosure made					Celgene; Roche; Sierra Oncology; Promedior		Janssen; Celgene; CTI; Gilead; Incyte; Shire			No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dscrasias		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study	Simon	Harrison	MBBS, MRCP, FRCPath, FRACP, PhD	Peter MacCallum Cancer Centre	Presenter	Yes	Oral	Disclosure made		Janssen Cilag; Takeda; AbbVie; Celgene; Amgen; Novartis; GSK		Janssen Cilag; Takeda; AbbVie; Celgene; Amgen; Novartis; GSK	Janssen Cilag; Takeda; AbbVie; Celgene; Amgen; Novartis			Janssen Cilag; Takeda; AbbVie; Celgene; Amgen; Novartis		Yes	Venetoclax is a BCL-2 inhibitor that is FDA-approved in some indications. This presentation will focus on venetoclax for treatment of multiple myeloma, which is not an approved indication.
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Retrospective/Observational Studies: Population-Based Outcomes		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Incidence of Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden	Sara	Harryvan	MD	Division of Clinical Epidemiology, Dept of Medicine Solna, Karolinska Institutet	Presenter	Yes	Oral	Disclosure made										No	
Oral and Poster Abstracts	231. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Identification of Thrombospondin-1 As a Novel Substrate of Ceneblon Responsible for IMiDs-Induced Venous Thromboembolism	Kiwamu	Hatakeyama	MD	Ayushu University Hospital	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia	Masayasu	Hayashi	MD, PhD	Ayushu University Graduate School of Medical Sciences	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Rhoa Targeting Suppresses Cold-Induced Platelet Lesion and Allows Refrigerated Storage of Functional Human Platelets to Fourteen Days	Shailaja	Hegde	PhD	University of Cincinnati	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels	Alâ€dger	Hehlmann	MD	ELN-Foundation	Presenter	Yes	Oral	Disclosure made				Novartis						No	
Oral and Poster Abstracts	652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Functional Characterization of Novel Molecular Drivers and Vulnerabilities of Myeloma Cells		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	The IMID-Target Ceneblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism	Michael	Heider		Technichal University Munich	Presenter	Yes	Oral	Nothing to disclose										No	
Special-Interest Sessions	Special Symposium on Quality: ASH EQ|IPS-Learning from Medical Errors and Other Incidents		Saturday, December 7, 2019	2:00 PM	2:30 PM	Yes	1.1		Nicole	Held	DO	Medical College of Wisconsin	Panelist	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	621. Lymphomaâ€"Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	An OCT2 / OCA-B / METZ8 Ternary Complex Controls the Activity and Architecture of an Essential Locus Control Region for Normal and Malignant Germinal Center B-Cells	Johannes	Hellmuth	MD	Department of Medicine III, University Hospital, LMU	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromesâ€"Clinical Studies: Lower-Risk MDS and CMML		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)	David	Henry	MD	Pennsylvania Hospital, University of Pennsylvania	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	605. Molecular Pharmacology, Drug Resistanceâ€"Lymphoid and Other Diseases II		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax	Charles	Herbaux	MD, MSc	Dana Farber Cancer Institute	Presenter	Yes	Oral	Disclosure made							Abbvie; Janssen; Takeda; BMS; Gilead					No	
Oral and Poster Abstracts	211. Disorders of Platelet Number or Function: Insights into the Pathophysiology of Platelet Disorders		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	An Adapting Bone Marrow Niche Creates a Nurturing Environment for Hematopoiesis during Immune Thrombocytopenia Progression	Oliver	Herd	BSc	University of York	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphomaâ€"Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma	Alex	Herrera	MD	City of Hope	Presenter	Yes	Oral	Disclosure made		Adaptive Biotechnologies; Bristol-Myers Squibb; Gilead Sciences; Seattle Genetics; AstraZeneca; Merck; Genentech, Inc.; Kite Pharma		Bristol-Myers Squibb; Gilead Sciences; Seattle Genetics; AstraZeneca; Merck; Genentech, Inc.; Pharmacyclics; Immune Design; Kite Pharma						No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Preliminary Results from a Phase 1 Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma	Alex	Herrera	MD	City of Hope National Medical Center	Presenter	Yes	Oral	Disclosure made		Adaptive Biotechnologies; Bristol-Myers Squibb; Gilead Sciences; Seattle Genetics; AstraZeneca; Merck; Genentech, Inc.; Kite Pharma		Bristol-Myers Squibb; Gilead Sciences; Seattle Genetics; AstraZeneca; Merck; Genentech, Inc.; Pharmacyclics; Immune Design; Kite Pharma						No	
Oral and Poster Abstracts	636. Myelodysplastic Syndromesâ€"Basic and Translational Studies: RNA Processing and Signatures in MDS		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.1	The Biological and Clinical Implications of the Alternative Splicing Landscape of: L,F5R Myeloid Neoplasm Cases	Courtney	Hershberger	BS	Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Molecular Insights and Modeling		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Mouse Erythroid Cells Originate from a Megakaryocyte Precursor in Common Myeloid Progenitors	Elisabeth	Heuston	PhD	NHGRI	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.1	Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation	Cindy Lynn	Hickey	MD,FRCPC	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	801. Health Services Researchâ€"Non-Malignant Conditions: Bleeding and Blood Loss		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Patient Harm from Repetitive Blood Draws and Blood Waste in the ICU: A Retrospective Cohort Study	Lisa	Hicks	MD, MSc	St. Michael's Hospital	Presenter	Yes	Oral	Nothing to disclose										No	
Spotlight Sessions	Diane Into Rare Childhood Leukemias		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Childhood Chronic Myeloid Leukemia	Nobuko	Hiiiva	MD	Columbia University Medical Center	Speaker	Yes	Oral	Disclosure made		Novartis			Novartis						Yes	
Oral and Poster Abstracts	622. Lymphoma Biology â€"Non-Genetic Studies: Tumor Microenvironment		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma	Johannes	Heidebrand	MSc, BSc	University Hospital, LMU Munich	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Stromal Cell Immune Regulation in the Microenvironment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.1		Geoffrey	Hill	MD	Fred Hutchinson Cancer Research Center	Chair	No	Oral	Disclosure made				Pharmacyclics; Roche; Commonwealth Serum Laboratories; Implicit								
Scientific Program	Stromal Cell Immune Regulation in the Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.1		Geoffrey	Hill	MD	Fred Hutchinson Cancer Research Center	Chair	No	Oral	Disclosure made				Pharmacyclics; Roche; Commonwealth Serum Laboratories; Implicit								
How I Treat: Bringing Science to Clinical Dilemmas	Update on Complement Inhibition in PNH, Atypical HUS, and other Hemolytic Anemias		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Peter	Hillmen	MD, PhD	St. James's University Hospital	Speaker	No	Oral	Disclosure made		AbbVie; Janssen; Pharmacyclics LLC, an AbbVie Company		AbbVie; Janssen; Pharmacyclics LLC, an AbbVie Company; Roche; Gilead; Apellis	AbbVie; Janssen; Pharmacyclics LLC, an AbbVie Company			AbbVie; Janssen; Acerta			
Oral and Poster Abstracts	638. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genomic Landscape and Disease Classification		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis From the Pontie Di Lagno Childhood ALL Working Group	Shinsuke	Hirabayashi		Hokkaido University, Graduate school of Medicine	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction	Johann	Hitzler	MD	The Hospital for Sick Children	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphomaâ€"Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma	Jessica	Hochberg	MD	New York Medical College	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Nilotinib Vs Nilotinib Plus Pegylated Interferon Is (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy For Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response	Andreas	Hochhaus	MD	Universitätsklinikum Jena	Presenter	Yes	Oral	Disclosure made				Pfizer; Novartis; BMS; Incyte; MRD						Yes	Combination of Nilotinib and PEG-IFN alpha is being tested is off-label and being tested in the TIGER study
Oral and Poster Abstracts	636. Myelodysplastic Syndromesâ€"Basic and Translational Studies: RNA Processing and Signatures in MDS		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Bolf-Karsten	Hofmann	MD, PhD	Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.1		Craig	Hofmeister	MD,MPH	Emory University School of Medicine	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Marie	Hollenhorst	MD, PhD	Stanford	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Risk Stratification and Novel Approaches to Reduce Toxicity in Allogeneic Transplantation		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation	Sherman	Holtan	MD	University of Minnesota	Presenter	Yes	Oral	Disclosure made		Incyte; Bristol-Myers Squibb; Janssen; CSL Behring									No	
Oral and Poster Abstracts	503. Clonal Hematopoiesis: Aging and Inflammation		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Infection Is a Driver of Dnmt3a-Mutant Clonal Hematopoiesis	Daniel	Hormaechea Aguila	PhD	Baylor College of Medicine/Texas Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
General Sessions	Presidential Symposium	The Use of Big Data in Hematology Research and Delivery of Personalized Healthcare	Tuesday, December 10, 2019	9:45 AM	11:15 AM	Yes	1.5	The Use of Registries to Inform Therapeutic Decisions for the Treatment of Hematologic Diseases with Cellular and Immune Therapies	Mary	Horowitz	MD, MS	Medical College of Wisconsin	Speaker	Yes	Oral	Disclosure made				Sanofi							Yes	Many of the drugs commonly used in hematopoietic stem cell transplantation do not have a label indication for this use. I will be presenting some examples that may mention one or more of these drugs.

Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma“Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5	A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma	Steven	Horwitz	MD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made		Affimed; Affimed; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Astex; Astex; Celgene; Celgene; Infinity/Verastem; Infinity/Verastem; Innate Pharma; Innate Pharma; Kura; Kura; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Millennium/Takeda; Millennium/Takeda; Miragen; Affimed; Miragen; Mundipharma; Affimed; Mundipharma; Portola; Corvus Pharmaceuticals; Portola; Seattle Genetics; Astex; Corvus Pharmaceuticals; Seattle Genetics; Celgene; Astex; Celgene; Infinity/Verastem; Infinity/Verastem; Innate Pharma; Kura; Innate Pharma; Kyowa Hakko Kirin; Kura; Millennium/Takeda; Kyowa Hakko Kirin; Miragen; Millennium/Takeda; Mundipharma; Miragen; Portola; Mundipharma; Seattle Genetics; Portola; Seattle Genetics		ADCT Therapeutics; ADCT Therapeutics; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Celgene; Celgene; Infinity/Verastem; Infinity/Verastem; Millennium/Takeda; Millennium/Takeda; ADCT Therapeutics; Corvus Pharmaceuticals; ADCT Therapeutics; Seattle Genetics; Corvus Pharmaceuticals; Seattle Genetics; Aileron; Celgene; Aileron; Forty-Seven; Celgene; Infinity/Verastem; Forty-Seven; Trillium; Infinity/Verastem; Trillium; Millennium/Takeda; Millennium/Takeda; Seattle Genetics; Aileron; Seattle Genetics; Forty-Seven; Aileron; Trillium; Forty-Seven; Trillium				Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals		No	
Oral and Poster Abstracts	601. Health Services Research“Non-Malignant Conditions: Cancers and Thrombosis		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study	Damon	Houghton	MD,MS	Mayo Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5		Christopher	Hourigan	MD PhD	NIH/NHLBI	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1.5	The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Glycogen and Glycosylation-Umbrella (GUMB) Hypothesis	Tom	Howard	M.D., Ph.D.	The University of Texas Rio Grande Valley	Presenter	Yes	Oral	Disclosure made			Haplogenics Corporation						Haplogenics Corporation		No	
Oral and Poster Abstracts	605. Outcomes Research“Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed	Bei	Hu	MD	Levine Cancer Institute, Atrium Health	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	From Blood to Single Cells: Emerging Concepts and Technologies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5		Lily	Huang	PhD	University of Texas, Southwestern Medical Center	Chair	No	Oral	Nothing to disclose													
Scientific Program	From Blood to Single Cells: Emerging Concepts and Technologies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5		Lily	Huang	PhD	University of Texas, Southwestern Medical Center	Chair	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Advances in ITP Therapy		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5	Combination of ATRA and High-Dose Dexamethasone As First-Line Treatment in Adult Immune Thrombocytopenia(ITP): Randomized, Phase 2, Open-Label Trial	Qiu-Sha	Huang		Peking University People's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Insights into the Pathophysiology of Platelet Disorders		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	ATRA Could Correct the Defective S1P-Mediated Cytoskeletal Reorganization in Propleteleat Formation of ITP	Qiu-Sha	Huang		Peking University People's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	A Combination of CD102 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib	Timothy	Hughes	MD,MBBS,FRACP,FRCPA	South Australian Health and Medical Research Institute	Presenter	Yes	Oral	Disclosure made				Novartis; BMS							No	
Education Program	DOACS in the Real World		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	Is there a Role for Low Dose DOACs as Prophylaxis?	Beverley	Hunt		Guy's & St Thomas' NHS foundation Trust	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	DOACS in the Real World		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	Is there a Role for Low Dose DOACs as Prophylaxis?	Beverley	Hunt		Guy's & St Thomas' NHS foundation Trust	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Cure at What (Systemic) Financial Cost?	Scott	Huntington	MD, MPH	Yale University School of Medicine	Speaker	Yes	Oral	Disclosure made		Celgene; Bayer; Genentech; AbbVie		Celgene; DTRM Biopharm	Bayer; Pharmacyclics						No	
Education Program	Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Cure at What (Systemic) Financial Cost?	Scott	Huntington	MD, MPH	Yale University School of Medicine	Speaker	Yes	Oral	Disclosure made		Celgene; Bayer; Genentech; AbbVie		Celgene; DTRM Biopharm	Bayer; Pharmacyclics						No	
General Sessions	ASH-EHA Joint Symposium: Hemato-Metabolism - Linking Cellular Metabolism to Blood Diseases		Sunday, December 8, 2019	12:30 PM	1:30 PM	Yes		1	European Perspective: Systems Biology Approaches Identify Metabolic Mechanisms Underlying Hematologic Disorders	Brian	Huntly	MB ChB, FRCPath, PhD	University of Cambridge	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Biology and Therapeutic Opportunities		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL	Christian	Hurtz	PhD	University Of Pennsylvania	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genomic Landscape and Disease Classification		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5		Christian	Hurtz	PhD	University Of Pennsylvania	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	T Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature	Jani	Huuhtanen	BMed	Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Insights into the Pathophysiology of Platelet Disorders		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Pathogenic Antibodies in Heparin-Induced Thrombocytopenia Specifically Target an Immunodominant Region on Platelet Factor 4	Angela	Huynh	PhD	McMaster University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	901. Health Services Research“Non-Malignant Conditions: Improving Quality in Hematology		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Cerebrovascular Disease and Cognition in Adults with Sickle Cell Disease	Princess	Hamenago	BS, MS	Washington University at St. Louis, School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Novel Target		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Deficiency of CUL1, Encoded on 7q, Blocks the Normal HSC DNA Damage Response and Drives Highly Penetrant Therapy-Related Myeloid Neoplasms in Mice	Molly	Imgruet	BS	University of Chicago	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5		Philip	Imus	MD	Johns Hopkins University	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Novel Target		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias	Daichi	Inoue	MD, PhD	Foundation for Biomedical Research and Innovation at Kobe	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Advances in Lindersanding the Pathophysiology of AML		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5	Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias	Daichi	Inoue	MD, PhD	Foundation for Biomedical Research and Innovation at Kobe	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	201. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Molecular Insights and Modeling		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5		Achille	Iolascon	MD, PhD	CEINGE University Federico II of Naples	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: New Regulators of Stem and Progenitor Cell Survival and Differentiation		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	ER-1 Transcriptionally Integrates Microenvironmental Cues Sensing By Self-Renewing Hematopoietic Stem and Progenitor Cells	Tomer	Itkin	PhD	Ansary Stem Cell Institute, Weill Cornell Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromes“Clinical Studies: Lower-Risk MDS and CMML		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5		Raphael	Itzykson	MD, PhD	Hôpital Saint-Louis	Moderator	No	Oral	Nothing to disclose													
Education Program	Indolent Lymphomas: The Marathon Has a New Course		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Pushing the Pace with Novel Agents	Caron	Jacobson	MD	Dana Faber Cancer Institute	Speaker	Yes	Oral	Disclosure made		Kite, a Gilead Company; Novartis; Pfizer; Bayer; Humanigen; Celgene; Precision Biosciences		Kite, a Gilead Company; Pfizer	Kite, a Gilead Company; Novartis						No	
Education Program	Indolent Lymphomas: The Marathon Has a New Course		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Pushing the Pace with Novel Agents	Caron	Jacobson	MD	Dana Faber Cancer Institute	Speaker	Yes	Oral	Disclosure made		Kite, a Gilead Company; Novartis; Pfizer; Bayer; Humanigen; Celgene; Precision Biosciences		Kite, a Gilead Company; Pfizer	Kite, a Gilead Company; Novartis						No	
Education Program	Indolent Lymphomas: The Marathon Has a New Course		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5		Caron	Jacobson	MD	Dana Faber Cancer Institute	Chair	No	Oral	Disclosure made		Kite, a Gilead Company; Novartis; Pfizer; Bayer; Humanigen; Celgene; Precision Biosciences		Kite, a Gilead Company; Pfizer	Kite, a Gilead Company; Novartis							
Education Program	Indolent Lymphomas: The Marathon Has a New Course		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5		Caron	Jacobson	MD	Dana Faber Cancer Institute	Chair	No	Oral	Disclosure made		Kite, a Gilead Company; Novartis; Pfizer; Bayer; Humanigen; Celgene; Precision Biosciences		Kite, a Gilead Company; Pfizer	Kite, a Gilead Company; Novartis							
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)“Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5		Caron	Jacobson	MD	Dana Faber Cancer Institute	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	604. Outcomes Research“Non-Malignant Conditions III		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5		Julie	Jaffray	MD	Children's Hospital of Los Angeles	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?	Deepa	Jagadeesh	MD,MPH	Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Mechanisms of and Therapies for cGVHD		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	KDQ25 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) “Long-Term Follow-up of a Phase 2a Study (KDQ25-208)	Madan	Jagasia	MBBS, MS, MRHC	Vanderbilt University Medical Center	Presenter	Yes	Oral	Disclosure made		Eadmor; Incyte		Janssen							No	
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)“Results from Retrospective/Observational Studies: Cellular Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry	Samantha	Jaglowski	MD	The James Cancer Hospital and Solove Research Institute of The Ohio State University Comprehensive Cancer Center,	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)“Results from Prospective Clinical Trials: Results from CAR T-Cell Trials		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium	Michael	Jain	MD,PhD	Moffitt Cancer Center	Presenter	Yes	Oral	Disclosure made		Kite/Gilead									No	

Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)	Nitin	Jain	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		AbbVie; Pharmacyclics, an AbbVie company; Janssen Pharmaceuticals, Inc.; Genentech; Pfizer; ADC Therapeutics; Incyte; AstraZeneca; Servier; Cellectis; Verastem; Precision Biosciences; Adaptive Biotechnologies		AbbVie; Pharmacyclics, an AbbVie company; Genentech; BMS; Pfizer; ADC Therapeutics; Incyte; AstraZeneca; Servier; Cellectis; Verastem; Precision Biosciences; Adaptive Biotechnologies			AbbVie; Pharmacyclics, an AbbVie company; Janssen Pharmaceuticals, Inc.; Genentech; Pfizer; ADC Therapeutics; AstraZeneca; Servier; Verastem; Precision Biosciences; Adaptive Biotechnologies			Yes	Combination of Ibrutinib and venetoclax is not FDA approved
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: First Line Treatment		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)	Nitin	Jain	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		AbbVie; Pharmacyclics, an AbbVie company; Janssen Pharmaceuticals, Inc.; Genentech; Pfizer; ADC Therapeutics; Incyte; AstraZeneca; Servier; Cellectis; Verastem; Precision Biosciences; Adaptive Biotechnologies		AbbVie; Pharmacyclics, an AbbVie company; Genentech; BMS; Pfizer; ADC Therapeutics; Incyte; AstraZeneca; Servier; Cellectis; Verastem; Precision Biosciences; Adaptive Biotechnologies	AbbVie; Pharmacyclics, an AbbVie company; Janssen Pharmaceuticals, Inc.; Genentech; Pfizer; ADC Therapeutics; AstraZeneca; Servier; Verastem; Precision Biosciences; Adaptive Biotechnologies			AbbVie; Pharmacyclics, an AbbVie company; Janssen Pharmaceuticals, Inc.; Genentech; Pfizer; ADC Therapeutics; AstraZeneca; Servier; Verastem; Precision Biosciences; Adaptive Biotechnologies			Yes	Combination of Ibrutinib and venetoclax is not FDA approved
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53	Nitin	Jain	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		AbbVie; Pharmacyclics, an AbbVie company; Janssen Pharmaceuticals, Inc.; Genentech; Pfizer; ADC Therapeutics; AstraZeneca; Servier; Cellectis; Verastem; Precision Biosciences; Adaptive Biotechnologies		AbbVie; Pharmacyclics, an AbbVie company; Genentech; BMS; Pfizer; ADC Therapeutics; Incyte; AstraZeneca; Servier; Cellectis; Verastem; Precision Biosciences; Adaptive Biotechnologies	AbbVie; Pharmacyclics, an AbbVie company; Janssen Pharmaceuticals, Inc.; Genentech; Pfizer; ADC Therapeutics; AstraZeneca; Servier; Verastem; Precision Biosciences; Adaptive Biotechnologies			AbbVie; Pharmacyclics, an AbbVie company; Janssen Pharmaceuticals, Inc.; Genentech; Pfizer; ADC Therapeutics; AstraZeneca; Servier; Verastem; Precision Biosciences; Adaptive Biotechnologies			Yes	Combination of Ibrutinib with chemotherapy is not FDA approved
Education Program	Junior Faculty Career Development Session		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Looking for an Academic Job and Show Me the Money: Negotiating Your Salary and Benefits	Siddhartha	Jaiswal	MD,PhD	Stanford University	Speaker	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	CD47 Regulates Red Blood Cell Alloimmunization in Mice	Ryan	Jajosky	MD	Emory University	Presenter	Yes	Oral	Nothing to disclose												No	
Education Program	Coagulation Conundrum Roundtable: Case-based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	The Obstetricians View	Andra	James	MD, MPH	Duke University	Speaker	Yes	Oral	Disclosure made						American Regent						No	
Education Program	Coagulation Conundrum Roundtable: Case-based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	The Obstetricians View	Andra	James	MD, MPH	Duke University	Speaker	Yes	Oral	Disclosure made						American Regent						No	
Oral and Poster Abstracts	703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors	Max	Jan	MD, PhD	Massachusetts General Hospital	Presenter	Yes	Oral	Disclosure made												No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Comparative Analyses		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	The Prognostic Impact of the Diagnostic CD34+/CD38- Cell Burden and Expression of the Stem Cell Marker GPR56 after Stem Cell Transplantation Depends on the AML Origin	Madlen	Jentzsch	MD	University Hospital Leipzig	Presenter	Yes	Oral	Disclosure made						Novartis; Jazz Pharmaceuticals						No	
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Clonal Evolution		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Notch1 mutation in B-Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression	Andres	Jerez		Hematology and Medical Oncology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain	Presenter	Yes	Oral	Disclosure made		Celgene				Celgene, Novartis			Celgene			No	
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Deepa	Jeyakumar	MD	UC Irvine Medical Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Feng	Ji	MD,PhD	Northwestern University Medical School	Moderator	No	Oral	Disclosure made		Longbiopharma											
Oral and Poster Abstracts	705. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD and Thymus Regeneration: Role of Innate Cells and Non-Hematopoietic Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	IL-22 Therapy Prevents Acute Lung Injury after Transplantation Via IL-9-Producing Type 2 Innate Lymphoid Cells Induction	Hua	Jiang	PhD	Indiana University	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351(Ξ) Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI) in Patients with TKI Resistant Chronic Myeloid Leukemia	Qian	Jiang	MD	Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Novel Target		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Integrating Enhancer Profiling and CRISPR Dropout Screen Revealed Selenoprotein Synthesis Pathway As a New Vulnerability in AML	Yajian	Jiang	MBBS	Baylor College of Medicine	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of Pathogenesis, Drug Sensitivity, and Resistance; and Role of Bone Marrow Microenvironment and Host Microbiome in Myeloma Pathogenesis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	BRF1 Is Reciprocally Dysregulated Via NF-ΙΚΒ-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma	Fengyun	Jin	MD, PhD	The First Hospital of Jilin University	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	621. Lymphoma: Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution	Erel	Joffe	MD,MSc	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia: Clinical: Optimizing and Improving Access to High-Quality Care		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Optimizing Hydroxyurea Dosing In Sickle Cell Anemia: The Uganda MTD Study	Chandy	John	MD,MS	Indiana University	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphoma): Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 PHoenix Trial	Peter	Johnson	MD,FRCP	Cancer Research UK Clinical Centre, University of Southampton	Presenter	Yes	Oral	Disclosure made		Janssen		Janssen; Epizyme		Takeda; Bristol-Myers Squibb; Novartis; Celgene; Kite; Genmab; Incyte; Janssen; Epizyme; Boehringer Ingelheim						No	
Oral and Poster Abstracts	606. Outcomes Research: Non-Malignant Conditions III		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Post-Discharge Risk of Venous Thromboembolism in a Primary Care Population	Nimena	Jordan Bruno	MD	Larner College of Medicine at the University of Vermont	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia: Clinical: Predicting Risk: A Focus on Disease Severity and Fertility		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Effect of Hydroxyurea Exposure before Puberty on Sperm Parameters in Males with Sickle Cell Disease	Laure	Joseph	MD.	Necker-Enfants Malades Hospital	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	608. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	A Novel Source of Endogenous DNA Damage That Requires Repair by the Fanconi Anemia Pathway	Moonjung	Jung	MD	The Rockefeller University	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma: Clinical Studies: Follicular Lymphoma: Biomarkers and Clinical Trials		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: CZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy	Vindi	Jurinovic	PhD	University Hospital, LMU Munich	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Molecular Insights and Modeling		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Evaluating Metabolic Regulation of Human Erythropoiesis By Profiling Nutrient Transporter Expression	David	Justus	MD	NYP Weill Cornell Medical Center	Presenter	Yes	Oral	Nothing to disclose												No	
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Genomic Analysis of Hodgkin Lymphoma	Ralf	Küppers	PhD	University of Duisburg-Essen	Speaker	Yes	Oral	Nothing to disclose												No	
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Genomic Analysis of Hodgkin Lymphoma	Ralf	Küppers	PhD	University of Duisburg-Essen	Speaker	Yes	Oral	Nothing to disclose												No	
Scientific Program	Chromatin Structure in Development and Disease		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Structure and Function of ATP-Dependent Chromatin Remodeling Complexes in Human Cancer	Cigall	Kadoch	PhD	Dana-Farber Cancer Institute, Harvard Medical School	Speaker	Yes	Oral	Disclosure made		Foghorn Therapeutics	Foghorn Therapeutics						Foghorn Therapeutics			No	
Scientific Program	Chromatin Structure in Development and Disease		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Structure and Function of ATP-Dependent Chromatin Remodeling Complexes in Human Cancer	Cigall	Kadoch	PhD	Dana-Farber Cancer Institute, Harvard Medical School	Speaker	Yes	Oral	Disclosure made		Foghorn Therapeutics	Foghorn Therapeutics						Foghorn Therapeutics			No	
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Chromatin Structure in Development and Disease		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Cigall	Kadoch	PhD	Dana-Farber Cancer Institute, Harvard Medical School	Speaker	No	Oral	Disclosure made		Foghorn Therapeutics	Foghorn Therapeutics						Foghorn Therapeutics				
Education Program	Junior Faculty Career Development Session		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Understanding Promotion and Tenure	Marc	Kahn	MD, MBA	Tulane University	Speaker	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results from Prospective Clinical Trials		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches	Martin	Kaiser		The Institute of Cancer Research	Presenter	Yes	Oral	Disclosure made		Abbvie, Celgene, Takeda, Janssen, Amgen, Abbvie, Karyopharm		Celgene, Janssen		Takeda, Janssen, Celgene, Amgen						No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia: Clinical: Emerging Therapies: Reports from Recent Clinical Trials		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects	Theodosia	Kalfa	MD, PhD	Cincinnati Children's Hospital Medical Center	Presenter	Yes	Oral	Disclosure made												No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Microbiome and Immune Regulation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Christopher	Kanakry	MD	The Johns Hopkins Sidney Kimmel Comprehensive Cancer Ctr.	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	802. Health Services Research: Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Abraham	Kanate	MD	West Virginia University	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma	Prashant	Kapoor	MD	Mayo Clinic	Presenter	Yes	Oral	Disclosure made		Sanofi; Cellectar		Amgen; Takeda; Glaxo Smith Kline; Sanofi; Janssen		Takeda; Celgene						Yes	Daratumumab in combination with Ixazomib, lenalidomide and dexamethasone for the management of newly diagnosed multiple myeloma
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dicrasias		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Prashant	Kapoor	MD	Mayo Clinic	Moderator	No	Oral	Disclosure made		Sanofi; Cellectar		Amgen; Takeda; Glaxo Smith Kline; Sanofi; Janssen		Takeda; Celgene							
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Molecular Analysis and Areas of Unmet Need		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	ATM Germline Variant Increases the Risk of MPN Progression	Theodoros	Karantanos	MD,PhD	Johns Hopkins University,Sidney Kimmel Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Molecular Analysis and Areas of Unmet Need		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden	Theodoros	Karantanos	MD,PhD	Johns Hopkins University,Sidney Kimmel Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include up-Regulated Innate Immune Modulators	Ahmad	Karim	PhD	Uniformed Services University of the Health Sciences	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia	Seth	Karol	MD	St. Jude Children's Research Hospital	Presenter	Yes	Oral	Disclosure made												No	Venetoclax is not approved in pediatrics
Special Scientific Symposia	Special Symposium on the Basic Science in Hemostasis and Thrombosis		Monday, December 9, 2019	4:30 PM	6:30 PM	Yes	2	Angiogenic Factors and Endothelial Dysfunction in Pre-eclampsia	Subban	Karumanchi	MD	Cedars-Sinai Medical Center	Speaker	Yes	Oral	Disclosure made		Thermofisher Scientific	Aggenin Pharmaceuticals										
Oral and Poster Abstracts	731. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Innovative Approaches in Allogeneic Transplantation for Pediatric or Nonmalignant Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507	Adesola	Kassim	MD,MS	Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Marano Trial	Arnon	Kater	MD, PhD	Amsterdam University Medical Centers, University of Amsterdam	Presenter	Yes	Oral	Disclosure made		AbbVie		AbbVie; Roche; Genentech	AbbVie							No	

Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: Fusion Genes		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Gata2 Expression and Function in PML-RARA-driven Preleukemia and APL	Casey	Katerndahl	PhD	Washington University in St. Louis	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: New Regulators of Stem and Progenitor Cell Survival and Differentiation		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Ingd Regulates Stress Hematopoiesis and Represses Self-Renewal in Multipotent Progenitor Cells	Katie	Kathmin	PhD	University of South Carolina	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hemophagocytic Lymphohistiocytosis and Other Immune Disorders		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Marie-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation	Karan	Kathuria		Stanford University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Challenges in Myeloma Therapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Roundtable: How Do I Treat a High-Risk Myeloma Patient?	Jonathan	Kaufman	MD	Emory University School of Medicine	Speaker	Yes	Oral	Disclosure made		Sanofi/Genzyme; Amgen; Celgene; Janssen: BMS: Takeda		Amgen; Celgene; Janssen; BMS; Takeda				Karyopharm; Incyte; TG Therapeutics		No	
Education Program	Challenges in Myeloma Therapy		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Roundtable: How Do I Treat a High-Risk Myeloma Patient?	Jonathan	Kaufman	MD	Emory University School of Medicine	Speaker	Yes	Oral	Disclosure made		Sanofi/Genzyme; Amgen; Celgene; Janssen: BMS: Takeda		Amgen; Celgene; Janssen; BMS; Takeda				Karyopharm; Incyte; TG Therapeutics		No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Jonathan	Kaufman	MD	Emory University School of Medicine	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	803. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule Sequencing	Eisko	Kautto	BS	The Ohio State University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Predicting Results		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age	Koji	Kawamura		Jichi Medical University Saitama Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	How to Peer Review a Scientific Paper		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Leslie	Kean	MD, PhD	Boston Children's Hospital	Panelist	No	Oral	Disclosure made		Kymab; FortySeven; EMDSerono; HiFiBio		Bristol Meyers Squibb; Jazz; Magenta; Regeneron; Gilead; BlueBirdBio		Bristol Meyers Squibb						
Oral and Poster Abstracts	621. Lymphomas‚Genetic/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Colm	Keane	MD	Princess Alexandra Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	904. Outcomes Research‚Non-Malignant Conditions III		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Validation of Instrument to Assess Hemophilia-Related Distress	Christine	Kempton	MD, MSc	Emory University School of Medicine	Presenter	Yes	Oral	Disclosure made				Novo Nordisk		Octapharma; Genentech; Spark Therapeutics					No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Christine	Kempton	MD, MSc	Emory University	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate GvHd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation	Glen	Kennedy	MBBS FRACP FRCPA	Royal Brisbane and Women's Hospital	Presenter	Yes	Oral	Nothing to disclose											Yes	Use of Tocilizumab for the prevention of acute GVHD
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas‚Clinical Studies: Clinical Trials in Waldenstrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroglobulinemia: Results of the Prospective Phase I/II HOVON 124/Eowm-R2 Trial	Marie JosÃ©	Kersten	MD, PhD	Amsterdam UMC, University of Amsterdam	Presenter	Yes	Oral	Disclosure made				Takeda Oncology; Roche; Celgene; Kite Pharma; Mundipharma; Bristol-Myers Squibb; Amgen	Roche; Celgene; Gilead; Novartis; Millenniy; Kite Pharma; Mundipharma; Bristol-Myers Squibb; Amgen						Yes	Ixazomib in Waldenstrom's Macroglobulinemia
Special-Interest Sessions	Medical Educators Symposium: General Session		Sunday, December 8, 2019	7:30 AM	9:30 AM	Yes	2	Medical Education Scholarship	Jennifer	Kesselheim	MD, MEd	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Comparative Analyses		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL)	Issa	Khouri	MD	University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromes‚Clinical Studies: Lower-Risk MDS and CMML		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial	Toru	Kiguchi	MD, PhD	Chugoku Central Hospital	Presenter	Yes	Oral	Disclosure made				Bristol-Myers Squibb Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Kyowa Hakko Kirin Co., Ltd.; MSD CO., Ltd.; Astellas Pharmaceutical Co., Ltd.; Nippon Shinyaku Co., Ltd.; Novartis Pharmaceutical Co., Ltd.; Sumitomo Dainippon Pharmaceutical Co., Ltd.; Janssen Pharmaceutical Co., Ltd.; Celgene Co., Ltd.; Symlio Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Teijin Co., Ltd.; Sanofi K.K., Ltd.; Celltrion, Inc.								No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical Emerging and Novel Targeted Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study	Jean-Jacques	Kiladjian	MD, PhD	Hopital Saint-Louis	Presenter	Yes	Oral	Disclosure made		Celgene		Novartis; AOP Orphan	Novartis; AOP Orphan						No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Insights Into the Pathophysiology of Platelet Disorders		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Taylor	Kim	MD	Texas Children's Cancer and Hematology Centers	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	901. Health Services Research‚Non-Malignant Conditions: Cancers and Thrombosis		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy	Miriam	Kempton	MD	Ottawa Hospital Research Institute	Presenter	Yes	Oral	Nothing to disclose											Yes	Apixaban can be used as postoperative prophylaxis of DVT/PE and for treatment of DVT/PE. We performed a cost-utility analysis of apixaban 2.5mg BID for the primary thromboprophylaxis of ambulatory cancer patients initiating chemotherapy, at intermediate-high risk of venous thromboembolism.
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Topic 2: Sickle Cell Disease-Related Cerebrovascular Disease	Allison	King	MD, MPH, PhD	Washington University in St. Louis, School of Medicine	Speaker	Yes	Oral	Disclosure made		Bioline; Celgene; Cell Works; Incyte; Biverlver; Tiosta Therapeutics (Formerly Vasculax, Inc.)	WUGEN	Amphivena Therapeutics; Novimmune				Magenta Therapeutics				
Oral and Poster Abstracts	705. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD and Thymus Regeneration: Role of Innate Cells and Non-Hematopoietic Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Homeostatic Regulation of Apoptosis Governs Thymus Regeneration	SinÃ©ad	Kinsella	MSc,PhD	Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	704. Immunotherapies II		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis	Adam	Rittai	MD	The Ohio State University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	113. Hemoglobinopathies, Excluding Thalassemia‚Basic and Translational Science: Novel Therapeutic Approaches for Pain and Organ Pathology in Sickle Cell Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Calpain-1 Contributes to Pain and Organ Damage in Sickle Cell Disease	Stacy	Kiven	BS	University of Minnesota	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Hemophilia-Associated Complications		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays	Hande	Korlocak		Children's Hospital Los Angeles	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2	Role of Genetic Evolution and Germline Mutations in SAMD9 and SAMD9L Genes	Jeffery	Kico	MD, PhD	St Jude Children's Research Hospital	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Sunday, December 8, 2019	9:30 AM	11:30 AM	Yes	2	Role of Genetic Evolution and Germline Mutations in SAMD9 and SAMD9L Genes	Jeffery	Kico	MD, PhD	St Jude Children's Research Hospital	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Clonal Evolution		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)	Geffen	Kleinstern	PhD	Mayo Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Aging and Hematologic Disorders: Exploring the Evidence		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	How do Geriatric Assessments Impact the Quality of Health Care Delivery Across Hematologic Disorders?	Heidi	Klepin	MD	Wake Forest University School of Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Aging and Hematologic Disorders: Exploring the Evidence		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	How do Geriatric Assessments Impact the Quality of Health Care Delivery Across Hematologic Disorders?	Heidi	Klepin	MD	Wake Forest University School of Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Aging and Hematologic Disorders: Exploring the Evidence		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Heidi	Klepin	MD	Wake Forest University School of Medicine	Chair	No	Oral	Nothing to disclose												
Education Program	Aging and Hematologic Disorders: Exploring the Evidence		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Heidi	Klepin	MD	Wake Forest University School of Medicine	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	503. Clonal Hematopoiesis: Aging and Inflammation		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Induction of Truncating ASXL1 Mutations in Human CD34+ HSPCs Mimics Human ASXL1-Mutated Clonal Hematopoiesis and Progression to Myeloid Malignancies	Thomas	Koehnke	MD	Stanford University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical Emerging and Novel Targeted Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Rami	Komrokji	MD	H. Lee Moffitt Cancer Center & Research Institute	Moderator	No	Oral	Disclosure made		Celgene; pfizer; DSI; Incyte; Agios; JAZZ					Novartis; JAZZ					
Oral and Poster Abstracts	321. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg46 Site	Vijay Kumar Reddy	Kondreddy	MSc,PhD	The University of Texas Health Science Center at Tyler	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS	Sunice	Konglizekarmon		Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Heiko	Konig	MD,PhD	Indiana University Simon Comprehensive Cancer Center	Moderator	No	Oral	Disclosure made		Agios			Amgen							
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Marina	Konopleva	MD, PhD	M.D. Anderson Cancer Center	Moderator	No	Oral	Disclosure made		Abbkbio, Genentech, F. Hoffman-La-roche, Stemline Therapeutics, Amgen, Forty-Seven		Abbkbio, Genentech, F. Hoffman-La-roche, Eli Lilly, Cellectis, Calithera, Ablyne, Semline Therapeutics, Agios, Ascentage		Abbkbio, Genentech, F. Hoffman-La-roche, Stemline Therapeutics, Amgen, Forty-Seven						
Oral and Poster Abstracts	332. Anticoagulation and Antithrombotic Therapy I		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels	Ahmed	Kouta		Loyola University Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	503. Clonal Hematopoiesis: Aging and Inflammation		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Inflammaging of Hematopoietic Stem Cells Is Driven By IL-1	Larisa	Kovtonyuk	Ph.D.	University Hospital and University of Zurich	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-free Remission		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Daniela	Krause	MD	University of Frankfurt	Moderator	No	Oral	Disclosure made				Merck KGaA								
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dicrasias		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)	Amrita	Krishnan	MD	City of Hope Medical Center	Presenter	Yes	Oral	Disclosure made		Celgene, Janssen, Sanofi, BMS; Sutro BioPharma, oPredicta		Takeda			Amgen, Takeda				Yes	Investigation of TAK-079 for the treatment of relapsed and/ or refractory multiple myeloma
General Sessions	Ernest Beutler Lecture and Prize	Blood Coagulation: From Molecular Mechanisms to Treatment of Thrombosis	Monday, December 9, 2019	1:30 PM	2:30 PM	Yes		Basic Research	Sriram	Krishnaswamy	PhD	Children's Hospital of Philadelphia	Speaker	Yes	Oral	Disclosure made		Novo Nordisk; Bayatta		Portola; Janssen				Janssen				
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Sriram	Krishnaswamy	PhD	Children's Hospital of Philadelphia	Co-Chair	No	Oral	Disclosure made		Novo Nordisk; Bayatta		Portola; Janssen				Janssen				

Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Sriram	Krishnaswamy	PhD	Children's Hospital of Philadelphia	Co-Chair	No	Oral	Disclosure made		Novo Nordisk; Bayalta		Portola; Janssen				Janssen			
Special Scientific Sessions	Special Symposium on the Basic Science in Hemostasis and Thrombosis		Monday, December 9, 2019	4:30 PM	6:30 PM	Yes	2		Sriram	Krishnaswamy	PhD	Children's Hospital of Philadelphia	Co-Chair	No	Oral	Disclosure made		Novo Nordisk; Bayalta		Portola; Janssen				Janssen			
Education Program	Why Patients Fail After Allogeneic Stem Cell Transplantation		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Nicolaus	Kroeger	MD	University Hospital Eppendorf	Chair	No	Oral	Disclosure made				Kiermaier; Novo; Celgene; DKMS; Novartis	Novo; Celgene; Novartis; Medac; Sanofi-Aventis, JAZZ						
Education Program	Why Patients Fail After Allogeneic Stem Cell Transplantation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Nicolaus	Kroeger	MD	University Hospital Eppendorf	Chair	No	Oral	Disclosure made				Kiermaier; Novo; Celgene; DKMS; Novartis	Novo; Celgene; Novartis; Medac; Sanofi-Aventis, JAZZ						
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Advances in Understanding the Pathophysiology of AML		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5		Florian	Kuchenbauer	MD, PhD	BC Cancer Agency	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Retrospective/Observational Studies: Cellular Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England	Andrea	Kuhnl		King's College Hospital	Presenter	Yes	Oral	Disclosure made					Kite-Gilead						No	
Special-Interest Sessions	Special Symposium on Quality: ASH EQUIPS - Learning from Medical Errors and Other Incidents		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Vishal	Kukreti	MD	Princess Margaret Cancer Centre	Co-chair	No	Oral	Disclosure made					Celgene; Amgen; Takeda							
Oral and Poster Abstracts	903. Health Services Research†Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Anita	Kumar	MD,MS	Tufts Medical Center	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Replication Stress Response and CDKN1A Engagement Constrain Fetal Hematopoietic Stem Cell Pool Size in Fanconi Anemia	Peter	Kurre	MD	University of Pennsylvania	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Aggressive Non-Hodgkin Lymphomas: It's Genine Personal		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Prognostication with Circulating Tumor DNA: Is It Ready for Prime Time?	David	Kurtz	MD,PhD	Stanford Cancer Institute	Speaker	Yes	Oral	Disclosure made		Roche									No	
Education Program	Aggressive Non-Hodgkin Lymphomas: It's Genine Personal		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Prognostication with Circulating Tumor DNA: Is It Ready for Prime Time?	David	Kurtz	MD,PhD	Stanford Cancer Institute	Speaker	Yes	Oral	Disclosure made		Roche									No	
Oral and Poster Abstracts	621. Lymphoma†"Genetic/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA	David	Kurtz	MD,PhD	Stanford University	Presenter	Yes	Oral	Disclosure made		Roche									No	
Oral and Poster Abstracts	802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia	Stephen	Kurtz	PhD	Oregon Health & Science University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	211. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia	David	Kuter		Massachusetts General Hospital Cancer Center	Presenter	Yes	Oral	Disclosure made		Actelion (Syntimmune); Agios; Alnylam; Argenx; Bristol Myers Squibb (BMS); Caremark; Daiichi Sankyo; Amgen; Dova; Kyowa-Kirin; Merck Sharp Dohme; Momenta; Novartis; Pfizer; Platelet Disorder Support Association; Principia; Protalex; Protalix; Rigel; Sanofi; Genzyme; Shionogi; Shire; Takeda (Bioverativ); UCB; Up-to-Date; Zafgen		Actelion (Syntimmune); Agios; Alnylam; Argenx; Bristol Myers Squibb (BMS); Caremark; Daiichi Sankyo; Amgen; Dova; Kyowa-Kirin; Merck Sharp Dohme; Momenta; Novartis; Pfizer; Platelet Disorder Support Association; Principia; Protalex; Protalix; Rigel; Sanofi; Genzyme; Shionogi; Shire; Takeda (Bioverativ); UCB; Up-to-Date; Zafgen						Yes	Yes, this was an investigational clinical phase I/II study of PRN 1008 in patients with relapsed/refractory ITP. Phase I dose escalation phase is now complete and expanded phase II studies ongoing.
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia†"Clinical: Emerging Therapies: Reports from Recent Clinical Trials		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Phase-I Study of ETA-Receptor Antagonist Ambrisentan in Sickle Cell Disease	Abdullah	Kutlar	MD	Augusta University	Presenter	Yes	Oral	Disclosure made		Novartis		Global Blood Therapeutics, Inc. (GBT); Novo Nordisk							Yes	Ambrisentan is an approved FDA drug used for treatment of another condition but it is expected that it will also help improve and/or prevent kidney damage that can be caused by sickle cell disease.
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia†"Clinical: Emerging Therapies: Reports from Recent Clinical Trials		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias	Janet	Kwiatkowski	MD, MSCE	The Children's Hospital of Philadelphia	Presenter	Yes	Oral	Disclosure made		Bluebird bio, Inc.; Agios; Celgene; Jazara		bluebird bio, Inc.; Apopharma; Terumo; Novartis							Yes	Deferiprone is an oral iron chelator.
Special-Interest Sessions	Blood & Beyond		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Bob	Löwenberg	MD, PhD	Editor-in-Chief, Blood, Erasmus University Medical Center	Chair	No	Oral	Disclosure made		Clear Creek Bio Ltd	Frame Pharmaceuticals		Clear Creek Bio Ltd			Up-to-Date®(Section editor leukemia; Abbvie; Agios Pharmaceuticals; Astellas; Astex; Celgene; CELYAD; Chairman Scientific Committee and Member Executive Committee, European School of Hematology (ESH, Paris, France); Chairman, Leukemia Cooperative Trial Group HOVON (Netherlands; Editorial Board †EuropeanOncology & Haematology@Elected member, Royal Academy of Sciences and Arts, The Netherlands; Hoffman-La Roche Ltd; Royal Academy of Sciences and Arts, The Netherlands; Supervisory Board, National Comprehensive Cancer Center (IRNL), Netherland			
Special-Interest Sessions	Global Hematology Symposium	Exploring Models of Global Affordable Access to Cutting-Edge Drugs	Monday, December 9, 2019	12:15 PM	1:15 PM	Yes	1		Bob	Löwenberg	MD, PhD	Editor-in-Chief, Blood, Erasmus University Medical Center	Co-chair	No	Oral	Disclosure made		Clear Creek Bio Ltd	Frame Pharmaceuticals		Clear Creek Bio Ltd			Up-to-Date®(Section editor leukemia; Abbvie; Agios Pharmaceuticals; Astellas; Astex; Celgene; CELYAD; Chairman Scientific Committee and Member Executive Committee, European School of Hematology (ESH, Paris, France); Chairman, Leukemia Cooperative Trial Group HOVON (Netherlands; Editorial Board †EuropeanOncology & Haematology@Elected member, Royal Academy of Sciences and Arts, The Netherlands; Hoffman-La Roche Ltd; Royal Academy of Sciences and Arts, The Netherlands; Supervisory Board, National Comprehensive Cancer Center (IRNL), Netherland			
Special-Interest Sessions	How to Get Published in a Peer-Reviewed Journal		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Bob	Löwenberg	MD, PhD	Editor-in-Chief, Blood, Erasmus University Medical Center	Chair	No	Oral	Disclosure made		Clear Creek Bio Ltd	Frame Pharmaceuticals		Clear Creek Bio Ltd			Up-to-Date®(Section editor leukemia; Abbvie; Agios Pharmaceuticals; Astellas; Astex; Celgene; CELYAD; Chairman Scientific Committee and Member Executive Committee, European School of Hematology (ESH, Paris, France); Chairman, Leukemia Cooperative Trial Group HOVON (Netherlands; Editorial Board †EuropeanOncology & Haematology@Elected member, Royal Academy of Sciences and Arts, The Netherlands; Hoffman-La Roche Ltd; Royal Academy of Sciences and Arts, The Netherlands; Supervisory Board, National Comprehensive Cancer Center (IRNL), Netherland			
Education Program	Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Novel Agents and Immune Invasion in Hodgkin Lymphoma	Ann	LaCasce	MD, MMSc	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made		Seattle Genetics; BMS; Humanigen		Seattle Genetics		Research to Practice				Yes	
Education Program	Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Novel Agents and Immune Invasion in Hodgkin Lymphoma	Ann	LaCasce	MD, MMSc	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made		Seattle Genetics; BMS; Humanigen		Seattle Genetics		Research to Practice				Yes	
Education Program	Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Ann	LaCasce	MD, MMSc	Dana-Farber Cancer Institute	Chair	No	Oral	Disclosure made		Seattle Genetics; BMS; Humanigen		Seattle Genetics		Research to Practice					
Education Program	Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Ann	LaCasce	MD, MMSc	Dana-Farber Cancer Institute	Chair	No	Oral	Disclosure made		Seattle Genetics; BMS; Humanigen		Seattle Genetics		Research to Practice					
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma	Norman	Lacayo	MD	Stanford University	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	ASH Practice Partnership Lunch	Genomic/Genetic Testing: The Who, What, Where, When, & Why	Sunday, December 8, 2019	11:15 AM	12:30 PM	Yes	1.25	Genetic Testing in Benign Hematology	Michele	Lambert	MD	Children's Hospital of Philadelphia	Speaker	Yes	Oral	Disclosure made		CSL Behring; Amgen; Shionogi; Bioblast; Sysmex		Novartis; AstraZeneca; POSA						Amgen		
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group	Adam	Lamble	MD	Seattle Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: First Line Treatment		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)	Benjamin	Lampson	MD, PhD	Dana Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose											Yes	Acalabrutinib, venetoclax, obinutuzumab--combination therapy for previously untreated CLL
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2	Single Cell Approaches - Drilling Down Deeper Using Technology and Integrated Data Analyses	Dan	Landau	MD	New York Genome Center	Speaker	Yes	Oral	Disclosure made		Illumina Inc		Celgene; Pharmacyclics	Illumina Inc			Illumina Inc			No	
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2	Single Cell Approaches - Drilling Down Deeper Using Technology and Integrated Data Analyses	Dan	Landau	MD	New York Genome Center	Speaker	Yes	Oral	Disclosure made		Illumina Inc		Celgene; Pharmacyclics	Illumina Inc			Illumina Inc			No	
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	11:30 AM	12:30 PM	Yes	1		Dan	Landau	MD	New York Genome Center	Speaker	No	Oral	Disclosure made		Illumina Inc		Celgene; Pharmacyclics	Illumina Inc			Illumina Inc				
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRD D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study	Ola	Landgren	MD, PhD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made				Amgen; Celgene; Janssen; Takeda	Amgen; Celgene; Janssen; Takeda; Adaptive			Amgen; Celgene; Janssen; Takeda; Adaptive; Abbvie; Sanofi; Karyopharm		Yes	Dara-KRd is not an FDA approved combination therapy for newly diagnosed multiple myeloma.
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Retrospective/Observational Studies: Cellular Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Daniel	Landsburg	MD	University of Pennsylvania	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Melissa	Larson	MD	Rush University Medical Center	Moderator	No	Oral	Nothing to disclose												
Education Program	What's New in the Diagnosis and Management of von Willebrand Disease?		Saturday, December 7, 2019	2:00 PM	2:30 PM	Yes	1.5	Perioperative Management of patients with vWD	Michelle	Lavin	MD, PhD, FRCPath	Royal College of Surgeons in Ireland	Speaker	Yes	Oral	Disclosure made				Shire		Shire					No	
Education Program	What's New in the Diagnosis and Management of von Willebrand Disease?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Perioperative Management of patients with vWD	Michelle	Lavin	MD, PhD, FRCPath	Royal College of Surgeons in Ireland	Speaker	Yes	Oral	Disclosure made				Shire		Shire					No	
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Clonal Evolution		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	B Cell Restricted Expression of Mutated IGF2 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL	Gregory	Lazarian	PharmD	Dana Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Alan	Lazarus	PhD	The Canadian Blood Services	Moderator	No	Oral	Nothing to disclose												

Oral and Poster Abstracts	904. Outcomes Research†Non-Malignant Conditions II		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1-5		Jeffrey	Lebensburger	DO, MSPH	University of Alabama at Birmingham	Moderator	No	Oral	Disclosure made		Novartis		Pfizer								
Oral and Poster Abstracts	101. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1-5		Agnes	Lee	MD, MSc, FRCPC	University of British Columbia	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	625. Lymphoma: Pre-Clinical†Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1-5	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling	Jeewoong	Lee	PhD	City of Hope Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No
General Sessions	Plenary Scientific Session		Sunday, December 8, 2019	2:00 PM	4:00 PM	Yes	2		Stephanie	Lee	MD, MPH	Fred Hutchinson Cancer Research Center	Co-chair	No	Oral	Disclosure made		Pfizer; Kadmon		Pfizer; Kadmon; Takeda; Novartis; Amgen; Syndax; Incyte; AstraZeneca								
Education Program	Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1-5	Management of Bleeding in Critical Care Setting	Frank W.G.	Leebeek	MD, PhD	Erasmus University Medical Center	Speaker	Yes	Oral	Disclosure made		UniQure; Novo Nordisk; Shire/Takeda		CSL Behring; Shire/Takeda								
Education Program	Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1-5	Management of Bleeding in Critical Care Setting	Frank W.G.	Leebeek	MD, PhD	Erasmus University Medical Center	Speaker	Yes	Oral	Disclosure made		UniQure; Novo Nordisk; Shire/Takeda		CSL Behring; Shire/Takeda								
Oral and Poster Abstracts	620. Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1-5	The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt	Laurence	Legros	MD, PhD	HÔpital Paul Brousse	Presenter	Yes	Oral	Disclosure made				Pfizer; Incyte Biosciences		Novartis; BMS; Pfizer; Incyte Biosciences						No
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1-5	Cofactor and Cofactor Mimetics	Peter	Lenting	PhD	Inserm U 1176, UniversitÃƒ Paris-Saclay, UniversitÃƒ Paris-Saclay	Speaker	Yes	Oral	Disclosure made			Sarepta therapeutics		Roche; LFB; Biotest; NovoNordisk; Shire/Takeda; Sobi; Catalyst Biosciences; Spark Therapeutics							No
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1-5	Cofactor and Cofactor Mimetics	Peter	Lenting	PhD	Inserm U 1176, UniversitÃƒ Paris-Saclay, UniversitÃƒ Paris-Saclay	Speaker	Yes	Oral	Disclosure made			Sarepta therapeutics		Roche; LFB; Biotest; NovoNordisk; Shire/Takeda; Sobi; Catalyst Biosciences; Spark Therapeutics							No
Education Program	Challenges in Myeloma Therapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1-5	Roundtable: How Do I Treat a Refractory Myeloma Patient Who is Not Eligible for a Clinical Trial	Suzanne	Lentzsch	MD, PhD	Columbia University	Speaker	Yes	Oral	Disclosure made		Bayer; Janssen; Takeda; BMS; Proclara; Abbvie; Sanofi	Caelum Biosciences	Sanofi; Karyopharm	Multiple Myeloma Research Foundation; International Myeloma Foundation		Clinical Care Options	Caelum Biosciences		No	
Education Program	Challenges in Myeloma Therapy		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1-5	Roundtable: How Do I Treat a Refractory Myeloma Patient Who is Not Eligible for a Clinical Trial	Suzanne	Lentzsch	MD, PhD	Columbia University	Speaker	Yes	Oral	Disclosure made		Bayer; Janssen; Takeda; BMS; Proclara; Abbvie; Sanofi	Caelum Biosciences	Sanofi; Karyopharm	Multiple Myeloma Research Foundation; International Myeloma Foundation		Clinical Care Options	Caelum Biosciences		No	
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1-5		John	Leonard	MD	Weill Cornell Medical College	Co-Chair	No	Oral	Disclosure made		AstraZeneca; Bayer Corporation; Celgene; Epizyme, Inc; Genentech, Inc./F. Hoffmann-La Roche Ltd; Karyopharm Therapeutics; Satro Biopharma; Merck; MorphoSys; Gilead; BeiGene; Nordic Nanovector; ADC Therapeutics; Sandoz; Millenyi; Alcera Therapeutics									
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1-5		John	Leonard	MD	Weill Cornell Medical College	Co-Chair	No	Oral	Disclosure made		AstraZeneca; Bayer Corporation; Celgene; Epizyme, Inc; Genentech, Inc./F. Hoffmann-La Roche Ltd; Karyopharm Therapeutics; Satro Biopharma; Merck; MorphoSys; Gilead; BeiGene; Nordic Nanovector; ADC Therapeutics; Sandoz; Millenyi; Alcera Therapeutics									
Special-Interest Sessions	Featured Topic: Aging and Hematopoiesis		Monday, December 9, 2019	12:15 PM	1:15 PM	Yes	1		Ross	Levine	MD	Memorial Sloan Kettering Cancer Center	Speaker	No	Oral	Disclosure made		Celgene; Roche; Novartis; Gilead		Celgene; Roche; Prelude Therapeutics		Lilly; Amgen		Qiagen; Loxo; Imago Biosciences; C4 Therapeutics; Isoplexis			
Oral and Poster Abstracts	704. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD and Thymus Regeneration: Role of Innate Cells and Non-Hematopoietic Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1-5		Robert	Levy	PhD	Univ. of Miami School of Med.	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Risk Stratification and Novel Approaches to Reduce Toxicity in Allogeneic Transplantation		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1-5	Soluble CD6-9 As a Prognostic Biomarker for Thrombotic Microangiopathy at the Onset of Graft-Versus-Host Disease	Ang	Li	MD	University of Washington School of Medicine	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	652. Myeloma: Biology and Pathophysiology, excluding Therapy: Novel Molecular Dependencies and Targets in Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1-5	TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression	Can	Li	MD	University of Iowa	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	638. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genomic Landscape and Disease Classification		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1-5	Inherited GATA3 Variants Associated with Positive Minimal Residual Disease in Childhood B-ALL Via Autophagy-Induced Asparaginase Resistance	Chunjie	Li	PhD	Guangzhou Women and Children's Medical Center	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1-5	Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma	Chunrui	Li	MD,PhD	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Novel Target		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1-5	HDACII Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation	Man	Li	PhD	City of Hope	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	321. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1-5	Structural Basis of Vitamin K Antagonism	Weikai	Li	PhD	Washington University School of Medicine	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	102. Regulation of Iron Metabolism: Novel Players in Iron Homeostasis in Health and Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1-5	NCOA4 Expression in Hepatic Cells Is Upregulated Under Physiological and Pathophysiological Conditions Associated with Hypoxia	Xiuqi	Li	MS	Yale School of Medicine	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	638. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genomic Landscape and Disease Classification		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1-5	Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children	Yishen	Li	PhD	St. Jude Children's Research Hospital	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	906. Outcomes Research†Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1-5	Identification of an Immune Risk Score to Predict the Prognosis of Acute Myeloid Leukemia	Yang	Liang	Ph.D.	Sun Yat-sen University Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	803. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1-5	Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial	Nora	Liebers		University of Heidelberg	Presenter	Yes	Oral	Nothing to disclose												No
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1-5	Introduction to ASH Clinical Practice Guidelines on Sickle Cell Disease and Methylcobalamin	Robert	Liem	MD, MS	Lurie Children's Hospital, Northwestern University Feinberg School of Medicine	Speaker	Yes	Oral	Nothing to disclose												
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1-5		Robert	Liem	MD	Lurie Children's Hospital	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Hemophilia-Associated Complications		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1-5	Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study	Ri	Liesner		Haemophilia Comprehensive Care Centre	Presenter	Yes	Oral	Disclosure made		Octapharma, Bayer, Takeda, Novo Nordisk, CSL Behring, Roche		Octapharma, Bayer, Takeda			Octapharma, SOBI, Novo Nordisk			No	
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1-5		Jane	Liesveld	MD	University of Rochester Medical Center	Moderator	No	Oral	Disclosure made								Abbvie			
Special Scientific Symposia	Special Symposium on the Basic Science in Hemostasis and Thrombosis		Monday, December 9, 2019	4:30 PM	6:30 PM	Yes	2	The FVIII/VWF Axis: Consequences of an Unequal Partnership	David	Lillicrap	MD	Queen's University	Speaker	Yes	Oral	Disclosure made				Bayer; Biomarin; Bioverativ; CSL-Behring; Octapharma								
Special Scientific Symposia	Changing the Taxonomy of Aggressive Lymphoma: Ready to Impact Clinical Management?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1-5	The Pathology of Grey Zone Lymphomas and Rarer Entities	Megan	Lim	MD, PhD	University of Pennsylvania	Speaker	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Hemophilia-Associated Complications		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1-5	All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia T Patients in the United States	Ming	Lim	MBBCh/ JAA	University of Utah	Presenter	Yes	Oral	Nothing to disclose												No
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1-5	Sensing and Sensibility: Programming Smarter Chimeric Antigen Receptor T Cells	Wendell	Lim	PhD	University of California-San Francisco	Speaker	Yes	Oral	Disclosure made		Allogene										No
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1-5	Sensing and Sensibility: Programming Smarter Chimeric Antigen Receptor T Cells	Wendell	Lim	PhD	University of California-San Francisco	Speaker	Yes	Oral	Disclosure made		Allogene										No
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Wendell	Lim	PhD	University of California-San Francisco	Speaker	No	Oral	Disclosure made		Allogene										
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Immune Thrombocytopenia		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1-5	Speaker 1	Wendy	Lim	MD, MSc	McMaster University	Speaker	Yes	Oral	Disclosure made		Pfizer Canada; Portola Pharmaceuticals			Pfizer Canada; Bristol-Myers Squibb							
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Novel Target		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1-5	An Oncogenic Enhancer Encodes Selective Selenian Dependency in AML	Charles	Lin	PhD	Baylor College of Medicine	Presenter	Yes	Oral	Disclosure made			Syros Pharmaceuticals				Syros Pharmaceuticals				No	
Education Program	Transfusion Medicine: Optimizing Patient Blood Management (PBM)		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1-5	Preoperative Anemia Screening Clinics	Yulia	Lin	MD	Sunnybrook Health Sciences Center	Speaker	Yes	Oral	Disclosure made		Amgen; Pfizer		Novartis; Octapharma								
Education Program	Transfusion Medicine: Optimizing Patient Blood Management (PBM)		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1-5	Preoperative Anemia Screening Clinics	Yulia	Lin	MD	Sunnybrook Health Sciences Center	Speaker	Yes	Oral	Disclosure made		Amgen; Pfizer		Novartis; Octapharma								
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Molecular Insights and Modeling		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1-5	A Genome Scale CRISPR Screen Identifies the ER Cargo Receptor That Facilitates the Efficient Secretion of Erythropoietin	Jesen	Lin	B. S.	University of Michigan	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1-5	Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)	R. Coleman	Lindsley	MD, PhD	Dana-Farber/Harvard Cancer Center	Presenter	Yes	Oral	Disclosure made		Takeda Pharmaceuticals		Jazz Pharmaceuticals; Medimmune								No
Oral and Poster Abstracts	803. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1-5		R. Coleman	Lindsley	MD, PhD	Dana-Farber Cancer Institute	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	627. Myelodysplastic Syndromes†Clinical Studies: Lower-Risk MDS and CMML		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1-5	Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower-Risk Non-Deletion 5q (Del(5q) MDS: *Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health*	Alan	List	MD	H. Lee Moffitt Cancer Center & Research Institute	Presenter	Yes	Oral	Disclosure made				Celgene						Celgene		Yes	Lenalidomide used for treatment non-del 5q myelodysplastic syndromes.
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1-5	Speaker 4	Mark	Litzow	MD	Mayo Clinic	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Risk Stratification and Novel Approaches to Reduce Toxicity in Allogeneic Transplantation		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1-5	First-In-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction	Yang	Liu	MD, PhD	Chengdu Military General Hospital	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: MYC and Beyond		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1-5	Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis	Huden	Liu	PhD	Wuhan University	Presenter	Yes	Oral	Nothing to disclose												No

Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refining the Approach		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Corticosteroids Do Not Influence the Efficacy and Kinetics of CAR-T Cells for B-Cell Acute Lymphoblastic Leukemia	Shuangyou	Liu		Beijing Boren Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma	Wei	Liu		Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: New Regulators of Stem and Progenitor Cell Survival and Differentiation		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Yan	Liu	PhD	Indiana University School of Medicine	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Maturation and Enucleation		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Formin Links Erythroid Cytoskeleton to Organelle Clearance through Exc+III Complex during Reticulocyte Maturation	Yijie	Liu	PhD	Feinberg School of Medicine, Northwestern University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	704. Immunotherapies II		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Frederick	Locke	MD	Moffitt Cancer Center	Moderator	No	Oral	Nothing to disclose												
Education Program	Junior Faculty Career Development Session		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Looking for an Academic Job and Show Me the Money: Negotiating Your Salary and Benefits	Jose	Lopez	MD,BS	Bloodworks Northwest	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Jose	Lopez	MD,BS	Bloodworks Northwest	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	621. Lymphoma: Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Abner	Louissaint	MD, PhD	Massachusetts General Hospital	Moderator	No	Oral	Nothing to disclose												
Scientific Program	Understanding and Targeting TP53 in Myeloid Malignancies		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	TP52 Action and the Consequences of TP53 Mutation in Acute Myeloid Leukemia	Scott	Lowe	PhD	Memorial Sloan Kettering Cancer Center	Speaker	Yes	Oral	Disclosure made		Blueprint Medicines; ORIC pharmaceuticals; Mirimus; Constellation Pharma; Petra Pharmaceuticals; PMV Pharmaceuticals; Faeth Therapeutics	Blueprint Medicines; ORIC pharmaceuticals; Mirimus; Constellation Pharma; Petra Pharmaceuticals; PMV Pharmaceuticals; Faeth Therapeutics								No	
Scientific Program	Understanding and Targeting TP53 in Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	TP52 Action and the Consequences of TP53 Mutation in Acute Myeloid Leukemia	Scott	Lowe	PhD	Memorial Sloan Kettering Cancer Center	Speaker	Yes	Oral	Disclosure made		Blueprint Medicines; ORIC pharmaceuticals; Mirimus; Constellation Pharma; Petra Pharmaceuticals; PMV Pharmaceuticals; Faeth Therapeutics	Blueprint Medicines; ORIC pharmaceuticals; Mirimus; Constellation Pharma; Petra Pharmaceuticals; PMV Pharmaceuticals; Faeth Therapeutics								No	
Meet the Scientist	TP53 Action and the Consequences of p53 Mutation in Acute Myeloid Leukemia		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Scott	Lowe	PhD	Memorial Sloan Kettering Cancer Center	Speaker	No	Oral	Disclosure made		Blueprint Medicines; ORIC pharmaceuticals; Mirimus; Constellation Pharma; Petra Pharmaceuticals; PMV Pharmaceuticals; Faeth Therapeutics	Blueprint Medicines; ORIC pharmaceuticals; Mirimus; Constellation Pharma; Petra Pharmaceuticals; PMV Pharmaceuticals; Faeth Therapeutics									
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia	Peihua	Lu		Beijing Lu Daopei Institute of Hematology	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia	Peihua	Lu		Beijing Lu Daopei Institute of Hematology	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (ASPIRT MM-02)	Heinz	Ludwig	MD	1.Med.Abt. Wilhelminenspital	Presenter	Yes	Oral	Disclosure made		Pharmamar		Amgen; Takeda			Amgen; Takeda; Celgene; Janssen; BMS			Yes	Carfilzomib 56mg/m2 in weekly dosing in combination with either Lenalidomide and low dose dexamethasone (KRd), or with thalidomide and low dose dexamethasone (KTd) was evaluated for first line treatment is TNE NDMM patients. After 9 cycles pts were randomized to K biweekly maintenance therapy for 12 months or to observation.
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas): Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	First-In-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3/A—CD20) in B-Cell Non-Hodgkin Lymphomas	Reiternella	Lugtenburg	MD, PhD	Erasmus MC Cancer Institute	Presenter	Yes	Oral	Disclosure made		Roche; Takeda; Servier; Celgene; Genmab; BMS		Roche; Takeda; Servier	Roche; Takeda; Servier; Celgene; Janssen-Cilag; Genmab		Roche				No	
Oral and Poster Abstracts	603. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Mettl3- Loss Reinforces CTCF Defined Chromatin Boundaries and Drives Wnt Target Gene Expression in AML Leukemogenesis	Huacheng	Luo		Pennsylvania State University Hershey College of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Mechanisms of and Therapies for cGVHD		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	From In-Vivo T-Cell Depletion to Post-Transplant Cyclophosphamide: Improved GvHD-Free & Relapse-Free Survival but Comparable Chronic GvHD Incidence in Haploidentical Transplantation. A 15 Years EBMT Registry Analysis on Behalf of the TCWP-EBMT	Maria Teresa	Lupo-Stanghellini	MD	Sen Raffaele Scientific Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Emerging Role of Haploidentical Stem Cell Transplantation	Leo	Luznik	MD	Johns Hopkins University	Speaker	Yes	Oral	Disclosure made		Abbvie		Merck; Genentech			Merck				No	
Education Program	Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Emerging Role of Haploidentical Stem Cell Transplantation	Leo	Luznik	MD	Johns Hopkins University	Speaker	Yes	Oral	Disclosure made		Abbvie		Merck; Genentech			Merck				No	
Education Program	Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Leo	Luznik	MD	Johns Hopkins University	Chair	No	Oral	Disclosure made		Abbvie		Merck; Genentech			Merck					
Education Program	Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Leo	Luznik	MD	Johns Hopkins University	Chair	No	Oral	Disclosure made		Abbvie		Merck; Genentech			Merck					
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Epigenetic Regulation		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Functional Complementation between β-Catenin and Hoxa9 Sustains HSC Self-Renewal in a Prmt1-Dependent Manner	Jennifer	Lynch	PhD	King's College London	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	902. Health Services Research: Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy	Ryan	Lynch	MD	University of Washington/Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Disclosure made		Johnson Graffe Keay Moniz & Wick LLP		Incyte Corporation; T.G. Therapeutics; Takeda Pharmaceuticals; Rhizen Pharmaceuticals S.A; Juno Therapeutics							No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Shuo	Ma	MD, PhD	Northwestern University	Moderator	No	Oral	Disclosure made		Astra Zeneca; Janssen; Pharmacyclics; Bioveratiz; Genentech; Xlite; Abbvie		Astra Zeneca; Pharmacyclics; Abbvie; Beigene; Incyte; Juno; Acerta; Gilead; Novartis; Xeme; TG Therapeutics		Astra Zeneca; Janssen; Pharmacyclics					
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Kellie	Machlus	PhD	Brigham and Women's Hospital, Harvard Medical School	Co-Chair	No	Oral	Nothing to disclose												
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Kellie	Machlus	PhD	Brigham and Women's Hospital, Harvard Medical School	Co-Chair	No	Oral	Nothing to disclose												
Education Program	Bone Marrow Failure and Clonal Evolution		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Diagnosis of Bone Marrow Failure Versus Hypocellular MDS in Older Adults	Jaroslaw	Maciejewski	MD, PhD	Cleveland Clinic	Speaker	Yes	Oral	Disclosure made		Novartis; Alexion									No	
Education Program	Bone Marrow Failure and Clonal Evolution		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Diagnosis of Bone Marrow Failure Versus Hypocellular MDS in Older Adults	Jaroslaw	Maciejewski	MD, PhD	Cleveland Clinic	Speaker	Yes	Oral	Disclosure made		Novartis; Alexion									No	
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Update from the Lab: Analysis of Mechanistic Studies of Pathways of Cancer-Associated Thrombosis using Mouse Models	Nigel	Mackman	PhD	University of North Carolina at Chapel Hill	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Update from the Lab: Analysis of Mechanistic Studies of Pathways of Cancer-Associated Thrombosis using Mouse Models	Nigel	Mackman	PhD	University of North Carolina at Chapel Hill	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2	The Role of Interferon, Inflammation and Infection in Aplastic Anemia	Katherine	MacNamara	PhD	Albany Medical College	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Sunday, December 8, 2019	9:30 AM	11:30 AM	Yes	2	The Role of Interferon, Inflammation and Infection in Aplastic Anemia	Katherine	MacNamara	PhD	Albany Medical College	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Increased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC Alloimmunization	Emaan	Madany	BS	Cedars-Sinai Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma: Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Kami	Maddocks	MD	The James Cancer Hospital at The Ohio State University	Moderator	No	Oral	Disclosure made				AbbVie; Merck; Pharmacyclics; Novartis				Pharmacyclics; Celgene; Teva				
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Novelty In CAR T in Relapsed/Refractory Multiple Myeloma		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)	Deepu	Madduri	MD	Icahn School of Medicine at Mount Sinai	Presenter	Yes	Oral	Disclosure made		Foundation Medicine; AbbVie; Celgene; Takeda									No	
Oral and Poster Abstracts	903. Health Services Research: Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Changes in Intensive Care Unit Admission Rates, Organ Support, and Mortality in Patients with Acute Myeloid Leukemia: A Danish Nationwide Cohort Study	Cecilie	Maeng	BSc	Aarhus University Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	EPCR Deficiency Prevents Development of Hemophilic Arthropathy	Ihanxi	Megkietty	PhD, MSc	The University of Texas Health Science Center at Tyler	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	231. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning	Arash	Mahajerin	MD, MS	CHOC Children's Hospital	Presenter	Yes	Oral	Disclosure made		Genentech					Genentech; Alexion; Spark	Kedrion			No	
Scientific Program	Stromal Cell Immune Regulation in the Microenvironment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	From Graft-Versus-Host Disease to Lymphoma Pathogenesis: Emerging Roles for Stromal Notch Ligands in Hematology	Ivan	Maillard	MD, PhD	University of Pennsylvania	Speaker	Yes	Oral	Disclosure made		Genentech; Regeneron									No	
Scientific Program	Stromal Cell Immune Regulation in the Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	From Graft-Versus-Host Disease to Lymphoma Pathogenesis: Emerging Roles for Stromal Notch Ligands in Hematology	Ivan	Maillard	MD, PhD	University of Pennsylvania	Speaker	Yes	Oral	Disclosure made		Genentech; Regeneron									No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Non-Intensive Therapy		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia	Abhishek	Maiti	MBBS	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made											Yes	FLT3 inhibitors, used in combination with decitabine and venetoclax
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimen	Abhishek	Maiti	MBBS	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made											No	
Oral and Poster Abstracts	205. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	CRISPR/Cas9-Mediated ELANE Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensible Granulocyte Protease?	Vishagn	Makaryan	MD	University of Washington	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GvHD: Novel Mechanisms and Emerging Therapies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Impact of Gut Microbiota Composition on Outcomes after Allogeneic Hematopoietic Cell Transplantation	Florent	Malard	MD,PhD	Service d'HÃ©matologie Clinique et de ThÃ�rapie Cellulaire, Hospital Saint Antoine	Presenter	Yes	Oral	Disclosure made					Astellas; JAZZ pharmaceutical; Genzyme; Kiadis; Janssen; Therakos/Mallinckrodt							No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Hemophilia-Associated Complications		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5		Lynn	Melec	MD	Children's Hospital of Pittsburgh	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	801. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency	Harry	Malech	M.D.	LCIM, NIAID, NIH	Presenter	Yes	Oral	Nothing to disclose											No	

Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma	Shuan	Malek	MD	Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center	Presenter	Yes	Oral	Disclosure made		Celgene; Takeda; Sanofi; Adaptive		Medipacto			Janssen; Amgen			No	
Education Program	Patients, Bosdem, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	Meeting the Needs of CML Patients in Resource-Poor Countries: a Roundtable Discussion	Hemant	Malhotra	MD, FACP, FRCP (Lon), FRCP (Edin)	Mahatma Gandhi Medical College Hospital	Speaker	Yes	Oral	Disclosure made				Novartis; NATCO			Novartis; NATCO; Mylan; Cipla	Cipla; Eli Lily		Yes	Use of pioglitazone in combination with TKIs. Use of some ayurvedic products.
Education Program	Patients, Bosdem, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Meeting the Needs of CML Patients in Resource-Poor Countries: a Roundtable Discussion	Hemant	Malhotra	MD, FACP, FRCP (Lon), FRCP (Edin)	Mahatma Gandhi Medical College Hospital	Speaker	Yes	Oral	Disclosure made				Novartis; NATCO			Novartis; NATCO; Mylan; Cipla	Cipla; Eli Lily		Yes	Use of pioglitazone in combination with TKIs. Use of some ayurvedic products.
Education Program	Patients, Bosdem, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5		Hemant	Malhotra	MD, FACP, FRCP (Lon), FRCP (Edin)	Mahatma Gandhi Medical College Hospital	Chair	No	Oral	Disclosure made				Novartis; NATCO			Novartis; NATCO; Mylan; Cipla	Cipla; Eli Lily			
Education Program	Patients, Bosdem, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5		Hemant	Malhotra	MD, FACP, FRCP (Lon), FRCP (Edin)	Mahatma Gandhi Medical College Hospital	Chair	No	Oral	Disclosure made				Novartis; NATCO			Novartis; NATCO; Mylan; Cipla	Cipla; Eli Lily			
Oral and Poster Abstracts	704. Immunotherapies II		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5		David	Maloney	MD PhD	Fred Hutchinson Cancer Research Center	Moderator	No	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	801. Health Services Research: Non-Malignant Conditions: Improving Quality in Hematology		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders	Luis	Malpica Castillo	MD	University of North Carolina Hospital and Clinics	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	636. Myelodysplastic Syndromes: Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	EP300 Suppresses Leukemia Development in Myelodysplastic Syndrome through Myb Repression	Na	Men		Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Challenges in Myeloma Therapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	What to do with MRD Testing in Myeloma	Elisabet	Manasanch	MD	University of Texas MD Anderson Cancer Center	Speaker	Yes	Oral	Disclosure made				Quest Diagnostics; Sanofi; Merck; Skyline Diagnostics	Janssen; Sanofi; Takeda; Celgene						No	Dr. Manasanch will summarize recent clinical and technical advances in the area of minimal residual disease (MRD) detection in myeloma. She will also discuss current use of MRD in the clinic and potential future applications for disease monitoring and MRD-directed therapy.
Education Program	Challenges in Myeloma Therapy		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	What to do with MRD Testing in Myeloma	Elisabet	Manasanch	MD	University of Texas MD Anderson Cancer Center	Speaker	Yes	Oral	Disclosure made				Quest Diagnostics; Sanofi; Merck; Skyline Diagnostics	Janssen; Sanofi; Takeda; Celgene						No	Dr. Manasanch will summarize recent clinical and technical advances in the area of minimal residual disease (MRD) detection in myeloma. She will also discuss current use of MRD in the clinic and potential future applications for disease monitoring and MRD-directed therapy.
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Novel Molecular Dependencies and Targets in Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	MYC Overexpressing Multiple Myeloma Are Dependent on GLS1	Salomon	Meiser	MD, PhD	INSERM UMR-S 1172	Presenter	Yes	Oral	Disclosure made					Janssen; Celgene; Amgen						No	
Education Program	What's New in the Diagnosis and Management of von Willebrand Disease?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	What's New in Treatment of Von Willebrand Disease	Pier	Mannucci	MD	IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation	Speaker	Yes	Oral	Disclosure made							Bayer; Grifols; Kedrion; Novo Nordisk; Octapharma				No	
Education Program	What's New in the Diagnosis and Management of von Willebrand Disease?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	What's New in Treatment of Von Willebrand Disease	Pier	Mannucci	MD	IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation	Speaker	Yes	Oral	Disclosure made							Bayer; Grifols; Kedrion; Novo Nordisk; Octapharma				No	
Oral and Poster Abstracts	231. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Extended Mutational Profiling By MSK IMPACT™ Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy	Simon	Mandha	MD,MPH	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made		Heidell, Pittoni, Murphy & Bach, LLP; Medical Case Management Group	Daboia Consulting LLC	Janssen							No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Molecular Analysis and Areas of Unmet Need		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Ruxopaulin	Bridget	Mercellino	MD, PhD	Icahn School of Medicine at Mount Sinai	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations	Maanpa	Marshall	MD	University of Minnesota	Presenter	Yes	Oral	Disclosure made								Sanofi		Yes	Rituximab for immunosuppression in TTP.
Oral and Poster Abstracts	901. Health Services Research: Non-Malignant Conditions: Cancers and Thrombosis		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5		Kelsey	Martin	MD	Yale	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Mechanisms of and Therapies for cGVHD		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5		Paul	Martin	MD	Fred Hutchinson Cancer Research Center	Moderator	No	Oral	Disclosure made		Enlivex Therapeutics; Genentech	Procter and Gamble	Algenomics; Xenikos								
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Molecular Drivers and Targets in Myeloproliferative Neoplasms		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5		Caroline	Marty	PhD	Gustave Roussy	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies		Monday, December 9, 2019	10:30 AM	12:30 PM	Yes		1.5	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BET), As Monotherapy or JAK/ABI-ons®Ilko Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis	John	Mascarenhas	MD	Icahn School of Medicine at Mount Sinai	Presenter	Yes	Oral	Disclosure made		Incyte; Roche; Celgene; CTI Biopharma; Pharmaessentia		Incyte; Novartis; Roche; Merck; Celgene; CTI Biopharma; Janssen; Promedior; Menus				Incyte; Celgene; CTI Biopharma; Pharmaessentia		No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Insights into the Pathophysiology of Platelet Disorders		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Exome Sequencing Identifies Glycosylation Defects As a Probable Cause of Immune Thrombotic Thrombocytopenic Purpura	Felige	Messicano	Ph.D.	The University of Alabama at Birmingham	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone	María-Victoria	Mateos		University Hospital of Salamanca/IBSAL	Presenter	Yes	Oral	Disclosure made					Janssen; Celgene; Takeda; Amgen; Adaptive				Janssen; Celgene; Takeda; Amgen; GSK; Abbvie; EDO; Pharmamar		No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd	María-Victoria	Mateos		University Hospital of Salamanca	Presenter	Yes	Oral	Disclosure made					Janssen; Celgene; Takeda; Amgen; Adaptive				Janssen; Celgene; Takeda; Amgen; GSK; Abbvie; EDO; Pharmamar		No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies	Anthony	Meto	MD MSCE	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made		AstraZeneca; AbbVie; Sunesis; Celgene; Johnson & Johnson; TG Therapeutics; LOXO; Genentech; Pharmacyclics; Acerta; Janssen		AstraZeneca; AbbVie; Sunesis; Johnson & Johnson; TG Therapeutics; LOXO; DFRM Biopharma; Genentech; Pharmacyclics; Gilead							No	
Oral and Poster Abstracts	605. Molecular Pharmacology, Drug Resistance: Lymphoid and Other Diseases II		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas	Anthony	Meto	MD MSCE	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made		AstraZeneca; AbbVie; Sunesis; Celgene; Johnson & Johnson; TG Therapeutics; LOXO; Genentech; Pharmacyclics; Acerta; Janssen		AstraZeneca; AbbVie; Sunesis; Johnson & Johnson; TG Therapeutics; LOXO; DFRM Biopharma; Genentech; Pharmacyclics; Gilead						Yes	Everolimus in B cell lymphomas and CLL Pomalidomide in B cell lymphomas and CLL
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor	Anthony	Meto	MD MSCE	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made		AstraZeneca; AbbVie; Sunesis; Celgene; Johnson & Johnson; TG Therapeutics; LOXO; Genentech; Pharmacyclics; Acerta; Janssen		AstraZeneca; AbbVie; Sunesis; Johnson & Johnson; TG Therapeutics; LOXO; DFRM Biopharma; Genentech; Pharmacyclics; Gilead							No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5		Anthony	Meto	MD MSCE	Memorial Sloan Kettering Cancer Center	Moderator	No	Oral	Disclosure made		AstraZeneca; AbbVie; Sunesis; Celgene; Johnson & Johnson; TG Therapeutics; LOXO; Genentech; Pharmacyclics; Acerta; Janssen		AstraZeneca; AbbVie; Sunesis; Johnson & Johnson; TG Therapeutics; LOXO; DFRM Biopharma; Genentech; Pharmacyclics; Gilead							
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Timing the Initiation of Multiple Myeloma	Francesco	Maura	MD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas): Results from Retrospective/Observational Studies: Population-Based Outcomes		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)	Matthew	Maurer	MS	Mayo Clinic	Presenter	Yes	Oral	Disclosure made				Celgene; Nanostring				Morphosys		No	
Oral and Poster Abstracts	703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5		Marcela	Maus	MD, PhD	Massachusetts General Hospital, Harvard Medical School	Moderator	No	Oral	Nothing to disclose												
Special-Interest Sessions	ASH Practice Partnership Lunch	Genomic/Genetic Testing: The Who, What, Where, When, & Why	Sunday, December 8, 2019	11:15 AM	12:30 PM	Yes		1.25	Genomic Testing in Malignant Hematology	Rebecca	McClure	MD	Health Sciences North	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	902. Health Services Research: Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Levofloxacin Prophylaxis Is Effective and Cost-Effective in Pediatric Patients with Acute Myeloid Leukemia	Meghan	McCormick	MD	UPMC Children's Hospital of Pittsburgh	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Epigenetic Regulation		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5		Shannon	McKinney-Freeman	PhD	St. Jude Children's Research Hospital	Moderator	No	Oral	Nothing to disclose												
Education Program	Myeloproliferative Neoplasms: Managing the Cue that Bunneth Over		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	Diagnostic Workflow for Hereditary Erythrocytosis and Thrombocytosis	Mary Frances	McMullin	MD,FRCPath,FRCP	Queens University	Speaker	Yes	Oral	Disclosure made					Novartis		Novartis	Italopharma; Daiko Sanyo; Celgene		No	
Education Program	Myeloproliferative Neoplasms: Managing the Cue that Bunneth Over		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Diagnostic Workflow for Hereditary Erythrocytosis and Thrombocytosis	Mary Frances	McMullin	MD,FRCPath,FRCP	Queens University	Speaker	Yes	Oral	Disclosure made					Novartis		Novartis	Italopharma; Daiko Sanyo; Celgene		No	
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes		2	Unravelling Heterogeneity of Stem and Progenitor Cells in Myeloid Neoplasms Through Single Cell Multi-omics	Adam	Mead	MD, PhD	University of Oxford	Speaker	Yes	Oral	Disclosure made		Novartis; Bristol Myers-Squibb; Pfizer; Celgene		Novartis; Celgene; CTI	Novartis; CTI		Novartis				No	
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes		2	Unravelling Heterogeneity of Stem and Progenitor Cells in Myeloid Neoplasms Through Single Cell Multi-omics	Adam	Mead	MD, PhD	University of Oxford	Speaker	Yes	Oral	Disclosure made		Novartis; Bristol Myers-Squibb; Pfizer; Celgene		Novartis; Celgene; CTI	Novartis; CTI		Novartis				No	
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Insights Into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	11:30 AM	12:30 PM	Yes		1		Adam	Mead	MD, PhD	University of Oxford	Speaker	No	Oral	Disclosure made		Novartis; Bristol Myers-Squibb; Pfizer; Celgene		Novartis; Celgene; CTI.	Novartis; CTI		Novartis					
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5		Shannon	Meeks	MD	Emory University	Co-Chair	No	Oral	Disclosure made								Bayer; Bioverativ; Takeda-Shire; Genentech; Novo Nordisk; HEMA Biologics				
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5		Shannon	Meeks	MD	Emory University	Co-Chair	No	Oral	Disclosure made								Bayer; Bioverativ; Takeda-Shire; Genentech; Novo Nordisk; HEMA Biologics				
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas): Results from Retrospective/Observational Studies: Cellular Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5		Amitkumar	Mehta	MD	University of Albama At Birmingham	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Maturation and Enucleation		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1.5	Elucidating an Erythroblast Survival Mechanism: Differential Contributions of Exosome Complex Catalytic Subunits	Chanu	Mehta	MS	University of Wisconsin - Madison	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Medical Educators Symposium: General Session		Sunday, December 8, 2019	7:30 AM	9:30 AM	Yes		2		Rakesh	Mehta	MD	Indiana University School of Medicine	Chair	No	Oral	Nothing to disclose												
Education Program	Aggressive Non-Hodgkin Lymphomas: It's Getting Personal		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Emerging Strategies in Peripheral T-Cell Lymphoma	Neha	Mehta-Shah	MD	Washington University in St Louis	Speaker	Yes	Oral	Disclosure made				Celgene; Roche/Genentech; Bristol Myers Squibb; Verastem Pharmaceuticals; Innate Pharmaceuticals	Kowa Hakka Kirin						No	

Education Program	Aggressive Non-Hodgkin Lymphomas: It's Getting Personal		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Emerging Strategies in Peripheral T-Cell Lymphoma	Neha	Mehta-Shah	MD	Washington University in St Louis	Speaker	Yes	Oral	Disclosure made		Kowa Hakko Kirin		Celgene; Roche/Genentech; Bristol-Myers Squibb; Verastem Pharmaceuticals; Innate Pharmaceuticals							No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphomas|*Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Neha	Mehta-Shah	MD	Washington University	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Innovative Approaches in Allogeneic Transplantation for Pediatric or Nonmalignant Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Long-Term Outcome of Children with Acute Leukemia (AL) Given Alpharetro T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBEp2-haploHSCT)	Pietro	Merli	MD	IRCCS Bambino GesÃ¯ Children's Hospital	Presenter	Yes	Oral	Disclosure made				Sobi; Bellicum			Novartis; Amgen				No	
Oral and Poster Abstracts	704. Immunotherapies II		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death-1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort	Reid	Merryman	MD	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose													No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma|*Clinical Studies: Follicular Lymphoma: Biomarkers and Clinical Trials		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Reid	Merryman	MD	Dana-Farber Cancer Institute	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	806. Outcomes Research	*Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study	Ruben	Mesa	MD	University of Texas Health Science Center at San Antonio	Presenter	Yes	Oral	Disclosure made		Novartis; Sierra Oncology; Lilly; Bavarian Nordic; Galena Biopharma; Genentech		Celgene Corporation; AbbVie; Incyte; Samus; Genotech; CTI; Gilead Sciences; NS Pharma; Pfizer; PharmaEssentia; Promedior	Novartis; AOP Orphan Pharmaceuticals; Shire						No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Hemophilia-Associated Complications		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters	Akram	Mesleh Sharpe	MD	University of California San Diego	Presenter	Yes	Oral	Nothing to disclose													No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Advances in ITP Therapy		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5		Ara	Metjian	MD	Duke University School of Medicine	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	332. Anticoagulation and Antithrombotic Therapy I		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Validation of the Ottawa Score in Cancer Patients with Venous Thromboembolism: the Predicare Cohort Study	Guy	Meyer		Department of Respiratory Disease, HÃ´pital EuropÃ�en Georges Pompidou, UniversitÃ� Paris Descartes	Presenter	Yes	Oral	Disclosure made				LEO pharma; Boehringer Ingelheim; BMS-Pfizer; SANOFI							No	
Oral and Poster Abstracts	605. Molecular Pharmacology, Drug Resistance|*Lymphoid and Other Diseases II		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Protein Translocation Inhibition Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia	Lauren	Meyer		University of California, San Francisco	Presenter	Yes	Oral	Nothing to disclose													No	
Oral and Poster Abstracts	203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hemophagocytic Lymphohistiocytosis and Other Immune Disorders		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis	Lauren	Meyer		University of California, San Francisco	Presenter	Yes	Oral	Nothing to disclose													No	
Education Program	Junior Faculty Career Development Session		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Looking for an Academic Job and Show Me the Money: Negotiating Your Salary and Benefits	Sara	Meyer	PhD	Thomas Jefferson University, Sidney Kimmel Cancer Center	Speaker	Yes	Oral	Nothing to disclose													No	
Oral and Poster Abstracts	902. Health Services Research|*Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort	Hira	Mian	MD	McMaster University	Presenter	Yes	Oral	Disclosure made		Celgene; Janssen; Amgen			Celgene; Janssen								No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Predicting Results		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT)	Maurizio	Miano		IRCCS Istituto Giannina Gaslini	Presenter	Yes	Oral	Nothing to disclose													No	
Oral and Poster Abstracts	801. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Annarita	Miccio	PhD	IMAGINE Institute, UniversitÃ© Paris Descartes, Sorbonne Paris CitÃé	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Minimal Residual Disease and KCF2 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study	Naomi	Michels	BSc	Princess Máxima Center for Pediatric Oncology	Presenter	Yes	Oral	Nothing to disclose													No	
Education Program	Coagulation Conundrum Roundtable: Case-based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Saskia	Middeldorp	MD, PhD	University of Amsterdam	Chair	No	Oral	Disclosure made				Daiichi Sankyo; Bayer; Boehringer Ingelheim; BMS/Pfizer									
Education Program	Coagulation Conundrum Roundtable: Case-based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Saskia	Middeldorp	MD, PhD	University of Amsterdam	Chair	No	Oral	Disclosure made				Daiichi Sankyo; Bayer; Boehringer Ingelheim; BMS/Pfizer									
Special Scientific Symposia	Special Symposium on the Basic Science in Hemostasis and Thrombosis		Monday, December 9, 2019	4:30 PM	6:30 PM	Yes	2		Saskia	Middeldorp	MD, PhD	Academic Medical Center	Co-Chair	No	Oral	Disclosure made				Daiichi Sankyo; Bayer; Portola Pharmaceuticals; Aspen				Sanofi	Bayer; Boehringer Ingelheim; Pfizer; Portola Pharmaceuticals; Bristol-Myers Squibb				
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Alternative Doners, Novel Regimens		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	No Engraftment Advantage After Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial	Filippo	Milano	MD, PhD	Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Disclosure made				EsCellTherx; Amgen									No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Comparative Analyses		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Filippo	Milano	MD, PhD	Fred Hutchinson Cancer Research Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Advances in Understanding the Pathophysiology of AML		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies	Linde	Miles	PhD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Mechanistic Basis and Efficacy of Targeting P-Catenin-TCF7L2-IMDM-MYC Axis to Overcome Resistance to BET Inhibitors	Christopher	Mill	PhD, BA	MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose													No
Spotlight Sessions	Is Chemoimmunotherapy for CLL on Life Support? Phase Countersignoff		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Carole	Miller	MD	St. Agnes Healthcare Cancer Ctr.	Chair	No	Oral	Disclosure made		Verastem; Incyte		Verastem; Incyte; Novartis; Takeda	Verastem; Incyte; Novartis; Takeda		Verastem; Incyte; Novartis; Takeda						
Oral and Poster Abstracts	903. Health Services Research|*Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)	Tamara	Miller	MD,MSc	Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	903. Health Services Research|*Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Tamara	Miller	MD,MSc	Children's Healthcare of Atlanta	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Alice	Mims	MD	The Ohio State University	Moderator	No	Oral	Disclosure made									Abbvie; Agios Pharmaceuticals; PTC Therapeutics; Astellas Pharmaceuticals; Jazz Pharmaceuticals				
Oral and Poster Abstracts	113. Hemoglobinopathies, Excluding Thalassemia|*Basic and Translational Science: Novel Therapeutic Approaches for Pain and Organ Pathology in Sickle Cell Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Caterina	Minniti	MD	National Institutes of Health Clinical Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	203. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Active DNA Demethylation Mediated By GADD45P is Essential during G-CSF Triggered Granulocytic Differentiation	Perihan	Mir		Department of Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University Hospital Tuebingen	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: MYC and Beyond		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability	Sara	Mirali	BSc	University of Toronto	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	403. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Genetically Engineered Hematopoietic Progenitors Derived from Human Induced Pluripotent Stem Cells Achieve the Feeder-Free and Robust Production of Neutrophils with the Functional Capacity in Vivo	Masashi	Miyauchi		The University of Tokyo	Presenter	Yes	Oral	Disclosure made				Kyowa Hakko Kirin Co. Ltd.									No
Oral and Poster Abstracts	625. Lymphoma: Pre-Clinical|*Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Pacs Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL	Kohta	Miyawaki	MD, PhD	Kyushu University Graduate School of Medical Sciences	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	203. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Defects in Signal Recognition Particle (SRP) Components Reveal an Essential and Non-Redundant Role for Granule Biogenesis and Differentiation of Neutrophil Granulocytes	Yoko	Mizoguchi	MD PhD	Dr. von Hauner Children's Hospital, Ludwig-Maximilians-UniversitÃ¤t MÃnchen	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD: Novel Mechanisms and Emerging Therapies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Recipient Signaling through the Cannabinoid Type 2 Receptor Regulates IL-6 Independent Neuroinflammation during Graft Versus Host Disease	Alison	Moe	PhD	Medical College of Wisconsin	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Molecular Drivers and Targets in Myeloproliferative Neoplasms		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models	Alison	Moliterno	MD	Johns Hopkins University School of Medicine	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Alison	Moliterno	MD	Johns Hopkins University School of Medicine	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma|*Clinical Studies: Follicular Lymphoma: Biomarkers and Clinical Trials		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Intrafollicular CD8+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma	Patrizia	Mondello	MD, PhD, MSc	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Non-Intensive Therapy		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy	Guillermo	Montalban-Bravo	MD	University of Texas MD Anderson Cancer Center, Department of Leukemia	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14	Anthony	Moorman		Newcastle University	Presenter	Yes	Oral	Nothing to disclose													No

Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study	Philippe	Moreau	MD	Hematology, University Hospital HÃ´tel-Dieu	Presenter	Yes	Oral	Disclosure made		Celgene; Janssen; Amgen; Takeda; AbbVie			Celgene; Janssen; Amgen; Takeda; AbbVie					Yes	Bortezomib/thalidomide/dexamethasone (VTd) + autologous stem cell transplantation (ASCT) is standard of care in Europe for transplant-eligible patients with newly diagnosed multiple myeloma. The phase 3 CASSIOPEIA trial evaluated the efficacy and safety of adding daratumumab to VTd (D-VTd) before and after ASCT. Although daratumumab is approved as monotherapy and in combination with standard-of-care regimens for the treatment of NBM, D-VTd has not yet been approved. This presentation/paper includes information/discussion of D-VTd in the CASSIOPEIA companion study to CASSIOPEIA.
Oral and Poster Abstracts	652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Functional Characterization of Novel Molecular Drivers and Vulnerabilities of Myeloma Cells		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma	Eugenio	Morelli	MD	Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose										No	
Spotlight Sessions	Redox Biology in Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Oxidative Sensitive in Platelets	Craig	Morrell	PhD	University of Rochester	Speaker	Yes	Oral	Nothing to disclose										No	
Spotlight Sessions	Redox Biology in Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Craig	Morrell	PhD	University of Rochester	Co-chair	No	Oral	Nothing to disclose											
Special Scientific Symposia	Changing the Taxonomy of Aggressive Lymphoma: Ready to Impact Clinical Management?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Vicki	Morrison	MD	Hennepin County Medical Center, University of Minnesota	Co-Chair	No	Oral	Disclosure made								Celgene; genentech; pharmacyclics; seattle genetics					
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomaâ€"Clinical Studies: Follicular Lymphoma: Biomarkers and Clinical Trials		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma	Franck	Morschhauser	MD, PhD	CHRU Lille	Presenter	Yes	Oral	Disclosure made			Gilead; Servier; Roche/Genentech		Celgene; BMS; Janssen					No	
Oral and Poster Abstracts	203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hemophagocytic Lymphohistiocytosis and Other Immune Disorders		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis	Despina	Moshous	MD, PhD	Necker Enfants Malades University Hospital, Assistance Publique-HÃ´pitaux de Paris	Presenter	Yes	Oral	Nothing to disclose										Yes	Alemtuzumab (Campath) has been used in a prospective trial to evaluate its efficacy as first line treatment in familial lymphohistiocytosis.
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphomaâ€"Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study	Alison	Moskowitz	MD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made		ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; Erytech Pharma; ADC Therapeutics; Erytech Pharma; ADC Therapeutics; Erytech Pharma; ADC Therapeutics; Erytech Pharma; ADC Therapeutics; Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Erytech Pharma; Erytech Pharma; Erytech Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Erytech Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Erytech Pharma; Erytech Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; millagen Therapeutics Inc; millagen Therapeutics Inc; Bristol-Myers Squibb; millagen Therapeutics Inc; millagen Therapeutics Inc; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; millagen Therapeutics Inc; Bristol-Myers Squibb; Bristol-Myers Squibb; millagen Therapeutics Inc; millagen Therapeutics Inc;		Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics						No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphomaâ€"Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Alison	Moskowitz	MD	Memorial Sloan Kettering Cancer Center	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	905. Outcomes Researchâ€"Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Prognostic Value of Disease Risk Score Versus Gait Speed in Older Adults with Lymphoma	Lee	Mozessohn	MD	Sunnybrook Odette Cancer Centre	Presenter	Yes	Oral	Nothing to disclose										No	
Education Program	Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Pediatric-Inspired Protocols in Adult ALL: Are the Results Bearing Fruit?	Lori	Muffly	MD	Stanford Cancer Institute	Speaker	Yes	Oral	Disclosure made		Pfizer; KITE		Adaptive						No	
Education Program	Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Pediatric-Inspired Protocols in Adult ALL: Are the Results Bearing Fruit?	Lori	Muffly	MD	Stanford Cancer Institute	Speaker	Yes	Oral	Disclosure made		Pfizer; KITE		Adaptive						No	
Oral and Poster Abstracts	905. Outcomes Researchâ€"Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type	Lori	Muffly	MD	Stanford University Medical Center	Presenter	Yes	Oral	Disclosure made		Pfizer; KITE		Adaptive						No	
Oral and Poster Abstracts	906. Outcomes Researchâ€"Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Lori	Muffly	MD	Stanford University Medical Center	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns	Muharrem	Muftuoglu	MD	MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose										No	
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Speaker 1	Sudipto	Mukherjee	MD, PhD, MPH	Cleveland Clinic	Speaker	Yes	Oral	Disclosure made				Novartis; Celgene Corporation; Partnership for Health Analytic Research, LLC (PHAR, LLC)	Novartis; Celgene Corporation	Pfizer; Projects in Knowledge	Bristol-Myers Squibb	Takeda; Novartis; Celgene Corporation			
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Sudipto	Mukherjee	MD, PhD, MPH	Cleveland Clinic	Moderator	No	Oral	Nothing to disclose											
General Sessions	Best of ASH		Tuesday, December 10, 2019	11:30 AM	1:00 PM	Yes	1.5		Charles	Mullighan	MBBS, MD	St. Jude Children's Hospital	Co-chair	No	Oral	Disclosure made					Loxo Oncology: AbbVie: Pfizer	Amgen: Pfizer: Illumina			Illumina			
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomaâ€"Clinical Studies: Clinical Trials in Waldenstrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naï¯ve or Relapsed/Refractory Waldenstrï¯m Macroglobulinemia	Wirsiru	Munakata		National Cancer Center Hospital	Presenter	Yes	Oral	Disclosure made					Ono						Yes	Tirabrutinib. Clinical trial for WM/LPL.
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Results from CAR T-Cell Trials		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	A Phase 1 Study of ACT1B67 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma	Javier	Munoz	MD	Banner MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Pharmacyclics /Janssen; Bayer; Merck; Kyowa; Seattle Genetics; Celgene/Juno; Genentech; Kite/Gilead; Bristol-Myers Squibb; Alexion; Pfizer		Pharmacyclics /Janssen; Seattle Genetics; Celgene/Juno; Genentech; Kite/Gilead; Portola; Incyte	Kyowa; Seattle Genetics	Pharmacyclics /Janssen; Bayer; Kyowa; Seattle Genetics; Genentech; Kite/Gilead; Fosunkite; AstraZeneca			No	
Special-Interest Sessions	How to Peer Review a Scientific Paper		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Nikhil	Munshi	MD	Dana-Farber Cancer Institute	Panelist	No	Oral	Disclosure made		AbbVie; Adaptive; Amgen; Celgene; Janssen; Takeda; Oncopep										
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Epigenetic Alterations		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	SETD81-Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation	Andrew	Muntean	PhD	The Univ. of Michigan	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Predicting Results		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission	H. Moses	Murdock	BS	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose										No	
Education Program	Transfusion Medicine: Optimizing Patient Blood Management (PBM)		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Patient Blood Management as Standard of Care	Michael	Murphy	MD, FRCP, FRCPath	Oxford University Hospitals	Speaker	Yes	Oral	Nothing to disclose										No	
Education Program	Transfusion Medicine: Optimizing Patient Blood Management (PBM)		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Patient Blood Management as Standard of Care	Michael	Murphy	MD, FRCP, FRCPath	Oxford University Hospitals	Speaker	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Maturation and Enucleation		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	The Condensin II Subunit, Ncaph2, Is Required for Proper Embryonic Erythroid Terminal Maturation and Embryonic Viability in a Primary Mouse Model	Zachary	Murphy	PhD	University of Rochester Medical Center	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	The Unfolded Protein Response Causes Prothrombotic Transformation of Pancreatic Cancer Linking Tumor Progression with Cancer-Associated Thrombosis	Oluwatoyosi	Muse	PhD	Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Understanding and Targeting TP53 in Myeloid Malignancies		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Satu	Mustjoki	MD, PhD	University of Helsinki	Co-Chair	No	Oral	Disclosure made				BMS; Novartis; Pfizer	BMS						
Scientific Program	Understanding and Targeting TP53 in Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Satu	Mustjoki	MD, PhD	University of Helsinki	Co-Chair	No	Oral	Disclosure made				BMS; Novartis; Pfizer	BMS						
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Regulation of Coagulation by Polyphosphate	Nicola	Mutch	BSc, PhD	University of Aberdeen	Speaker	Yes	Oral	Nothing to disclose										No	
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Regulation of Coagulation by Polyphosphate	Nicola	Mutch	BSc, PhD	University of Aberdeen	Speaker	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: MYC and Beyond		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity	Tomoya	Muto	MD, PhD	Cincinnati Children's Hospital Medical Center	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	802. Health Services Researchâ€"Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of Life		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019	Regina	Myers	MD	Children's Hospital of Philadelphia	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Molecular Drivers and Targets in Myeloproliferative Neoplasms		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis	Elena	Mylonas		ChariÃ©Ã¨ Universitï¿½medizin Berlin	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Outcomes Following Second Allogeric Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT	Mitja	Nabergoj	MD	HÃ´pitaux Universitaires De GenÃ¨ve	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	643. CLL: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Clonal Evolution		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia	Jerran	Nadeu		Centro de Investigaciï¿½n BiomÃ©dica en Red de CÃ¡ncer (CIBERONC)	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	CD38 Knockout Primary NK Cells to Prevent MiCaFraricidal‚Â€Boost Daratumumab Activity	Yuya	Nagai	MD	John's Hopkins Hospital	Presenter	Yes	Oral	Nothing to disclose										No	
Education Program	Junior Faculty Career Development Session		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		RAKhi	Naik	MD	Johns Hopkins Hospital	Chair	No	Oral	Disclosure made											
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	CRISPR-Cas9 Screen Identifies Ndc2, a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML	Fumihiko	Nakao	MD	Kyushu University Graduate School of Medical Sciences	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Advances in Understanding the Pathophysiology of AML		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Longitudinal Tracking of Acute Myeloid Leukemia Stem Cells in Xenografts and Patients By microRNA Reporters and Single Cell RNA Sequencing	Matteo Maria	Naldini		San Raffaele Scientific Institute	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2		Anupama	Narla	MD	Stanford University	Co-Chair	No	Oral	Nothing to disclose											
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Sunday, December 8, 2019	9:30 AM	11:30 AM	Yes	2		Anupama	Narla	MD	Stanford University	Co-Chair	No	Oral	Nothing to disclose											

Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Maturation and Enucleation		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Mohandas	Narla	Ctic	New York Blood Center	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Disease Modeling of Severe Congenital Neutropenia Using CRISPR/Cas9 Gene Correction or Knockout of ELANE in Patients Derived Induced Pluripotent Stem Cells	Mosouf	Nasri	MSc	Department of Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University Hospital Tuebingen	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas“Clinical Studies: Follicular Lymphoma: Biomarkers and Clinical Trials		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)	Loretta	Nastoupil	MD, MSc	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made				Celgene; Genentech, Inc.; Janssen; TG Therapeutics		Bayer; Celgene; Genentech, Inc.; Gilead; Janssen; Novartis; TG Therapeutics; Spectrum				Yes	Lenalidomide in untreated follicular lymphoma
General Sessions	Harn-Wasserman Lecture		Saturday, December 7, 2019	12:45 PM	1:45 PM	Yes	1	Gene Therapy for Haemophilia	Amit	Nathwani	MD, PhD	University College London	Speaker	Yes	Oral	Disclosure made		Freeline	Freeline			Freeline		Freeline			No	
Oral and Poster Abstracts	627. Myelodysplastic Syndromes“Clinical Studies: Combination Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Phase II Study of Oral Bigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)	Shyamala	Navada	MD	Icahn School of Medicine at Mount Sinai	Presenter	Yes	Oral	Disclosure made				Onconova Therapeutics Inc							No	
Special-Interest Sessions	How to Peer Review a Scientific Paper		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Robert	Negrin	MD	Stanford University	Chair	No	Oral	Nothing to disclose												
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Elizabeta	Nemeth	PhD	University of California-Los Angeles	Co-Chair	No	Oral	Disclosure made		Intrinsic LifeSciences; Silarus Therapeutics; Protagonist; Keryx; Ionis Pharmaceuticals; La Jolla Pharma	Intrinsic LifeSciences; Silarus Therapeutics								
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Elizabeta	Nemeth	PhD	University of California-Los Angeles	Co-Chair	No	Oral	Disclosure made		Intrinsic LifeSciences; Silarus Therapeutics; Protagonist; Keryx; Ionis Pharmaceuticals; La Jolla Pharma	Intrinsic LifeSciences; Silarus Therapeutics								
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients	Paola	Neri	MD, PhD	University of Calgary	Presenter	Yes	Oral	Disclosure made		Celgene, Janssen		Celgene, Janssen	Celgene, Janssen						No	
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Biology and Therapeutic Opportunities		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Martin	Neumann		ChariÃ© University Hospital Benjamin Franklin	Moderator	No	Oral	Nothing to disclose												
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Immune Thrombocytopenia		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Cynthia	Neunert		Columbia University	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Peter	Newburger	MD	Pediatric Hematology/Oncology Division	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Advances in ITP Therapy		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Phase 2 Study of Efgartigimod, a Novel Fcrn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia	Adrian	Newland		The Royal London Hospital	Presenter	Yes	Oral	Disclosure made		Amgen; Argenx; Argenx; Dova; Novartis; Ono; Rigel; Shionogi		Amgen; Novartis; Rigel	Amgen; Argenx; Argenx; Dova; Novartis; Ono; Rigel; Shionogi						No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Microbiome and Immune Regulation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Antibiotic Exposures and Dietary Intakes Are Associated with Changes in Microbiota Compositions in Allogeneic Hematopoietic Stem Cell Transplant Patients	Chi	Nguyen	BA	Gerstner Sloan-Kettering Graduate School of Biomedical Sciences	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	801. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration	Giang	Nguyen	BS	The Children's Hospital of Philadelphia	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	*The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M48 Versus Nilotinib Alone in Newly Diagnosed CP-CML Patients. Updated Results of the Petals Phase III National Study.*	Franck	Nicolini	MD,PhD	Centre LÃ£on BÃ�rard	Presenter	Yes	Oral	Disclosure made		Sun Pharma Ltd		Incyte Biosciences; Novartis	Incyte Biosciences		Incyte Biosciences; Novartis				Yes	Pegylated Interferon alpha 2 a is not licensed in this setting
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Franck	Nicolini	MD,PhD	Centre Hospitalier Lyon Sud	Moderator	No	Oral	Disclosure made		Sun Pharma Ltd		Incyte Biosciences; Novartis	Incyte Biosciences		Incyte Biosciences; Novartis					
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chemo Immuno and Targets--Improving Combinations in ALL		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Intensive Chemotherapy for High-Risk ALL in Children â€" the Nordic Collaborative Approach	Atte	NiklÃ©n	MD	Tampere University	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Primary Immunodeficiencies for the Hematologist: Finding the Needle in the Haystack		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Primary Immunodeficiency: Novel Genes and Unusual Presentations	Luigi	Notarangelo	MD	National Institutes of Health	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Primary Immunodeficiencies for the Hematologist: Finding the Needle in the Haystack		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Primary Immunodeficiency: Novel Genes and Unusual Presentations	Luigi	Notarangelo	MD	National Institutes of Health	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	622. Lymphoma Biology“Non-Genetic Studies: Molecular Mechanisms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Anne	Novak	PhD	Mayo Clinic	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Epigenetic Alteration		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Christopher	Oakes	PhD	OSU	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Epigenetic Regulation		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Esther	Oberg	MD,PhD	St. Jude Children's Research Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and its Treatment		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Esther	Oberg	MD,PhD	St. Jude Children's Research Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)“Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (GENIOR Study). a Multicentric Randomized Phase III Study of the Lysa	Lucie	Oberic	MD	Institut Universitaire Cancerologie Toulouse-Oncopole	Presenter	Yes	Oral	Disclosure made					Janssen		Roche; Takeda			No	
Oral and Poster Abstracts	634. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chemo Immuno and Targets--Improving Combinations in ALL		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621	Maureen	O'Brien	MD	Cincinnati Children's Hospital Medical Center	Presenter	Yes	Oral	Disclosure made				Pfizer; Celgene; AbbVie; Amgen; BMS; BTG							Yes	Inotuzumab ozogamicin is FDA-approved for adults with relapsed B-ALL but is not approved for children. Its use in a pediatric population with relapsed B-ALL will be presented
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Speaker 4	Sarah	O'Brien	MD	Nationwide Children's Hospital	Speaker	Yes	Oral	Nothing to disclose												
Special-Interest Sessions	Special Symposium on Quality: ASH EQUIPS-Learning from Medical Errors and Other Incidents		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Sarah	O'Brien	MD	Nationwide Children's Hospital	Co-chair	No	Oral	Disclosure made				Bristol-Myers Squibb				Bristol-Myers Squibb; Pfizer				
Special-Interest Sessions	ASH Choosing Wisely® Campaign: The ASH-ASPHO Pediatric Choosing Wisely List		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Sarah	O'Brien	MD	Nationwide Children's Hospital	Chair	No	Oral	Disclosure made				Bristol-Myers Squibb				Bristol-Myers Squibb; Pfizer				
Spotlight Sessions	Is Chemoimmunotherapy for CLL on Life Support? (Point- Counterpoint)		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Full Code (Resuscitate)	Susan	O'Brien	MD	UCI Cancer Center	Speaker	Yes	Oral	Disclosure made		Amgen; Astellas; Celgene; GlaxoSmithKline; Janssen Oncology; Aptose Biosciences Inc; Verstam Group LLC; AbbVie; Alexion; Verastem; Eisai; Gilead; Pharmacyclics; TG Therapeutics; Pfizer; Sunesis		Kite; Regeneron; Acerta; Gilead; Pharmacyclics; TG Therapeutics; Pfizer; Sunesis							No	
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans	Adrian	Ochsenbein	MD	Department of BioMedical Research (DBMR), University of Bern	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	113. Hemoglobinopathies, Excluding Thalassemia“Basic and Translational Science: Novel Therapeutic Approaches for Pain and Organ Pathology in Sickle Cell Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Targeted Therapy of Acute Chest Syndrome with Recombinant Heme Oxygenase-1 Revealed By the Resistance of Young Transgenic Sickle Cell Mice to Heme-Induced Acute Lung Injury	Solomon	Ofori-Acquah		University of Pittsburgh	Presenter	Yes	Oral	Disclosure made											No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical JAK Inhibitors and Combination Therapies		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Stephen	Oh	MD	Washington University School of Medicine	Moderator	No	Oral	Disclosure made		Novartis						Incyte; Blueprint Medicines				
Special-Interest Sessions	TRTH Scientific Symposium: A Decade of Training the Future Leaders in Translational Research		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2	Metabolic Perturbations in Follicular Lymphoma: Clues from the Genetics	Jessica	Okosun	MD, PhD	Barts Cancer Institute, Queen Mary University of London	Speaker	Yes	Oral	Disclosure made				Gilead Sciences	Gilead Sciences						No	
Oral and Poster Abstracts	624. Myeloproliferative Syndromes: Clinical-Emerging and Novel Targeted Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)	Sara	Olalla Saad	Ph.D	Hematology and Transfusion Medicine Center - University of Campinas/Hemocentro- Unicamp	Presenter	Yes	Oral	Nothing to disclose											No	Metformin (MTF) is a biguanide used in diabetic patients that also exerts selective antineoplastic activity in a variety of malignancies, through its action on nutrients privation and hypoxia, leading to apoptosis. In JAK2-mutated cell lines, MTF reduced cell viability, proliferation and clonogenicity, while in Jak2V617F knock-in induced mice, MTF reduced Bal/F3 JAK2V617F tumor burden and splenomegaly. These data suggest that MTF could have a therapeutic effect in PMF patients.
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Intrinsic and Extrinsic Control of HSPC Maintenance and Differentiation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Heather	O'Leary	PhD	IUPUI (IU School of Medicine)	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: New Regulators of Stem and Progenitor Cell Survival and Differentiation		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Heather	O'Leary	PhD	IUPUI (IU School of Medicine)	Moderator	No	Oral	Nothing to disclose												
Education Program	Aging and Hematologic Disorders: Exploring the Evidence		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Overcoming Barriers in Providing Individualized Care for Older Adults with Heme Malignancies	Rebecca	Olin	MD	University of California - San Francisco	Speaker	Yes	Oral	Disclosure made		Genentech; Jazz Pharmaceuticals; Revolution Medicine		Daiichi Sankyo; Astellas; Genentech; Pfizer; AstraZeneca; Clovis; Ignyta; Medimmune; Mirati Therapeutics; Novartis; Spectrum	Jazz Pharmaceuticals						No	
Education Program	Aging and Hematologic Disorders: Exploring the Evidence		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Overcoming Barriers in Providing Individualized Care for Older Adults with Heme Malignancies	Rebecca	Olin	MD	University of California - San Francisco	Speaker	Yes	Oral	Disclosure made		Genentech; Jazz Pharmaceuticals; Revolution Medicine		Daiichi Sankyo; Astellas; Genentech; Pfizer; AstraZeneca; Clovis; Ignyta; Medimmune; Mirati Therapeutics; Novartis; Spectrum	Jazz Pharmaceuticals						No	
Oral and Poster Abstracts	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia - Final Results of the Qalaxo AZA-Ante Randomized Trial	Esther	Oliva	MD	Grande Ospedale Metropolitano Bianchi Melacrino Morelli	Presenter	Yes	Oral	Disclosure made		Celgene Corporation; Novartis; Agelio			Celgene Corporation		Celgene Corporation; Novartis				No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Adamts13-Cultured Red Blood Cells to Treat Thrombotic Thrombocytopenic Purpura	Emmanuel	Olivier	PhD	Albert Einstein College of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Regulation of Myeloid Cell Differentiation and Functions		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	PML Plays a Key Role in Severe Congenital Neutropenia with Mutant ELANE Causing Neutrophil Elastase Protein Misfolding	Patricia	Olofsen	MSc	Erasmus MC	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Special Symposium on Quality: ASH EQUIPS-Learning from Medical Errors and Other Incidents		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Sven	Olson	MD	Oregon Health & Science University	Panelist	No	Oral	Nothing to disclose												

Oral and Poster Abstracts	802. Health Services Research|Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes		Saturday, December 7, 2019	2:00 PM	2:30 PM	Yes		1.5	Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study	Adam	Chizewski	MD	Alpert Medical School of Brown University	Presenter	Yes	Oral	Disclosure made				Genentech; TG Therapeutics; Spectrum Pharmaceuticals; Adaptive Biotechnologies							No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia|Clinical: Emerging Therapies: Reports from Recent Clinical Trials		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Oral Arginine Therapy As a Novel Adjuvant In the Management of Acute Pain in Children with Sickle Cell Anemia in Nigeria: A Randomized Placebo-Controlled Trial	Richard	Onalo	FCPaed	University of Abuja, Nigeria	Presenter	Yes	Oral	Nothing to disclose											Yes	Oral L-arginine for treatment of acute sickle cell disease vaso-occlusive pain
Oral and Poster Abstracts	731. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?		Saturday, December 7, 2019	2:00 PM	2:30 PM	Yes		1.5	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients	Betul	Oran	MD,MS	The University of Texas, MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made				Astex pharmaceuticals; ARDG pharmaceuticals							No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Predicting Results		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients	Betul	Oran	MD,MS	The University of Texas, MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made				Astex pharmaceuticals; ARDG pharmaceuticals							No	
Spotlight Sessions	Diving Into Rare Childhood Leukemias		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	How to Treat Childhood Mixed-Phenotype Acute Leukemia	Stan	Orgel	MD, MS	Children's Hospital Los Angeles	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Chromatin Structure in Development and Disease		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Histone Modifications in Development and Malignancy	Elisa	Orzechio	DPhil	Ecole Polytechnique Federale de Lausanne	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Chromatin Structure in Development and Disease		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	Histone Modifications in Development and Malignancy	Elisa	Orzechio	DPhil	Ecole Polytechnique Federale de Lausanne	Speaker	Yes	Oral	Nothing to disclose											No	
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Chromatin Structure in Development and Disease		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes		1		Elisa	Orzechio	DPhil	Ecole Polytechnique Federale de Lausanne	Speaker	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	625. Lymphoma: Pre-Clinical|Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Development of Novel Second-Generation DC/Tumor Fusion Vaccine in Lymphoma	Shira	Orr	PhD	Beth Israel Deaconess Medical Center, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose											No	
Spotlight Sessions	Street Drugs: Emerging Hematologic Complications of Illicit Drug Use		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Cannabinoid-Associated Coagulopathy	Thomas	Ortel	MD, PhD	Duke University Medical Center	Speaker	Yes	Oral	Disclosure made		Instrumentation Laboratories										
Spotlight Sessions	Street Drugs: Emerging Hematologic Complications of Illicit Drug Use		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5		Thomas	Ortel	MD, PhD	Duke University Medical Center	Chair	No	Oral	Disclosure made		Instrumentation Laboratories										
Oral and Poster Abstracts	601. Health Services Research|Non-Malignant Conditions: Cancers and Thrombosis		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5		Thomas	Ortel	MD, PhD	Duke University Medical Center	Moderator	No	Oral	Disclosure made		Instrumentation Laboratories										
Oral and Poster Abstracts	903. Health Services Research|Non-Malignant Conditions: Improving Quality in Hematology		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Use of Buprenorphine/Naloxone in Ameliorating Acute Care Utilization and Chronic Opioid Use in Adults with Sickle Cell Disease	Feyitawa (Ify)	Osunkwo	MD, MPH	Sickle Cell Disease Enterprise at The Levine Cancer Institute/Atrium Health	Presenter	Yes	Oral	Disclosure made		Novartis; Pfizer					Novartis; Tenumo				No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data	Megan	Othus	PhD	Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Disclosure made											No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia|Clinical: Optimizing and Improving Access to High-Quality Care		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Assessing Feasibility of a Focused Geriatric Assessment in Older Adults with Sickle Cell Disease to Address Functional Risk Factors for Morbidity and Mortality	Charity	Oyedeji	MD	Duke University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Depletion of Neoplastic CD61b-Positive Cells in Jak2V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis	Yoshinori	Ozono	MD	Faculty of Medicine, University of Miyazaki	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5		Ingrid	Pabinger	MD	Medical University of Vienna	Co-Chair	No	Oral	Disclosure made				CSL Behring; Novo Nordisk; Sobi								
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5		Ingrid	Pabinger	MD	Medical University of Vienna	Co-Chair	No	Oral	Disclosure made				CSL Behring; Novo Nordisk; Sobi								
Oral and Poster Abstracts	906. Outcomes Research|Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5		Leslie	Pedrosa	MD	Mayo Clinic Arizona	Moderator	No	Oral	Nothing to disclose												
Education Program	Primary Immunodeficiencies for the Hematologist: Finding the Needle in the Haystack		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Treatment of Primary Immunodeficiency with Allogeneic Transplant and Gene Therapy	Sung-Yun	Pai	MD	Boston Children's Hospital	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Primary Immunodeficiencies for the Hematologist: Finding the Needle in the Haystack		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	Treatment of Primary Immunodeficiency with Allogeneic Transplant and Gene Therapy	Sung-Yun	Pai	MD	Boston Children's Hospital	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Primary Immunodeficiencies for the Hematologist: Finding the Needle in the Haystack		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5		Sung-Yun	Pai	MD	Boston Children's Hospital	Chair	No	Oral	Nothing to disclose												
Education Program	Primary Immunodeficiencies for the Hematologist: Finding the Needle in the Haystack		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5		Sung-Yun	Pai	MD	Boston Children's Hospital	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: New Regulators of Stem and Progenitor Cell Survival and Differentiation		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Loss of Dnmt3a Dyregulates Hematopoietic Homeostasis and Myeloid Skewing Via the PI3K/mTor Pathway: PI3K/δ/γ Inhibition Corrects Extramedullary Hematopoiesis and Myeloid Skewing Due to Loss of Dnmt3a	Lakshmi Reddy	Palam	PhD	Indiana University School of Medicine	Presenter	Yes	Oral	Nothing to disclose												No	
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes		2		James	Palis	MD	University of Rochester Medical Center	Co-Chair	No	Oral	Disclosure made		Rubius Therapeutics										
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes		2		James	Palis	MD	University of Rochester Medical Center	Co-Chair	No	Oral	Disclosure made		Rubius Therapeutics										
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	11:30 AM	12:30 PM	Yes		1		James	Palis	MD	University of Rochester Medical Center	Co-Chair	No	Oral	Disclosure made		Rubius Therapeutics										
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Molecular Analysis and Areas of Unmet Need		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5		Giuseppe	Palumbo	MD, PhD	UniversitÃ degli Studi di Catania	Moderator	No	Oral	Disclosure made					Novartis; Celgene; Janssen; Amgen; Hospira; Teva							
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Biology and Therapeutic Opportunities		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Association of Genetic Factors with Long-Term Outcome in Refractory CR-B-ALL Patients after CAR T-Cell Therapy	Jing	PAN		Beijing Boren Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Biology and Therapeutic Opportunities		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions	Lili	Pan	MD	City of Hope Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5		Agne	Paner	MD	Rush University Medical Center	Moderator	No	Oral	Disclosure made	Rush University Medical Center	Amgen; Celgene; Takeda; Abbvie; Janssen; Cellectar; Dova; Oncopeptides			Amgen; Celgene; Takeda; Abbvie; Janssen; Cellectar; Dova; Oncopeptides							
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Novel Target		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	CircPCMTD1 : A Protein-Coding Circular RNA That Regulates DNA Synthesis in Leukemic Myeloblasts	Dimitrios	Papaioannou	MD	The Ohio State University, Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5		Sameer	Parikh	MD	Mayo Clinic	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Preclinical Models, Immunotherapy, and CAR T Cells		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	T Cell Determinants of Response and Resistance to FD-1 Blockade in Richter|s Transformation	Erin	Parry	MD, PhD	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)|Results from Retrospective/Observational Studies: Cellular Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)	Marcelo	Pasquini	MD,MS	Medical College of Wisconsin	Presenter	Yes	Oral	Disclosure made		Medigene; Amgen		Novartis; Kit Pharma; BMS									No	
General Sessions	ASH-EHA Joint Symposium: Hemato-Metabolism - Linking Cellular Metabolism to Blood Diseases		Sunday, December 8, 2019	12:30 PM	1:30 PM	Yes		1	North American Perspective: Metabolic Control of Emergency Hematopoiesis	Emmanuelle	Passegue	PhD	Columbia University	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Molecular Drivers and Targets in Myeloproliferative Neoplasms		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5	PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617 Mutant MPN	Friederike	Pastore	MD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	903. Health Services Research|Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of Life		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001	Dorvid	Patrick		University of Washington Department of Health Services	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	621. Lymphoma|Genetic/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5		Jacqueline	Payton	MD,PhD	Washington Univ. in St. Louis	Moderator	No	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)|Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas	William	Pearse	MD	Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia|Clinical: Predicting Risk: A Focus on Disease Severity and Fertility		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5	Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of Hydroxyurea	Lydia	Pecker	MD	Johns Hopkins University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia|Clinical: Optimizing and Improving Access to High-Quality Care		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5		Lydia	Pecker	MD	Johns Hopkins University	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic Factors and Evaluation of Therapy Response in AML		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1.5	Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy	Shanshan	Pei	PhD	University of Colorado	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	636. Myelodysplastic Syndromes|Basic and Translational Studies: RNA Processing and Signatures in MDS		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5		Andrea	Pellagatti		University of Oxford	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	652. Myeloma: Biology and Pathophysiology, excluding Therapy: Novel Molecular Dependencies and Targets in Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5		Catherine	Pellat-Deceunynck	PhD	CRCINA	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis	Naveen	Pemmaraju	MD	University of Texas MD Anderson Cancer Center, Department of Leukemia	Presenter	Yes	Oral	Disclosure made		mustangbio; abbvie; celgene; Stemline Therapeutics; novartis; incyte		mustangbio; abbvie; samus; cellectis; Stemline Therapeutics; novartis; plexxikon; Daiichi-Sankyo; sagerstrong; affymetrix; incyte	abbvie; celgene; Stemline Therapeutics						Yes	LCL161- not yet FDA-approved drug; investigational agent = SMAC mimetic/IAP antagonist
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis	Naveen	Pemmaraju	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		mustangbio; abbvie; celgene; Stemline Therapeutics; novartis; incyte		mustangbio; abbvie; samus; cellectis; Stemline Therapeutics; novartis; plexxikon; Daiichi-Sankyo; sagerstrong; affymetrix; incyte	abbvie; celgene; Stemline Therapeutics							

Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Effect of Co-Mutations and FLT2 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	Alexander	Perl	MD	Abramson Cancer Center of the University of Pennsylvania	Presenter	Yes	Oral	Disclosure made		Astellas; Daiichi Sankyo; Arog; AbbVie; Actinium Pharmaceuticals; Agios; Jazz; NewLink Genetics; Takeda		Astellas; Daiichi Sankyo; Actinium Pharmaceuticals; Bayer; BioMed Valley Discoveries; FujiFilm; Novartis	Astellas; Daiichi Sankyo; AbbVie; Actinium Pharmaceuticals; Agios; Jazz; NewLink Genetics; Takeda; Novartis			Agios	Daiichi Sankyo		No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001	Daniel	Persky	MD	University of Arizona	Presenter	Yes	Oral	Disclosure made		Sandoz; Bayer								Yes	Brifumomab tiuxetan in diffuse large B-cell lymphoma
Education Program	New Diagnostic and Treatment Strategies for Antiphospholipid Syndrome		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Improvements in Diagnosis and Risk Assessment of Antiphospholipid Syndrome	Michelle	Petri	MD, MPH	Johns Hopkins University School of Medicine	Speaker	Yes	Oral	Disclosure made		Astrazeneca; Exagen; Abbvie; Alexion Pharmaceuticals; Amgen; Astellas; Blackrock Pharmaceuticals; Bristol-Myers Squibb; Decision Resources; EMD Serono; Eli Lilly; Glenmark Pharmaceuticals; GSK; IQVIA; Janssen Pharmaceuticals; Kezaar Life Sciences; Momenta Pharmaceuticals; Novartis; Principia Biopharma; Ojaiger; UCB Pharmaceuticals		Astrazeneca; Exagen						Yes	eculizumab - in clinical trials for SLE
Education Program	New Diagnostic and Treatment Strategies for Antiphospholipid Syndrome		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Improvements in Diagnosis and Risk Assessment of Antiphospholipid Syndrome	Michelle	Petri	MD, MPH	Johns Hopkins University School of Medicine	Speaker	Yes	Oral	Disclosure made		Astrazeneca; Exagen; Abbvie; Alexion Pharmaceuticals; Amgen; Astellas; Blackrock Pharmaceuticals; Bristol-Myers Squibb; Decision Resources; EMD Serono; Eli Lilly; Glenmark Pharmaceuticals; GSK; IQVIA; Janssen Pharmaceuticals; Kezaar Life Sciences; Momenta Pharmaceuticals; Novartis; Principia Biopharma; Ojaiger; UCB Pharmaceuticals		Astrazeneca; Exagen						Yes	eculizumab - in clinical trials for SLE
Oral and Poster Abstracts	221. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	Characterization of the Interaction between Tissue Factor Pathway Inhibitor Ia (TFPIIa) and Factor V Species	Teodolinda	Petrillo	PhD	The Children's Hospital of Philadelphia	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	638. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	A Phase 2a Study of the I-SS1 Inhibitor Img-7289 (Bomedemstat) for the Treatment of Myelofibrosis	Kristen	Pettit	MD	The University of Michigan	Presenter	Yes	Oral	Disclosure made				Samus Therapeutics						No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	The Multidrug Transporter MRP4/ABCC4 Involved in the Leukemia Clinical Course Specifies the Novel IRL Human Blood Group Sutsen	Thierry	Peyrard	PharmD/PhD	UniversitÃ© de Paris/Inserm/INTS	Presenter	Yes	Oral	Nothing to disclose										No	
Education Program	Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5	Management of Rare Acquired Bleeding Disorders	Flora	Peyvandi	MD, PhD	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Speaker	Yes	Oral	Disclosure made					Octapharma	Grifols; Kedrion; Roche; Alnylam; Takeda		Roche; Takeda; Bioverativ; Sanofi		Yes	
Education Program	Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Management of Rare Acquired Bleeding Disorders	Flora	Peyvandi	MD, PhD	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Speaker	Yes	Oral	Disclosure made					Octapharma	Grifols; Kedrion; Roche; Alnylam; Takeda		Roche; Takeda; Bioverativ; Sanofi		Yes	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas†"Clinical Studies: Clinical Trials in Waldenstrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5		Tycel	Phillips	MD	University of Michigan Cancer Center	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5		Joseph	Pidala	MD	H. Lee Moffitt Cancer Center and Research Institute	Moderator	No	Oral	Nothing to disclose											
Education Program	Junior Faculty Career Development Session		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	Looking For an Academic Job and Show Me the Money: Negotiating Your Salary and Benefits	Eric	Pietras	PhD	University of Colorado	Speaker	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: Fusion Genes		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5		Yana	Pikman	MD	Dana Farber Cancer Institute	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Core Transcriptional Regulatory Circuitries in AML	Maxim	Pinkus	MD, PhD	Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	VCAM1 Confers Innate Immune Tolerance on Hematopoietic and Leukemic Stem Cells	Sandra	Pinho	PhD	Department of Cell Biology, Albert Einstein College of Medicine	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	705. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD: Novel Mechanisms and Emerging Therapies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1.5	Single Cell Immune Profiling of Colitogenic T Cells during Acute Graft Versus Host Disease Reveals Two Novel Transcriptionally Distinct CD4+ GM-CSF+ Lineages	Clinton	Piper	BS	Medical College of Wisconsin	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: Fusion Genes		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Transformation Mechanisms of the Nfia-ETO2 Fusion Gene Associated with Pediatric Pure Acute Erythroleukemia	Maria-Riera	PiqueÃ©-borrÃ s	Msc	University Children's Hospital Basel (UHBB)	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5		France	Pirenne	MD,PhD	Etablissement FranÃ§ais Du Sang	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	231. Disorders of Platelet Number or Function: Advances in ITP Therapy		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5		Allyson	Pishko	MD	Hospital of University of Pennsylvania	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Non-Intensive Therapy		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZAD Trial	Uwe	Platzbecker	MD	University Hospital Leipzig	Presenter	Yes	Oral	Disclosure made		Novartis; Abbvie; Celgene			Novartis; Abbvie; Celgene					No	
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5	Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury	William	Plautz	BS	Student	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromes†"Clinical Studies: Lower-Risk MDS and CMML		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group	Lisa	Pleyer		3rd Medical Dept. with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University	Presenter	Yes	Oral	Disclosure made										Yes	Azacitidine is not approved for the treatment of MP-CMML or CMML with
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Mechanisms of and Therapies for cGvHD		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd	Jonathan	Poe	PhD	Duke University Medical Center	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	804. Outcomes Research†"Non-Malignant Conditions III		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5	Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Non-Hodgkin's Lymphoma: Analysis of the California Cancer Registry	Christina	Poh	MD	University of California Davis	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis	Christina	Poh	MD	University of California Davis School of Medicine	Presenter	Yes	Oral	Nothing to disclose										Yes	The use of blinatumomab and lenalidomide in patients with aggressive lymphoma
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Sorafenib in Combination with Standard Chemotherapy for Children with High-Allelic-Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031	Jessica	Pollard	MD	Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose										Yes	sorafenib for high allelic ratio FLT3/ITD+ AML
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Risk Stratification and Novel Approaches to Reduce Toxicity in Allogeneic Transplantation		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	Multidimensional Geriatric Assessment for Elderly Patients (≥Ã‰60 years) Submitted for Allogeneic Stem Cell Transplantation: a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients	Nicola	Polveroni		Unit of Blood Diseases and Stem Cell Transplantation, Dpt of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili di Brescia	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	653. Myeloma Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma	Alexandra	Poos	PhD	University Hospital Heidelberg	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study	Uday	Popat	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Jazz		Bayer; Incyte						Yes	fludarabine & busulfan as conditioning agent prior to transplant
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Prospective Clinical Trials: Results from CAR T-Cell Trials		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5		Leslie	Popplewell	MD, FRCPA	City of Hope Medical Center	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma†"Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5	Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDAC), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study	Pierluigi	Porcu	MD	Thomas Jefferson University	Presenter	Yes	Oral	Disclosure made		Spectrum		Viracta; Innate Pharma; BeiGene; Incyte; Daiichi; Kyowa; ADCT	Viracta; Innate Pharma; Kyowa						No	
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)â€"Results from Retrospective/Observational Studies: Population-Based Outcomes		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1.5		Craig	Portell	MD	University of Virginia	Moderator	No	Oral	Disclosure made		Pharmacyclics; Janssen; Genentech; Amgen; Bayer; BeiGene; Kite		AbbVie; Genentech; BeiGene; Kite; Acerta/AstraZeneca; TG Therapeutics; Xencor; Roche/Genentech; Infinity								
Oral and Poster Abstracts	506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development	Rassul	Pourebrahimabadi	MD, PhD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose										Yes	Mdm2 inhibitor-DS-5272
Oral and Poster Abstracts	804. Outcomes Research†"Non-Malignant Conditions III		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5		Jacquelyn	Powers	MD,MS	Baylor College of Medicine; Texas Children's Hospital	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Hemophilia-Associated Complications		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5	Higher Incidence of Neutralizing Anti-FVIII Antibodies (Inhibitors) in Black and Hispanic American Hemophilia A Patients Enrolled in the My Life, Our Future Programme	Kathleen	Pratt	PhD	Uniformed Services University of the Health Sciences	Presenter	Yes	Oral	Disclosure made					Grifols, Inc						No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5	Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies	Keith	Pratz	MD	Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University	Presenter	Yes	Oral	Disclosure made					AbbVie; Agios; Astellas; Millenium/Takeda			AbbVie; Agios; Astellas			No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromes†"Clinical Studies: Combination Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5		Thomas	Prebet	MD, PhD	Yale University	Moderator	No	Oral	Disclosure made					Boehringer Ingelheim	novartis; novartis; pfizer; pfizer						
Spotlight Sessions	Molecular Hematopathology Tumor Board		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Molecular Diagnostician	Richard	Press	MD, PhD	Oregon Health & Science University	Speaker	Yes	Oral	Nothing to disclose											

Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5	Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial	Noemi	Puig	MD, PhD	Departamento de Hematología-a, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC	Presenter	Yes	Oral	Disclosure made		Taleda; Janssen; Celgene; Amgen		Janssen; Celgene	Taleda; The Binding Site; Janssen; Celgene; Amgen		Celgene	Celgene			No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1-5	Gip-Mass Spectrometry in High-Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment	Noemi	Puig	MD, PhD	Hospital Universitario de Salamanca Hematología-a. Instituto de investigaciÃ³n biomÃ�dica de Salamanca (IBSAL)	Presenter	Yes	Oral	Disclosure made		Taleda, Amgen; Janssen; Celgene		Janssen; Celgene	Taleda, Amgen; The Binding Site; Janssen; Celgene		Celgene	Celgene			No	
Oral and Poster Abstracts	802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5	The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies	Alexandre	Puissant	PhD	Institute of Hematology - St Louis Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas‚€"Clinical Studies: Follicular Lymphoma: Biomarkers and Clinical Trials		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1-5	EARLY STAGE Follicular Lymphoma: First Results of the FIL Â€œMinimalÂ€Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy	Alessandro	Pulsoni	MD	Sapienza University of Rome, Italy	Presenter	Yes	Oral	Disclosure made		Roche; Takeda; Pfizer; Sandoz; Merk					Roche; Gilead; Bristol Meyer Squibb				Yes	The anti-CD20 MoAb Ofatumomab is employed to eradicate Minimal Residual Disease in early stage Follicular lymphoma(FL). The drug is registered for Chronic Lymphocytic Leukemia, not for FL.
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1-5		Mira	Pasic	MD	Washington University School of Medicine	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	231. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1-5	Monitoring the â€œLifetimeâ€Œof a Thrombus over Long Timescales By Leveraging a Novel Microvasculature-on-Chip Thrombosis Resolution Assay	Yongzhi	Qiu	PhD	Aflac Cancer and Blood Disorder Center of Childrenâ€™s Healthcare of Atlanta and Department of Pediatrics, Emory University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Epigenetic Alteration		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1-5	A MYC Driven and Metabolite Executed Axis Controls the Subcellular Localization and Activity of TET DNA Hydroxylases and RNA Demethylases In B Cell Lymphomas	Zhijun	Qiu	PhD	University of Texas Health Science Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	102. Regulation of Iron Metabolism: Novel Players in Iron Homeostasis in Health and Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1-5	SLC25A1 at the Interface between Macrophages and Red Blood Cells	Federica	Quattrone	MSc	Medical University of Vienna	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia‚€"Clinical: Predicting Risk: A Focus on Disease Severity and Fertility		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1-5	Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Disease-Modifying Therapy	Charles	Quinn	MD	Cincinnati Children's Hospital Med. Ctr.	Presenter	Yes	Oral	Disclosure made								Celgene			No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia	Christoph	hÃ¶lzig	MD, MSC.	UniversitÃ¤tsklinikum Carl Gustav Carus	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1-5		Ria	Raanani	MD	Davidoff Cancer Center, Beilinson Hospital	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Biology and Therapeutic Opportunities		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1-5		Keren	Rabin	MD,PhD	Baylor College of Medicine TX Children's Cancer Center	Moderator	No	Oral	Nothing to disclose													
Education Program	Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	Meeting the Needs of CML Patients in Resource-Poor Countries: a Roundtable Discussion	Jerald	Radich	MD	Fred Hutchinson Cancer Research Center	Speaker	Yes	Oral	Disclosure made				Twistbrand Biosciences							Yes	Use of pioglitazone in combination with TKIs. Use of some ayurvedic products.
Education Program	Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1-5	Meeting the Needs of CML Patients in Resource-Poor Countries: a Roundtable Discussion	Jerald	Radich	MD	Fred Hutchinson Cancer Research Center	Speaker	Yes	Oral	Disclosure made				Twistbrand Biosciences							Yes	Use of pioglitazone in combination with TKIs. Use of some ayurvedic products.
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5	Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd	Jerald	Radich	MD	Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Disclosure made				Twistbrand Biosciences							No	
Education Program	Coagulation Conundrum Roundtable: Case-based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1-5	The Hematologists View	Margaret	Ragni	MD, MPH	University of Pittsburgh	Speaker	Yes	Oral	Disclosure made				Alnylam/Sanofi; BioMarin; Bioverativ/Sanofi; OPKO; Sangamo; Shire/Takeda; Spark Therapeutics							No	
Education Program	Coagulation Conundrum Roundtable: Case-based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5	The Hematologists View	Margaret	Ragni	MD, MPH	University of Pittsburgh	Speaker	Yes	Oral	Disclosure made				Alnylam/Sanofi; BioMarin; Bioverativ/Sanofi; OPKO; Sangamo; Shire/Takeda; Spark Therapeutics							No	
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1-5	IL-1β Secreted from Mutant Cells Carrying JAK2- V617F Favors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression	Shivani	Rai		University Hospital Basel, University of Basel	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	ASH Choosing Wisely‚€" Campaign: 2019 ASH Choosing Wisely Clinicians		Monday, December 9, 2019	12:15 PM	1:15 PM	Yes		1		Anita	Rajkumar	MD	University of Florida Health Shands Hospital	Chair	No	Oral	Disclosure made										Alexion; Bayer; Octapharma; Kedrion Biopharma			
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)‚€"Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1-5	Phase 2 Results of the iR² Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell‚€"like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)	Radhakrishnan	Ramchandren	MD	University of Tennessee Health Science Center	Presenter	Yes	Oral	Disclosure made		Pharmacyclics LLC, an AbbVie company; Bristol-Myers Squibb; Sandoz-Novartis; Seattle Genetics, Inc.		Pharmacyclics LLC, an AbbVie company; Janssen; Genentech; Merck; Seattle Genetics, Inc.				Pharmacyclics LLC, an AbbVie company; Bristol-Myers Squibb; Sandoz-Novartis; Seattle Genetics, Inc.			Yes	Brutinib in combination with lenalidomide and rituximab is not approved by the FDA for treatment of diffuse large B-cell lymphoma (DLBCL)
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Non-Intensive Therapy		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5	A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group	Fernando	Ramos		Programa EspaÃ±ol de Tratamientos en Hematología, PETHEMA	Presenter	Yes	Oral	Disclosure made		Celgene; Janssen		Celgene	Celgene; Janssen; Abbvie; Daiichi Sankyo			Celgene			No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Molecular Analysis and Areas of Unmet Need		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5		Raajit	Rampal	MD, PhD	Memorial Sloan Kettering Cancer Center	Moderator	No	Oral	Nothing to disclose													
Education Program	Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	The US Experience with Generic Imatinib in CML: Did Cost Predictions Meet Reality?	Scott	Ramsay	MD, PhD	Fred Hutchinson Cancer Research Center	Speaker	Yes	Oral	Disclosure made											No	
Education Program	Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1-5	The US Experience with Generic Imatinib in CML: Did Cost Predictions Meet Reality?	Scott	Ramsay	MD, PhD	Fred Hutchinson Cancer Research Center	Speaker	Yes	Oral	Disclosure made											No	
Education Program	New Diagnostic and Treatment Strategies For Antiphospholipid Syndrome		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1-5		Jacob	Rand	MD	Weill Cornell Medical College	Chair	No	Oral	Nothing to disclose													
Education Program	New Diagnostic and Treatment Strategies For Antiphospholipid Syndrome		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1-5		Jacob	Rand	MD	Weill Cornell Medical College	Chair	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	903. Health Services Research‚€"Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1-5	Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies	Vinay	Rao		Warren Alpert Medical School of Brown University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1-5	Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012	Marelike	Rasche	MD	University Hospital Essen	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	232. Anticoagulation and Antithrombotic Therapy I		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1-5	Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study	Gary	Raskob	PhD	University of Oklahoma Health Sciences Center	Presenter	Yes	Oral	Disclosure made		Janssen R&D, LLC; Bayer Healthcare; BMS; Daiichi Sankyo; Boehringer Ingelheim; Eli Lilly; Pfizer; Portola; Novartis; Anthos; Tetherex			Janssen R&D, LLC; Bayer Healthcare; BMS; Daiichi Sankyo; Pfizer							Yes	Rivaroxaban is a factor Xa inhibitor and is currently under review by the FDA for thromboprophylaxis in patients with acute medical illness
Oral and Poster Abstracts	905. Outcomes Research‚€"Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1-5	Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients	Gayathri	Ravi	MD	University Hospitals Seidman Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Novel Molecular Dependencies and Targets in Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5	Preclinical Validation of Alpha-Enolase (ENO1)Â- As a Novel Immunometabolic Target in Multiple Myeloma	Aseghya	Ray	PhD	Dana-Farber Cancer Institute, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1-5	Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor-Promoting Transcriptional Changes in Multiple Myeloma Cells	Aseghya	Ray	PhD	Dana-Farber Cancer Institute, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update	Delphine	Rea	MD	Saint Louis University Hospital	Presenter	Yes	Oral	Disclosure made				Novartis; BMS; Incyte Biosciences; Pfizer				Novartis; Pfizer			No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia‚€"Clinical: Emerging Therapies: Reports from Recent Clinical Trials		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5	Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia	David	Ewes		King's College Hospital NHS Foundation Trust	Presenter	Yes	Oral	Disclosure made											Yes	canakinumab use in the treatment of sickle cell anemia.
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: MYC and Beyond		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1-5	Post-Translational Mechanisms of NTSC2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia	Clara	Pagliero	PhD	Institute for Cancer Genetics, Columbia University	Presenter	Yes	Oral	Nothing to disclose											No	
How I Treat: Bringing Science to Clinical Dilemmas	Hypereosinophilia: An Approach to Diagnosis and Management		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes		1		Andreas	Reiter	MD	Department of Hematology and Oncology, University Hospital Mannheim	Speaker	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD and Thymus Regeneration: Role of Innate Cells and Non-Hematopoietic Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1-5		Ran	Reshef	MD,MSc	Columbia University	Moderator	No	Oral	Nothing to disclose													
Scientific Program	Dynamic Change of the Hematopoietic Stem Cell Niche		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	Mapping Stem Cell Dependencies in Cancer Heterogeneity and Therapy Resistance	Tannishtha	Reya	PhD	University of California-San Diego	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Dynamic Change of the Hematopoietic Stem Cell Niche		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1-5	Mapping Stem Cell Dependencies in Cancer Heterogeneity and Therapy Resistance	Tannishtha	Reya	PhD	University of California-San Diego	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1-5	Functionally Distinct Subsets of Monocytes in Mouse and Human Blood	Catherine	Rhee	PhD	Harvard University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD): Final Results of the Pethema ALL-HR-11 Trial	Josep-Maria	Ribera	MD, PhD	ICO-Hospital Germans Trias i Pujol. Josep Carreras Research Institute. Universitat AutÃ²noma de Barcelona	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5		Josep-Maria	Ribera	MD, PhD	Ico-Hospital Universitari Germans Trias Y Pujol	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	627. Myelodysplastic Syndromes‚€"Clinical Studies: Targeting Gene Mutations in MDS		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5	Preliminary Results from the Phase II Study of the IDH2- Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)	Guillaume	Richard-Carpentier	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose											Yes	Enasidenib is not approved for the treatment of myelodysplastic syndrome
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogeneous AML		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1-5	Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene â€" a COG/Tpam Study	Rhonda	Ries	MA	Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Nothing to disclose											No	

Oral and Poster Abstracts	631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-free Remission		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	CD60: Signaling Regulates Self-Renewal and Proliferation of Chronic Myeloid Leukemia Stem Cells in Mice and Humans and Might be a Promising Target for Treatment	Carsten	Karther	PhD	University and University Hospital of Bern	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS): Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study	Robert	Rifkin	MD	US Oncology Research, Rocky Mountain Cancer Centers	Presenter	Yes	Oral	Disclosure made									Amgen; Celgene; Takeda		Yes	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		David	Ritchie	MD, PhD	Royal Melbourne Hospital	Moderator	No	Oral	Disclosure made		Amgen; Pfizer		Amgen; BMS; Takeda; Beigene; Imago								
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Zinc-Dependent Homomultimerization of Mutant Calreticulin is Required for MPN Phenogenesis	Jeanne	Rivera	BSc	University of Leeds	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Advances in ITP Therapy		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia	Tadeusz	Robak	MD	Medical University of Lodz, Copernicus Memorial Hospital	Presenter	Yes	Oral	Disclosure made		Takeda; Janssen; Amgen; Roche; AbbVie; Gilead; BeiGene		Takeda; UCB; Janssen; Roche; AbbVie; Gilead; BeiGene; Acerta; Morphosys AG								
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia: Clinical: Optimizing and Improving Access to High-Quality Care		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease	John	Roberts	MD	Yale University	Presenter	Yes	Oral	Disclosure made		Community Health Network of Connecticut; Truven Health Analytics									No	
Oral and Poster Abstracts	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genomic Landscape and Disease Classification		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia	Kathryn	Roberts	PhD	St. Jude Children's Research Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Predicting Results		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT	Marie	Robin	MD	HÃ´pital Saint-Louis, APHP, UniversitÃ© Paris 7	Presenter	Yes	Oral	Disclosure made				Novartis Neovii								No	
Oral and Poster Abstracts	653. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Aldo	Roccaro	MD,PhD	ASST Spedali Civili di Brescia	Moderator	No	Oral	Disclosure made				Associazione Italiana per al Ricerca sul Cancro (AIRC); European Hematology Association; Transcan2-ERANET; AstraZeneca				Amgen; Celgene; Janssen				
Oral and Poster Abstracts	704. Immunotherapies II		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion	Claire	Roddie	PhD, MD	UCL Cancer Institute	Presenter	Yes	Oral	Disclosure made		Novartis; Gilead; Celgene					Gilead; Celgene				No	
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refining the Approach		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL	Claire	Roddie	PhD, MD	University College London	Presenter	Yes	Oral	Disclosure made		Novartis; Gilead; Celgene					Gilead; Celgene				No	
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Hemophilia-Associated Complications		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5		George	Rodgers	MD, PhD	Univ. of Utah Medical Center	Moderator	No	Oral	Disclosure made		AstraZeneca; Sanofi; Novartis; Octapharma; Pfizer									No	
Oral and Poster Abstracts	653. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	The Pathogenesis of Multiple Myeloma (MM) is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)	Sara	Rodríguez	PhD	Clínica Universidad de Navarra	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Epigenetic Regulation		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Combined Single Cell Lineage and Transcriptome Sequencing Unveils Cell-Autonomous Regulators of Hematopoietic Stem Cell Fate	Alejo	Rodriguez-Fraticelli	PhD	Boston Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: Molecular Analysis and Areas of Unmet Need		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-PDGFRa-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients	Julien	Rohmer	MD	Hopital Foch	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Epigenetic Regulation		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Loss of KLF6 Recapitulates Molecular and Functional Changes Associated with Aging in Human Hematopoietic Stem and Progenitor Cells	Alejandro	Rosiman	PhD	University of Miami Miller School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	904. Outcomes Research: Non-Malignant Conditions II		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Neuropathic Pain Is Associated with Poor Health-Related Quality of Life in Adolescents with Sickle Cell Disease	Marisa	Roman	BA	Medical College of Wisconsin	Presenter	Yes	Oral	Nothing to disclose											No	
Special-Interest Sessions	Systems-Based Hematology: How to Implement Evidence-Based Programs for Virtual Hematology Consults and Anticoagulation Stewardship		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	1	How I Setup a Virtual Hematology Consult Service	Michal	Rose	MD	VA CT Healthcare System	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	902. Health Services Research: Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of Life		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Aaron	Rosenberg	MD	University of California Davis School of Medicine	Moderator	No	Oral	Disclosure made		Celgene; Amgen; Karyopharm		Amgen			Millennium-Takeda; Janssen					
Oral and Poster Abstracts	902. Health Services Research: Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma	Kristen	Rosenthal	PhD	Clinical Care Options, LLC	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	621. Lymphoma: Genetic/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	RNA Sequencing of Hodgkin Lymphoma Reed-Sternberg Cells Uncovers a Plasma Cell Signature and Escape From NK Cell Recognition	Mikhail	Roshal	MD, PhD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made			Auron Therapeutics									No
Oral and Poster Abstracts	905. Outcomes Research: Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Ashley	Rosko	MD	The Ohio State University	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma: Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Stage III-High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response	CÃ�dric	Rossi	MD, PhD	University Hospital F. Mitterrand and Inserm UMR 1231	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	203. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Maturation and Enucleation		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Transcriptional Regulation of Coenzyme Q Biosynthesis By TIF1$^{\beta}$ Drives Erythropoiesis	Marlies	Rossmann	MD, PhD	Harvard	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Ferroportin in Erythrocytes: Importance for Iron Homeostasis and Its Role in Infection	Tracey	Rouault	MD	National Institutes of Health	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Ferroportin in Erythrocytes: Importance for Iron Homeostasis and Its Role in Infection	Tracey	Rouault	MD	National Institutes of Health	Speaker	Yes	Oral	Nothing to disclose											No	
Meet the Scientist	Ferroportin in Erythrocytes: Importance for Iron Homeostasis and Its Role in Infection		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Tracey	Rouault	MD	National Institute of Child Health and Human Development	Speaker	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Storage-Induced Micro-Erythrocytes Are Rapidly Cleared from Recipient Circulation and Predict Transfusion Recovery	Camille	Roussel	MD,PhD	UniversitÃ© de Paris, Biologie InsÃ©rÃ©e du Globule Rouge, UMR_S1134, BIGR, INSERM, F-75015	Presenter	Yes	Oral	Disclosure made				Zimmer Biomet								No
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts	Philippe	Rousselot	MD PhD	Centre Hospitalier de Versailles	Presenter	Yes	Oral	Disclosure made				Pfizer; Incyte								No
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse		Saturday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses	Pier Edoardo	Rovatti	MD	IRCCS San Raffaele Scientific Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	205. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: New Concepts and Perspectives		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Megakaryocyte Reprogramming in Breast Cancer	Harvey	Roweth	BSc,PhD	Brigham and Women's Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Mechanisms of and Therapies for cGVHD		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial	Jean	Roy	MD	University of Montreal	Presenter	Yes	Oral	Disclosure made		Celgene		ExCellThera; Celgene; Sanofi Canada	Celgene; Amgen Canada; Janssen Canada						Yes	Rabbit ATG (Sanofi) for chronic GVHD prophylaxis.
Education Program	Aggressive Non-Hodgkin Lymphomas: It's Getting Personal		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Molecular Profiling and Management of Mantle Cell Lymphoma	Ila	Ruan	MD, PhD	Weill Cornell Medicine	Speaker	Yes	Oral	Disclosure made		Celgene; Seattle Genetics; Juno Therapeutics		Celgene; Pharmacyclics; Seattle Genetics	Janssen							No
Education Program	Aggressive Non-Hodgkin Lymphomas: It's Getting Personal		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Molecular Profiling and Management of Mantle Cell Lymphoma	Ila	Ruan	MD, PhD	Weill Cornell Medicine	Speaker	Yes	Oral	Disclosure made		Celgene; Seattle Genetics; Juno Therapeutics		Celgene; Pharmacyclics; Seattle Genetics	Janssen							No
Education Program	Aggressive Non-Hodgkin Lymphomas: It's Getting Personal		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Ila	Ruan	MD, PhD	Weill Cornell Medicine	Chair	No	Oral	Disclosure made		Celgene; Seattle Genetics; Juno Therapeutics		Celgene; Pharmacyclics; Seattle Genetics	Janssen							
Education Program	Aggressive Non-Hodgkin Lymphomas: It's Getting Personal		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Ila	Ruan	MD, PhD	Weill Cornell Medicine	Chair	No	Oral	Disclosure made		Celgene; Seattle Genetics; Juno Therapeutics		Celgene; Pharmacyclics; Seattle Genetics	Janssen							
Oral and Poster Abstracts	625. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma: Clinical Studies: Clinical Trials in Waldenstrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Ila	Ruan	MD, PhD	New York Presbyterian Hospital (Cornell Campus)	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma: Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085	Paul	Rubinstein	MD	Ruth M. Rothstein CORE Center	Presenter	Yes	Oral	Nothing to disclose											Yes	Brentuximab Vedotin has been approved for the upfront treatment of advanced stage cHL in combination with AVD though not specifically approved for use in patients infected with HIV or stage 2 cHL.
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Links Between Complement Activation and Thrombosis	Wolfram	Ruf	MD	The Scripps Research Institute	Speaker	Yes	Oral	Disclosure made		Iconic Therapeutics	MeraVaximmune								No	
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Links Between Complement Activation and Thrombosis	Wolfram	Ruf	MD	The Scripps Research Institute	Speaker	Yes	Oral	Disclosure made		Iconic Therapeutics	MeraVaximmune								No	
Meet the Scientist	Links between Complement Activation and Thrombosis		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Wolfram	Ruf	MD	The Scripps Research Institute	Speaker	No	Oral	Disclosure made		Iconic Therapeutics	MeraVaximmune									
Education Program	Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Optimizing Cord Blood Selection	Annalisa	Ruggeri	MD	Hopital Saint Antoine	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Optimizing Cord Blood Selection	Annalisa	Ruggeri	MD	Hopital Saint Antoine	Speaker	Yes	Oral	Nothing to disclose											No	

Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	Comparative Analysis of Alpha-Beta T-Cell and B-Cell Depleted (abTCD) HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) Versus Abtcd Haplo-HSCT with T-Cell Add-Back of Rivogenlecleucel Cell (Donor T Cells Transduced with the Inducible Caspase 9 (iC9) Gene Safety Switch) in Children with High-Risk Acute Leukemia (AL) in Remission	Annalisa	Ruggeri	MD	Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino GesÃ¹	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Clinical Insights Into ITP and TTP		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	Comparing the Risk of Complications for Second-Line Treatments of Immune Thrombocytopenia in Veterans: A U.S. National Study	Natalia	Ruiz-Negron	PharmD	University of Utah	Presenter	Yes	Oral	Disclosure made					Novartis Pharmaceuticals						Yes	On-label indications for TPO-RAs (including eltrombopag and romiplostim), but off-label use of rituximab; all medications were evaluated in the treatment of chronic immune thrombocytopenia.
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomaâ€"Clinical Studies: Clinical Trials in Waldenstrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with WaldenstrÃ¶m's Macroglobulinemia (WM): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the SKL WALT-2008 MAINTAIN trial)	Mathias	Rummel	MD, PhD	Justus Liebig University	Presenter	Yes	Oral	Disclosure made					Roche Pharma AG	Roche Pharma AG; Celgene; Janssen; Sandoz						No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of Pathogenesis, Drug Sensitivity, and Resistance, and Role of Bone Marrow Microenvironment and Host Microbiome in Myeloma Pathogenesis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Myeloma Derived Extracellular Vesicles Containing Endoplasmic Reticulum Remodel the Bone Marrow Microenvironment Towards a Pro-Tumoral Senescent Phenotype	Stuart	Rushworth	PhD	The University of East Anglia	Presenter	Yes	Oral	Disclosure made					Abbvie; Janssen						No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Revealing the Impact of Recurrent and Rare Structural Variations in Multiple Myeloma	Even	Ruetad	MD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5	Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123Â—CD3 Bispecific DartÂ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia	Sergio	Rutella	MD,PhD,FRCPath	Nottingham Trent University	Presenter	Yes	Oral	Disclosure made					MacroGenics, Inc. ; NanoString Technologies, Inc.						No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemiaâ€"Clinical: Predicting Risk: A Focus on Disease Severity and Fertility		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes		1.5	A Machine Learning Algorithm to Improve Risk Assessment for Patients with Sickle Cell Disease	Vandana	Sachdev	MD	National Institutes of Health	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	622. Lymphoma Biologyâ€"Non-Genetic Studies: Molecular Mechanisms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies	Teresa	Sadras	PhD	Department of Systems Biology, City of Hope Comprehensive Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	113. Hemoglobinopathies, Excluding Thalassemiaâ€"Basic and Translational Science: Novel Therapeutic Approaches for Pain and Organ Pathology in Sickle Cell Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1.5	Cannabidiol Reduces Acute and Chronic Hyperalgesia in Humanized Sickle Mice	Varun	Sagi	BS	University of Minnesota	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma	Reona	Sakemura	MD, PhD	Mayo Clinic	Presenter	Yes	Oral	Disclosure made								Humanigen				No	
Oral and Poster Abstracts	803. Health Services Researchâ€"Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes	Maria Querait	Salas	MD	Princess Margaret Cancer Centre, University Health Network	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	617. Myelodysplastic Syndromesâ€"Clinical Studies: Combination Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results	David	Sallman	MD	H. Lee Moffitt Cancer Center	Presenter	Yes	Oral	Disclosure made										Celyad		No	
Oral and Poster Abstracts	627. Myelodysplastic Syndromesâ€"Clinical Studies: Targeting Gene Mutations In MDS		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1.5	Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)	David	Sallman	MD	H. Lee Moffitt Cancer Center & Research Institute	Presenter	Yes	Oral	Disclosure made					Celgene; Jazz				Celgene; Incyte; Novartis; Abbvie	Celyad		No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromesâ€"Clinical Studies: Combination Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5		David	Sallman	MD	H. Lee Moffitt Cancer Center and Research Institute	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Clonal Evolution		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1.5		Deepa	Sampath	PhD	The Ohio State University Wexner Medical Ctr.	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)	Rachar	Samra	MD	University of Texas MD Anderson Cancer Center, Department of Leukemia	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial	Brenda	Sandmaier	MD	University of Washington	Presenter	Yes	Oral	Nothing to disclose												Yes	In the current study cyclosporine, mycophenolate mofetil and sirolimus are used to prevent graft versus host disease after allogeneic hematopoietic cell transplantation. Fludarabine is used together with total body irradiation as at part of the conditioning prior to allogeneic hematopoietic cell transplantation.
Oral and Poster Abstracts	731. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5		Brenda	Sandmaier	MD	Fred Hutchinson Cancer Research Center and Dept. of Medicine, University of Washington	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1.5	Interim Analysis of the Extension Study with Vihi-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)	Elena	Santagostino		IRCCS CÃ¸ Granda Foundation, Maggiore Hospital Policlinic	Presenter	Yes	Oral	Disclosure made		Shire / Takeda; Bayer; Pfizer						Shire / Takeda; Bayer; Pfizer			No	
Oral and Poster Abstracts	636. Myelodysplastic Syndromesâ€"Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5		Valeria	Santini	MD	AOU Careggi-University of Florence	Moderator	No	Oral	Nothing to disclose													
Education Program	Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia		Saturday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	In MDS, Is Higher-Risk, Higher Reward?	Guillermo	Sanz	MD, PhD	Hospital Universitario I PolitÃcnic La Fe	Speaker	Yes	Oral	Disclosure made					Abbvie; Amgen; Celgene; Helsinn Healthcare; Hoffman â€" La Roche; Janssen â€" Cilag; Novartis; Onconeva	Abbvie; Celgene; Hoffman â€" La Roche; Janssen â€" Cilag; Novartis			Abbvie; Amgen; Boehringer-Ingelheim; Celgene; Helsinn Healthcare; Hoffman â€" La Roche; Janssen â€" Cilag; Novartis; Onconeva		Yes	
Education Program	Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	In MDS, Is Higher-Risk, Higher Reward?	Guillermo	Sanz	MD, PhD	Hospital Universitario I PolitÃcnic La Fe	Speaker	Yes	Oral	Disclosure made					Abbvie; Amgen; Celgene; Helsinn Healthcare; Hoffman â€" La Roche; Janssen â€" Cilag; Novartis; Onconeva	Abbvie; Celgene; Hoffman â€" La Roche; Janssen â€" Cilag; Novartis			Abbvie; Amgen; Boehringer-Ingelheim; Celgene; Helsinn Healthcare; Hoffman â€" La Roche; Janssen â€" Cilag; Novartis; Onconeva		Yes	
Oral and Poster Abstracts	621. Lymphomaâ€"Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomaareas		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	Mutational Landscape of Grey Zone Lymphoma	Clementine	Sarkozy	MD	British Columbia Cancer	Presenter	Yes	Oral	Disclosure made					Takeda							No	
Education Program	DOACS in the Real World		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	DOAC Monitoring: What tests are available to guide us?	Ravindra	Sarode	MD	UT Southwestern Medical Center	Speaker	Yes	Oral	Disclosure made		Octapharma; CSL Behring			Siemens	Portola						No	
Education Program	DOACS in the Real World		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	DOAC Monitoring: What tests are available to guide us?	Ravindra	Sarode	MD	UT Southwestern Medical Center	Speaker	Yes	Oral	Disclosure made		Octapharma; CSL Behring			Siemens	Portola						No	
Education Program	DOACS in the Real World		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5		Ravindra	Sarode	MD	UT Southwestern Medical Center	Chair	No	Oral	Disclosure made		Octapharma; CSL Behring			Siemens	Portola						
Education Program	DOACS in the Real World		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5		Ravindra	Sarode	MD	UT Southwestern Medical Center	Chair	No	Oral	Disclosure made		Octapharma; CSL Behrine			Siemens	Portola						
Oral and Poster Abstracts	803. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System	Nimalee	Sasaki	MD	Ryoha University Graduate School of Medical Sciences	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemiaâ€"Clinical: Optimizing and Improving Access to High-Quality Care		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1.5	Neurocognitive Impairment Predicts Poor Transition Outcomes Among Patients with Sickle Cell Disease	Anjelica	Saulsberry	BA	St. Jude Children's Research Hospital	Presenter	Yes	Oral	Nothing to disclose												No	
Spotlight Sessions	Point-Counterpoint: Curative Therapies for SCD - Does It Make More Sense to Target the Root Cause Than All the Downstream Events		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1.5	The Case For:	Yogenthiran	Saunthararajah	MD	Cleveland Clinic	Speaker	Yes	Oral	Disclosure made		EpiDestiny; Novo Nordisk		EpiDestiny				EpiDestiny			No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphomaâ€"Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5	An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant	Kerry	Savage	BSc, MD, MSc	British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia and the Department of Medical Oncology	Presenter	Yes	Oral	Disclosure made		BMS, Merck, Novartis, Verastem, Abbvie, Servier, and Seattle Genetics; Seattle Genetics, Inc.			Seattle Genetics, Inc.	BMS, Merck, Novartis, Verastem, Abbvie, Servier, and Seattle Genetics; Seattle Genetics, Inc.						No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphomaâ€"Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1.5		Kerry	Savage	BSc, MD, MSc	BCCA	Moderator	No	Oral	Nothing to disclose													
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1.5	Novel Immunotherapeutic Approaches for Hodgkin Lymphoma	Barbara	Savoldo	MD, PhD	University of North Carolina at Chapel Hill	Speaker	Yes	Oral	Disclosure made												No	
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Novel Immunotherapeutic Approaches for Hodgkin Lymphoma	Barbara	Savoldo	MD, PhD	University of North Carolina at Chapel Hill	Speaker	Yes	Oral	Disclosure made												No	
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Molecular Insights and Modeling		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1.5	Maternal Erythrocyte ENT1-Mediated AMPK Activation and Oxygen Delivery: A Missing Component Counteracting Placental Hypoxia, Dysfunction, and Fetal Growth Restriction	Seisuke	Sayama	MD, PhD	University of Tokyo	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic Factors and Evaluation of Therapy Response in AML		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1.5	Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq	Caner	Saygin	MD	Department of Internal Medicine, The Ohio State University	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Epigenetic Regulation		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1.5	Pulsation Activates Mechanosensitive Piezo1 to Form Long-Term Hematopoietic Stem Cells	Giorgia	Scapin	PhD	The Research Institute at Nationwide Children's Hospital	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Comparative Analyses		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5	Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT	Stefan	SchÃ¶nland	MD	University Clinic Heidelberg	Presenter	Yes	Oral	Disclosure made					Janssen; Prothena; Takeda					Janssen; Prothena; Takeda		No	
Oral and Poster Abstracts	801. Health Services Researchâ€"Non-Malignant Conditions: Improving Quality in Hematology		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication	Jordan	Schaefer	MD	University of Michigan	Presenter	Yes	Oral	Nothing to disclose												No	
Special-Interest Sessions	ASH Choosing Wiselyâ€" Campaign: 2019 ASH Choosing Wisely Champions		Monday, December 9, 2019	12:15 PM	1:15 PM	Yes		1	Warfarin Monotherapy in Place of Combination Therapy of Aspirin and Warfarin	Jordan	Schaefer	MD	University of Michigan	Speaker	Yes	Oral	Nothing to disclose													
Oral and Poster Abstracts	801. Health Services Researchâ€"Non-Malignant Conditions: Improving Quality in Hematology		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1.5	A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism	Jordan	Schaefer	MD	University of Michigan	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	622. Lymphoma Biologyâ€"Non-Genetic Studies: Molecular Mechanisms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1.5		Jonathan	Schatz	MD	University of Miami, Sylvester Comprehensive Cancer Center	Moderator	No	Oral	Nothing to disclose													

Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma	Carolina	Schinke	MD	University of Arkansas for Medical Sciences	Presenter	Yes	Oral	Nothing to disclose											No	
Education Program	Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Inflammatory Bone Marrow Microenvironment	Rebekka	Schneider	MD,PhD	Erasmus University Medical Center	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Inflammatory Bone Marrow Microenvironment	Rebekka	Schneider	MD,PhD	Erasmus University Medical Center	Speaker	Yes	Oral	Nothing to disclose											No	
Education Program	Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Rebekka	Schneider	MD,PhD	Erasmus University Medical Center	Chair	No	Oral	Nothing to disclose												
Education Program	Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Rebekka	Schneider	MD,PhD	Erasmus University Medical Center	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myelodysplastic/Myeloproliferative Neoplasms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Rebekka	Schneider	MD,PhD	Erasmus MC	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: Fusion Genes		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Loss of Phospholipase C Gamma 1 (PLCG1) Impairs AML1-ETO Induced Leukemia Stem Cell Self-Renewal	Tina	Schroeder	PhD	University Hospital Jena	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	903. Health Services Research†"Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Outcomes in Multiple Myeloma Based on Comorbidities and Race	Martin	Schoen	MD,MPH	Saint Louis University School of Medicine	Presenter	Yes	Oral	Disclosure made				Pharmacyclics							No	
Oral and Poster Abstracts	903. Health Services Research†"Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Reuven	Schone	MD	Children's National Med. Ctr.	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Kristen	Schratz	MD	Johns Hopkins Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	201. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Mutation-Specific Dominant Negative Effects Determine the Phenotype in SRP54 D-efficiency	Christoph	Schuerch	MSc	Department of Biomedicine, University of Basel and University Hospital Basel	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refinine the Approach		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Andre	Schuh	MD	University Health Network	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: New Concepts and Perspectives		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Sol	Schulman	MD, PhD	Beth Israel Deaconess Medical Center and Harvard Medical School	Moderator	No	Oral	Disclosure made				CSL Behring								
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chemo Immune and Targets--Improving Combinations in ALL		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Phase I Trial Using CD3/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)	Laura	Schultz	MD	Stanford University	Presenter	Yes	Oral	Nothing to disclose											No	
Special Scientific Symposia	Changing the Taxonomy of Aggressive Lymphoma: Ready to Impact Clinical Management?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Gene Expression-based Classifications: Have They Finally Arrived?	David	Scott	MBChB, PhD	British Columbia Cancer	Speaker	Yes	Oral	Disclosure made		Celgene; Janssen		Roche/Genentech; Janssen; NanoString							No	
Oral and Poster Abstracts	805. Outcomes Research†"Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis	Michael	Sebag	MD, PhD	McGill University	Presenter	Yes	Oral	Disclosure made				Janssen					Janssen; Amgen; Takeda; Celgene		No	
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)†"Results from Retrospective/Observational Studies: Population-Based Outcomes		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)	Laurie	Sehn	MD	BC Cancer Centre for Lymphoid Cancer	Presenter	Yes	Oral	Disclosure made		Merck; Merck; TG Therapeutics; TG Therapeutics; Lundbeck; Lundbeck; Kite Pharma; Kite Pharma; Acerta; Astra Zeneca; Acerta; Seattle Genetics; Astra Zeneca; TEVA Pharmaceuticals Industries; Seattle Genetics; Morphosys; TEVA Pharmaceuticals Industries; F. Hoffmann-La Roche/Genentech; Morphosys; F. Hoffmann-La Roche/Genentech; Abbvie; Abbvie; Amgen; Amgen		F. Hoffmann-La Roche/Genentech; F. Hoffmann-La Roche/Genentech	Janssen-Ortho; Janssen-Ortho; Merck; Merck; TG Therapeutics; TG Therapeutics; Lundbeck; Lundbeck; Kite Pharma; Kite Pharma; Acerta; Acerta; Astra Zeneca; Astra Zeneca; Acerta; Seattle Genetics; Astra Zeneca; TEVA Pharmaceuticals Industries; Seattle Genetics; Morphosys; TEVA Pharmaceuticals Industries; F. Hoffmann-La Roche/Genentech; Morphosys; F. Hoffmann-La Roche/Genentech; Morphosys; F. Hoffmann-La Roche/Genentech; Abbvie; Abbvie; Amgen; Amgen						No	
Education Program	Myelodysplastic Syndromes: From Mild-Mannered to Lurkine Leukemia		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Lowering the Boom on Lower-Risk MDS	Mikkael	Sekeres	MD, MS	Cleveland Clinic	Speaker	Yes	Oral	Nothing to disclose											Yes	lenalidomide for non-del(5q) MDS; ATG for MDS; ESAs for MDS
Education Program	Myelodysplastic Syndromes: From Mild-Mannered to Lurkine Leukemia		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Lowering the Boom on Lower-Risk MDS	Mikkael	Sekeres	MD, MS	Cleveland Clinic	Speaker	Yes	Oral	Nothing to disclose											Yes	lenalidomide for non-del(5q) MDS; ATG for MDS; ESAs for MDS
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia	Mikkael	Sekeres	MD, MS	Leukemia Program, Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											Yes	Glasdegib is approved in the US in combination with low-dose cytarabine for treatment of newly diagnosed AML in patients not suitable for intensive chemotherapy due to comorbidities or age (75 years or older). Here we report data from a phase 1b trial where glasdegib was combined with azacitidine in patients with higher-risk myelodysplastic syndromes, AML, and chronic myelomonocytic leukemia similarly ineligible for intensive chemotherapy.
Education Program	Myelodysplastic Syndromes: From Mild-Mannered to Lurkine Leukemia		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Mikkael	Sekeres	MD, MS	Cleveland Clinic Taussig Cancer Institute	Chair	No	Oral	Nothing to disclose												
Education Program	Myelodysplastic Syndromes: From Mild-Mannered to Lurkine Leukemia		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Mikkael	Sekeres	MD, MS	Cleveland Clinic Taussig Cancer Institute	Chair	No	Oral	Nothing to disclose												
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Mikkael	Sekeres	MD, MS	Cleveland Clinic Taussig Cancer Institute	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Leopold	Sellner		National Center For Tumor Diseases	Moderator	No	Oral	Disclosure made	Takeda											
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Synthetic Platelets for Treatment of Traumatic Hemorrhage and Thrombocytopenia	Anitharn	Sen Gupta	PhD	Case Western Reserve University	Speaker	Yes	Oral	Disclosure made			Haima Therapeutics LLC								No	
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Synthetic Platelets for Treatment of Traumatic Hemorrhage and Thrombocytopenia	Anitharn	Sen Gupta	PhD	Case Western Reserve University	Speaker	Yes	Oral	Disclosure made			Haima Therapeutics LLC								No	
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Risk Stratification and Novel Approaches to Reduce Toxicity in Allogeneic Transplantation		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Multiplexed Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation: a Multicenter Prospective Study	Sophie	Servais		CHU and University of LiÈ ge	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Understanding and Targeting TP53 in Myeloid Melanocytes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	CD40 Antagonizes TP53-Induced Responses during Tumorigenesis	Veronika	Seol	MD, PhD	University of Veterinary Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Understanding and Targeting TP53 in Myeloid Melanocytes		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	CD40 Antagonizes TP53-Induced Responses during Tumorigenesis	Veronika	Seol	MD, PhD	University of Veterinary Medicine	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	802. Health Services Research†"Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of Life		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics	Erlene	Seymour	MD	Karmanos Cancer Institute/Wayne State University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (Ven R) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)	John	Seymour	MBBS, PhD, FRACP	Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne	Presenter	Yes	Oral	Disclosure made		AbbVie; Acerta; Celgene; Janssen; Roche; Takeda		AbbVie; Celgene; Janssen; Roche	AbbVie		AbbVie; Celgene; Roche				No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Maoyar	Shadman	MD	Uw/Fred Hutchinson Cancer Research Center	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	505. Hematopoietic Stem and Progenitor Biology: Intrinsic and Extrinsic Control of HSPC Maintenance and Differentiation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Dhvanil	Shah	PhD,PharmD	Nationwide Children's Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	805. Outcomes Research†"Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Gunjan	Shah	MD MS	Memorial Sloan Kettering Cancer Center	Moderator	No	Oral	Disclosure made				Janssen; Amgen								
Special-Interest Sessions	ASH Choosing Wisely®* Campaign: The ASH-ASPHO Pediatric Choosing Wisely List		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Mona	Shah		Baylor College of Medicine Texas Children's Hospital	Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Abatacept is Effective for GvHd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)	Niketa	Shah	MD	Yale New Haven Children's Hospital	Presenter	Yes	Oral	Disclosure made						Jazz pharmaceuticals					Yes	Abatacept, FDA approved for rheumatoid arthritis is a fusion protein that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells (APCs);it is used for acute graft-versus-host disease (aGVHD) prevention during unrelated-donor hematopoietic cell transplantation in this study
Education Program	Immunotherapy in Myeloma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	CAR-T Therapy - Is It Prime-Time in Myeloma?	Nina	Shah	MD	University of California - San Francisco	Speaker	Yes	Oral	Disclosure made	University of California, San Francisco	Bristol-Myers Squibb; Amgen; Nkartx; Kite; Teneobio	Indapta Therapeutics	Celgene, Janssen, Bluebird Bio, Sutro Biopharma; Poseida	Bristol-Myers Squibb; Amgen			Genentech, Seattle Genetics, Oncopeptides, Karyopharm, Surface Oncology, Precision biosciences GSK, Nektar, Amgen, Indapta Therapeutics, Sanofi; Bristol-Myers Squibb; Amgen; Nkartx; Kite; Teneobio		Yes	It will be clearly stated that these therapies have not yet been FDA-approved
Education Program	Immunotherapy in Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	CAR-T Therapy - Is It Prime-Time in Myeloma?	Nina	Shah	MD	University of California - San Francisco	Speaker	Yes	Oral	Disclosure made	University of California, San Francisco	Bristol-Myers Squibb; Amgen; Nkartx; Kite; Teneobio	Indapta Therapeutics	Celgene, Janssen, Bluebird Bio, Sutro Biopharma; Poseida	Bristol-Myers Squibb; Amgen			Genentech, Seattle Genetics, Oncopeptides, Karyopharm, Surface Oncology, Precision biosciences GSK, Nektar, Amgen, Indapta Therapeutics, Sanofi; Bristol-Myers Squibb; Amgen; Nkartx; Kite; Teneobio		Yes	It will be clearly stated that these therapies have not yet been FDA-approved
Education Program	Immunotherapy in Myeloma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Nina	Shah	MD	University of California - San Francisco	Chair	No	Oral	Disclosure made	University of California, San Francisco	Bristol-Myers Squibb; Amgen; Nkartx; Kite; Teneobio	Indapta Therapeutics	Celgene, Janssen, Bluebird Bio, Sutro Biopharma; Poseida	Bristol-Myers Squibb; Amgen			Genentech, Seattle Genetics, Oncopeptides, Karyopharm, Surface Oncology, Precision biosciences GSK, Nektar, Amgen, Indapta Therapeutics, Sanofi; Bristol-Myers Squibb; Amgen; Nkartx; Kite; Teneobio			
Education Program	Immunotherapy in Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Nina	Shah	MD	University of California - San Francisco	Chair	No	Oral	Disclosure made	University of California, San Francisco	Bristol-Myers Squibb; Amgen; Nkartx; Kite; Teneobio	Indapta Therapeutics	Celgene, Janssen, Bluebird Bio, Sutro Biopharma; Poseida	Bristol-Myers Squibb; Amgen			Genentech, Seattle Genetics, Oncopeptides, Karyopharm, Surface Oncology, Precision biosciences GSK, Nektar, Amgen, Indapta Therapeutics, Sanofi; Bristol-Myers Squibb; Amgen; Nkartx; Kite; Teneobio			
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Nina	Shah	MD	University of California San Francisco	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	806. Outcomes Research†"Non-Malignant Conditions II		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel	Nirmish	Shah		Duke University Health System	Presenter	Yes	Oral	Disclosure made		Novartis		Novartis; GBT		Novartis; Alexion					No	

Oral and Poster Abstracts	905. Outcomes Research|Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1-5	Hispanic and Black Patients with Adult B-Cell Acute Lymphoblastic Leukemia Have a Significantly Worse Survival in the Modern Era - a SEER 2010-2016 Analysis	Nishi	Shah	MBBS, MPH	Montefiore Medical Center/Albert Einstein College of Medicine	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	627. Myelodysplastic Syndromes|Clinical Studies: Targeting Gene Mutations in MDS		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5		Jamile	Shammo	MD	Rush University Medical Center	Moderator	No	Oral	Disclosure-made		Incyte; Celgene; Alexion; Sanofi; Novartis; Otsuka		Incyte; Celgene; Alexion; Oncoceuse; Aetex Pharma; CTI Pharma	Incyte; Celgene; Alexion; Sanofi; Novartis; Otsuka		Incyte; Celgene; Alexion; Sanofi	Agetlis			
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: First Line Treatment		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial	Tait	Shansfelt	MD	Stanford University	Presenter	Yes	Oral	Disclosure-made						Pharmacyclics; Abbvie; Genentech; Celgene; Cephalon; Hospira; Glaxo-Smithkline; Polyphenon E International; Merck								No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy; Response Monitoring and Prognosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5	RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal-Gene Deletion and Are Associated with TKI Resistance in CML	Naranie	Shanmuganathan	MBBS FRACP FRCPA	Royal Adelaide Hospital and SA Pathology	Presenter	Yes	Oral	Disclosure-made						Novartis; Bristol-Myers Squibb								No	
Oral and Poster Abstracts	301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: New Concepts and Perspectives		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	VWF Exocytosis and Biogenesis of Weibel Palade Bodies in Endothelial Cells Are Differentially Controlled by Interactions between Bloc-2 and the Exocyst Complex	Anish	Sharda	MBBS, MPH	Beth Israel Deaconess Medical Center	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	801. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1-5		Akshay	Sharma	MBBS	St. Jude Children's Research Hospital	Moderator	No	Oral	Disclosure-made						Doris Duke Foundation							
Oral and Poster Abstracts	901. Health Services Research|Non-Malignant Conditions: Bleeding and Blood Loss		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	Temporal Trends of Intracranial Hemorrhage Among Immune Thrombocytopenia Hospitalizations in the United States from 2007-2016	Mayank	Sharma		University of Miami	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Molecular Drivers and Targets in Myeloproliferative Neoplasms		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes		1-5	Selective Targeting of Histone Deacetylase 11 Ovcomes Metabolism of Myeloproliferative Neoplasms	Vasundhara	Sharma	PhD	Department of Immunology, H Lee Moffitt Cancer Center	Presenter	Yes	Oral	Nothing to disclose										No	
Education Program	Indolent Lymphomas: The Marathon Has a New Course		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1-5	Targeting CD20: Teaching an Old Dog New Tricks	Jeff	Sharman	MD	Willamette Valley Cancer Institute	Speaker	Yes	Oral	Disclosure-made		AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca; Janssen		AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca; Janssen	AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca					No	
Education Program	Indolent Lymphomas: The Marathon Has a New Course		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1-5	Targeting CD20: Teaching an Old Dog New Tricks	Jeff	Sharman	MD	Willamette Valley Cancer Institute	Speaker	Yes	Oral	Disclosure-made		AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca; Janssen		AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca; Janssen	AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca					No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: First Line Treatment		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)	Jeff	Sharman	MD	Willamette Valley Cancer Institute and Research Center & US-Oncology	Presenter	Yes	Oral	Disclosure-made		AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca; Janssen		AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca; Janssen	AbbVie; Genentech; TG Therapeutics; Pharmacyclics LLC, an AbbVie Company; Acerta; AstraZeneca					No	
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1-5		Jordan	Shavit	MD, PhD	University of Michigan	Co-Chair	No	Oral	Disclosure-made		Bayer; Shire/Takeda; CSL-Behring; Novo Nordisk; Spark Therapeutics; Sanofi											
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1-5		Jordan	Shavit	MD, PhD	University of Michigan	Co-Chair	No	Oral	Disclosure-made		Bayer; Shire/Takeda; CSL-Behring; Novo Nordisk; Spark Therapeutics; Sanofi											
Special Scientific Symposia	Special Symposium on the Basic Science in Hemostasis and Thrombosis		Monday, December 9, 2019	4:30 PM	6:30 PM	Yes		2		Jordan	Shavit	MD, PhD	University of Michigan	Co-Chair	No	Oral	Disclosure-made		Bayer; Shire/Takeda; CSL-Behring; Novo Nordisk; Spark Therapeutics; Sanofi											
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes		1-5	Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer	Joseph	Shaw	M.D.	The Ottawa Hospital	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes		1-5	Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Acute Leukemia in Children	Larisa	Shelikhova	MD	Dmitriy Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology	Presenter	Yes	Oral	Nothing to disclose										Yes	venetoclax daratumomab pleriixafor
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5	Effect of Dasatinib Vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized, Open-Label, Multicenter Study of the Chinese Children|s Cancer Group	Shuhong	Shen	MD, PhD	Key Laboratory of Pediatric Hematology and Oncology, Ministry of Health, Department of Pediatric Hematology and Oncology, Shanghai Children|s Medical Center, Shanghai Jiao Tong University School of Medicine	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5	Targeting NMRAT1 in Acute Myeloid Leukemia	Xiangguo	Shi	PhD	Baylor College of Medicine	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1-5	The Role of Calreticulin in Normal Hematopoiesis and Neoplastic Hematopoiesis of Myeloproliferative Neoplasms	Kotaro	Shide	MD, PhD	Faculty of Medicine, University of Miyazaki	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy; Predictors of TKI Discontinuation and TFR Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (iPLSG STI0-14 study)	Haruko	Shima	MD, PhD	Keio University School of Medicine	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)|Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1-5	Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMELIR-IVL)	Kazuyuki	Shimada	MD	Nagoya University Graduate School of Medicine	Presenter	Yes	Oral	Disclosure-made		Chugai Pharmaceutical		Kyowa Kirin; Eisai; Otsuka Pharmaceutical; MSD	AstraZeneca; Kyowa Kirin; Chugai Pharmaceutical; Eisai; Celgene; Takeda Pharmaceutical; Janssen Pharmaceutical; Bristol-Myers Squibb					No	
Education Program	Bone Marrow Failure and Clonal Evolution		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes		1-5	Genetic predisposition to MDS: Diagnosis and management	Akiko	Shimamura	MD, PhD	Boston Children's Hospital	Speaker	Yes	Oral	Nothing to disclose										No	
Education Program	Bone Marrow Failure and Clonal Evolution		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1-5	Genetic predisposition to MDS: Diagnosis and management	Akiko	Shimamura	MD, PhD	Boston Children's Hospital	Speaker	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes		1-5	Impact of Adding Melphalan to Fludarabine and a Myeloablative Dose of Intravenous Busulfan for Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation	Yoshimitsu	Shimomura		Kobe City Medical Center General Hospital	Presenter	Yes	Oral	Nothing to disclose										No	
Special Scientific Symposia	Changing the Taxonomy of Aggressive Lymphoma: Ready to Impact Clinical Management?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1-5	The Genetic Substructure of Diffuse Large B-cell Lymphoma: Implications for Diagnosis, Prognosis and Therapy	Margaret	Shipp	MD	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Disclosure-made		BMS		BMS; Merck & Co.; Bayer	BMS; Merck & Co.; AstraZeneca; Gilead Sciences; Takeda Pharmaceuticals		BMS; Merck & Co.; AstraZeneca; Gilead Sciences; Takeda Pharmaceuticals			No	
Oral and Poster Abstracts	652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Functional Characterization of Novel Molecular Drivers and Vulnerabilities of Myeloma Cells		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1-5	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins	Ryosuke	Shirasaki	MD, PhD	Dana-Farber Cancer Institute, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1-5	The Mitochondrion: A Link Between Hemostasis and Platelet Activation	Sruti	Shiva	PhD	University of Pittsburgh	Speaker	Yes	Oral	Nothing to disclose										No	
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1-5	The Mitochondrion: A Link Between Hemostasis and Platelet Activation	Sruti	Shiva	PhD	University of Pittsburgh	Speaker	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	303. Clonal Hematopoiesis: Aging and Inflammation		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5		Liran	Shlush	MD	The Weizmann Institute of Science	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1-5	Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy	Nicholas	Short	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure-made		Takeda Oncology; AstraZeneca		Takeda Oncology	Amgen					No	
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Therapeutic Strategies		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes		1-5	Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia	Nicholas	Short	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure-made		Takeda Oncology; AstraZeneca		Takeda Oncology	Amgen					Yes	The use of inotuzumab ozogamicin and blinatumomab as frontline therapy for older patients with ALL
Oral and Poster Abstracts	612. Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1-5	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Nicholas	Short	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure-made		Takeda Oncology; AstraZeneca		Takeda Oncology	Amgen					Yes	The use of ponatinib as frontline therapy for patients with Ph+ ALL.
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Predicting Results		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation	Roni	Shouval		Sheba Medical Center	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD: Novel Mechanisms and Emerging Therapies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes		1-5	Human CD81 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia	Bishwas	Shrestha	PhD	H. Lee Moffitt Cancer Center and Research Institute	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Innovative Approaches in Allogeneic Transplantation for Pediatric or Neoneoplasm Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes		1-5		David	Shyr	MD	University of Utah School of Medicine	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1-5	Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib	Tanya	Siddiqi	MD	City of Hope National Medical Center	Presenter	Yes	Oral	Disclosure-made		Juno Therapeutics; PCYC; AstraZeneca		Juno Therapeutics; PCYC; AstraZeneca; Kite, A Gilead Company; TG Therapeutics; Celgene; BeiGene		PCYC; AstraZeneca; Janssen; Seattle Genetics					No	
Education Program	DOACS in the Real World		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes		1-5	What We Have Learned About DOAC Reversal.	Deborah	Siegal	MD	McMaster University	Speaker	Yes	Oral	Disclosure-made						Bayer; BMS-Pfizer; Novartis; Leo Pharma; Aspen Pharma; Portola							No	
Education Program	DOACS in the Real World		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1-5	What We Have Learned About DOAC Reversal.	Deborah	Siegal	MD	McMaster University	Speaker	Yes	Oral	Disclosure-made						Bayer; BMS-Pfizer; Novartis; Leo Pharma; Aspen Pharma; Portola							No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Intensive Upfront Chemotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes		1-5	Final Results of the AML12 Trial of the Spanish Cattan Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk-Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease	Jorge	Sierra	MD	Hospital Santa Creu Sant Pau	Presenter	Yes	Oral	Disclosure-made				Novartis		Novartis; Astellas; Pfizer; Daiichi-Sankyo; Abbvie; Roche; Jazz Pharmaceuticals		Novartis; Daiichi-Sankyo; Abbvie					No	
Scientific Program	My Metabolism and Myelopoiesis		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes		1-5	Proteostasis and Myeloid Stem Cell Production	Robert	Signer	PhD	University of California-San Diego	Speaker	Yes	Oral	Nothing to disclose													No	
Scientific Program	My Metabolism and Myelopoiesis		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes		1-5	Proteostasis and Myeloid Stem Cell Production	Robert	Signer	PhD	University of California-San Diego	Speaker	Yes	Oral	Nothing to disclose													No	
Oral and Poster Abstracts	904. Outcomes Research	Non-Malignant Conditions II		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes		1-5	Engagement in Cognitive-Behavioral Therapy for Chronic Pain Management Is Associated with Reductions in Healthcare Utilization in Pediatric Sickle Cell Disease	Saumitri	Sil	PhD	Emory University School of Medicine and Children's Healthcare of Atlanta	Presenter	Yes	Oral	Nothing to disclose													No	
General Sessions	Ham-Wasserman Lecture		Saturday, December 7, 2019	12:45 PM	1:45 PM	Yes		1		Roy	Silverstein	MD	President, American Society of Hematology, Department of Medicine, Medical College of Wisconsin	Chair	No	Oral	Nothing to disclose													
General Sessions	Presidential Symposium	The Use of Big Data in Hematology Research and Delivery of Personalized Healthcare	Tuesday, December 10, 2019	9:45 AM	11:15 AM	Yes		1-5		Roy	Silverstein	MD	President, American Society of Hematology, Department of Medicine, Medical College of Wisconsin	Chair	No	Oral	Nothing to disclose													

General Sessions	ASH-EHA Joint Symposium: Hemato-Metabolism - Linking Cellular Metabolism to Blood Diseases		Sunday, December 8, 2019	12:30 PM	1:30 PM	Yes	1		Roy	Silverstein	MD	President, American Society of Hematology, Department of Medicine, Medical College of Wisconsin	Co-chair	No	Oral	Nothing to disclose													
General Sessions	Ernest Beutler Lecture and Prize	Blood Coagulation: From Molecular Mechanisms to Treatment of Thrombosis	Monday, December 9, 2019	1:30 PM	2:30 PM	Yes	1		Roy	Silverstein	MD	President, American Society of Hematology, Department of Medicine, Medical College of Wisconsin	Chair	No	Oral	Nothing to disclose													
General Sessions	E. Donnall Thomas Lecture and Prize	The Long Road to Develop Adoptive Therapy with T cells that can Effectively Target AML and Other Malignancies	Monday, December 9, 2019	9:00 AM	10:00 AM	Yes	1		Roy	Silverstein	MD	President, American Society of Hematology, Department of Medicine, Medical College of Wisconsin	Chair	No	Oral	Nothing to disclose													
General Sessions	Plenary Scientific Session		Sunday, December 8, 2019	2:00 PM	4:00 PM	Yes	2		Roy	Silverstein	MD	President, American Society of Hematology, Department of Medicine, Medical College of Wisconsin	Co-chair	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	901. Health Services Research&#8&#7;Non-Malignant Conditions: Bleeding and Blood Loss		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Use of Routine Bloodwork on General Internal Medicine Inpatients: A Retrospective Cohort Study	William	Silverstein	MD	University of Toronto	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	102. Regulation of Iron Metabolism: Novel Players in Iron Homeostasis in Health and Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	The Immunophilin FKBP12 Inhibits Hepcidin By Modulating BMP Type I-Type II Receptors Interaction and Ligand Responsiveness	Laura	Silvestri	PhD	Vita-Salute San Raffaele University	Presenter	Yes	Oral	Nothing to disclose											No		
Scientific Program	Mp Metabolism and Myelopoiesis		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Autophagy in the Hematopoietic System	Anna	Simon	PhD	University of Oxford	Speaker	Yes	Oral	Nothing to disclose											No		
Scientific Program	Mp Metabolism and Myelopoiesis		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Autophagy in the Hematopoietic System	Anna	Simon	PhD	University of Oxford	Speaker	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	703. Adoptive Immunotherapy: Mechanisms and New Approaches: New Approaches		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming	Federico	Simonetta	MD, PhD	Stanford University	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	803. Health Services Research&#8&#7;Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Increased Toxicity Among Adolescents and Young Adults Treated for Acute Myeloid Leukemia at US Children's Hospitals	Mohamad	Sinno	MD	Rainbow Babies & Children's Hospital	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	901. Health Services Research&#8&#7;Non-Malignant Conditions: Bleeding and Blood Loss		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Impact of Iron Supplementation on Patient Outcomes in Women Undergoing Gynecological Procedures: Systematic Review and Meta-Analysis of Randomized Trials	Emily	Sirotich	BS	McMaster University	Presenter	Yes	Oral	Nothing to disclose											No		
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Susan	Slager	PhD	Mayo Clinic	Co-Chair	No	Oral	Nothing to disclose													
Scientific Program	Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Susan	Slager	PhD	Mayo Clinic	Co-Chair	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia&#8&#7;Clinical: Emerging Therapies: Reports from Recent Clinical Trials		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Luke	Smart	MD	Cincinnati Children's Hospital Medical Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Epigenetic Alterations		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	DNMT3A^{R882} Alters the Epigenome of Hematopoietic Cells	Amanda	Smith	PhD	Washington University in St Louis	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	612. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		B. Douglas	Smith	MD	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Moderator	No	Oral	Disclosure made		Novartis; Agios; Pfizer; Jazz; Celgene											
Education Program	Therapy of Acute Myeloid Leukemia: Adapting to Change		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	The Growing Landscape of FLT3 Inhibition in AML	Catherine	Smith	MD	University of California - San Francisco	Speaker	Yes	Oral	Disclosure made				Astellas Pharma; Abbvie; Fujifilm; Revolution Medicines							Yes		Investigational use of lestaurtinib, FF-10101, PLX3397 (pexidartinib), quizartinib, crenolanib, ponatinib and sorafenib in AML.
Education Program	Therapy of Acute Myeloid Leukemia: Adapting to Change		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	The Growing Landscape of FLT3 Inhibition in AML	Catherine	Smith	MD	University of California - San Francisco	Speaker	Yes	Oral	Disclosure made				Astellas Pharma; Abbvie; Fujifilm; Revolution Medicines							Yes		Investigational use of lestaurtinib, FF-10101, PLX3397 (pexidartinib), quizartinib, crenolanib, ponatinib and sorafenib in AML.
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial	Catherine	Smith	MD	University of California San Francisco	Presenter	Yes	Oral	Disclosure made				Astellas Pharma; Abbvie; Fujifilm; Revolution Medicines							No		
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma&#8&#7;Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Minimal Residual Disease (MRD) Assessment in the ECOG-E4411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR): Based Induction Followed By Rituximab (R) As Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)	Mitchell	Smith	MD,PhD	George Washington Univ Cancer Center	Presenter	Yes	Oral	Disclosure made					Astra-Zeneca; ELISA		Astra-Zeneca; ELISA	Astra-Zeneca; ELISA			No		
Education Program	Management of Sickle Cell Disease Complications Beyond Acute Chest		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Pregnancy-Related Complications	Kim	Smith-Whitley	MD	Children's Hospital of Philadelphia	Speaker	Yes	Oral	Nothing to disclose													
Education Program	Management of Sickle Cell Disease Complications Beyond Acute Chest		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Pregnancy-Related Complications	Kim	Smith-Whitley	MD	Children's Hospital of Philadelphia	Speaker	Yes	Oral	Nothing to disclose													
Education Program	Management of Sickle Cell Disease Complications Beyond Acute Chest		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Kim	Smith-Whitley	MD	Children's Hospital of Philadelphia	Chair	No	Oral	Nothing to disclose													
Education Program	Management of Sickle Cell Disease Complications Beyond Acute Chest		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Kim	Smith-Whitley	MD	Children's Hospital of Philadelphia	Chair	No	Oral	Nothing to disclose													
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2	Fanconi Anemia: A Paradigm for Understanding DNA Repair During Replication	Agata	Smogorzewska	MD, PhD	The Rockefeller University	Speaker	Yes	Oral	Nothing to disclose											No		
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Sunday, December 8, 2019	9:30 AM	11:30 AM	Yes	2	Fanconi Anemia: A Paradigm for Understanding DNA Repair During Replication.	Agata	Smogorzewska	MD, PhD	The Rockefeller University	Speaker	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	703. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD: Novel Mechanisms and Emerging Therapies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Gerard	Socie	MD,PhD	UniversitÃ©d de Paris, INSERM U976, F-75010, Paris, France	Moderator	No	Oral	Disclosure made		Alexion											
Scientific Program	From Blood to Single Cells: Emerging Concepts and Technologies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Blood Cell Fate Decisions: Insights from Single-cell RNA-seq	Merav	Socolovsky	MRBS, PhD	University of Massachusetts Medical School	Speaker	Yes	Oral	Nothing to disclose											No		
Scientific Program	From Blood to Single Cells: Emerging Concepts and Technologies		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Blood Cell Fate Decisions: Insights from Single-cell RNA-seq	Merav	Socolovsky	MRBS, PhD	University of Massachusetts Medical School	Speaker	Yes	Oral	Nothing to disclose											No		
Meet the Scientist	Blood Cell Fate Decisions: Insights from Single-cell RNA-seq		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Merav	Socolovsky	MRBS, PhD	University of Massachusetts Medical School	Speaker	No	Oral	Nothing to disclose													
Special Scientific Symposia	Special Symposium on the Basic Science in Hemostasis and Thrombosis		Monday, December 9, 2019	4:30 PM	6:30 PM	Yes	2	Developmental Differences Between Neonatal and Adult Megakaryocytes	Martha	Sola-Visner	MD	Boston Children's Hospital	Speaker	Yes	Oral	Disclosure made				System America, Inc.							No		
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Novel Molecular Dependencies and Targets in Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival	Antonio	Soleimanda	MD	University Hospital WÃrzburg	Presenter	Yes	Oral	Nothing to disclose											No		
Special Scientific Symposia	Dragging the Undruggable		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Lessons from the Study of Exceptional Responders	David	Solit	MD	Memorial Sloan Kettering Cancer Center	Speaker	Yes	Oral	Disclosure made		Pfizer; Loxo Oncology; Illumina; Vividion Therapeutics	Loxo Oncology		Lilly Oncology						Yes		Will discuss off label use of mTOR and MEK inhibitors.
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Molecular Insights and Modeling		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mice'Mice	Yuanbin	Song	MD	Yale University School of Medicine	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma&#8&#7;Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study	Yuqin	Song	MD, PhD	Peking University Cancer Hospital & Institute	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	901. Health Services Research&#8&#7;Non-Malignant Conditions: Bleeding and Blood Loss		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Suman	Sood	MD	University of Michigan	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	632. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making	Simona	Soverini	PhD	University of Bologna	Presenter	Yes	Oral	Disclosure made		Incyte									No		
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2	Developmental Biology of the Blood System	Nancy	Speck	PhD	University of Pennsylvania	Speaker	Yes	Oral	Nothing to disclose											No		
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2	Developmental Biology of the Blood System	Nancy	Speck	PhD	University of Pennsylvania	Speaker	Yes	Oral	Nothing to disclose											No		
Continuing Conversations	Continuing Conversations With the Speakers on Insights Into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided By Single Cell Approaches		Saturday, December 7, 2019	11:30 AM	12:30 PM	Yes	1		Nancy	Speck	PhD	University of Pennsylvania	Speaker	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	802. Health Services Research&#8&#7;Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma: BC' s Myeloma and Related Diseases Registry Analysis	Andrew	Spencer	MBBS, FRACP, FACPA, DM	Alfred Health-Monash University	Presenter	Yes	Oral	Disclosure made		Takeda; Janssen Oncology; Amgen; AbbVie; Servier; Secura Bio; Haematologic; Celgene; Sanofi; Specialised Therapeutics Australia		Takeda; Janssen Oncology; Amgen; AbbVie; Celgene	Takeda; Janssen Oncology; Amgen; AbbVie; Servier; Secura Bio; Haematologic; Celgene; Sanofi; Specialised Therapeutics Australia		Takeda; Janssen Oncology; Celgene	Takeda; Janssen Oncology; Amgen; AbbVie; Servier; Secura Bio; Haematologic; Celgene; Sanofi			No		
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphoma)&#8&#7;Results from Retrospective/Observational Studies: Population-Based Outcomes		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective 'Elderly Project'Elder 1353 Patients By the Fondazione Italiana Linfomi	Michele	Spina	MD	Division of Medical Oncology and immune-related tumors, National Cancer Institute	Presenter	Yes	Oral	Disclosure made				Menarini				Menarini; Mundipharma; Teva; GILEAD; Janssen-Cilag; CTI; Servier; Sandoz; Novartis; Pfizer	Mundipharma		No		
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease	Hrishikesh	Srinagesh	BA	Icahn School of Medicine at Mount Sinai	Presenter	Yes	Oral	Disclosure made				National Institutes of Health							No		
Oral and Poster Abstracts	636. Myelodysplastic Syndromes&#8&#7;Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Deconstructing the Clonal Advantage and Clonal Stability of Sg- Candidate Genes in Del(5q) MDS on a Single-Cell Level	Ursula	Stalmann	MD	Erasmus MC	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma&#8&#7;Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (CT) before Autologous Transplantation. Final Analysis of Phase II Study	Aspasia	Stamatoullas	MD	Centre Henri Becquerel, Rouen, France	Presenter	Yes	Oral	Disclosure made		Takeda		Celgene							No		
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: MYC and Beyond		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Daniel	Starczynowski	PhD	Cincinnati Children's Hospital Medical Center	Moderator	No	Oral	Disclosure made		Eurome Therapeutics											
Oral and Poster Abstracts	903. Health Services Research&#8&#7;Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?	Abby	Statler	PhD,MPH	Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy	Abby	Statler	PhD,MPH	Cleveland Clinic	Presenter	Yes	Oral	Nothing to disclose											No		
Oral and Poster Abstracts	321. Blood Coagulation and Fibrinolytic Factors: Molecular Mechanisms of Coagulation		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Evi	Stavrou	MD	Case Western Reserve University School of Medicine	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Evi	Stavrou	MD	Case Western Reserve University School of Medicine	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	622. Lymphoma Biology&#8&#7;Non-Genetic Studies: Tumor Microenvironment		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma	Chloe	Steen	MSc	Stanford University	Presenter	Yes	Oral	Nothing to disclose											No		

Oral and Poster Abstracts	637. Myelodysplastic Syndromes	Clinical Studies: Targeting Gene Mutations in MDS		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)	David	Steensma	MD	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Disclosure made		Steemline; Pfizer; Summer Road; Astex; Oncoveva	Arrowhead	Agena						Yes	H3B-8800 (experimental, unapproved)
How I Treat: Bringing Science to Clinical Dilemmas	How to Integrat Next Generation Sequencing Panels in Patients with CHIP and Hematolymphoid Neoplasms		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		David	Steensma	MD	Dana-Farber Cancer Institute	Speaker	No	Oral	Disclosure made		Steemline; Pfizer; Summer Road; Astex; Oncoveva	Arrowhead	Agena							
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Efficacy and Tolerability of Isatuximab, Bortezomib and Low Dose Dexamethasone (Isa-Dara-dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim - Efficacy Analysis of the Phase II HOVON 143 Study	Claudia	Stege	MD	Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Updated Results from the German Mpnrg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia	Frank	Stegelmann	MD	University Hospital of Ulm	Presenter	Yes	Oral	Disclosure made		Novartis; Incyte			Novartis; Incyte					No	
Special Scientific Symposia	Dragging the Undruggable		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Finding Achilles' Heels of Fusion-driven Malignancies	Kimberly	Stegmaier	MD	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made		Rigel Pharmaceuticals		Novartis						No	
Special Scientific Symposia	Dragging the Undruggable		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Kimberly	Stegmaier	MD	Dana-Farber Cancer Institute	Chair	No	Oral	Disclosure made		Rigel Pharmaceuticals		Novartis							
Special Scientific Symposia	Changing the Taxonomy of Aggressive Lymphoma: Ready to Impact Clinical Management?		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Christian	Steidl	MD	British Columbia Cancer Agency	Co-Chair	No	Oral	Disclosure made		Bayer; Seattle Genetics; Roche; Juno Therapeutics									
Scientific Program	Understanding and Targeting TP53 in Myeloid Malignancies		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Activating TP53 by Dual Inhibition of MDMX and MDM2	Ulrich	Steidl	MD, PhD	Albert Einstein College of Medicine, Montefiore Medical Center	Speaker	Yes	Oral	Disclosure made		BayerHealthcare; Novartis; Celgene; Aileron Therapeutics; Pieries Pharmaceuticals	Stelexis Therapeutics	BayerHealthcare; Novartis; GlaxoSmithKline; Aileron Therapeutics					Stelexis Therapeutics		No	
Scientific Program	Understanding and Targeting TP53 in Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Activating TP53 by Dual Inhibition of MDMX and MDM2	Ulrich	Steidl	MD, PhD	Albert Einstein College of Medicine, Montefiore Medical Center	Speaker	Yes	Oral	Disclosure made		BayerHealthcare; Novartis; Celgene; Aileron Therapeutics; Pieries Pharmaceuticals	Stelexis Therapeutics	BayerHealthcare; Novartis; GlaxoSmithKline; Aileron Therapeutics					Stelexis Therapeutics		No	
Education Program	Myeloproliferative Neoplasms: Managing the Cup that Runneth Over		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	From Budd-Chiari to Acquired von Willebrand Disease: Thrombosis and Bleeding Risk in MPN	Brady	Stein	MD	Northwestern University	Speaker	Yes	Oral	Disclosure made										Yes	Pegylated Interferon
Education Program	Myeloproliferative Neoplasms: Managing the Cup that Runneth Over		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	From Budd-Chiari to Acquired von Willebrand Disease: Thrombosis and Bleeding Risk in MPN	Brady	Stein	MD	Northwestern University	Speaker	Yes	Oral	Disclosure made										Yes	Pegylated Interferon
Education Program	Myeloproliferative Neoplasms: Managing the Cup that Runneth Over		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Brady	Stein	MD	Northwestern University	Chair	No	Oral	Disclosure made											
Education Program	Myeloproliferative Neoplasms: Managing the Cup that Runneth Over		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Brady	Stein	MD	Northwestern University	Chair	No	Oral	Disclosure made											
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Maturation and Enucleation		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Terminal Erythroid Maturation Is Associated with Dynamic Changes in the Abundance of Histone Marks Associated with Active Transcription Elongation and RNA Polymerase II Pausing	Laurie	Steiner	MD	University of Rochester	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis: Molecular Insights and Modeling		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Laurie	Steiner	MD	University of Rochester	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)	Elizabeth	Stenger	MD	UPMC Children's Hospital of Pittsburgh	Presenter	Yes	Oral	Nothing to disclose										No	
Spotlight Sessions	Is Chemoimmunotherapy for CLL on Life Support? (Point- Counterpoint)		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	DNR (Do Not Resuscitate)	Stephan	Stilgenbauer	MD	University of Ulm	Speaker	Yes	Oral	Disclosure made		AbbVie; Amgen; AstraZeneca; Celgene; Gilead; GSK; Hoffmann-La-Roche; Janssen; Novartis		AbbVie; Amgen; AstraZeneca; Celgene; Gilead; GSK; Hoffmann-La-Roche; Janssen; Novartis	AbbVie; Amgen; AstraZeneca; Celgene; Gilead; GSK; Hoffmann-La-Roche; Janssen; Novartis		AbbVie; Amgen; AstraZeneca; Celgene; Gilead; GSK; Hoffmann-La-Roche; Janssen; Novartis			Yes	Venetoclax Front line use in CLL
Special-Interest Sessions	Featured Topic: Taking a bite out of CAR T Cells		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Wendy	Stock	MD	University of Chicago	Speaker	No	Oral	Disclosure made					UpToDate; Research to Practice					Kite, a Gilead Company; Pfizer; Dalichi; Astellas; Astex		
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Epigenetic Alteration		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia	Friedrich	Stoelzel	MD	Universitätsklinikum Carl Gustav Carus Dresden	Presenter	Yes	Oral	Disclosure made		JAZZ Pharmaceuticals; Shire								No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Friedrich	Stoelzel	MD	Universitätsklinikum Carl Gustav Carus Dresden	Moderator	No	Oral	Disclosure made		JAZZ Pharmaceuticals; Shire									
Oral and Poster Abstracts	403. Basic Science and Clinical Practice in Blood Transfusion: Clinical Sciences		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Evaluation of Efficacy and Safety of Cold-Stored Platelets in Healthy Human Subjects Treated with Dual Antiplatelet Therapy	Moritz	Stolla	MD	Bloodworks Northwest	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: New Concepts and Perspectives		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Platelet Activation State Intermixing in a Venous Puncture Model Indicates Novel Patterns of Thrombus Formation	Brian	Storrie	PhD	University of Arkansas for Medical Sciences	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)	Results from Retrospective/Observational Studies: Cellular Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma	Paolo	Strati	MD	MD Anderson Cancer Center.	Presenter	Yes	Oral	Nothing to disclose										No	
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Update from the Clinic: What's New in the Diagnosis of Cancer-Associated Thrombosis?	Michael	Streiff	MD	Johns Hopkins Medical Institutions	Speaker	Yes	Oral	Disclosure made		Janssen; Daiichi-Sankyo; Bayer; Pfizer; Portola		Janssen; Roche					Janssen		
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Update from the Clinic: What's New in the Diagnosis of Cancer-Associated Thrombosis?	Michael	Streiff	MD	Johns Hopkins Medical Institutions	Speaker	Yes	Oral	Disclosure made		Janssen; Daiichi-Sankyo; Bayer; Pfizer; Portola		Janssen; Roche	Daiichi-Sankyo; Bayer; Pfizer; Portola				Janssen		
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia	Stephen	Strickland	MD, MSCI	Vanderbilt University Medical Center	Presenter	Yes	Oral	Disclosure made		Abbkie; Astellas; Jazz; Kite; Pfizer; Novartis		Sunesis						No	
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Effective Novel Rx Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance	Rui	Su	PhD	City of Hope Medical Center	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	636. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	Marion	Subklewe	MD	University Hospital, LMU Munich	Presenter	Yes	Oral	Disclosure made		AMGEN; Roche; Gilead; Pfizer; Celgene; Janssen		AMGEN; Roche; Gilead; Miltenyi; Oxford Biotherapeutics; Morphosys	AMGEN; Gilead; Pfizer; Celgene					No	
Scientific Program	Dynamic Change of the Hematopoietic Stem Cell Niche		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Toshio	Suda	MD, PhD	National University of Singapore	Chair	No	Oral	Nothing to disclose											
Scientific Program	Dynamic Change of the Hematopoietic Stem Cell Niche		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Toshio	Suda	MD, PhD	National University of Singapore	Chair	No	Oral	Nothing to disclose											
Education Program	Management of Sickle Cell Disease Complications Beyond Acute Chest		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Management of Liver Complications in SCD	Abid	Suddle	MD	King's College Hospital	Speaker	Yes	Oral	Nothing to disclose											
Education Program	Management of Sickle Cell Disease Complications Beyond Acute Chest		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Management of Liver Complications in SCD	Abid	Suddle	MD	King's College Hospital	Speaker	Yes	Oral	Nothing to disclose											
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chemo Immune and Targeted—Improving Combinations in ALL		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study	Naoto	Sugiura	MD	Toyohashi Municipal Hospital	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents	Bruce	Sullenger	PhD	Duke University	Speaker	Yes	Oral	Disclosure made		Baxalta Biosciences	Baxalta Biosciences			Baxalta Biosciences		Baxalta Biosciences		No	
Scientific Program	Blood Coagulation: From Structure and Function to Therapeutics		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents	Bruce	Sullenger	PhD	Duke University	Speaker	Yes	Oral	Disclosure made		Baxalta Biosciences	Baxalta Biosciences			Baxalta Biosciences		Baxalta Biosciences		No	
Meet the Scientist	Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Bruce	Sullenger	PhD	Duke University	Speaker	No	Oral	Disclosure made		Baxalta Biosciences	Baxalta Biosciences			Baxalta Biosciences		Baxalta Biosciences			
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Advances in ITP Therapy		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	High-Dose Dexamethasone (HD-DXM) Plus Oseltamivir Versus High-Dose Dexamethasone for Treatment of Adult Primary Immune Thrombocytopenia: Interim Analysis of a Prospective, Multicenter, Randomized, Controlled Trial	Lu	Sun	PhD	Qilu Hospital, Shandong University	Presenter	Yes	Oral	Nothing to disclose										Yes	Oseltamivir, a sialidase inhibitor which is extensively used in the treatment of or prophylaxis against influenza virus A and B. It has been reported that the treatment of oseltamivir could concomitantly increase platelet counts, which was independent whether influenza was diagnosed. Along those lines, several studies showed successful treatment of ITP patients with oseltamivir. We hypothesize that HD-DXM and oseltamivir might complement each other in terms of the mechanisms and achieve better response rates in ITP patients.
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Intrinsic and Extrinsic Control of HSPC Maintenance and Differentiation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Transcriptional and Spatial Heterogeneity of Mouse Megakaryocytes at Single-Cell Resolution	Shu	Sun	BS	Beijing Institute of Genomics, Chinese Academy of Sciences	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma	Clinical Studies: Follicular Lymphoma: Biomarkers and Clinical Trials		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Suchitra	Sundaram		Roswell Park	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Microbiome and Immune Regulation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Anthony	Sung	MD	Duke University Hospital	Moderator	No	Oral	Disclosure made				Novartis; Merck; Seres							
Oral and Poster Abstracts	625. Lymphoma: Pre-Clinical	Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL	Nicole	Sunseri	MD, PhD	University of Chicago	Presenter	Yes	Oral	Disclosure made				iTeos Therapeutics						No	
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Update from the Lab: What's New in our Understanding of the Mechanism of Cancer Associated Thrombosis?	Katsue	Suzuki-Inoue	MD, PhD	University of Yamanashi	Speaker	Yes	Oral	Nothing to disclose										No	
Education Program	Combined Basic Science and Education Session on Cancer-Associated Thrombosis		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Update from the Lab: What's New in our Understanding of the Mechanism of Cancer Associated Thrombosis?	Katsue	Suzuki-Inoue	MD, PhD	University of Yamanashi	Speaker	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: MYC and Beyond		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling	Sividya	Swaminathan	PhD	Department of Systems Biology, Beckman Research Institute of City of Hope	Presenter	Yes	Oral	Nothing to disclose										No	
Scientific Program	Stromal Cell Immune Regulation in the Microenvironment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Lymphatic Control of the Tumor Immune Microenvironment	Melody	Swartz	PhD	University of Chicago	Speaker	Yes	Oral	Nothing to disclose										No	
Scientific Program	Stromal Cell Immune Regulation in the Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Lymphatic Control of the Tumor Immune Microenvironment	Melody	Swartz	PhD	University of Chicago	Speaker	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	625. Lymphoma	Genetic/Epigenetic Biology: Innovative Genomic and Immunogenomic Approaches		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy	Brian	Swerdlow	MD, PhD	Stanford University	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: Fusion Genes		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Stephen	Sykes	PhD	Fox Chase Cancer Center	Moderator	No	Oral	Nothing to disclose											

Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Predicting Results		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Jeffrey	Szer	MBBS	Royal Melbourne Hospital	Moderator	No	Oral	Disclosure made				Sanofi; Takeda; Pfizer; Alexion; Amgen; Celgene; MSD; Novartis; Prevail Therapeutics	Sanofi; Takeda; Pfizer; Alexion; Amgen; Celgene; MSD; Novartis; Prevail Therapeutics							
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML	Yoko	Tabe	MD, PhD	Juntendo University Graduate School of Medicine	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	791. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD and Thymus Regeneration: Role of Innate Cells and Non-Hematopoietic Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	T-Cell Derived Interferon-Gamma Directly Targets Intestinal Epithelium to Induce Stem Cell Apoptosis in GI GvHd	Shuichiro	Takashima	MD, PhD	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Advances in Understanding The Pathophysiology of AML		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia	June	Takeda	MD	Graduate School of Medicine, Kyoto University	Presenter	Yes	Oral	Nothing to disclose												No	
Scientific Program	Dynamic Change of the Hematopoietic Stem Cell Niche		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Innate Immune Signal-Regulated Hematopoiesis	Hitoshi	Takizawa	PhD	Kumamoto University	Speaker	Yes	Oral	Nothing to disclose												No	
Scientific Program	Dynamic Change of the Hematopoietic Stem Cell Niche		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Innate Immune Signal-Regulated Hematopoiesis	Hitoshi	Takizawa	PhD	Kumamoto University	Speaker	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: First Line Treatment		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study	Constantine	Tam	MBBS, MD	Peter MacCallum Cancer Centre	Presenter	Yes	Oral	Disclosure made				Janssen; AbbVie	Janssen; Pharmacyclics LLC, an AbbVie company; AbbVie; BeiGene; Novartis; Roche						Yes	Ibrutinib in combination with venetoclax is not approved in any indication.
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial	Constantine	Tam	MBBS, MD	Peter MacCallum Cancer Centre	Presenter	Yes	Oral	Disclosure made				Janssen; AbbVie	Janssen; AbbVie; BeiGene; Novartis; Roche						Yes	Zanubrutinib is an investigational agent and has not yet been approved in the US
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111): Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial	Constantine	Tam	MBBS, MD	Peter MacCallum Cancer Centre	Presenter	Yes	Oral	Disclosure made				Janssen; AbbVie	Janssen; AbbVie; BeiGene; Novartis; Roche						Yes	Zanubrutinib is an investigational agent and has not yet been approved in the US
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)	Tomoyuki	Tanaka		MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Functional Characterization of Novel Molecular Drivers and Vulnerabilities of Myeloma Cells		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Functional Characterization of Genes Driving Enhanced Biological Aggressiveness of Myeloma Cells: Identification of Novel and Understudied â€œDriversâ€ Myeloma	Nulhul	Tang	PhD	Dana-Farber Cancer Institute, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic Factors and Evaluation of Therapy Response in AML		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation	Katherine	Tarlock	MD	University of Washington	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Response to Sorafenib in FLT3/ITD AML Is Dependent on Co-Occurring Mutational Profile	Katherine	Tarlock	MD	Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Nothing to disclose												Yes	Sorafenib in FLT3/ITD-positive AML
Education Program	Expanding Horizons for Immunotherapy in Pediatric Leukemia		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Opportunities for Immunotherapy in AML	Sarah	Tasian	MD	Children's Hospital of Philadelphia	Speaker	Yes	Oral	Disclosure made				Incyte Corportation; Gilead Sciences					Aleta Biotherapeutics			No	
Education Program	Expanding Horizons for Immunotherapy in Pediatric Leukemia		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Opportunities for Immunotherapy in AML	Sarah	Tasian	MD	Children's Hospital of Philadelphia	Speaker	Yes	Oral	Disclosure made				Incyte Corportation; Gilead Sciences					Aleta Biotherapeutics			No	
Education Program	Expanding Horizons for Immunotherapy in Pediatric Leukemia		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Sarah	Tasian	MD	Children's Hospital of Philadelphia	Chair	No	Oral	Disclosure made				Incyte Corportation; Gilead Sciences					Aleta Biotherapeutics				
Education Program	Expanding Horizons for Immunotherapy in Pediatric Leukemia		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Sarah	Tasian	MD	Children's Hospital of Philadelphia	Chair	No	Oral	Disclosure made				Incyte Corportation; Gilead Sciences					Aleta Biotherapeutics				
Oral and Poster Abstracts	622. Lymphoma Biology â€"Non-Genetic Studies: Tumor Microenvironment		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Clinical Holdgkin Lymphoma Microenvironment	Joseph	Taylor	MBBS, BSc	Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	622. Lymphoma Biology â€"Non-Genetic Studies: Tumor Microenvironment		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Skin-Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL	Cosmin	Teglia	MD	New York University School of Medicine	Presenter	Yes	Oral	Nothing to disclose												No	
Spotlight Sessions	Point-Counterpoint: Curative Therapies for SCD - Does it Make More Sense to Target the Root Cause Than All the Downstream Events		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	The Case Against:	Marilyn	Telen	MD	Duke University Medical Center	Speaker	Yes	Oral	Disclosure made				Forma Therapeutics								Yes	It will include discussion of both FDA-approved drugs being investigated for SCD but currently off-label, as well as drugs not currently FDA-approved.
Spotlight Sessions	Point-Counterpoint: Curative Therapies for SCD - Does it Make More Sense to Target the Root Cause Than All the Downstream Events		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Marilyn	Telen	MD	Duke University Medical Center	Chair	No	Oral	Disclosure made				Forma Therapeutics									
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Preclinical Models, Immunotherapy, and CAR T Cells		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations	Elisa	Ten Hacken	PhD	Dana Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results from Prospective Clinical Trials		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics	Evangelos	Terpos	MD,PhD	National and Kapodistrian University of Athens, School of Medicine	Presenter	Yes	Oral	Disclosure made				Amgen; Genesis; Janssen; Takeda	Amgen; Celgene; Genesis; Janssen; Medicus; Takeda							No	
Oral and Poster Abstracts	604. Outcomes Research â€"Non-Malignant Conditions III		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5	Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study	Deindra	Terrell	PhD	University of Oklahoma Health Sciences Center	Presenter	Yes	Oral	Disclosure made				National Institutes of Health								No	
Education Program	Sickle Cell Disease in Young and Old: A Time for Re-Evaluation		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Optimal Disease Manage and Health Monitoring in Older Adults	Swee Lay	Thein	DSc, MBBS	National Institutes of Health	Speaker	Yes	Oral	Nothing to disclose												No	
Education Program	Sickle Cell Disease in Young and Old: A Time for Re-Evaluation		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Optimal Disease Manage and Health Monitoring in Older Adults	Swee Lay	Thein	DSc, MBBS	National Institutes of Health	Speaker	Yes	Oral	Nothing to disclose												No	
Education Program	Sickle Cell Disease in Young and Old: A Time for Re-Evaluation		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Swee Lay	Thein	DSc, MBBS	National Institutes of Health	Chair	No	Oral	Nothing to disclose													
Education Program	Sickle Cell Disease in Young and Old: A Time for Re-Evaluation		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Swee Lay	Thein	DSc, MBBS	National Institutes of Health	Chair	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic Factors and Evaluation of Therapy Response in AML		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation	Felicitas	Thol	MD	Hannover Medical School	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Felicitas	Thol	MD	Hannover Medical School	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic Factors and Evaluation of Therapy Response in AML		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Ella	Thompson	BSc (Hons), PhD	Peter MacCallum Cancer Centre	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RT31]	Philip	Thompson	MBBS	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made			Amgen; Genentech; Gilead		AbbVie; Amgen; Pfizer; Pharmacyclics	Genentech; Gilead							No	
Oral and Poster Abstracts	653. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of Pathogenesis, Drug Sensitivity, and Resistance; and Role of Bone Marrow Microenvironment and Host Microbiome in Myeloma Pathogenesis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	G/T2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage	Natthakan	Thongon	PhD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No	G/T2 Antisense Oligonucleotides are developed by IONIS company
Oral and Poster Abstracts	637. Myelodysplastic Syndromes â€"Clinical Studies: Lower-Risk MDS and CMML		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Swapna	Thota	MD	CCF	Moderator	No	Oral	Disclosure made								Incyte, Inc.					
Oral and Poster Abstracts	791. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD: Novel Mechanisms and Emerging Therapies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Graft-Versus-Host Disease Causes the Failure of Donor Hematopoietic Progenitor Cells to Reconstitute Plasmacytoid Dendritic Cells That Promote Tolerance of Donor T Cells Against the Host	Xiangyuan	Tian		Temple University	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	651. Myeloma Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma	Stephan	Tirier	PhD	German Cancer Research Center (DKFZ) and BioQuant	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	801. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates	John	Tisdale	MD	NIH	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	641. CLL: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Clonal Evolution		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	The VLA-4 Integrin Is Constitutively Activated in a Fraction of CD49d-Expressing Chronic Lymphocytic Leukemia Via Autonomous BCR-Mediated Signaling	Erika	Tasino	PhD	IRCCS Centro Di Riferimento Oncologico	Presenter	Yes	Oral	Nothing to disclose												No	
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	New Insights into Heme Utilization Pathways	Emanuela	Tolosano	PhD	University of Torino	Speaker	Yes	Oral	Nothing to disclose												No	
Scientific Program	Pumping Iron, Handling Heme: Forging New Links in Health and Disease		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	New Insights into Heme Utilization Pathways	Emanuela	Tolosano	PhD	University of Torino	Speaker	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas â€"Clinical Studies: Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Open Label Non-Randomized Phase II Study Exploring Ai-Chemo-Free Ai-Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (WM), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase	Cecile	Tomowiak	MD	Department of Oncology-Haematology and Cell Therapy, CHU, Poitiers, INSERM, Inserm CIC 1402, Poitiers, France	Presenter	Yes	Oral	Disclosure made					Janssen; AbbVie							No	
Oral and Poster Abstracts	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas â€"Results from Prospective Clinical Trials: Results from CAR T-Cell Trials		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma	Max	Topp	MD	Medizinische Klinik und Poliklinik II, Universitätsklinikum, Würzburg	Presenter	Yes	Oral	Disclosure made			Amgen; Kite, A Gilead Company; Roche; Novartis; Regeneron		Amgen; Kite, A Gilead Company; Roche; Regeneron	Amgen		Prime				No	
Oral and Poster Abstracts	801. Health Services Research â€"Non-Malignant Conditions: Bleeding and Blood Loss		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Duc	Tran	MD	Emory University, Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory	Moderator	No	Oral	Disclosure made						Bayer; Pfizer; Bioverativ; Novo Nordisk; Takeda							
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas â€"Clinical Studies: Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Subgroup Analyses of Elderly Patients Aged â‰¥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R*) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)	Marek	TroÃ¤Ã¤	MD	Charles University General Hospital	Presenter	Yes	Oral	Disclosure made			Takeda; Bristol-Myers Squibb; Incyte; Abbvie; Amgen; F. Hoffmann-La Roche; Gilead Sciences; Janssen; Celgene; Morphosys			Takeda; Bristol-Myers Squibb; Incyte; Abbvie; Amgen; F. Hoffmann-La Roche; Gilead Sciences; Janssen; Morphosys						No	Lenalidomide is an investigational therapeutic agent used in a clinical trial setting for patients with indolent non-Hodgkin lymphoma.
Oral and Poster Abstracts	503. Clonal Hematopoiesis: Aging and Inflammation		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Repetitive Elements Enhance Hematopoietic Regeneration Via Activation of the Innate Immune Receptor MDA5	Eirini	Trompouki	PhD	Max Planck Institute of Immunobiology and Epigenetics	Presenter	Yes	Oral	Nothing to disclose												No	

Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2	Intrinsic and Extrinsic Factors Driving Hematopoietic Stem Cell Aging and Bone Marrow Failure	Jennifer	Trowbridge	PhD	The Jackson Laboratory	Speaker	Yes	Oral	Disclosure made											No	
Scientific Program	Molecular Mechanisms of Bone Marrow Failure		Sunday, December 8, 2019	9:30 AM	11:30 AM	Yes	2	Intrinsic and Extrinsic Factors Driving Hematopoietic Stem Cell Aging and Bone Marrow Failure	Jennifer	Trowbridge	PhD	The Jackson Laboratory	Speaker	Yes	Oral	Disclosure made											No	
Oral and Poster Abstracts	508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Pharmacologic Activation of Aldehyde Metabolism to Protect Hematopoietic Stem Cells (HSC) in Murine Models of Fanconi Anemia (FA)	Jennifer	Tsai	MD	Stanford University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	603. Oncogenes and Tumor Suppressors: Fusion Genes		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Selective Dependency of MLL-Rearranged Leukemia on Immunoproteasome Function	Nuria	TubÃ©s Santamarãa		University Hospital Jena	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	801. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model	Naoya	Uchida	MD	NIH	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation	Masumi	Ueda	MD	Fred Hutchinson Cancer Research Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Flotetuzumab, an Investigational CD123 x CD3 Bispecific DartÂ® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients	Geoffrey	Uy	MD	Washington University School of Medicine	Presenter	Yes	Oral	Disclosure made		Astellas; Pfizer; Curis; GlycoMimetics									No	
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study	Geoffrey	Uy	MD	Washington University School of Medicine	Presenter	Yes	Oral	Disclosure made		Astellas; Pfizer; Curis; GlycoMimetics									No	
Education Program	Why Patients Fail After Allogeneic Stem Cell Transplantation		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Late Mortality without Relapse	Luca	Vago	MD, PhD	San Raffaele Scientific Institute	Speaker	Yes	Oral	Disclosure made				GenDx; Moderna Therapeutics							No	
Education Program	Why Patients Fail After Allogeneic Stem Cell Transplantation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Late Mortality without Relapse	Luca	Vago	MD, PhD	San Raffaele Scientific Institute	Speaker	Yes	Oral	Disclosure made				GenDx; Moderna Therapeutics							No	
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Mapping the Evolution of the Mutational Landscape of Acute Myeloid Leukemia from Diagnosis to Post-Transplantation Relapse and Its Interplay with Immune Evasion Mechanisms	Luca	Vago	MD, PhD	IRCCS San Raffaele Scientific Institute	Presenter	Yes	Oral	Disclosure made				GenDx; Moderna Therapeutics							No	
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	9:30 AM	11:30 AM	Yes	2		Peter	Valk	PhD	Erasmus University Medical Center	Co-Chair	No	Oral	Nothing to disclose												
Scientific Program	Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2		Peter	Valk	PhD	Erasmus University Medical Center	Co-Chair	No	Oral	Nothing to disclose												
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches		Saturday, December 7, 2019	11:30 AM	12:30 PM	Yes	1		Peter	Valk	PhD	Erasmus University Medical Center	Co-Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	636. Myelodysplastic Syndromes â€"Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo Models of Cohesin-Mutant Myeloid Diseases	Mounica	Vallurupalli	MD	Broad Institute	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	622. Lymphoma Biology â€"Non-Genetic Studies: Molecular Mechanisms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	High-Throughput BCR Sequencing and Single-Cell Transcriptomics Reveal Distinct Transcriptional Profiles Associated with Subclonal Evolution of Follicular Lymphoma	Cornelis	van Bergen		Leiden University Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON-129 Study	Niels	Van De Donk	MD, PhD	Amsterdam University Medical Center, Vrije Universiteit Amsterdam	Presenter	Yes	Oral	Disclosure made				Janssen Pharmaceuticals; AMGEN; Celgene; Novartis; Bristol-Myers Squibb				Janssen Pharmaceuticals; AMGEN; Celgene; Novartis; Bristol-Myers Squibb; Bayer; Servier; Takeda; Roche		Yes	6Rd is used for primary plasma cell leukemia
Special-Interest Sessions	TRTH Scientific Symposium: A Decade of Training the Future Leaders in Translational Research		Sunday, December 8, 2019	4:30 PM	6:30 PM	Yes	2	TRTH Symposium: A Decade of Training the Future Leaders in Translational Research	Pieter	Van Vlierberghe	PhD	Ghent University	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Targeting Apoptosis in Myeloma		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	MCL1 Inhibitors in Multiple Myeloma	Karin	Vanderkerken	PhD	Free University of Brussels	Speaker	Yes	Oral	Nothing to disclose											No	
Scientific Program	Targeting Apoptosis in Myeloma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	MCL1 Inhibitors in Multiple Myeloma	Karin	Vanderkerken	PhD	Free University of Brussels	Speaker	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	653. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Karin	Vanderkerken	PhD	Free University of Brussels	Moderator	No	Oral	Nothing to disclose												
Spotlight Sessions	Redox Biology in Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	N-acetylcysteine for Thrombotic Thrombocytopenic Purpura	Karen	Vanhoorelbeke	PhD	Katholieke Universiteit Leuven	Speaker	Yes	Oral	Disclosure made		Ablynx, a Sanofi Company		Shire							No	
Spotlight Sessions	Redox Biology in Thrombosis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Karen	Vanhoorelbeke	PhD	Katholieke Universiteit Leuven	Co-chair	No	Oral	Disclosure made		Ablynx, a Sanofi Company		Shire							No	
Oral and Poster Abstracts	905. Outcomes Research â€"Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies		Saturday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Racial and Socioeconomic Disparities in the Utilization of Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in the Era of Novel Agents	Victoria	Vandell	MD	Huntsman Cancer Institute University of Utah	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	803. Emerging Diagnostic Tools and Techniques: Novel Laboratory Techniques in Hematologic Diseases		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection	Elena	Varotto	MD, PhD	Pediatric Hematology-Oncology, Department of Women's and Children's Health, University of Padova	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Non-Intensive Therapy		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Jennifer	Vaughn	MD, MSPH	Ohio State University Wexner Medical Center / The James	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	903. Health Services Research â€"Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Jennifer	Vaughn	MD, MSPH	Ohio State University Wexner Medical Center / The James	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks	Kartika	Venugopal	MS	University of Florida College of Medicine	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results From Prospective Clinical Trials		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial	Ravi	Vij	MBBS	Washington University School of Medicine	Presenter	Yes	Oral	Disclosure made				Takeda; Celgene; Bristol-Myers Squibb		Takeda; Celgene; Bristol-Myers Squibb; Janssen; Sanofi; Genentech; Karyopharm					No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma â€"Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Diego	Villa	MD, FRCPC	BC Cancer Centre for Lymphoid Cancer	Moderator	No	Oral	Disclosure made		Roche, Celgene, Seattle Genetics, Abbvie, Lundbeck, AstraZeneca, Abbvie, Nanostring			Roche, Celgene, Seattle Genetics, Abbvie, Lundbeck, AstraZeneca, Abbvie, Nanostring							
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma â€"Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5		Jose	Villadobos	MD	Mayo Clinic	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Untangling the Transcriptional Mis-Regulation Driven by Pretzyara	William	Villiers	MSc	King's College	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Francesca	Vinchi	PhD	New York Blood Center	Moderator	No	Oral	Disclosure made		Silence Therapeutics		Novartis; Vifor Pharma; Pharmanutra								
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Stag2 Regulates Hematopoietic Differentiation and Self-Renewal through Alterations in Gene Expression and Topological Control	Aaron	Viny	MD,MS	Memorial Sloan Kettering Cancer Center	Presenter	Yes	Oral	Disclosure made								Hematology News		No	
Oral and Poster Abstracts	636. Myelodysplastic Syndromes â€"Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia	Valeria	Visconte	PhD		Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria		Monday, December 9, 2019	6:15 PM	7:45 PM	Yes	1.5		Valeria	Visconte	PhD		Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Adrianne	Vlachos	MD		Moderator	No	Oral	Disclosure made												
Oral and Poster Abstracts	311. Disorders of Platelet Number or Function: Insights into the Pathophysiology of Platelet Disorders		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Platelet Desialylation As a Predictive Marker in Childhood Immune Thrombocytopenia (ITP)	Jana	Volejnikova	MD	Pelacky University and University Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma â€"Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Dose-Intensification in Early Unfavorable Hodgkin Lymphoma : Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial	Bastian	von Tresckow	MD	University Hospital of Cologne	Presenter	Yes	Oral	Disclosure made		MSD; Novartis; Takeda		MSD; Novartis; Takeda		MSD; Novartis; Takeda; Pfizer; Amgen; Roche					No	
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update	Peter	Voorhees	MD	Levine Cancer Institute, Atrium Health	Presenter	Yes	Oral	Disclosure made		Celgene; Novartis; Oncopeptides		Celgene; Janssen; GSK; Takeda; Tenebio		Adaptive Biotechnologies; BMS; Celgene; Janssen; Takeda; Tenebio				Yes	D-Rvd is being investigated in transplant-eligible NDMM
Oral and Poster Abstracts	902. Health Services Research â€"Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	The Prognostic Factors for Early Fatal Outcome in Patients with Multiple Myeloma	Sowjanya	Vuyyala	MD	University Hospitals Cleveland Medical Center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	725. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Innovative Approaches in Allogeneic Transplantation for Pediatric or Nonmalignant Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Mga-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)	john	Wagner	MD	University of Minnesota	Presenter	Yes	Oral	Disclosure made		Magenta; Rocket Pharmaceuticals		Magenta; BlueRock; Novartis				Gadeta		No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma â€"Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5		Nina	Wagner-Johnston	MD	Johns Hopkins University	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Functional Characterization of Novel Molecular Drivers and Vulnerabilities of Myeloma Cells		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma	Johannes	Waldschmidt	MD	Dana-Farber Cancer Institute	Presenter	Yes	Oral	Nothing to disclose											Yes	Dabrafenib is a potent inhibitor of BRAF mutated at codon 600 (BRAFV600). Here we explored the efficacy of dabrafenib a preclinical model of multiple myeloma cell lines with BRAFV600E and BRAFR603N mutations.
Scientific Program	Understanding and Targeting TP53 in Myeloid Malignancies		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Matthew	Walter	MD	Washington University in St. Louis	Co-Chair	No	Oral	Nothing to disclose												
Scientific Program	Understanding and Targeting TP53 in Myeloid Malignancies		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Matthew	Walter	MD	Washington University in St. Louis	Co-Chair	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Roland	Walter	MD,PhD,MS	Fred Hutchinson Cancer Research Center	Moderator	No	Oral	Nothing to disclose												

Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)	Bin-Yan	Wang	MD, PhD	The Second Affiliated Hospital of Xi'an Jiaotong University	Presenter	Yes	Oral	Nothing to disclose												No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Evaluation of the Functional Effects of an African American Glucose-6-Phosphate Dehydrogenase (G6PD) Polymorphism (Val68Met) on RBC Hemolytic Propensity and Post-Transfusion Recovery in a Humanized Mouse Model	Ling	Wang	MD, PhD	University of Pittsburgh	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	802. Health Services Research: Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of Life		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy	Michael	Wang	MD	MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Janssen; AstraZeneca; MoreHealth; Acerta Pharma; Kite Pharma; Guidepoint Global; Biolinvent	MoreHealth	Janssen; Pharmacyclics; AstraZeneca; Acerta Pharma; Kite Pharma; Biolinvent; Velosbio; Loxo Oncology; Celgene; Juno Therapeutics; Aviara	Janssen; Pharmacyclics; AstraZeneca; Celgene; Dava Oncology		Janssen; AstraZeneca			No	
Oral and Poster Abstracts	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma: Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study	Michael	Wang	MD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Disclosure made		Janssen; AstraZeneca; MoreHealth; Acerta Pharma; Kite Pharma; Guidepoint Global; Biolinvent	MoreHealth	Janssen; Pharmacyclics; AstraZeneca; Acerta Pharma; Kite Pharma; Biolinvent; Velosbio; Loxo Oncology; Celgene; Juno Therapeutics; Aviara	Janssen; Pharmacyclics; AstraZeneca; Celgene; Dava Oncology		Janssen; AstraZeneca			Yes	ZUMA-2 is a clinical trial evaluating KTE-X19, an investigational CAR T cell therapy.
Oral and Poster Abstracts	901. Health Services Research: Non-Malignant Conditions: Cancers and Thrombosis		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea	Rong	Wang	PhD	Yale University School of Public Health	Presenter	Yes	Oral	Disclosure made				Celgene Corporation						No	
Special-Interest Sessions	ASH Choosing Wisely® Campaign: 2019 ASH Choosing Wisely Champions		Monday, December 9, 2019	12:15 PM	1:15 PM	Yes	1	Reduction in IVCF Utilization and Increase in IVCF Retrievals	Stephen	Wang	MD	Kaiser Permanente	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD: Novel Mechanisms and Emerging Therapies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Stat3$^{-/-}$ Alloreactive Donor T Cells Reduce EAD but Increase Leakage of ROS in Response to PD-1 Signaling Triggered By Host-Tissue PD-L1, Leading to Prevention of GvHD While Preserving GVL Effect	Xiaoqi	Wang	MD	Department of Hematology, Xinqiao Hospital, Army Medical University	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma: Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen	Xinhua	Wang	PhD	Department of Oncology, the First Affiliated Hospital of Zhengzhou University	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Functional Characterization of Novel Molecular Drivers and Vulnerabilities of Myeloma Cells		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Xiuli	Wang	PhD	City of Hope, Beckman Research Institute	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	205. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: New Concepts and Perspectives		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Alpha-Dystroglycan Supports Platelet Aggregation and Thrombus Formation	Yiming	Wang	MD, PhD	Clinical and Metabolic Genetics, The Hospital for Sick Children	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	636. Myelodysplastic Syndromes: Basic and Translational Studies: RNA Processing and Signatures in MDS		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes	Grace	Ward	BS	Moffitt Cancer Center	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	114. Hemoglobinopathies, Excluding Thalassemia: Clinical: Optimizing and Improving Access to High-Quality Care		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa	Russell	Ware	MD, PhD	Cincinnati Children's Hospital Medical Center	Presenter	Yes	Oral	Disclosure made									Global Blood Therapeutics; Agios; Nova Laboratories; CSL Behring		No	
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Speaker 1	Ted	Warkentin	MD	McMaster University	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	205. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Heterozygous Mutations of Cjip6 As a Newly Identified and Frequent Cause of Severe Congenital Neutropenia	Julia	Warren	MD, PhD	Washington University in St. Louis	Presenter	Yes	Oral	Nothing to disclose												No
Oral and Poster Abstracts	802. Health Services Research: Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of Life		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Rahma	Warsame	MD	Mayo Clinic	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Microbiome and Immune Regulation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Transcriptomic Analysis of CD4+ T Cell Dysfunction during GvHd: Evidence for Profound Reprogramming of T Cell Signaling during Acute GvHd That Is Controlled during CD28-CD80/86 Costimulation Blockade with Abatacept	Benjamin	Watkins		Emory University	Presenter	Yes	Oral	Nothing to disclose											Yes	Abatacept: Approved for Rheumatoid Arthritis; used in this trial for prevention of GVHD.
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Olutasidenib (FT-2102), an IDH1mt Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study	Justin	Watts	MD	University of Miami Sylvester Comprehensive Cancer Center	Presenter	Yes	Oral	Disclosure made				Takeda			Jazz Pharmaceuticals	Pfizer; Celgene; Jazz Pharmaceuticals		No	
Oral and Poster Abstracts	637. Myelodysplastic Syndromes: Clinical Studies: Combination Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome	Andrew	Wei		The Alfred Hospital and Monash University	Presenter	Yes	Oral	Disclosure made				Novartis; AbbVie; Servier; Celgene; Amgen; AstraZeneca	Novartis; Astellas; Pfizer; Macrogenics; AbbVie; Genentech; Servier; Celgene; Amgen; AstraZeneca; Janssen					Yes	Venetoclax is a BCL-2 inhibitor that is FDA-approved in some indications. This presentation will focus on venetoclax for treatment in myelodysplastic syndromes, which is not an approved indication.
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Andrew	Wei	MBBS,PhD	The Alfred Hospital	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	636. Myelodysplastic Syndromes: Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice	Yue	Wei	PhD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	636. Myelodysplastic Syndromes: Basic and Translational Studies: RNA Processing and Signatures in MDS		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Excessive R-Loops Trigger an Inflammatory Cascade Leading to Aberrant Hematopoietic Stem and Progenitor Cell Expansion	Joshua	Weinreb	MSc	Albert Einstein College of Medicine	Presenter	Yes	Oral	Nothing to disclose												No
General Sessions	Ernest Beutler Lecture and Prize	Blood Coagulation: From Molecular Mechanisms to Treatment of Thrombosis	Monday, December 9, 2019	1:30 PM	2:30 PM	Yes	1	Clinical Science/Translational Research	Jeffrey	Weitz	MD	McMaster University, and the Thrombosis and Atherosclerosis Research Institute	Speaker	Yes	Oral	Disclosure made		Janssen R&D, LLC; Bayer Healthcare; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi-Sankyo; Ionis; Merck; Novartis; Pfizer; Portola			Bayer Healthcare; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi-Sankyo; Ionis; Merck; Novartis; Pfizer; Portola							
Oral and Poster Abstracts	631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-free Remission		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Rob	Weiner	PhD	Beth Israel Deaconess Medical Center	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	205. Granulocytes, Monocytes, and Macrophages: Genetics and Biology of Congenital Neutropenia		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5		Karl	Welte	Professor of Pediatrics	The University Children's Hospital Tuebingen	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	701. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Innovative Approaches in Allogeneic Transplantation for Pediatric or Nonmalignant Disorders		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Post-Transplant Cyclophosphamide Improved Outcomes of HLA Mismatched Hematopoietic Stem Cell Transplantation in Children with β- Thalassemia Major	Jianyun	Wen		Department of Pediatrics, Nanfang Hospital, Southern Medical University	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Microbiome and Immune Regulation		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Regulation of the Elevated T Cell Glycolysis May Alleviate Acute Graft-Versus-Host Disease Post-Allotransplant	Qi	Wen	MD	Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of HSCT, Peking University	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR	Matthew	Wieduwilt	MD, PhD	University of California, San Diego	Presenter	Yes	Oral	Disclosure made			Rexita Pharmaceuticals	Amgen, Leadiant, Merck, Servier				Daiichi Sankyo; Celgene		No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of Pathogenesis, Drug Sensitivity, and Resistance; and Role of Bone Marrow Microenvironment and Host Microbiome in Myeloma Pathogenesis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Arun	Witta	MD, PhD	UCSF	Moderator	No	Oral	Disclosure made			Indapta Therapeutics; Protocol Intelligence			UCSF		Indapta Therapeutics; Protocol Intelligence			
Oral and Poster Abstracts	508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Pharmacological Inhibition of Nemo-like Kinase Rescues mTOR-Mediated Translation and Primes Progenitors for Leucine-Stimulated Erythroid Expansion in Pre-Clinical Models of Diamond Blackfan Anemia	Mark	Wilkes	Ph.D.	Stanford University School of Medicine	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: New Regulators of Stem and Progenitor Cell Survival and Differentiation		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	KIFC1 Mediates Centrosome Clustering Prior to Proplaletet Formation from Megakaryocytes	Adrian	Wilkie	PhD	Brigham and Women's Hospital, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	906. Outcomes Research: Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group	Lena	Winestone	MD, MSHP	UCSF	Presenter	Yes	Oral	Nothing to disclose										No	
Oral and Poster Abstracts	802. Health Services Research: Malignant Conditions (Lymphoid Disease): Advances in Healthcare Delivery		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Lena	Winestone	MD, MSHP	UCSF	Moderator	No	Oral	Nothing to disclose												
Oral and Poster Abstracts	506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5		Ingrid	Winkler	PhD	Mater Research Institute - University of Queensland	Moderator	No	Oral	Nothing to disclose												
Special-Interest Sessions	Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	Speaker 2	Daniel	Witt	PharmD	University of Utah- College of Pharmacy	Speaker	Yes	Oral	Nothing to disclose												
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma: Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study	Thomas	Witzig	MD	Mayo Clinic	Presenter	Yes	Oral	Nothing to disclose										No	

Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic Factors and Evaluation of Therapy Response in AML		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		B.J.	Wouters		Erasmus University Medical Center	Moderator	No	Oral	Disclosure made				Agios; Celgene									
Education Program	Response Comes of Age in Chronic Lymphocytic Leukemia		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Treatment-naive CLL: Lessons from the phase III and phase II combo trials	Jennifer	Woyach	MD	The Ohio State University	Speaker	Yes	Oral	Disclosure made		Janssen; Pharmacyclics LLC, an AbbVie Company		Janssen; Pharmacyclics LLC, an AbbVie Company; AbbVie; Karyopharm; Loxo; Morphosys; Verastem									
Education Program	Response Comes of Age in Chronic Lymphocytic Leukemia		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Treatment-naive CLL: Lessons from the phase III and phase II combo trials	Jennifer	Woyach	MD	The Ohio State University	Speaker	Yes	Oral	Disclosure made		Janssen; Pharmacyclics LLC, an AbbVie Company		Janssen; Pharmacyclics LLC, an AbbVie Company; AbbVie; Karyopharm; Loxo; Morphosys; Verastem									
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: BTK inhibitors and CAR T Cells in CLL		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations	Jennifer	Woyach	MD	The Ohio State University	Presenter	Yes	Oral	Disclosure made		Janssen; Pharmacyclics LLC, an AbbVie Company		Janssen; Pharmacyclics LLC, an AbbVie Company; AbbVie; Karyopharm; Loxo; Morphosys; Verastem								No	
How I Treat: Bringing Science to Clinical Dilemmas	MRD Testing to Guide Treatment Decisions in CLL		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Jennifer	Woyach	MD	The Ohio State University	Speaker	No	Oral	Disclosure made		Janssen; Pharmacyclics LLC, an AbbVie Company		Janssen; Pharmacyclics LLC, an AbbVie Company; AbbVie; Karyopharm; Loxo; Morphosys; Verastem									
Education Program	Response Comes of Age in Chronic Lymphocytic Leukemia		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Clonal Dynamics in CLL	Catherine	Wu	MD	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made				Pharmacyclics								No	
Education Program	Response Comes of Age in Chronic Lymphocytic Leukemia		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Clonal Dynamics in CLL	Catherine	Wu	MD	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made				Pharmacyclics								No	
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5		Catherine	Wu	MD	Dana-Farber Cancer Institute	Co-Chair	No	Oral	Disclosure made				Pharmacyclics									
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5		Catherine	Wu	MD	Dana-Farber Cancer Institute	Co-Chair	No	Oral	Disclosure made				Pharmacyclics									
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Catherine	Wu	MD	Dana-Farber Cancer Institute	Co-Chair	No	Oral	Disclosure made				Pharmacyclics									
Meet the Scientist	Clonal Dynamics in Chronic Lymphocytic Leukemia		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Catherine	Wu	MD	Dana-Farber Cancer Institute	Speaker	No	Oral	Disclosure made				Pharmacyclics									
Special-Interest Sessions	ASH Practice Partnership Lunch	Genomic/Genetic Testing: The Who, What, Where, When, & Why	Sunday, December 8, 2019	11:15 AM	12:30 PM	Yes	1.25	The Basics of Genetic and Genomic Testing	David	Wu	MD, PhD	University of Washington	Speaker	Yes	Oral	Nothing to disclose													
Oral and Poster Abstracts	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic Factors and Evaluation of Therapy Response in AML		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Paired Analyses of AML at Diagnosis and Relapse By Single-Cell RNA Sequencing Identifies Two Distinct Relapse Patterns	Kai	Wu		University of Michigan	Presenter	Yes	Oral	Nothing to disclose													No	
Oral and Poster Abstracts	501. Hematopoietic Stem and Progenitor Biology: Intrinsic and Extrinsic Control of HSPC Maintenance and Differentiation		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Complete Spatial Mapping of Steady-State Erythropoiesis	Qingqing	Wu	PhD	Cincinnati Children's Medical center	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	211. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Application of High-Throughput Sequencing in the Diagnosis of Inherited Immune-Thrombocytopenia from Children Chronic/Refractory ITP	Runhui	Wu	MD, PhD	Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Prothrombin R543W Mutation Impairs Protein C Activation and Constitutes a New Genetic Risk Factor for Venous Thrombosis	Ai	WU	M.S.	Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating *Perp* gene in Vivo and in Vitro	Yu	Wu	MD	West China Hospital, Sichuan University	Presenter	Yes	Oral	Nothing to disclose													No
Scientific Program	Stromal Cell Immune Regulation in the Microenvironment		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Immune-Tumor Interactions in Resistance to Cancer Immunotherapy	Kai	Wucherpfennig	MD, PhD	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made				TCR2; Tican		BMS; Novartis							No
Scientific Program	Stromal Cell Immune Regulation in the Microenvironment		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Immune-Tumor Interactions in Resistance to Cancer Immunotherapy	Kai	Wucherpfennig	MD, PhD	Dana-Farber Cancer Institute	Speaker	Yes	Oral	Disclosure made				TCR2; Tican		BMS; Novartis							No
Oral and Poster Abstracts	322. Disorders of Coagulation or Fibrinolysis: Pathophysiology and Mechanisms		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Prevention of Bleeding-Induced Vascular Abnormalities in the Hemophilic Mouse Joint By Increasing TAR Levels or Inhibiting uPA Activity	Tine	Wyseure	PhD	The Scripps Research Institute	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	732. Clinical Allogeneic Transplantation: Results: Outcomes		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Impact of FLT3 -ITD Remission Depth in Acute Myeloid Leukemia Patients Prognosis Prediction before Allogeneic Hematopoietic Cell Transplantation	Aiaoyu	Xu		the first affiliated hospital of Soochow University, Jiangsu Institute of hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation	Feixi	Yabiz		The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Sequential CD19- and BCma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study	Lingshi	Yan		the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	625. Lymphoma: Pre-Clinical's Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK^{C481S} Mediated Ibrutinib Resistance *in Vitro* and *in Vivo* in MYD88 Mutated B-Cell Lymphomas	Guang	Yang	PhD	Dana-Farber Cancer Inst.	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	An Open Label Study of Alpin-101, a First-in-Class Dual CD28/CD6 Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)	Jing	Yang	PhD	Alpine Immune Sciences, Inc.	Presenter	Yes	Oral	Disclosure made	Alpine immune sciences		Alpine immune sciences										No
Oral and Poster Abstracts	638. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genomic Landscape and Disease Classification		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia	Jun	Yang	PhD	St. Jude Children's Research Hospital	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	635. Myeloproliferative Syndromes: Basic Science: Molecular Drivers and Targets in Myeloproliferative Neoplasms		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	TGF-β Signaling Contributes to Myelofibrosis and Clonal Dominance of Myeloproliferative Neoplasms	Juo-Chin	Yao		Washington University School of Medicine	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma's Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged 3%-60 Years	Christopher	Yasenchak	MD	Willamette Valley Cancer Institute and Research Center/US Oncology Research	Presenter	Yes	Oral	Disclosure made		Seattle Genetics; BMS											No
Scientific Program	Ex Vivo Bioengineering of Blood Products for Transfusion		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Karina	Yazdanbakhsh	PhD	New York Blood Center	Chair	No	Oral	Nothing to disclose													
Scientific Program	Ex Vivo Bioengineering of Blood Products for Transfusion		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Karina	Yazdanbakhsh	PhD	New York Blood Center	Chair	No	Oral	Nothing to disclose													
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Ex Vivo Bioengineering of Blood Products for Transfusion		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Karina	Yazdanbakhsh	PhD	New York Blood Center	Chair	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Basic and Translational Studies to Improve Treatment Outcomes and Identify Immune Mediators of Treatment-free Remission		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	The Ahl-1-BCR-ABL-DNMD Complex Mediates Mitochondrial Dynamics in Drug-Resistant BCR-ABL^{+} Cells	Ryan	Yen	BSc	British Columbia Cancer Research Centre	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	638. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genomic Landscape and Disease Classification		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	RNA Sequencing in Childhood B-Lymphoblastic Leukemia Improves Molecular and Risk Assignment	Allen Eng Juh	Yeoh	MD	National University Hospital Singapore	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Rara is a Druggable Super-Enhancer Regulated Dependency in Pediatric AML	Jianma	Yi	MD	Texas Children's Hospital, Baylor College of Medicine	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	102. Regulation of Iron Metabolism: Novel Players in Iron Homeostasis in Health and Disease		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Regulation of Erythroid Heme Synthesis By the Mitochondrial Clps Unfoldase	Yvette	Yien	PhD	University of Delaware	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Efficacy and Safety of Carfilzomib at 56mg/m^{2} with Cyclophosphamide and Dexamethasone (KSAC) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or KSACd Consolidation: Initial Results of the Phase 2 Cardamon Study	Gawe	Yong		University College London Hospitals NHS Foundation Trust	Presenter	Yes	Oral	Disclosure made		Autolus		Amgen; Takeda			Amgen; Janssen; Takeda; Sanofi					Yes	Carfilzomib is used with cyclophosphamide as 1st line treatment for myeloma
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Novel Target		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Akihide	Yoshimi	MD,PhD	Memorial Sloan Kettering Cancer Center	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	332. Anticoagulation and Antithrombotic Therapy I		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation	Guy	Young	MD	University of Southern California	Presenter	Yes	Oral	Disclosure made		Bioverativ/Sanofi; CSL Behring; Freeline; Genentech/Roche; Grifols; Kedrion; Novo Nordisk; Spark; Shire/Takeda; Uniqure		Genentech/Roche	Bioverativ/Sanofi; CSL Behring; Freeline; Genentech/Roche; Grifols; Kedrion; Novo Nordisk; Spark; Shire/Takeda; Uniqure							Yes	Pediatric treatment of VTE for a drug approved only in adults.
Oral and Poster Abstracts	506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Decline in Insulin-like Growth Factor-1 (IGF1) from Aged Mesenchymal Stromal Cells Is a Targetable Mechanism to Rescue Hematopoietic Stem Cell Aging	Ilira	Young	PhD	The Jackson Laboratory	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: New Regulators of Stem and Progenitor Cell Survival and Differentiation		Monday, December 9, 2019	2:45 PM	4:15 PM	Yes	1.5	FoxM1 Haploinsufficiency Drives Clonal Hematopoiesis	Chunjie	Yu	PhD	University of Illinois at Chicago	Presenter	Yes	Oral	Nothing to disclose													No
Special Scientific Symposia	Machine Learning in Hematology		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Integrating Quantitative Pathology and Multi-Omics Profiles using Machine Learning	Kun-Hsing	Yu	MD, PhD	Harvard Medical School	Speaker	Yes	Oral	Disclosure made													No
Meet the Scientist	Artificial Intelligence in Pathology: Opportunities and Challenges		Sunday, December 8, 2019	11:15 AM	12:15 PM	Yes	1		Kun-Hsing	Yu	MD, PhD	Harvard Medical School	Speaker	No	Oral	Disclosure made													
Oral and Poster Abstracts	602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Transcriptional Dysregulation via Chromatin 3D Structure		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction	Haiyang	Yun	PhD	Wellcome - MRC Cambridge Stem Cell Institute	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	621. Lymphoma's Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell-Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome	Nevin	Yusufova		Biochemistry, Cell & Molecular Biology Graduate Program, Weill Cornell Medicine	Presenter	Yes	Oral	Nothing to disclose													No
Oral and Poster Abstracts	653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Elena	Zamagni	MD	Bologna University School of Medicine	Moderator	No	Oral	Nothing to disclose													
Oral and Poster Abstracts	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphoma's Results from Retrospective/Observational Studies: Population-Based Outcomes		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis	Adam	Zayac	MD	Alpert Medical School of Brown University	Presenter	Yes	Oral	Nothing to disclose													No

Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study	Amer	Zeidan	MBBS, MHS	Yale University and Yale Cancer Center	Presenter	Yes	Oral	Disclosure made		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Medimmune/Astra3eneca; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; ADC Therapeutics	Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; Jazz; Ariad; Agios; Novartis; Astellas; Daiichi Sankyo; Cardinal Health; Seattle Genetics; BeyondSpring					Yes	Durvalumab is a PD-L1 blocking antibody indicated for the treatment of patients with 1) locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, or 2) unresectable, stage 3 NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Oral and Poster Abstracts	627. Myelodysplastic Syndromes&#8"Clinical Studies: Combination Therapies		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or In Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome	Amer	Zeidan	MBBS, MHS	Yale School of Medicine and Yale Cancer Center, Yale University	Presenter	Yes	Oral	Disclosure made		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Medimmune/Astra3eneca; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; ADC Therapeutics	Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; Jazz; Ariad; Agios; Novartis; Astellas; Daiichi Sankyo; Cardinal Health; Seattle Genetics; BeyondSpring					Yes	Venetoclax is a BCL-2 inhibitor that is FDA-approved in some indications. This presentation will focus on venetoclax for treatment in myelodysplastic syndromes, which is not an approved indication.
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targets and Combinations		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DAC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	Amer	Zeidan	MBBS, MHS	Yale University and Yale Cancer Center	Presenter	Yes	Oral	Disclosure made		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Medimmune/Astra3eneca; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; ADC Therapeutics	Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; Jazz; Ariad; Agios; Novartis; Astellas; Daiichi Sankyo; Cardinal Health; Seattle Genetics; BeyondSpring					No	
Oral and Poster Abstracts	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study	Amer	Zeidan	MBBS, MHS	Yale University School of Medicine and Yale Cancer Center	Presenter	Yes	Oral	Disclosure made		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Medimmune/Astra3eneca; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; ADC Therapeutics	Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; Jazz; Ariad; Agios; Novartis; Astellas; Daiichi Sankyo; Cardinal Health; Seattle Genetics; BeyondSpring					No	
Oral and Poster Abstracts	613. Acute Myeloid Leukemia: Clinical Studies: Non-Intensive Therapy		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States	Amer	Zeidan	MBBS, MHS	Yale School of Medicine and Yale Cancer Center, Yale University	Presenter	Yes	Oral	Disclosure made		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda		Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Medimmune/Astra3eneca; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; ADC Therapeutics	Acceleron Pharma; Celgene Corporation; Abbvie; Otsuka; Pfizer; Boehringer-Ingelheim; Trovagene; Incyte; Takeda; Jazz; Ariad; Agios; Novartis; Astellas; Daiichi Sankyo; Cardinal Health; Seattle Genetics; BeyondSpring					No	
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML	Joshua	Zeidner	MD	University of North Carolina	Presenter	Yes	Oral	Disclosure made		Celgene; AyuvBio Laboratories		Celgene; Tolero; Merck; Takeda	Agios; Celgene; Daiichi Sankyo; Tolero; Pfizer; AbbVie					Yes	Pembrolizumab is investigational for AML.
Oral and Poster Abstracts	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Joshua	Zeidner	MD	University of North Carolina	Moderator	No	Oral	Disclosure made		Celgene; AyuvBio Laboratories		Celgene; Tolero; Merck; Takeda	Agios; Celgene; Daiichi Sankyo; Tolero; Pfizer; AbbVie						
Education Program	IRON: How to Manage When There is Too Much or Too Little of It		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Management of Iron Deficiency	Michelle	Zeller	MD, FRCPC, MHPE	McMaster University	Speaker	Yes	Oral	Disclosure made		Canadian Blood Services; Ontario Ministry of Health and Long Term Care								Yes	In discussion of IV iron, some formulations are indicated only for certain patient populations. Use of IV iron and specific formulations will be described for managing iron deficiency in general.
Education Program	IRON: How to Manage When There is Too Much or Too Little of It		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Management of Iron Deficiency	Michelle	Zeller	MD, FRCPC, MHPE	McMaster University	Speaker	Yes	Oral	Disclosure made		Canadian Blood Services; Ontario Ministry of Health and Long Term Care								Yes	In discussion of IV iron, some formulations are indicated only for certain patient populations. Use of IV iron and specific formulations will be described for managing iron deficiency in general.
Education Program	IRON: How to Manage When There is Too Much or Too Little of It		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5		Michelle	Zeller	MD, FRCPC, MHPE	McMaster University	Chair	No	Oral	Disclosure made		Canadian Blood Services; Ontario Ministry of Health and Long Term Care									
Education Program	IRON: How to Manage When There is Too Much or Too Little of It		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5		Michelle	Zeller	MD, FRCPC, MHPE	McMaster University	Chair	No	Oral	Disclosure made		Canadian Blood Services; Ontario Ministry of Health and Long Term Care									
Oral and Poster Abstracts	701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: GVHD: Novel Mechanisms and Emerging Therapies		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Defu	Zeng	MD, PhD	The Beckman Research. Inst. City of Hope	Moderator	No	Oral	Nothing to disclose											
Oral and Poster Abstracts	802. Gene Therapy and Transfer: Gene Therapies for Non-Malignant Disorders		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Therapeutic Base Editing of Human Hematopoietic Stem Cells	Jing	Zeng	MD	Boston Children&#6"s Hospital, Harvard Medical School	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	642. CLL: Therapy, excluding Transplantation: First Line Treatment		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5		Thorsten	Zenz	MD	University Hospital Zurich	Moderator	No	Oral	Disclosure made					Roche; Abbvie; Janssen; Gilead							
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Novel Molecular Dependencies and Targets in Multiple Myeloma		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5		Fenghuang	Zhan	MD, PhD	University of Iowa Carver School of Medicine	Moderator	No	Oral	Disclosure made												
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	Biology and Application of Genome Editing	Feng	Zhang	PhD	Massachusetts Institute of Technology	Speaker	Yes	Oral	Disclosure made		Editas Medicine; Beam Therapeutics; Pairwise Plants; Sherlock Biosciences; Arbor Biotechnologies	Editas Medicine; Beam Therapeutics; Pairwise Plants; Sherlock Biosciences; Arbor Biotechnologies								No	
Scientific Program	Genome Editing for Transplantation and Cellular Therapies		Sunday, December 8, 2019	7:30 AM	9:00 AM	Yes	1.5	Biology and Application of Genome Editing	Feng	Zhang	PhD	Massachusetts Institute of Technology	Speaker	Yes	Oral	Disclosure made		Editas Medicine; Beam Therapeutics; Pairwise Plants; Sherlock Biosciences; Arbor Biotechnologies	Editas Medicine; Beam Therapeutics; Pairwise Plants; Sherlock Biosciences; Arbor Biotechnologies								No	
Continuing Conversations With the Speakers	Continuing Conversations With the Speakers on Genome Editing for Transplantation and Cellular Therapies		Saturday, December 7, 2019	11:15 AM	12:15 PM	Yes	1		Feng	Zhang	PhD	The Broad Institute	Speaker	No	Oral	Disclosure made		Editas Medicine; Beam Therapeutics; Pairwise Plants; Sherlock Biosciences; Arbor Biotechnologies	Editas Medicine; Beam Therapeutics; Pairwise Plants; Sherlock Biosciences; Arbor Biotechnologies									
Oral and Poster Abstracts	506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells		Monday, December 9, 2019	7:00 AM	8:30 AM	Yes	1.5	Spatial Mapping of Myelopoiesis Reveals the Bone Marrow Niche for Monocyte Dendritic Cell Progenitors	Jichou	Zheng		Cincinnati Children&#6"s Medical center	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	625. Lymphoma: Pre-Clinical&#8"Chemotherapy and Biologic Agents: Immune Signaling and Immunotherapy in Lymphoma		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5	Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma	Liang	Zhang	MD, PhD	The University of Texas MD Anderson Cancer Center	Presenter	Yes	Oral	Nothing to disclose											No	
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Nanoparticles Mimicking Platelets and Platelet Cloaking	Liangfang	Zhang	PhD	University of California-San Diego	Speaker	Yes	Oral	Disclosure made		Cellics Therapeutics, Inc; Cello Therapeutics, Inc	Cellics Therapeutics, Inc; Cello Therapeutics, Inc								No	
Scientific Program	Filling a Clinical Void: Engineering Platelets In Vitro		Sunday, December 8, 2019	4:30 PM	6:00 PM	Yes	1.5	Nanoparticles Mimicking Platelets and Platelet Cloaking	Liangfang	Zhang	PhD	University of California-San Diego	Speaker	Yes	Oral	Disclosure made		Cellics Therapeutics, Inc; Cello Therapeutics, Inc	Cellics Therapeutics, Inc; Cello Therapeutics, Inc								No	
Oral and Poster Abstracts	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refining the Approach		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy For Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)	Ran	Zhang	MD	Hebei Yanda Lu Daopei Hospital	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	622. Lymphoma Biology&#8"Non-Genetic Studies: Molecular Mechanisms		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5	Disrupting GRINL1A Association with Ceredibin Accelerates H2O/L2 Degradation and IMID Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition	Nicole	Zhao		Stony Brook University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	401. Basic Science and Clinical Practice in Blood Transfusion: Basic Sciences		Saturday, December 7, 2019	9:30 AM	11:00 AM	Yes	1.5	An Authentic Murine Model of Fetal/Neonatal Alloimmune Thrombocytopenia	Huiying	Zhi	PhD	Blood Center of Wisconsin	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of Pathogenesis, Drug Sensitivity, and Resistance; and Role of Bone Marrow Microenvironment and Host Microbiome in Myeloma Pathogenesis		Monday, December 9, 2019	10:30 AM	12:00 PM	Yes	1.5	Alterations of Gut Microbiome Accelerate Multiple Myeloma Progression By Increasing the Relative Abundances of Nitrogen Recycling Bacteria	Wen	Zhou	PhD	Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education; Key Laboratory of Carcinogenesis, National Health and Family Planning Commission, Xiangya Hospital, Central South University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	605. Molecular Pharmacology, Drug Resistance&#8"Lymphoid and Other Diseases I		Monday, December 9, 2019	4:30 PM	6:00 PM	Yes	1.5	Blockade of Yes-Associated Protein As a Novel Therapeutic Approach in Diffuse Large B-Cell Lymphoma	Xiangxiang	Zhou	MD	Shandong Provincial Hospital Affiliated to Shandong University	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	331. Pathophysiology of Thrombosis: Prothrombotic Mechanisms and Assessment		Sunday, December 8, 2019	12:00 PM	1:30 PM	Yes	1.5	Antibody Cloning Identifies Pathogenic and Non-Pathogenic Antibodies in Heparin-Induced Thrombocytopenia and Defines the Molecular Signatures That Differentiate the Two Types of Antibodies	Wen	Zhu		Medical College of Wisconsin	Presenter	Yes	Oral	Nothing to disclose											No	
Oral and Poster Abstracts	802. Health Services Research&#8"Malignant Conditions (Lymphoid Disease): Health Care Utilization and Quality of Life		Saturday, December 7, 2019	7:30 AM	9:00 AM	Yes	1.5	Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV^PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry	Heiner	Zimmermann	MD	Diako Hospital	Presenter	Yes	Oral	Disclosure made				Atara Biotherapeutics; Roche								No	
Oral and Poster Abstracts	624. Hodgkin Lymphoma and T/NK Cell Lymphoma&#8"Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma		Saturday, December 7, 2019	2:00 PM	3:30 PM	Yes	1.5	Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma	Pier	Zinzani		Institute of Hematology &Gacute;&#8"gro3&#8"l University of Bologna	Presenter	Yes	Oral	Disclosure made		VERASTEM; MSD; EUSAPHARMA; SANOFI				VERASTEM; CELLTRION; GILEAD; JANSSEN-CILAG; BMS; SERVIER; MSD; IMMUNE DESIGN; CELGENE; PORTOLA; ROCHE; EUSAPHARMA; KYOWA KIRIN	VERASTEM; CELLTRION; GILEAD; JANSSEN-CILAG; BMS; SERVIER; SANDOZ; MSD; IMMUNE DESIGN; CELGENE; PORTOLA; ROCHE; EUSAPHARMA; KYOWA KIRIN				No	
Oral and Poster Abstracts	332. Anticoagulation and Antithrombotic Therapy I		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5	Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL)	Jeffrey	Zuckier	MD	Beth Israel Deaconess Medical Center, Harvard Medical School	Presenter	Yes	Oral	Disclosure made		Seattle Genetics; Bayer; Parexel; Portola; Daiichi		Querogen; Incyte							No	
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Saturday, December 7, 2019	4:00 PM	5:30 PM	Yes	1.5		Jeffrey	Zuckier	MD	Beth Israel Deaconess Medical Center	Co-Chair	No	Oral	Disclosure made		Seattle Genetics; Bayer; Parexel; Portola; Daiichi		Querogen; Incyte								
Scientific Program	Hemolytic Disorders and Thrombosis: Mechanistic and Clinical Insights		Sunday, December 8, 2019	9:30 AM	11:00 AM	Yes	1.5		Jeffrey	Zuckier	MD	Beth Israel Deaconess Medical Center	Co-Chair	No	Oral	Disclosure made		Seattle Genetics; Bayer; Parexel; Portola; Daiichi		Querogen; Incyte								
Special Scientific Symposia	Special Symposium on the Basic Science in Hemostasis and Thrombosis		Monday, December 9, 2019	4:30 PM	6:30 PM	Yes	2		Jeffrey	Zuckier	MD	Beth Israel Deaconess Medical Center, Harvard Medical School	Co-Chair	No	Oral	Disclosure made		Seattle Genetics; Bayer; Parexel; Portola; Daiichi		Querogen; Incyte								
Oral and Poster Abstracts	332. Anticoagulation and Antithrombotic Therapy I		Saturday, December 7, 2019	12:00 PM	1:30 PM	Yes	1.5		Jeffrey	Zuckier	MD	Beth Israel Deaconess Medical Center Harvard Medical School	Moderator	No	Oral	Nothing to disclose												